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Abstract 
ABSTRACT 
Following a review of treatment outcome study methodology, a comparative study 
of psychological versus pharmacological treatments was conducted; subsidiary 
studies investigated aspects of treatment outcome in more detail. 
1 
193 patients with DSM I1I-R panic disorder with or without agoraphobia were 
randomly allocated to; fluvoxamine, placebo, fluvoxamine + CBT (cognitive 
behaviour therapy), placebo + CBT, or CBT alone. Patients received no concurrent 
treatments and were treated to the same schedule, with therapist contact balanced 
across groups. Treatments were conducted in the primary care setting. Outcome at 
treatment end-point and 6 month follow-up, assessed in terms of both statistical and 
clinical significance, showed patients receiving active treatments improved 
significantly, with improvement better preserved over follow-up in the groups 
receiving CBT. The CBT alone and fluvoxamine + CBT groups showed the most 
consistent gains, the latter group showing gains earliest in treatment. Outcome was 
also investigated using brief global ratings of symptom severity, change in 
symptoms following treatment, general wellbeing and social disruption, completed 
by psychologist, referring GPs, and patients. Using these measures all active 
treatments showed statistical advantage over placebo with the groups employing 
CBT showing the most robust and consistent response. Overall there were no 
significant differences in drop-out rates between groups although the drop-out rate 
for patients receiving CBT alone was higher than that for placebo + CBT. 
Agreement with main outcome measures was demonstrated for psychologist and 
patient ratings, but not for GP ratings. An investigation of panic attack variables as 
treatment outcome measures indicated that these did not function as discriminative 
treatment outcome measures with all treatment groups showing significant 
reductions in panic attack variables over treatment with few significant differences 
between treatment groups on any variable throughout treatment. An investigation of 
prognostic indicators of treatment outcome indicated good prediction of post 
treatment response using pre-treatment measures of anxiety level, frequency of 
panic attacks, extroversion and treatment group. Predictions of outcome at 6 month 
follow-up were less robust. Results are discussed in terms of their relevance to 
wider clinical practice. 
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CHAPTER 1 INTRODUCTION AND HISTORICAL PERSPECTIVE 
Chapter 1 
1.1 Introduction 
Panic, the sudden onset of overwhelming physical and psychological symptoms 
coupled with feelings offear, terror or extreme discomfort has long been recognised 
as part of human emotional experience. The term panic is deeply entrenched in our 
cultural mythology being named after the ancient Greek god Pan, the god of nature. 
Pan lived in the countryside where he presided over the flora and fauna (Smith 
3 
1872). Mythology has it that Pan'would sleep in thickets or caves near the roadside, 
and if disturbed from his sleep by passers-by would, from his hiding place, emit a 
blood-curdling scream terrorising those who heard it. ''Hence sudden fright without 
any visible cause was ascribed to Pan, and was called a Panic fear." (Smith 1872 
p518). Whilst the origins of the term may have faded into the myths from which they 
arose, panic remains a current and ubiquitous emotional descriptor, In everyday 
terms we "panic" in a range of situations, from failing to meet a deadline, to being 
faced with immediate life-threatening danger. Such ubiquity might suggest that the 
term panic has little practical or clinical utility, being all things to all men, On the 
contrary, many have argued that panic, or more accurately panic attacks, are a 
definable, recognisable and common clinical occurrence giving rise, particularly in 
the past 15-20 years, to a substantial clinical literature (Rachman & Maser 1988, 
Barlow 1988, Baker 1989, McNally 1994, Wolfe & Maser 1994). The following 
thesis will describe the clinical phenomenon of panic attacks, their high prevalence, 
and given the latter, necessary treatment strategies. The thesis will focus on 
treatment outcome research in panic disorder with particular attention being paid to 
the methodological adequacy of treatment outcome research. Treatment outcome 
studies designed to address methodological shortcomings in previous research will be 
described, and the relevance of findings to wider clinical practice discussed. 
1.2 Historical Perspective 
The origins of the concept of panic in ancient mythology have been described. The 
construct also has a considerable clinical history. Freud coined the term "anxiety 
attacks" for what he described as "spontaneous anxiety attacks which take the form 
of vertigo, palpitation, dyspnoea, trembling, sweating, and so on." (Freud 
1895/1962, p133). He noted that these attacks can erupt into consciousness without 
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apparently being triggered by any antecedent thoughts whilst commonly being 
accompanied by fears of impending death or insanity. Freud also presaged much later 
psychological discussion in noting that " .. .in the case of agoraphobia, etc., we often 
find the recollection of an anxiety attack; and what the patient actually fears is the 
occurrence of such an attack under the special conditions in which he believes he 
cannot escape it." (Freud 1985/1962, p81). Similar descriptions of agoraphobia as 
resulting from a fear of untoward physical sensations were encapsulated in the 
contemporary theories of Benedikt (1870) and Westphal (1871) and described under 
the terms Platzschwindel (dizziness occurring in open spaces) and Platzangst (fear of 
open spaces). It has been argued (Barlow 1988, McNally 1994) that much of the 
clarity of Freud's original thinking on the phenomenology of panic was lost with the 
development of his ideas of sexual aetiology and psychodynamic treatment. 
Nonetheless, all of the theories described above recognise the central notion of 
distressing sudden attacks involving physiological disruption, with emotional and 
behavioural change occurring subsequent to them. As such they can be seen as the 
foundation on which many current notions of panic disorder rest. 
Ideas on panic attacks were not restricted to the field of psychopathology, with 
descriptions of similar phenomena provided in the medical literature. Such accounts 
were often given by physicians working in situations where people experienced 
intense threat or stress, thus the history of the construct of panic runs as a thread 
through the recent history of medical practice in warfare. For example, the physician 
De Costa described a syndrome he encountered in a series of 300 patients seen 
during the American Civil War (De Costa 1871). The syndrome was characterised by 
dizziness, palpitations and unexplained distress that arose without any clear or 
obvious cause. Relying on his training as a physician De Costa labelled these 
phenomena "irritable heart" or "irritable heart of the soldier". The Great War of 
1914-1918 also gave rise to further descriptions of similar events. Lewis (1917) 
described a collection of symptoms similar to those noted by De Costa. Noting that 
these symptoms occurred amongst battle weary soldiers especially on physical 
exertion associated with combat activities Lewis coined the term "effort syndrome". 
In an early reference to the relevance of stress and personality as precipitants for the 
condition, Lewis emphasised the importance of individual physical and psychological 
constitution and the relevance of continuous exposure to battle. At the same time, 
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with regard to seemingly the same syndrome Oppenheim and colleagues coined the 
term "neurocirculatory asthenia", (Oppenheim et aI1918). This subsequently became 
a term commonly applied to anxiety states with marked cardiovascular features 
(Cohen & White 1950). Cohen & White (1950) also list other labels that have been 
employed for similar collections of symptoms. These include, ''vasoregulatory 
asthenia", "nervous tachycardia", ''vasomotor neurosis", and "nervous exhaustion", 
(Cohen & White 1950). All of these clinical syndromes share features in common 
with the present day understanding of panic attacks. They are not, however, 
described with sufficient scientific accuracy to allow the conclusion that they are 
relevant only to panic attacks. Indeed some of these descriptions have been included 
in historical perspectives on other anxiety disorders, in particular Generalised 
Anxiety Disorder. It is also likely, given the war setting of many of these descriptions 
that there will be considerable overlap with what is now classified as Post-Traumatic 
Stress Disorder. Some evidence for the existence of a panic-based disorder as 
distinct from other forms of anxiety was provided in the work of Roth (Roth 1959, 
1960). In analysing data on 135 patients, Roth (1959) identified a syndrome, which 
he argued was separate from what he termed anxiety neurosis. This "phobic anxiety-
depersonalisation syndrome" was characterised by attacks similar to panic attacks in 
which the phenomenon of depersonalisation was suggested to be a major factor. 
These patients were also suggested to develop agoraphobic avoidance secondary to 
these attacks. One of the most important features of Roth's work was the 
differentiation of this syndrome from other anxiety disorders. At the same time that 
Roth was conducting his studies further evidence of the distinct nature of panic 
attacks was emerging from work on patients response to pharmacological treatment. 
With this work Donald Klein (Klein & Fink 1962, Klein 1964, Klein 1981) is 
popularly credited with recognising the relevance of panic attacks in the 
psychopathology of anxiety disorders and beginning the more recent scientific study 
of the phenomenon. In the late 1950s Klein was studying the effects and treatment 
efficacy of the then experimental drug, imipramine, which was synthesised by small 
changes to the chemical structure of the major tranquilliser chlorpromazine. It was 
assumed that this new drug would be effective in the treatment of schizophrenia. 
Klein and colleagues used imipramine to treat a group of highly anxious in-patients 
labelled as "schizophrenic" but who nonetheless had neither delusions nor 
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hallucinations and who had previously failed to respond to chlorpromazine. 
Following the open clinical trial (Klein & Fink 1962), the patients reported that they 
continued to experience their chronic anxiety unabated. Their therapists were in 
agreement with the patients assessment of their condition. Nursing staff, however, 
reported a significant change in the patients. Prior to starting on imipramine the 
patients would rush to the nursing station repeatedly claiming they were about to die 
and expressing considerable terror. The patients would respond to comfort from 
nursing staff and the terror would eventually pass. During treatment with imipramine 
this behaviour stopped and patients became apparently more able to move around the 
hospital unaccompanied. Klein reported this finding (Klein & Fink 1962) and 
conducted a further small placebo controlled trial of 14 similar patients of whom 6 
received placebo, 7 received imipramine, and 1 received chlorpromazine (Klein 
1964). This more controlled study produced similar findings with the patients 
receiving imipramine showing the same pattern of improvement. It appeared therefor 
that treatment response to imipramine differentiated between two forms of anxiety. 
The sudden-onset episodes of terror which Klein identified as panic attacks were 
responsive to the drug, whilst the more chronic anxiety which Klein suggested was 
anticipatory anxiety secondary to the panic attacks did not. This "pharmacological 
dissection" (Klein 1981) of panic attacks as a form of anxiety qualitatively distinct 
from anticipatory, or chronic general anxiety is the central feature of Klein's 
reasoning and represents the modem beginning of the study of panic attacks as a 
disorder in it's own right. Klein's observations of the response to imipramine led him 
not only to distinguish between panic attacks and other forms of anxiety, but also to 
view agoraphobia as a secondary complication of panic attacks (Klein 1981, Klein & 
Klein 1989). For Klein, people with agoraphobia were not afraid of crowded or 
public places per se, indeed he observed that they were often able to enter such 
places if accompanied by trusted companions, rather they feared the occurrence of 
panic attacks in those or similar situations where escape might be difficult or 
embarrassing. 
It is clear that the notion of panic or panic attacks has a considerable history. It is 
only relatively recently, through the work of Roth and Klein that panic attacks came 
to be regarded as a clinical phenomenon in their own right distinguished from 
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anticipatory and general anxiety and with particular consequences as seen in the 
development of agoraphobic avoidance. 
1.3 Classification 
7 
Western psychiatry has developed two main classification systems in order to identifY 
and collate clinically observed symptom groupings. 
The first of these is the World Health Organisation sponsored International 
Classification of Diseases, now in it's tenth revision (lCD 10, WHO 1992). The ICD 
system is not a diagnostic manual but a less descriptive compendium developed to 
aid the gathering of statistical information on morbidity and mortality (Lipshitz 
1988). The diagnoses contained in the ICD system are guides for classification rather 
than a set of operationalised rules by which a definitive classification can be achieved. 
These limitations mean that categories employed in the ICD system are overinclusive 
and too ambiguous for it to function as a clinically useful diagnostic system 
(Jablensky 1985). 
A more clinically useful diagnostic system is provided by the American 
Psychiatric Association in the Diagnostic and Statistical Manual of Mental Disorders 
(DSM). This system provides detailed criteria against which symptomatology can be 
assessed for each diagnostic category and specifies inclusion and exclusion criteria 
thus permitting operationalised research classifications. The Diagnostic and 
Statistical Manual of Mental Disorders has been adopted as an international standard 
in research classification. 
The development of present day concepts of anxiety can be traced through the 
development of the DSM. Early versions of the manual, DSM I (1952) and DSM II 
(1968), reflected the theoretical zeitgeist by adopting a predominantly 
psychodynamic perspective, classifYing the anxiety disorders under the heading of 
neuroses. In DSM III (1980), however, the anxiety disorders emerged as a category 
in their own right with the term "neuroses" being retained only as a parenthetic 
subcategory. In contrast to the previous DSM I & II systems, DSM III takes an 
atheoretical stance holding no implications for aetiology, and also includes somatic 
aspects of anxiety in classifYing disorders, which were not discussed in DSM I or 
DSM II. In DSM TIl the anxiety disorders are classified in two groups, the Phobic 
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Disorders (or phobic neuroses), and the Anxiety States (or anxiety neuroses). The 
classifications permissible under each category are given in Table 1.1. 
Table 1.1. Anxiety Disorders: Diagnostic and Statistical Manual of Mental Disorders, American 
Psychiatric Association 
DSM III (1980) 
ANXIETY DISORDERS 
Phobic Disorders 
(or Phobic Neuroses) 
DSM III-R (1987) 
ANXIETY DISORDERS 
(OR ANXIETY AND PHOBIC 
NEUROSES 
Agoraphobia with panic attacks Panic Disorder 
Agoraphobia without panic Panic Disorder With 
attacks Agoraphobia 
DSM IV (1994) 
ANXIETY DISORDERS 
Panic Disorder Without 
Agoraphobia 
Panic Disorder With 
Agoraphobia 
8 
Social phobia Agoraphobia Without History of Agoraphobia Without History of 
Panic Disorder Panic Disorder 
Simple phobia 
Social Phobia Specific Phobia 
Anxiety State 
(or Anxiety Neuroses) Simple Phobia Social Phobia 
Panic Disorder Obsessive-Compulsive Disorder Obsessive-Compulsive Disorder 
Generalised Anxiety Disorder Post-Traumatic Stress Disorder Post-Traumatic Stress Disorder 
Obsessive-Compulsive Disorder Generalised Anxiety Disorder Acute Stress Disorder 
(or Obsessive-Compulsive 
Neurosis) 
Post-Traumatic Stress Disorder 
Atypical Anxiety Disorder 
Anxiety Disorder Not 
Otherwise Specified 
Generalised Anxiety Disorder 
Anxiety Disorder Due to 
General 
Medical Condition/Substance 
Abuse 
Anxiety Disorder Not 
Otherwise Specified 
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Panic Disorder was recognised as a discrete psychiatric entity for the fist time in 
DSM III. A panic attack was defined as an episode of sudden onset intense 
apprehension, fear or terror occurring in circumstances other than during marked 
physical exertion or in a life-threatening situation. The attacks should not be 
precipitated only by exposure to a circumscribed phobic stimulus. A panic attack 
comprised at least four of a list of twelve physical symptoms namely, dyspnoea, 
palpitations, chest pain or discomfort, choking sensations, dizziness, unreality 
feelings, tingling in hands and feet, hot and cold flushes, and trembling and shaking. 
F or a classification of panic disorder at least three attacks must have occurred within 
a three week period. Agoraphobia was regarded as one of the Phobic Disorders and 
classified separately, although the relevance of panic attacks to agoraphobic 
avoidance was recognised in the sub-categorisation of agoraphobia as either with or 
without panic attacks. 
It was recognised after the introduction ofDSM III that there were some 
difficulties and ambiguities with the system. Thus ongoing discussion led to the 
publication of the revised version, DSM III-R in 1987. The first striking difference in 
DSM III-R was the abolition of the separate categories of phobic disorders and 
anxiety states with all the anxiety disorders both phobic and non-phobic being 
classified under the heading of Anxiety Disorders. Clinical observations led to several 
important revisions in the classification of panic disorder. By this time it had become 
apparent that most cases of clinical agoraphobia developed secondary to panic 
attacks and rarely otherwise. These observations suggested that agoraphobia did not 
constitute a distinct syndrome in it's own right and was better seen as a consequence 
of the core disorder of panic attacks. Thus in DSM III-R agoraphobia was classified 
as secondary to panics in the classification of Panic Disorder With Agoraphobia, 
whereas those patients displaying no agoraphobic avoidance would be classified as 
Panic Disorder Without Agoraphobia. DSM III-R retained the category of 
Agoraphobia Without History of Panic Disorder but this was expected to be seldom 
used. The classification of panic attacks was also revised in DSM III-R to 
accommodate more recent observations. Firstly, the list of twelve symptoms was 
expanded to thirteen by the separation of fear of dying and fear of going crazy or 
doing something uncontrolled. These latter two symptoms were recognition of the 
Chapter 1 10 
psychological element of panic attacks and the fact that the majority of patients 
expressed specific catastrophic fears as to the consequences of their panic attacks. A 
panic attack was again arbitrarily defined as comprising at least four of the thirteen 
symptoms and sudden onset was specified in DSM III-R as rising to a peak within 10 
minutes of onset. DSM III-R also permitted a new classification for those panics 
which comprised less than the required four symptoms. These were defined as 
Limited Symptom Attacks and were suggested to be in all respects less severe than 
full-blown panic attacks of four symptoms or more. The actual classification of Panic 
Disorder was expanded in DSM III-R, again to accommodate a psychological 
perspective. A frequency criterion was retained in that four panic attacks occurring 
within a four week period would permit a classification of panic disorder. An 
additional or alternative criterion was added, however, in that a classification of 
panic disorder was also permitted if one or more panic attacks was followed by at 
least one month of persistent fear of subsequent attacks. Thus the psychological 
criterion of fear of panic attacks became an important part of the diagnosis which 
had previously, (in DSM III), been conceptualised in purely physical terms. 
Subsequent research and discussion has ratified this expansion to include 
psychological factors. The concept of persistent anxiety about bodily sensations 
related to panic has been variously termed, anxious apprehension (Barlow 1988), 
fear offear (Goldstein & Chambless 1978) and anxiety sensitivity (Reiss & McNally 
1985). Instruments designed to measure this construct (Chambless et al 1984, 
McNally & Lorenz 1987) have confirmed it as a hallmark of panic disorder to the 
extent that elevated anxiety sensitivity secondary to unexpected panic attacks is what 
distinguishes panic disorder from other anxiety disorders in which panic attacks 
occasionally occur (Taylor et al 1992). DSM III-R also introduced a rating of 
severity of panic attacks where "mild" was defined as, all attacks during the past 
month have been limited symptom attacks, or only one panic attack has occurred, 
"moderate" meant during the past month attacks have been intermediate between 
mild and severe, and "severe" meant that during the past month there have been at 
least eight panic attacks. These criteria of severity are essentially arbitrary and 
require empirical validation. 
The criteria for agoraphobia in DSM III-R firmly defined this avoidance as 
secondary to panic attacks in that agoraphobia was classified as ''fear of being in 
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places or situations from which escape might be difficult (or embarrassing) or in 
which help might not be available in the event ofa panic attack" (DSM III-R 1987, 
p238). Severity of agoraphobia was also possible again on an essentially arbitrary 
scale ranging from "in remission" through "in partial remission" "mild", "moderate" 
to "severe". The main points of change in DSM III-R as compared to DSM III are 
that the classification of a panic attack was no longer based on solely physical 
symptoms with the inclusion of psychological symptoms in the list of thirteen 
symptoms. Agoraphobia was recognised as likely to occur secondary to panic 
disorder and was thus relegated to the status of a secondary qualification of a 
classification of panic disorder. Lastly, in recognition of the importance of 
psychological factors, particularly anxiety sensitivity or fear of fear in the 
development of panic disorder, the addition of the criterion of one month of 
continuous fear of recurrence following a single panic attack as an alternative to the 
frequency criterion of four panic attacks in the past four weeks was introduced. 
As testament to the pace at which research proceeds in the area of panic, work on 
the fourth revision of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM IV 1994) began only one year after the publication ofDSM Ill-R. The fourth 
revision was strongly influenced by Barlow (1988) who reported that panic attacks 
occurred across the full range of anxiety disorders. Thus in DSM IV panic attacks 
are defined separately from panic disorder and the classification of both has been 
clarified. The classification of a panic attack is the same as that in DSM III-R, 
namely four symptoms from the list of thirteen with a rise time within 10 minutes of 
onset. DSM IV further distinguishes between unexpected (uncued panic) attacks, 
situationally bound (cued) panic attacks, and situationally predisposed panic attacks. 
Unexpected panic attacks occur classically "out of the blue" and are not associated 
with any situational trigger. Although unexpected attacks are central to the diagnosis 
of panic disorder they do occur in other anxiety disorders (McNally 1994). 
Situationally bound attacks occur almost invariably and immediately on exposure to a 
situational trigger, and are characteristic of specific and social phobias. Situationally 
predisposed attacks have an increased probability of occurring on exposure to a 
trigger situation but do not invariably occur. They are typical in panic disorder with 
agoraphobia but can also occur in specific and social phobia (McNally 1994). The 
classification of panic disorder has also been revised and now requires both a 
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frequency criterion (repeated panic attacks), and the fear of recurrence of panic 
attacks criterion this being clarified as either, persistent concern about having further 
attacks, worry about the consequences of attacks, or a significant change in 
behaviour related to the attacks (DSM IV 1994). Thus in contrast to DSM III-R, 
under DSM IV a patient cannot qualify for a classification of panic disorder merely 
by experiencing a single panic attack followed by a persistent fear of subsequent 
attacks, or merely by experiencing repeated attacks without developing a fear of 
panic. Both aspects of the disorder are required under DSM IV. The classification of 
agoraphobia in DSM IV remains essentially unchanged from DSM III-R although the 
rating of severity has been dropped, as has that for panic disorder. 
The studies to be presented in this thesis were all conducted before the 
introduction ofDSM IV and thus used the definitions outlined in DSM Ill-R. The 
implications that any differences between the DSM III-R and DSM IV systems have 
for these studies will be discussed in Chapter 8. 
1.4 Definition 
The DSM III-R definition of panic disorder both with and without agoraphobia is 
given below. 
1. Diagnostic Criteria for Panic Disorder 
A. At some time during the disturbance, one or more panic attacks (discrete periods 
of intense fear or discomfort) have occurred that were (1) unexpected, i.e., did not 
always occur immediately before or on exposure to a situation that always caused 
anxiety, and (2) not triggered by situations in which the person was the focus of 
other's attention. 
B. Either four attacks as defined in criterion A, have occurred within a four week 
period, or one or more attacks have been followed by a period of at least a month of 
persistent fear of having another attack. 
C. At least four of the following symptoms developed during at least one of the 
attacks: 
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(1) shortness of breath (dyspnoea) or smothering sensations 
(2) dizziness, unsteady feelings, or faintness 
(3) palpitations or accelerated heart rate (tachycardia) 
(4) trembling or shaking 
(5) sweating 
(6) choking 
(7) nausea or abdominal distress 
(8) depersonalisation or derealisation 
(9) numbness or tingling sensations (parasthesias) 
(10) flushes (hot flashes) or chills 
(11) chest pain or discomfort 
(12) fear of dying 
(13) fear of going crazy or of doing something uncontrolled 
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Attacks involving four or more symptoms are panic attacks; attacks involving fewer 
than four symptoms are limited symptom attacks. 
D. During at least some of the attacks, at least four of the C symptoms developed 
suddenly and increased in intensity within ten minutes of the beginning of the first C 
symptoms noticed in the attack. 
E. It cannot be established that an organic factor initiated and maintained the 
disturbance, e.g., Amphetamine or Caffeine intoxication, hyperthyroidism. 
2. Diagnostic Criteria for Panic Disorder With Agoraphobia 
A. Meets the criteria for Panic Disorder as defined in section 1. above. 
B. Agoraphobia: Fear of being in places or situations from which escape might be 
difficult (or embarrassing) or in which help might not be available in the event of a 
panic attack (includes cases in which persistent avoidance behaviour originated 
during an active phase of Panic Disorder, even if the person does not attribute the 
avoidance behaviour to fear of having a panic attack.) As a result of this fear, the 
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person either restricts travel or needs a companion when away from home, or else 
endures agoraphobic situations despite intense anxiety. Common agoraphobic 
situations include being outside the home alone, being in a crowd or standing in a 
line, being on a bridge, and travelling in a bus, train or car. 
3. Diagnostic Criteria for Panic Disorder Without Agoraphobia 
A. Meets the criteria for Panic Disorder as defined in section 1. above. 
B. Absence of Agoraphobia as defined in 2. above. 
1.5 Differential Diagnosis 
14 
The Diagnostic and Statistical Manual of Mental Disorders was constructed to 
facilitate the separation of the anxiety disorders by listing criteria on which they can 
be differentiated. The underlying assumption is, of course, that such a differentiation 
is possible and is scientifically valid. Aronson (1987a) suggests that the anxiety 
disorders may not be as separable as the DSM system implies, and questions whether 
panic disorder can be viewed as a distinct diagnostic entity. Tyrer (1989) also argues 
that the anxiety disorders are most usefully classified under one diagnostic grouping, 
which he terms the "general neurotic syndrome". Thus whilst the DSM classification 
seeks that which is unique to each anxiety disorder, others such as Tyrer look to the 
commonalties that are shared amongst the disorders. Both positions find support in a 
recent factor analytic study (Zinbarg & Barlow 1996), which analysed data from self-
report questionnaires completed by 423 patients with anxiety disorders and 32 non-
patient controls. Questionnaires were chosen to cover a broad range of symptom 
presentation across differing DSM III-R anxiety disorders. Factor analysis revealed a 
higher order general factor common to all the anxiety disorders that differentiated the 
patient groups from the non-patient controls. Zinbarg & Barlow described this factor 
as "negative affectivity", arguing that a dispositional tendency towards experiencing 
negative affective states underlay all of the DSM III-R anxiety disorders. Several 
lower order factors provided the basis for differentiating amongst the individual 
anxiety disorders, as did a number of factors derived from a discriminant function 
analysis. This most recent work suggests that there are both commonalities and 
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unique properties for each anxiety disorder. Attention must still be paid to the 
boundaries of the classification of panic disorder. There has been considerable debate 
as to whether panic disorder is a separate diagnostic entity or whether it is better 
regarded simply as a more intense form of generalised anxiety. This debate often 
confounds two different questions. Firstly, can a panic attack be differentiated from 
anxiety, or is it simply a more intense form of the same emotion, and secondly, can 
panic disorder be differentiated from generalised anxiety disorder or is the level of 
diagnostic overlap such that they are best regarded as different facets of the same 
disorder? For panic disorder to be a separate diagnostic entity it is important to show 
not only that the central symptom complex, the panic attack, can be differentiated 
from other forms of anxiety, but also that the syndrome itself can be distinguished 
from other anxiety disorders. 
In discussing the clarity of panic disorder as a diagnosis, Tyrer confidently asserts 
that " .... there is no doubting the clarity and reliability of its main feature, the panic 
attack" (Tyrer 1989 p25). For this certainty to be justified the defining features of a 
panic attack should be readily observable. A panic attack should therefor be 
distinguishable from anxiety by being, of sudden onset, involving notable 
physiological arousal and being characterised by feelings of fear and impending 
catastrophe. Several lines of evidence justify this distinction. Regarding abruptness of 
onset, Argyle & Roth (1989a, 1989b) found, in a study of 90 patients with panic 
disorder, that episodes of severe anxiety with gradual onset were not associated with 
fears of dying or going crazy, nor were they associated with as many symptoms as 
were episodes of anxiety with a rapid onset, i.e. panic attacks. Evidence for increased 
physiological arousal in panic attacks as compared to anxiety is found in prospective 
studies employing physiological measurement. Taylor et al (1986) had panic patients 
record both anticipatory anxiety and panic over a 6 day period. They found that in 
periods of intense anticipatory anxiety heart rate remained relatively stable, and 
importantly was significantly lower than heart rate recorded during panic attacks. 
Heart rate averaged 89.2 BPM during anticipatory anxiety and 108.2 BPM during 
panic attacks, despite patients' subjective ratings of intensity of the two types of 
anxiety being virtually identical. In a similar design Freedman et al (1985) measured 
heart rate during self-reported panic attacks and also during "control periods" where 
anxiety was rated as equally intense but was not labelled as panic. Abrupt heart rate 
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increases occurred during the panic episodes but not during the control periods, 
again indicating the suddenness of onset and characteristic physiological arousal 
attributed to panic attacks. This abruptness of onset is not consistent with the notion 
that panic is continuous with lower levels of anxiety and simply a more intense form 
of them. Were this the case, panic attacks would be expected to occur following a 
period of build up of, or at least the presence of, underlying anxiety. The finding that 
panic attacks can occur during periods of relaxation and even during sleep (i.e. 
relaxation induced panic, Adler et al 1987), indicates that panic attacks can occur 
discontinuous with anxiety state (Uhde & Mellman 1987). Investigations of patterns 
of appraisal and cognitive content also reveal differences between anxiety and panic. 
Both Hibbert (1984) and Rapee (1985) observed more intense cognitions focusing 
on physiological, psychological or social disaster in panic patients than in patients 
without panic. Rapee et al (1992) studied 90 patients with panic disorder (DSM III-
R) who also had an additional diagnosis of either simple or social phobia and 
compared cognitive content during panic attacks with that during anxiety 
experienced during exposure to feared objects or situations. They found that fears of 
dying and fears of going crazylloosing control were more frequently experienced 
during panic attacks than during phobic anxiety. This pattern of catastrophic 
cognition in panic patients finds further elaboration in the Cognitive Model of panic 
(Clark 1986, 1988, Beck & Emery 1985, Beck 1988). Some caution is warranted in 
interpreting these findings. As Barlow (1988) points out, such differences in 
cognitive style may be epiphenominal, reflecting defining characteristics of patients 
faIling into the category of panic disorder rather than something fundamental about 
panic itself 
The evidence above indicates, at least tentatively, that panic is separable from 
anxiety. What of the distinction of the clinical syndromes, is panic disorder distinct 
from generalised anxiety disorder? Again several lines of evidence would suggest this 
to be the case. As previously mentioned the contemporary distinction between panic 
disorder and generalised anxiety disorder is based on the differentiation of symptom 
presentation (Roth 1960) and also on the distinction in response to pharmacological 
treatment, or pharmacological dissection, proposed by Klein (e.g. Klein 1981). 
Several more recent discussions (Barlow 1988, McNally 1994) have questioned the 
theoretical and clinical validity of the concept of pharmacological dissection. The 
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notion of difference in symptom presentation is however supported in studies that 
compared panic disorder with generalised anxiety disorder patients on a range of 
symptom measures. Several studies indicated that panic disorder patients reported a 
greater somatic component in symptoms than generalised anxiety disorder patients 
did (Hoehn-Saric 1982, Barlow et al1984, Anderson et al1984, Rapee 1985). This 
difference was restricted to somatic symptoms, however, with reports of psychic or 
cognitive symptoms of anxiety being similar across both patient groups (Barlow et al 
1984, Anderson et al 1984, Rapee 1985, Noyes et al 1992). This finding is 
interesting in that panic disorder patients evidently do not score higher than 
generalised anxiety disorder patients on scales of general anxiety as might be the case 
if panic disorder were simply a more intense form of"'generalised anxiety disorder. 
Panic disorder patients do score higher than generalised anxiety disorder patients on 
measures of anxiety sensitivity such as the Anxiety Sensitivity Index (ASI, Reiss et al 
1986). Thus although both disorders experience anxiety symptoms, only the panic 
disorder patients show a marked fear of and sensitivity to these symptoms leading 
McNally (1992) to suggest that this validates the distinction between panic disorder 
and generalised anxiety disorder. Other research has indicated that panic disorder 
patients report a greater incidence of negative affect such as depression and 
irritability (Hoehn-Saric 1982) and a greater incidence of major depressive episodes 
prior to the onset of their anxiety disorder (Raskin et al 1982), than do generalised 
anxiety disorder patients. Genetic and family aggregation studies also indicate 
differences that are consistent with the separation of the disorders. Panic disorder 
and panic attacks have been shown to aggregate in families (Crowe et al1983, 
Crowe 1990) whereas such aggregation has not been consistently found for 
generalised anxiety disorder (Noyes et al 1992). Of the twin studies which have been 
published the first, Torgefflen(1983) found that monozygotic (MZ) twins had a rate 
ofDSM III panic disorder and agoraphobia with panic attacks five times that for 
dizygotic (DZ) twins. In the same study, there was no significant MZ vs. DZ 
difference found for generalised anxiety disorder. These results have been taken as 
indicative ofa specific genetic linkage for PD but not for GAD (Weissman 1990). 
Results from more recent twin studies suggest the difference is less clear cut. Further 
twin studies have indicated increased MZ vs. DZ rates ofDSM III-R panic disorder 
of similar magnitude to the original Torgersen study (Kendler et al 1993, Skre et al 
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1993). For generalised anxiety disorder, a recent Australian study using DSM III 
criteria found an increased MZ vs. DZ concordance rate (Andrews et al 1990). 
Although this difference failed to reach statistical significance it was taken as an 
indication of a possible genetic component to generalised anxiety disorder. In a more 
detailed analysis ofDSM III-R generalised anxiety disorder in women Kendler et al 
(1992) also found an increased MZ vs. DZ concordance rate which was greatly 
reduced when generalised anxiety disorder cases with concomitant depression were 
excluded. This led others (Skre et al1993) to argue that concomitant mood disorders 
are a major influence on twin concordance rates for generalised anxiety disorder. 
Genetic and family aggregation data would seem to suggest that there is reasonably 
strong evidence for genetic linkage in panic disorder whereas the case is more 
equivocal for generalised anxiety disorder. The limitations of these twin studies must 
also be borne in mind when considering their results. Samples were small and 
subjects were rarely assessed blindly for zygosity, diagnosis, or probands' diagnosis. 
Overall there is sufficient evidence to suggest that the separation of panic disorder 
from generalised anxiety disorder has some basis and this supports the distinction 
made in the DSM classification systems. 
1.6 Prevalence 
Whilst definition of disorder and method of survey will inevitably affect prevalence, 
panic disorder whether with or without agoraphobia, is regarded as a clinically 
prevalent condition. Psychiatric disorders have only relatively recently become the 
subject of epidemiological enquiry with the absence of explicit diagnostic criteria and 
the lack of any reliable means of establishing caseness restricting investigations. The 
establishment of diagnostic criteria in DSM III and the incorporation of such criteria 
into protocols such as the National Institute of Mental Health (NIMH) Diagnostic 
Interview Schedule (DIS, Robbins et al 1981) made epidemiological enquiry 
possible. The largest and most ambitious investigation of the prevalence of mental 
disorders undertaken to date is the Epidemiological Catchment Area survey (ECA). 
The DIS was developed for the ECA study and was administered by lay interviewers 
to a probability sample ofn=18,000 adults drawn from five communities in the 
United States. The ECA study indicated lifetime prevalence rates for DSM III panic 
disorder of 2.1 % for women and 1.0% for men giving a combined lifetime prevalence 
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of 1.7%. Panic disorder was most common amongst subjects aged 30-44 years, and 
least common among subjects who were over 65 years. Subjects with panic disorder 
were found to seek the help of mental health professionals more than subjects with 
any other mental health disorder (Weissman 1985, Robins & Regier 1991). These 
relatively low prevalence estimates for panic disorder lead Eaton et al (1991) to 
conclude that "Panic disorder is not very prevalent in the population " (Eaton et al 
1991, p159). The ECAdiagnoses were made using DSM ill under which panic 
disorder and agoraphobia with panic attacks were classified as separate disorders. 
Agoraphobia shows much higher prevalence rates in the ECA survey with lifetime 
rates of7.7% for women and 2.9% for men (Robins & Regier 1991). There is 
considerable dispute however over the reliability and accuracy of the ECA 
classifications of agoraphobia both with and without panic attacks (McNally 1994). 
Indeed in a reanalysis of some of the ECA samples Howarth et al (1993) found 
examples of misclassifications among the phobic disorders leading to grossly inflated 
estimates for agoraphobia without panic attacks and possibly low estimates for 
agoraphobia with panic attacks. Others have also disagreed with Eaton et ai's (1991) 
characterisation of panic disorder as an uncommon condition. Katon et al (1987) 
suggested that the DIS had high specificity but low sensitivity and thus failed to pick 
up many cases of panic disorder due to the way the panic disorder target question 
was phrased. Subjects were asked "have you ever had a spell or attack when all of a 
sudden you felt frightened, anxious or very uneasy in situations when most people 
would not be afraid?" (Robins & Regier 1991, p408). Katon et al (1987) observed 
that since panic disorder patients fear the symptoms of the panic attacks themselves 
and not the situations in which they occur, many panic patients might respond to this 
question in the negative on the grounds that anyone who felt like they did in such 
situations would feel frightened too. Thus the DIS may underestimate the prevalence 
of panic disorder. Subsequent studies using DSM criteria but different interview 
schedules to establish caseness have found higher prevalence rates for panic disorder. 
In a study employing DSM ill criteria and a DIS modified in the light of the above 
discussion Katon (1986) quote a lifetime prevalence rate of6.7% in a sample ofn= 
195 adults screened in a primary care practice. In a study employing DSM III-R 
criteria established via the Structured Clinical Interview for DSM III-R (SCID, 
Spitzer et al1988) Katemdahl & Realini (1993) evaluated a sample of 1,306 
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residents of San Antonio Texas, finding lifetime prevalence estimates of panic 
disorder of 4.1 % for women and 1.5% for men with a combined rate of 3 .8%. 
Katerndahl & Realini (1993) explained their lifetime prevalence rate of nearly double 
the ECA figure as arising due to the more sensitive SCID detecting more genuine 
cases of panic disorder than the relatively insensitive DIS. The DIS is also reportedly 
notably less reliable than other interview schedules (McNally 1994). Reliability 
studies using the DIS have yielded kappa values of between .40 (Robbins et al1981) 
to -.20 (Anthoney et al 1985) for panic disorder. These reliability estimates compare 
very unfavourably with studies using either the Anxiety Disorders Interview 
Schedule (ADIS-R, DiNardo & Barlow 1988) and DSM III-R criteria which yielded 
a kappa of .75 for panic disorder with or without agoraphobia (DiNardo et alI993), 
or those using the Structural Clinical Interview for DSM III-R (SCID, Williams et al 
1992a) which yielded kappas of .87 and .73 for panic disorder with and without 
agoraphobia respectively (Williams et al 1992b). The data does suggest, however, 
that panic disorder both with and without agoraphobia can be reliably diagnosed. 
1.7 Antecedents and Consequences 
Having discussed the classification, syndromal validity and estimated prevalence of 
panic disorder with and without agoraphobia, attention now turns to broader issues 
related to it's clinical presentation including the possible consequences of the 
disorder for sufferers. Panic disorder might be described as a disorder of early 
adulthood. In the ECA study, panic disorder had a mean age of onset of 24 years 
(Burke et al 1990). Agoraphobia has also been reported to have a similar mean age 
of onset in earlier studies (Burns & Thorpe 1977, Marks & Herst 1970). The lifetime 
prevalence for panic disorder in the ECA study was twice as high for women as for 
men (Eaton et alI991), as was that in the Katerndahl & Realini (1993) study. 
Reviewing recent studies Clum & Knowles (1991) found that women constituted 
59% of cases ofDSM III-R panic disorder without agoraphobia and 89% of cases of 
panic disorder with agoraphobia. Comparisons of male and female panic disorder 
patients have, however, revealed no differences in phobic severity, assertiveness, 
neuroticism, extraversion (Mavissakalian 1985), panic frequency (Chambless & 
Mason 1986), panic severity, trait anxiety, age of onset, and duration of illness (Oei 
et al 1990). Chambless & Mason (1986) did find that both male and female 
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agoraphobics scored below population norms for their respective gender on scales of 
masculine gender-role behaviour, leading to the speculation that cultural or other 
factors which discourage masculine methods of coping with panic may predispose 
towards the development of agoraphobic avoidance. Many factors have been 
suggested as possible precipitants for the onset of panic disorder particularly 
negative life events. Barlow notes that "a remarkably consistent observation of 
biological and psychological clinicians and investigators has been the evidence of 
negative life events preceding the first panic attack in patients who later present with 
panic disorder and agoraphobia." (Barlow 1988, p215). This suggestion of panic 
disorder arising during stress resulting from negative life events has great face 
validity for the practising clinician and is consistent with the findings of generalised 
anxiety preceding the emergence of panic (Fava et al 1988, 1992, Garvey et al 1988) 
and uncontrolled investigations of life events in panic disorder patients (Lteif & 
Mavissakalian 1995). Controlled studies also support the position. In an early study, 
Roth (1959) found that a sample ofn= 135 agoraphobics reported significantly more 
stressful events prior to the onset of their agoraphobia than did a control group of 
patients with "other neurotic disorders". Similarly F aravelli & Pallanti (1989) 
reported that panic patients experienced more serious negative life events in the year 
prior to the onset of their panic disorder than did a group of age-sex matched healthy 
controls. Other studies suggest it is not the increased occurrence of negative life 
events per se which is important, but the way in which such events are perceived. In 
two studies (Roy-Byrne et al 1986, Rapee et al 1990) panic patients reported no 
more life events during an equivalent time frame than did control groups of other 
anxiety disorders and healthy subjects. The panic patients in both studies rated the 
life events as more distressing, uncontrollable and undesirable and having a more 
negative impact on their lives than did subjects in the control groups. Thus the 
perceived negative impact of life events may be at least as important as their 
frequency. Accurately assessing the aetiological significance oflife events is difficult. 
The fact that such events occur prior to the onset of panic disorder and are often 
perceived by patients as being salient does not establish a causal role for them. 
Stressful life events would nonetheless seem to have a potential role in the 
precipitation of panic disorder. Researchers have also uncovered a host of other 
factors that may influence the occurrence of panic disorder or exacerbate an existing 
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disorder. The list of possible factors ranges from withdrawal from alcohol (Kushner 
et al 1990) or nicotine (Brodsky 1985), use of both illegal drugs and over-the-
counter proprietary cold medications containing pseudoepinephrine (Roy-Byrne & 
Uhde 1988), to anxiety provoking visual stimuli such as fluorescent strip-lighting 
(Watts & Wilkins 1989). In contradiction to early studies, recent research has 
confirmed a pattern of pre-menstrual exacerbation of panic symptoms with a 
prospective self-report study of 24 female panickers finding a 100% increase in panic 
attack frequency premenstrually (Kaspi et alI994). The research discussed so far 
implicates a wide variety of factors in the precipitation of panic disorder. It is 
perhaps surprising then that the first panic attack occurs so often in situations typical 
of the panic-agoraphobic symptom complex, that is in crowded public places or in 
restricted or enclosed situations often distant from the patients home (Barlow 1988, 
Lelliot et a11989, Faravelli et alI992). Some have attempted to explain the 
preponderance of "agoraphobic" situations among first panic attacks. Principal 
amongst these is Nesse (Nesse 1984, 1987,1988) who argues for an evolutionary 
perspective in which agoraphobic situations can be viewed as prepared fears. In early 
hominid societies situations which involved being in enclosed spaces or exposed in 
open ground, being far from home territory or amongst strangers or any of these in 
the absence of a trusted companion would represent a significant threat to well-
being. Thus it would be advantageous to respond readily with anxiety to such 
situations. Nesse (1987) further suggests a threshold model for the triggering of 
panic attacks suggesting that this threshold is lowered in vulnerable individuals under 
pressure, who then respond with a panic attack when in an agoraphobic triggering 
situation. If this first panic attack is responded to with fear the cycle of anxiety 
sensitivity is set in train and the panic disorder characterised by repeated panic 
attacks develops (Barlow 1988). This interesting speculation receives some support 
from a study which suggest that panic attacks do operate as initiating traumatic 
stressors (McNally & Lukach 1992), and from a study which found that 71 % of a 
sample of 57 patients with panic disorder with agoraphobia reported fleeing 
immediately on experiencing their first panic attack (Lelliot et al 1989). Nesse's 
evolutionary model has also been adopted as a useful explanatory construct in 
psychological treatment packages (Shear et al 1994). 
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Explanations for precipitation and onset aside there is little doubt that once 
established panic disorder is a distressing and disruptive condition that leads to 
sufferers making heavy demands on treatment services and resources. Regarding 
service usage, Uhlenhuth et al (1983) in a symptom checklist survey conducted on a 
general population and relating symptom grouping to psychotherapeutic drug use, 
found that the group defined as the "panic-agoraphobia complex" used more and a 
wider range of psychotropic medications than any other diagnosis. Using samples 
from the ECA study data (Robbins & Reiger 1991), others (Boyd 1986, Klerman et 
al 1991) have also shown that panic disorder patients are heavy users of ambulatory 
mental health and general healthcare facilities. In the only such study conducted on a 
UK sample Simpson et al (1994) compared a sample of 100 DSM III-R panic 
disorder with and without agoraphobia patients with 100 age sex matched controls 
from the same general practice lists on a range of indices of service usage, reported 
symptoms and diagnosed major and minor illnesses. This study found that panic 
patients had significantly higher surgery attendance rates, secondary referrals, clinical 
tests and investigations, and prescriptions for psychotropic and non-psychotropic 
medications than did the controls. There were no differences between the patients 
and controls in rates of major illnesses but significant difference in minor illnesses 
particularly respiratory, genitor-urinary and cardio-vascular minor illnesses. The 
clinical perception of panic disorder patients as frequent clinic or surgery attenders 
who receive repeated clinical investigations and frequent medication is supported by 
the findings of these studies. Panic disorder also impacts on individuals health and 
treatment service usage in other ways being associated with increased risk for other 
anxiety disorders and for depression (Wittchen & Essau 1993), for alcohol abuse 
(George et al 1990) and increased risk of suicide attempt (Johnson et al 1990, Noyes 
et a11991a, Lepine et a11993) although in the latter case debate continues as to the 
significance of co-morbid diagnoses to this increased risk (Hornig & McNally 1995). 
The relevance of panic disorder to general health is also suggested by two studies 
which have found reduced immune system function (Ramesh et al 1991) and 
increased allergenic sensitivity and allergic response (Schmidt-Traub & Bamler 1997) 
in panic disorder patients as compared to controls. If even only a proportion of these 
suggested risks consequent on a diagnosis of panic disorder are accurate, given the 
prevalence rates suggested for panic disorder earlier, it represents a significant drain 
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on healthcare resources. This is especially so given that in the absence of treatment 
panic disorder is argued to have a chronic or at best fluctuating course with few 
cases of genuine full remission (Wittchen & Essau 1993, Otto & Whittal 1995). 
Furthermore panic disorder has been found to present predominantly in the primary 
care setting (Ashcroft et al 1987, Katemdahl & Realini 1995) where resources 
available to tackle the disorder are limited. It is in this context that treatments for the 
disorder must be considered. 
1.8 Treatment 
The clinical prevalence, distressing nature and clinical consequences of a 
classification of panic disorder lend considerable impetus to the search for adequate 
treatments for the disorder. It is not surprising therefor that the past three decades 
have seen a proliferation in the number of treatment outcome studies published on 
panic disorder. This comparatively large literature demarcates along professional 
lines, with pharmacological treatments advocated by psychiatry/pharmacology and 
psychological treatments championed by psychologists. This has led some to 
characterise the resulting discussion as " .. a partisan debate among various interest 
groups who have become zealous in their advocacy of their preferred treatment 
models" (Jacobson & Hollon 1996 p74). It is the intention in this section to briefly 
review the findings of the treatment outcome literature for both pharmacological and 
psychological treatments for panic disorder. 
1.8.1 Pharmacological Treatments 
Drug treatments have influenced the nosology of panic disorder and are arguably the 
most commonly used treatment for the disorder. A wide variety of drugs have been 
advocated and investigated as potential treatments for panic. The following 
discussion will focus on the most common of these. 
1.8. 1.1 The Tricyclic Antidepressants 
The most commonly studied drug in the treatment of panic disorder is the tricyclic 
antidepressant imipramine. This was the drug used in the groundbreaking early work 
of Klein (Klein & Fink 1962, Klein 1964). In subsequent placebo controlled studies 
(Zitrin et al 1980, 1983), imipramine proved superior to placebo on global measures 
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of improvement and on retrospective ratings of panic attacks. Importantly, in these 
early controlled studies, imipramine was usually given in combination with 
psychological treatments, either exposure in vivo or supportive psychotherapy. The 
finding of superiority of imipramine over placebo when given in combination with 
psychological treatments was replicated in the work of Mavis sakal ian and colleagues 
(Mavissakalian et al 1983, Mavissakalian & Michelson 1986). Others have failed to 
replicate this finding. In a four-way double-placebo comparison of imipramine plus 
exposure, imipramine plus relaxation training, placebo plus exposure, and placebo 
plus relaxation training, Marks et al (1983) found no difference between imipramine 
and placebo. A subsequent reanalysis of this data (Raskin 1990) did however suggest 
that imipramine was superior to placebo on ratings of anticipatory anxiety and 
retrospective ratings of panic attacks. A later study which incorporated the 
prospective monitoring of panic attacks in a three group comparison of imipramine 
plus exposure, placebo plus exposure and imipramine plus anti-exposure (TeIch et al 
1985), found no significant between-group differences in frequency of panic attacks 
at end-point (8 week) analysis. Within-group comparisons revealed a significant 
reduction in panic attacks for the imipramine plus exposure group only. As a result 
of these findings some (McNally 1994) have suggested that imipramine may reduce 
panic attacks only in the presence of exposure treatments. This is reinforced by a 
placebo controlled study where imipramine was given in the absence of psychological 
treatments. Evans et al (1986) compared imipramine, placebo and the novel 
serotonin re-uptake inhibitor zimelidine. Rating scales for general anxiety, 
agoraphobic avoidance and depression suggested the superiority of zimelidine over 
both imipramine and placebo, there being no statistically significant differences 
between imipramine and placebo. This study was an early indication of the relevance 
of serotonin specific drugs to the treatment of panic disorder. Zimelidine was, 
unfortunately, taken off the market due to an apparent increased risk for Guillian-
Barre Syndrome. In summary, most studies have shown that imipramine benefits 
panic disorder and agoraphobia at least when given in combination with exposure 
treatments. There are several suggested hypotheses for the effectiveness of 
imipramine. The original hypothesis, the basis of Klein's pharmacological dissection, 
is that imipramine blocks panic attacks and affects secondary avoidance only through 
this mechanism. Some studies support this assertion (Klein et al 1987) while others 
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(TeIch et al1985) do not. Others (Marks et al1983) have suggested that imipramine 
exerts it's effect through it s antidepressant action with any benefits to panic and 
agoraphobia being secondary to this. Research evidence does not support this case 
with patients showing benefit with imipramine even when they exhibit few symptoms 
of depression (Clum & Pendrey 1987). A further hypothesis is that imipramine exerts 
an effect through the reduction of anticipatory anxiety characteristic of panic 
disorder patients (Barlow 1988). In support of this hypothesis Kahn et al (1986), 
found that imipramine benefited patients with GAD, suggesting that the drug 
attenuated the somatic symptoms underlying both panic attacks and anticipatory 
anxiety. As McNally (1994) points out, this is in keeping with the effect of 
imipramine on the supposed noradrenergic dysfunction underlying both forms of 
anxiety. This is in direct contradiction to the original view of imipramine as the panic 
specific drug implicated in Klein's pharmacological dissection. 
Other tricyclic drugs have also shown efficacy when used in the treatment of 
panic disorder. Clomipramine, a tricyclic antidepressant that blocks the reuptake of 
serotonin as well as noradrenaline, has shown superior efficacy when compared to 
placebo (Johnson et a11988, Modigh et al1992) and imipramine (Modigh et al 
1992). These findings led Modigh et al (1992) to suggest that serotonergic drugs 
may have a more potent anti-panic action than noradrenergic drugs. Others (Fahy et 
al 1992) have found that the superiority of clomipramine over placebo is reduced 
when both are combined with behaviour therapy. 
1.8.1.2 Monoamine Oxidase Inhibitors 
The second class of antidepressant drugs investigated for panic disorder is the 
monoamine oxidase inhibitors (MAOI). These drugs inhibit the action of the enzyme 
monoamine oxidase which deactivates monoamines such as serotonin, noradrenaline, 
dopamine and tyramine, thus increasing the availability of these monoamines in the 
central nervous system. The little research available on these drugs is equivocal with 
one study employing the MAOI phenelzine (Tyrer et al1973) finding no advantage 
over placebo, whilst a later study (Sheehan et al 1980), found an advantage over 
placebo and imipramine for phenelzine. It is impossible to judge the anti-panic 
efficacy of phenelzine as neither of these studies incorporated any measures of panic 
attacks. This lack of controlled evidence combined with the danger of potentially 
Chapter 1 27 
fatal hypertensive crises if certain foodstuffs are ingested have limited the usefulness 
and use of the MAOIs in the treatment of panic disorder. 
1.8.1.3 Benzodiazepines 
Benzodiazepines have been shown to have efficacy in the treatment of panic 
disorder. The most widely studied benzodiazepine is the high potency 
triazolobenzodiazepine, alprazolam. The efficacy of alprazolam was investigated in 
the largest pharmacological treatment outcome study in panic disorder conducted to 
date. The Cross-National Collaborative Panic Study (Klerman 1988) was a multi-
centre study conducted in two phases. The first phase established the superiority of 
alprazolam over placebo on measures of spontaneous and situational panic, 
anticipatory anxiety, and phobic avoidance. In this study 59% and 32% of the 
alprazolam and placebo groups were panic free at treatment end-point (Ballenger et 
al 1988). Phase two of the study involved a multi-centre three-way comparison of 
alprazolam, imipramine and placebo which again revealed a superiority of active drug 
over placebo but few significant differences between the active drugs alprazolam and 
imipramine (Cross National Collaborative Panic Study 1992). Others (Marks et al 
1989) have questioned the validity of the drug-placebo difference found for 
alprazolam suggesting that this difference existed early in treatment only and that if 
the trial were continued long enough the drug-placebo difference would disappear as 
the placebo group began to improve. Marks et al (1993) also failed two replicate the 
alprazolam placebo difference in a four group double-placebo design employing 
alprazolam plus exposure, alprazolam plus relaxation training, placebo plus exposure, 
and placebo plus relaxation training. Further difficulties with alprazolam arise when 
the drug is discontinued. In the Cross National Collaborative Panic Study fully 82% 
of patients given alprazolam relapsed on withdrawal of the drug (Pecknold et al 
1988). In a similar withdrawal study Rickels et al (1993) found that 63% of their 
sample suffered a marked withdrawal syndrome lasting around three weeks, whilst 
52% of their alprazolam patients suffered a rebound in panic frequency which 
exceeded baseline levels. Similar discontinuation problems were reported by Noyes 
et al (1991 b), while Otto et al (1993) found that the addition of cognitive behavioural 
therapy facilitated the discontinuation of alprazolam. Thus despite it's initial promise, 
the discontinuation problems with alprazolam limit its clinical usefulness. 
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Other lower potency benzodiazepines have also shown efficacy for panic disorder 
ifused in high doses. Three placebo controlled trials (Hafuer & Marks 1976, Noyes 
et al 1984, Dunner et al 1986) have shown a statistical superiority over placebo for 
diazepam, whilst a similar result was obtained for the newer high potency 
benzodiazepine clonazepam (Tesar et alI991). This evidence of efficacy is not 
matched by investigations of discontinuation effects however, and, given the findings 
for alprazolam caution would be advised. 
1.8.1.4 Beta-Adrenergic Blockers 
Beta-blockers counteract the peripheral effects of the sympathetic nervous system 
and thus reduce symptoms such as sweating, trembling and tachycardia. Thus these 
drugs have considerable intuitive appeal as a treatment for panic disorder. This 
appeal is not matched by research findings. There is limited controlled research on 
the drug but that which exists is not supportive. Noyes et al (1984) found 
propranolol ineffective against panic, a result supported by a later study (Munjack et 
al 1989) comparing propranolol, alprazolam and placebo. Despite one early study 
(Kathol et al 1980) which did find drug-placebo differences the consensus is that ''the 
outlook for the use of beta-blockers in the treatment of panic is bleak" (Barlow 1988 
p442). 
1.8.1.5 Selective Serotonin Reuptake Inhibitors 
In support of the suggestion (Modigh et al 1992) made earlier (section 1.8. 1. I.) 
regarding drugs affecting the serotonin systems, recent evidence has suggested 
considerable efficacy for relatively new group of drugs. These antidepressant drugs, 
known as the selective serotonin reuptake inhibitors (SSRI), selectively block the 
reuptake of serotonin at the synapse thus increasing the availability of this 
neurotransmitter. In an uncontrolled open label study Gorman et al (1987) found the 
drug fluoxetine to be an effective anti-panic agent with 7 out of 16 patients studied 
becoming panic free at treatment end-point. Oehrberg et al (1995) also found the 
SSRI paroxetine superior to placebo on a range of panic related measures. Both 
paroxetine and placebo were given with cognitive behaviour therapy in this study. 
Most research on the SSRIs has been conducted using the drug fluvoxamine. Studies 
have shown fluvoxamine to be superior to placebo (Den Boer et a11987, Den Boer 
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& Westenberg 1988, 1990, Hoehn-Saric et al1993, Black et al1993a, De Beurs et 
al 1995), the specific noradrenaline reuptake inhibitor maprotalin (Den Boer & 
Westenberg 1988), the serotonin antagonist ritanserin (Den Boer & Westenberg 
1990), and brief cognitive therapy (Black et al 1993a). Fluvoxamine was also found 
to be of equivalent potency to clomipramine (Den Boer et al 1987). In a controlled 
comparison of fluvoxamine plus exposure, placebo plus exposure, panic management 
plus exposure, and exposure alone, De Beurs et al (1995) found the combination 
treatment of fluvoxamine plus exposure to be more effective than the other three 
treatment groups. These findings for fluvoxamine have led some to suggest that 
" ... fluvoxamine warrants further investigation as an especially promising antipanic 
agent" (McNally 1994 p103). This enthusiasm may be further encouraged by the 
single study to date investigating discontinuation effects with fluvoxamine. Black et 
al (1 993b ) studied the patients treated in their outcome study (Black et al 1993a) 
following a further 8 months of additional treatment. They identified a mild 
withdrawal syndrome characterised by dizziness, nausea, headaches and irritability. 
Only one patient in their sample experienced a return of panic. These initial results 
suggest an impressive lack of withdrawal and rebound effects associated with the 
discontinuation of fluvoxamine, but require replication before firm conclusions can 
be drawn. 
1.8.1.6 Other Drugs 
The search for effective anti panic agents has also included studies on other drugs less 
obviously related to panic disorder, usually with limited or negative findings. Thus 
the non-benzodiazepine anti-convulsants carbamazepine (Uhde et al 1988) and 
valproate (Keck et al1993) were found to be of limited value in the treatment of 
panic disorder. A similar result was obtained in a study of the non-benzodiazepine 
anxiolytic buspirone (Robinson et al 1989). 
1.8.2 Psychological Treatments 
Psychological treatments have a 30 year history as treatments for anxiety disorders 
(McNally 1994). Psychological treatments targeted at panic attacks are more recent. 
The concept of panic attacks arose within the biological tradition, as did the notion 
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of specific panic focused treatment by drugs. Most early studies of behavioural 
treatments did not distinguish panic from other forms of anxiety either conceptually 
or operationally in clinical assessment. Most of these studies investigated behavioural 
treatments or agoraphobia, presumably in many cases with associated panic attacks. 
The effect of these treatments specifically on panic attacks is unknown as panic was 
not operationalised or measured. 
1.8.2.1 Early Treatments 
Early treatment techniques were based on laboratory findings from conditioned fear 
experiments usually conducted on animal analogues. Wolpe (1958) found that cats 
lost their conditioned fear of specific stimuli if they were fed in settings increasingly 
similar to the initial conditioning situation. Wolpe interpreted this finding as 
indicating that the stronger feeding response had inhibited the fear response and 
termed this action "reciprocal inhibition" (Wolpe 1958). Employing the principle of 
reciprocal inhibition in the treatment of fears that were presumed to be acquired via 
conditioning Wolpe developed the treatment technique systematic desensitisation. 
This involved the repeated pairing of the fear stimulus with fear inhibiting responses, 
usually progressive muscle relaxation. A hierarchy of stimulus situations was first 
confronted in imagination with the later transfer of practice to real life situations. 
Early treatment outcome studies with agoraphobic patients produced equivocal 
results with improvements after 16-20 sessions being limited at best (Gelder & 
Marks 1966, Gelder et al 1967). These limited gains following considerable clinical 
input prompted a search for faster and more effective treatments. Stampfl & Levis 
(1967) developed their "implosion therapy" as a theoretical and clinical alternative. 
Based on Mowrer's (1939) two-factor conditioning theory of fear and avoidance 
where classically acquired fears were maintained and reinforced by avoidance 
operants, Stampfl & Levis (1967) argued that neurotic symptoms could be 
eliminated by the extinction of the conditioned fear that motivated the avoidance, this 
being best achieved by maximal exposure to the feared stimulus. Thus the treatment 
technique of flooding developed. This was principally conducted in imagination and 
required the patient to maximise their fear by imagining extremely frightening scenes 
until their discomfort and anxiety diminished. Claims for the effectiveness of imaginal 
flooding led to its use with agoraphobics. In a cross-over design employing imaginal 
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flooding or imaginal desensitisation with agoraphobic and specific phobic patients, 
Marks et al (1971) found that, although overall treatment effects were not large, 
flooding was more effective than desensitisation for the agoraphobics, leading the 
authors to conclude that the relaxation and graduated exposure central to the 
systematic desensitisation treatment are unnecessary in the treatment of agoraphobia. 
A subsequent study (Stem & Marks 1973) suggested that real-life or in vivo, 
exposure was more effective than imaginal, and that massed rather than sporadic 
practice was most effective. These basic principals of massed practice of in vivo 
exposure, remain the foundation of behavioural treatments for agoraphobia to date. 
This exposure was conducted with the therapist present throughout. 
1.8.2.2 Exposure Based Treatments 
Despite some early contradictory findings of equivalence between imaginal and in 
vivo exposure from the Oxford research group (Gelder et al 1973, Mathews et al 
1976), the vast bulk of experimental evidence indicates a degree of efficacy for 
treatments for agoraphobia based on the principal of repeated prolonged exposure to 
the feared stimulus situations (Jansson & Ost 1982, Jacobson et al 1988). This 
efficacy is maintained in long term follow up studies conducted over 4-7 years post 
treatment (Emmelkamp & Kuipers 1979, McPherson et a11980, Munby & Johnson 
1980). In vivo exposure continues to date to form the basis of much of the 
psychological treatment offered for agoraphobia (and by this fact, panic attacks) 
(Marks 1987). There has been some debate over the finer details of the conduct of 
the exposure, with some suggesting that practice can be either massed or spaced by 
individual preference (Chambless 1990), whilst others argue that the diminution of 
anxiety during exposure sessions is not a hard and fast requirement of adequate 
treatment (Rachman et al 1986). Nonetheless the basic treatment principal of 
exposure to real life feared object or situation endures. The requirement that 
exposure be conducted with the therapist present during sessions led Marks (1987) 
to suggest that exposure is "boring, time-consuming and expensive" (Marks 1987 
p466). More recent work indicated that the presence of the therapist during sessions 
i.e. therapist accompanied exposure was indeed a cumbersome and unnecessary 
procedure, and that patients could construct and conduct their own exposure 
programmes. This idea forms the basis of the programmed practice self-exposure 
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treatments developed by Mathews and colleagues (Mathews et al 1981). This 
represented a significant advance in treatment delivery where patients conducted 
their own exposure sessions with possible support from spouse or partner, thus little 
therapist time was required. Exposure treatments have limitations however mainly in 
that gains can be limited and drop out rates high (Clum 1989), this leading Jacobson 
et al (1988) in their review to conclude that "exposure alone does not seem to be a 
total solution to the problem of agoraphobia" (Jacobson et al 1988 p552). 
1.8.2.3 Treatments Adjunctive to Exposure 
The acceptance of the limitations of exposure based treatments led on to a search for 
adjunctive treatment techniques that might enhance efficacy. Some groups suggested 
that spouse involvement in exposure treatments may be useful, although findings are 
equivocal with some supportive (Barlow et a11984) whilst others found no 
advantage to spouse involvement (Cobb et al 1984). Other research stemmed from a 
conceptualisation of agoraphobia as a tripartite syndrome encompassing disturbances 
in behavioural, cognitive, and physiological systems. As traditional exposure 
treatments had emphasised the behavioural expression of the disorder, additional 
treatments that targeted the other systems were investigated. In a series of three 
studies Emmelkamp and colleagues investigated the effects of adding cognitive 
procedures to exposure in vivo (Emmelkamp et al 1978, 1986, Emmelkamp & 
Mersch 1982). In these studies Rational-emotive therapy RET (Ellis 1962) and self-
instructional training SIT (Meichenbaum 1977) were used. These treatments (RET, 
SIT), attempt to identify and replace maladaptive inner monologues with coping self-
statements and to identify and change the irrational assumptions presumed to 
underlie the phobic behaviour. In these early studies the addition of these particular 
cognitive techniques did not significantly enhance the effects of exposure in vivo. 
Williams & Rapopport (1983) also compared exposure in vivo with exposure in vivo 
plus SIT for a group of agoraphobics with specific fears of driving. Again they found 
that for this rather restricted group, both groups improved significantly on self-rated 
anxiety with there being no advantage gained with the addition of SIT to exposure in 
vivo. Two later studies (Marchione et al1987, Michelson et al1988) compared the 
relative and combined efficacies of therapist assisted graduated exposure, relaxation 
training, and cognitive therapy. All subjects also received instruction in programmed 
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practice self-exposure. Again these studies provide little evidence that adjunctive 
treatments such as relaxation or cognitive techniques increase the effectiveness of 
exposure whether therapist assisted or self-directed exposure. Modem proponents of 
cognitive therapy dismiss these early studies suggesting that the cognitive therapies 
employed were " ... contrived and restricted variants of cognitive therapy procedures 
which bear little resemblance to the actual practice of cognitive therapy" (Clark & 
Beck 1988 p382). 
1.8.2.4 Cognitive Behaviour Therapy for Panic 
It appears that the noteworthy but limited gains achieved by exposure in vivo are not 
significantly enhanced by additional procedures. It has been suggested (Barlow 1988, 
McNally 1994) that both situations, the limited exposure gains and the 
ineffectiveness of adjunctive treatments, may be due to the fact that none of these 
treatment techniques directly target panic attacks. Indeed the early studies failed to 
measure panic at all. This is perhaps surprising given that the relevance of panic 
attacks to treatment outcome was recognised very early in the development of 
psychological treatments for agoraphobia. Gelder & Marks (1966) observed that 
exposure based treatment gains could be undone by a single panic attack and argued 
that "unless behaviour therapy can treat these apparently unexplained panic attacks 
little progress will be made" (Gelder & Marks 1966 p317). It has taken some 
considerable time for clinical psychology to live up to this prescient challenge, but it 
has recently done so with the development of cognitive and cognitive-behavioural 
treatments targeted specifically on panic attacks. These cognitive behaviour therapies 
developed in a number of centres from a variety of theoretical foundations, but share 
many overlapping features (Margraf et al 1993). As previously for therapies 
adjunctive to exposure the targets of cognitive behaviour therapy can be 
conceptualised as the disturbances to the cognitive, behavioural, and physiological 
systems caused this time by panic attacks. Thus comprehensive cognitive behaviour 
therapies such as Clark and Beck's Cognitive Therapy (Beck 1988, Clark 1988) or 
Barlow's Panic Control Treatment (Barlow & Cerny 1988) will include techniques 
designed to address disturbances in each of these systems. Taking each in tum, the 
classic cognitive model of panic (Clark 1986, 1988, Beck 1988) argues that panic 
attacks result from the catastrophic misinterpretation of bodily sensations, usually 
Chapter 1 34 
those of anxiety. Thus the panic patient in a stressful situation will become mildly 
anxious, will identify the normal physiological arousal attendant on such anxiety but 
crucially will misinterpret this as being much more dangerous than it truly is, this 
causing more anxiety, further misinterpretation and so on. The cognitive model of 
panic further asserts that panic patients have an enduring tendency to misinterpret 
physical sensations in a catastrophic manner. This makes them acutely sensitive to 
any untoward or unexpected physiological arousal and vulnerable to further panic 
attacks. Treatments based on this model emphasise the identification and alteration 
of maladaptive catastrophic cognitions through Socratic discussion and also 
behavioural experiments. The latter usually take place in vivo and involve the 
attempted alteration of panic and anxiety driven thoughts and actions in anxiety 
provoking situations. The treatment therefor includes a large exposure based 
element. Patterns of misinterpretation can also be altered by the provision of accurate 
educational information on panic attacks. Indeed some have argued that this 
educational component of treatment is a crucial active ingredient in treatment (Shear 
et al 1994). 
Behavioural components of treatment have included classic in vivo exposure for 
patients with obvious agoraphobic avoidance. This technique is not useful for 
patients with little or no agoraphobic avoidance where there are no avoided 
situations to form the basis of an exposure programme. Recognising that it is the 
sensations of panic as much as the situations in which they occur that patients 
attempt to avoid, Barlow and colleagues developed the concept of interoceptive 
exposure (Barlow 1988, Barlow & Cerny 1988). Interoceptive exposure consists of 
exposing the patient to the physical sensations of panic attacks either by their 
experiencing real panic attacks or by simulating the sensations via techniques such as 
chair spinning, vigorous exercise, straw breathing and so forth. During the 
interoceptive exposure the patient will be instructed not to avoid or attempt to 
ameliorate the sensations they experience. There are several suggested mechanisms 
for the effectiveness of interoceptive exposure, from a conditioning based extinction 
procedure through a cognitive explanation that the exposure to the sensations 
disconfirms patients catastrophic cognitions to a more behaviourally based 
explanation advanced by Barlow (Barlow 1988, Zinbarg et alI992). Barlow (1988) 
argues that although anxiety and panic have traditionally been viewed as emotions 
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comprising characteristic patterns of physiological arousal and subjective cognitions, 
emotion theorists (Izard & Blumberg 1985, Izard 1993, Lang 1985, 1988) have long 
recognised that emotions are primarily action tendencies. Thus the avoidance 
behaviours and safety behaviours (Salkovskis et al 1996) characteristic of panic 
patients are not seen as a response to the panic attack but as a defining and central 
feature of it. Barlow (1988) further argues that action tendencies are one of the 
essential targets of change in the treatment of panic attacks and that" the crucial 
function of exposure (both in vivo and interoceptive), instead of facilitating 
extinction, is to prevent the action tendencies associated with fear and anxiety" 
(Barlow 1988 p311 parentheses added). Thus the potent ingredient in exposure is the 
alteration of what patients actually do rather than what they think. There have been 
as yet no controlled experimental investigations of this difference in emphasis from 
the classic cognitive model of panic. 
Techniques focusing on the reduction of physiological arousal have also been 
developed and deployed in cognitive behavioural treatments for panic disorder. 
Recognising the limitations of traditional relaxation training Ost (1988) developed 
Applied Relaxation as a more potent alternative. Patients first learn progressive 
relaxation skills and then apply these in vivo in real anxiogenic situations in an 
attempt to prevent their anxiety spiralling into panic. This has been found to be an 
effective treatment technique that again includes the essential elements of in vivo 
practice and alteration of anxiety driven response. The other arousal reduction 
technique commonly employed in cognitive behavioural treatments is breathing 
retraining. This technique derived from the suggestion that panic attacks arise from a 
habit of chronic hyperventilation and are the physiological result of changes in 
pressure of carbon dioxide (pC02) in blood. A treatment technique known as 
respiratory control (Clark et al 1985) was developed. This involved the deliberate 
provocation of symptoms via voluntary hyperventilation, discussion of the similarity 
between these sensations and those experienced during panic attacks and attribution 
of the panic symptoms to overbreathing, and finally, and importantly, training in 
controlled breathing techniques. Uncontrolled studies have suggested the efficacy of 
breathing control techniques (Clark et al 1985, Salkovskis et al 1986) but there is 
considerable controversy as to the accuracy of the underlying model and the 
suggested link between panic attacks and changes in pC02. Garssen and colleagues 
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(Garssen et al 1992) in a critical review of the area found little evidence which 
supported a true hyperventilation model of panic and characterised breathing 
retraining as a "rational placebo" which exerts a therapeutic effect due to distraction 
effects and the provision of a sense of control rather than correction of 
hyperventilation induced decreases in pC02. Most cognitive or cognitive 
behavioural therapies will employ at least some of the treatment techniques outlined 
above. These packages have proved highly effective in clinical use with reviews 
(McNally 1990, Chambless & Gillis 1993, Margrafet al1993, Gould et al1995) 
reporting substantial proportions of patients free of panic attacks post treatment and 
impressive reductions in generalised anxiety and avoidance. 
1.8.3 Comparative Outcome Studies 
The foregoing discussion has outlined the parallel development of pharmacological 
and psychological treatments for panic disorder. These developments have occurred 
for the most part separately with more rivalry than co-operation between the 
competing schools. This is also reflected in reviews of treatment outcome studies of 
either pharmacological or psychological treatments. Reviews are often conducted on 
only pharmacological (Judd et al 1990, Lydiard et al 1996), or only psychological 
(McNally 1990, Brown & Schulberg 1995) treatments, by practitioners of those 
treatments. It is not surprising that these reviews generally produce positive 
endorsements for the treatment type studied. 
Some theorists have advocated combined pharmacological and psychological 
treatments (TeIch 1988, TeIch & Lucas 1994), and thus the consideration of relative 
efficacy inevitably arises. Given an extensive literature of variable quality on both the 
pharmacological and psychological treatment of panic disorder, the intending 
reviewer is faced with a daunting task. Comparisons between studies must be made 
not only both within the pharmacological and psychological treatment domains, but 
also between these two differing treatment types. Such comparisons may be difficult 
due to variations in basic study methodology such as differences in sample selection, 
outcome variables, control groups, and response rates. Despite these difficulties 
Clum (1989) undertook a comparative review of treatment efficacy of 
pharmacological and psychological treatments. This large scale review estimated the 
relative efficacies of pharmacological and psychological treatments on the basis of 
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three criteria; drop-out rates, treatment outcome rates, and relapse rates. Results 
from this review were complex but some general conclusions were drawn. Firstly, 
patients with panic disorder with agoraphobia showed poorer outcome than those 
with panic disorder without agoraphobia. Secondly, drop out rates were higher for 
the pharmacological interventions, especially antidepressants than for psychological 
treatments. Thirdly psychological treatments and high potency benzodiazepines 
showed the best outcomes, and lastly, psychological treatments had the lowest 
relapse rates. Considering all of these criteria Clum (1989) concluded that 
psychological treatments were superior to pharmacological treatments for panic 
disorder. These important findings should be considered with some caution however 
(Clum et al 1993). The review did not employ any method of weighting studies in the 
consideration of their outcome results. Thus, studies of vastly differing scientific 
rigour were afforded equal consideration in the review. It is clear that some method 
of facilitating the review and assessment of the literature on pharmacological and 
psychological treatments for panic disorder is required. 
1.8.3.1. Meta Analysis 
Meta analysis is the main method that has been employed to make sense of the large 
and variable treatment outcome literature for panic disorder. These techniques score 
over traditional reviews in that they yield standardised scores (known as effect sizes) 
for each treatment, facilitating comparisons between studies employing differing 
methodologies. Effect sizes can be calculated as either within treatment effect sizes 
(a), or between treatment effect sizes (b). Both are outlined below. 
(a) Within Treatment Effect Size Xp - Xpt 
SDp 
Xp = pre-treatment group mean 
Xpt = post-treatment group mean 
SOp = pre-treatment standard 
deviation 
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(b) Between Treatment Effect Size Xt - Xc 
SDc 
Xt = post-treatment index 
group mean 
Xc = post treatment control 
group mean 
SDc = post treatment control 
group standard deviation 
Other methods for the calculation of effect sizes using either the t or F statistic can 
also be employed for those studies where insufficient information is provided to 
permit the usual effect size calculations. 
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Five reviews of the panic disorder literature have employed meta-analytic 
procedures. Two of these reviewed only either pharmacological (Wilkinson et al 
1991) or psychological (Chambless & Gillis 1993) treatments, and thus contribute 
little further to the important debate on the relative efficacy of these two treatment 
types. The other three reviews (Clum et al 1993, Gould et a11995, Van Balkom et al 
1995) assessed the relative efficacy of both pharmacological and psychological 
treatments and are therefor of considerable relevance to the current discussion. The 
first major meta-analytic review (Clum et al1993) was designed and conducted 
specifically to overcome the problems noted with Clum's earlier non meta-analytic 
review (Clum 1989). The review examined 29 studies published between January 
1964 and January 1990 which had a valid control group and could thus be subjected 
to meta analysis. Results from Clum et al's analysis suggested that the greatest 
efficacy was associated with cognitive panic management treatments and exposure 
based treatments, followed by the combination of exposure based treatments plus 
medication, antidepressant medications and finally high potency benzodiazepines and 
other medications. Clum et al (1993) also examined other variables that were 
hypothesised to affect the effect size of interventions, presence of agoraphobia, 
duration of the disorder, type of control group, and type of outcome variable 
examined. Presence of agoraphobia and duration of disorder were not significantly 
related to outcome. Treatment effects were evident across a range of outcome 
variables in both pharmacological and psychological treatments. Regarding type of 
control group, the use of exposure as a control comparison was associated with 
smaller effect size than were comparisons with other controls such as drug placebo, 
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psychological placebo (e.g. therapist contact), or relaxation groups. This is entirely in 
keeping with the finding already discussed that exposure functions as an effective 
treatment in its own right. Clum et al's (1993) review was unable to comment on the 
more recently developed cognitive behavioural treatments published since January 
1990, or the recent studies on the SSRI antidepressants, or indeed on studies 
investigating their combined use. In an attempt to update the findings of Clum et al 
(1993), Gould et al (1995) conducted a further meta analysis on an expanded and 
updated sample of 43 studies of pharmacological, psychological or combined 
treatment outcome published between 1974 and March 1994. Effect sizes were 
averaged across treatment types. This meta analysis yielded the highest mean effect 
sizes for cognitive behavioural treatments (ES = 0.68) relative to pharmacological 
treatments (ES = 0.47) and combination treatments (ES = 0.56). Within cognitive 
behavioural treatments, studies that combined cognitive restructuring with 
interoceptive exposure yielded the strongest effect size (ES = 0.88). For 
pharmacological treatments, there was no significant difference between 
antidepressants (ES = 0.55) and benzodiazepines (ES = 0.40). Cognitive behavioural 
treatments also showed the smallest attrition rates compared to pharmacological and 
combined treatments. This appears at face value to be a resounding endorsement of 
psychological treatments for panic disorder, particularly cognitive behaviour therapy 
including cognitive restructuring and interoceptive exposure. Whilst Gould et al 
(1995) suggest that their meta analytic method provides a viable method '10 
adequately assess the relative effectiveness of pharmacotherapy, cognitive 
behavioural and combination treatments" (Gould et al 1995 p823), they nonetheless 
counsel some caution in the interpretation of their findings. Firstly they note that very 
few studies have investigated the efficacy of treatments combining medications with 
the new generation of potent cognitive behaviour therapies, and in addition they 
were unable to include in their analysis any of the recent studies on the SSRI 
antidepressants although they acknowledge the emerging consensus in 
psychopharmacology recognising the SSRIs as the pharmacological treatment of 
choice for panic disorder. The third meta analytic review (Van Balkom et al 1995) 
was conducted on 25 studies comparing pharmacological and psychological 
treatments for panic disorder published between 1964 and 1993. This review 
analysed a smaller sample of studies than the Gould et al (1995) review, as only 
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studies including within study comparisons of pharmacological and psychological 
treatments were included. This was reasoned to be a more controlled comparison 
than those made between studies in the other meta analyses. Van Balkom et aI 
(1995) reached similar conclusions to the previous reviews regarding the 
comparative efficacies of pharmacological and psychological treatments for panic 
disorder and agoraphobia. Whilst Van Balkom et ai's (1995) method ofutiIising only 
within study comparisons is a more controlled methodology than previous studies 
there are still problems with it. These more broad-based criticisms apply to the meta 
analytic method in general. There is a consistent difference between pharmacological 
and psychological studies in the choice of control groups against which target 
treatments are compared. Pharmacological studies tend to use drug placebo control 
groups whereas psychological studies have tended to use no treatment or waiting list 
controls. There is an obvious difference in the potential therapeutic potency of these 
two control groups that will tend to favour psychological treatments. That is, it is 
potentially easier for a psychological treatment to ''beat'' a no treatment control than 
it is for a pharmacological treatment to show efficacy against a drug placebo group. 
Thus the comparisons within a meta analysis may not be evenly weighted. 
Furthermore as it is the outcome data from each individual study which forms the 
basis of the meta analysis the claim that meta analysis permits the researcher to rise 
above the mundane consideration of individual study methodology is perhaps 
overstated. The position is exemplified by Gould et aI who state "our conclusions are 
necessarily specific to the conditions under which well controlled studies are 
conducted ......... Nonetheless we see no compelling evidence to lead us to doubt the 
validity of the results obtained in this meta analysis." (Gould et al 1995 p840). A 
cogent example of an area where concern and doubt remain is that relating to 
treatment outcome results for psychological treatments used alone. Outcome effect 
sizes are quoted for psychological treatments used alone, yet in many outcome 
studies of psychological treatments patients continued to take concurrent 
psychotropic medications (power & Sharp 1995). In Gould et ai's (1995) meta 
analysis, for example, of a total of 19 studies investigating psychological treatments 
supposedly used alone, only 5 studies required patients to discontinue concurrent 
psychotropic medications for the duration of the study. This represents a major 
confound in the data from such studies and the meta analyses derived from this data 
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are similarly suspect. This is only one example of potential methodological 
shortcomings in treatment outcome research, both pharmacological and 
psychological. A more fruitful approach to rectifYing such methodological problems 
may be to attempt to irradicate them at source rather than compensate for them later. 
In other words whilst a useful indicative tool, meta analysis is no substitute for 
adequate study design in the first place. For any researcher wishing to compare 
pharmacological with psychological treatments for panic disorder, the most useful 
initial route to take would be to do so within the framework of a coherent single 
study design ensuring that such a design rectifies any inadequacies in previous study 
design. Given that the meta analytic studies discussed here were unable to comment 
on the relative efficacies of the currently recommended pharmacological and 
psychological treatments for panic disorder and agoraphobia, namely the SSRI 
antidepressants and the newer cognitive behaviour therapies, this would seem a 
reasonable place to start. A useful next step would therefor be a controlled 
comparison of the relative and combined efficacies of these two treatments. If such a 
study is to attempt to rectifY some of the methodological problems of previous 
treatment outcome research, the first requirement will be a substantial consideration 
of treatment outcome methodology, its problems and potential solutions to them. 
This forms the basis of Chapter 2 of this thesis. 
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2.1 Introduction 
Panic disorder with or without agoraphobia is a prevalent and clinically demanding 
condition, with efficacy claimed for both pharmacological and psychological 
treatments (Wolfe & Maser 1994). Treatment outcome studies have been conducted 
by either pharmacologically or psychologically oriented researchers with study 
designs and subsequent conclusions often reflecting the allegiances of the researchers 
(Kendal & Lipmann 1991). The overall impression in this area remains one of 
confusion and conflict as to preferred treatment, resulting in considerable debate 
over methodology and study design. The debate has touched on specific issues such 
as concomitant treatments (Power & Sharp 1995, Otto et aI1996), and on the 
broader issue of methodology in studies assessing the relative and combined merits 
of pharmacological and psychological treatments (Jacobson & Hollon 1996, Klein 
1996). Other researchers have attempted to circumvent the problems of differing 
study designs by employing review techniques such as meta analysis (Gould et al 
1995). These meta analytic techniques, based on calculations of effect sizes, are 
useful indications of relative treatment efficacy when reviewing results from varying 
study designs. They are not, however, a replacement for adequate study design in the 
first place, and if study design is flawed, the results from any meta analysis are 
compromised. 
Study design is not only defined, and indeed constrained, by the conflicting 
demands of partisan researchers, but also more importantly by its ultimate task of 
informing clinical practice. There is little point in constructing an elegant study 
encompassing the most sensitive of scientific controls if the treatments employed, or 
populations studied become so restricted that they are no longer representative of 
wider clinical practice. Any study of either the relative or combined efficacies of 
pharmacological or psychological treatments must therefor attempt to balance and 
reconcile the demands and methodologies of both approaches. Furthermore, the 
study design must also be as representative as possible of wider clinical practice if 
results are to be of any practical value. Given the difficulty of this task it is no 
surprise that previous methodologies have been found wanting, to the extent that 
some have decried research in the area as " .... a waste of time and money, .... " (Klein 
1996 p86). 
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The aim in this chapter is to review the methodologies of treatment outcome 
studies in panic disorder and agoraphobia, covering firstly psychological treatments, 
and secondly studies where psychological treatments were compared and/or 
combined with pharmacological treatments. The review aims to highlight the main 
areas where the competing demands of research design and clinical applicability lead 
to dilemmas for the researcher. Attempts to overcome these dilemmas will be 
described and alternative solutions suggested where appropriate. Given the nature of 
the task the review will be illustrative rather than exhaustive, aiming to produce a set 
of compromises in research design for use in future treatment outcome studies. 
Particular emphasis will be given to the design of studies comparing the relative and 
combined efficacies of both pharmacological and psychological treatments. 
For psychological treatments, literature search revealed 41 studies published since 
1980 that investigated the treatment efficacy of one or more psychological 
treatments. Of the 41 studies 5 were reanalyses of previous studies or specific 
analyses of previous studies not directly related to treatment outcome. This review is 
therefor based upon the 36 core studies of this set listed in Table 2.1 (studies are 
subsequently referred to in text by number as illustrated in Table 2.1). 
For studies investigating pharmacological vs. psychological treatments, literature 
search revealed 24 studies published since 1980 that compared the efficacies of drug 
and psychological treatments employed either as individual or combined treatments. 
Of these 24 studies, 4 were reanalyses of previous studies, or continued analyses of 
expanded data sets. This review is therefor based upon the 20 core studies of this set 
which are enumerated and listed in Table 2.2 (studies are subsequently referred to in 
text by number as illustrated in Table 2.2). 
Table 2.1 Psychological Treatment Studies Included In Review 
AUTHORS TREATMENT STUDY SETTING OUTCOME 
COMPARISONS N = REFERRAL SOURCE 
I. Benjamin & Kincey BT =9 Hospital In-Patients 
(1982) Referral source-Unkn ----. 
2. Chambless et al FL =8 Hospital clinic FL > FL + Brev + ReI 
(1982) FL+Brev =7 Self referred 
ReI =6 
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3. EmmeIkamp & Exp -9 Hospital clinic Exp=Exp+CT>CT 
Mersch (1982) CT =9 Referral source-Unkn 
Exp+CT =9 
4. EmmeIkamp et al Exp =7 Hospital clinic AT +Exp= Exp> AT 
(1983) AT =7 Referral source- Unkn 
AT+Exp =7 
5. Mavissakalian et al SST+PP = 12 Hospital clinic SST + PP = PI + PP 
(1983) PI+PP = 12 Referral source- Unkn 
6. Williams & Exp =10 University clinic Exp=Exp+CT 
Rappoport (1983) Exp+CT =10 Self referred via advert 
7. Waddell et al (1984) WL- CT- Rei + CT University clinic 
=3 Referral source- Unkn -------
8. Ost et al (1984) Exp =20 Hospital clinic Exp=AR 
AR =20 Medical referral 
9. Alstrom et al (1984) Inf= PP = 19 University clinic Inf + PP = Inf + Exp = 
Inf+ Exp =11 Psychiatric referral Inf + Pther = Inf + Rei 
Inf= Pther = 14 
Inf+ Rei = 17 
10. Gittlin et al (1985) BT =11 Hospital clinic 
Referral source- Unkn -------
11. Clark et al (1985) BRT = 18 Hospital clinic 
Psychiatrist and GP -------
referral 
12. Michelson et al PI+PP =10 Hospital clinic Exp+ PP> Rei + PP 
(1985) Exp+PP =11 Referral source- Unkn >PI +PP 
Rei +PP = 10 
13. Burns et al (1986) Exp =20 Hospital clinic 
Referral source- Unkn ------
14. Himadi et al (1986) CT + PP + Spouse =28 University clinic CT + PP + Spouse = 
CT+PP = 14 Referral source- Unkn CT+PP 
15. Marchione et al CT+Exp+PP= Hospital clinic CT + Exp + PP = Rei + 
(1987) Unkn Referral source- Unkn Exp + PP > Exp + PP 
ReI + Exp + PP= Unkn 
Exp+PP =Unkn 
Total n = 14 
16. Ost et al (1988) ReI =8 Hospital clinic AR>Rel 
AR =8 Psychiatrist and GP 
referral 
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17. Craske et al (1989) CT + PP + Spouse University clinic 
=22 Referral source- Unkn 
---
18. Williams & Zane GM = 15 University clinic GM>Exp>WL 
(1989) Exp =11 GP Referred and self 
WL =6 referred via advert 
19. Sokol et al (1989) CT = 17 Hospital clinic 
Self referred 
---
20. Barlow et al (1989) Exp+CT = 15 University clinic Exp+ CT=Exp+ CT 
ReI =10 Psychiatrist and self +ReI>Rel>WL 
Exp+ CT + ReI =16 referred 
WL = 15 
21. Michelson et al CBT =10 University clinic 
(1990) Referral source- Unkn ------
22. Welkowitz et al CBT = 19 Hospital clinic 
(1991) Referral source- Unkn ----
23. Shear et al (1991) CBT = 23 Hospital clinic 
Referral source- Unkn -------
24. Salkovskis et al CT =7 Hospital clinic 
(1991) Psychiatrist and GP -------
referral 
25. Beck et al (1992) CT = 17 University clinic CT> Pther 
Pther = 16 Referral source- Unkn 
26. Ost et al (1993) AR = 15 Hospital clinic Exp= AR> CT 
CT = 15 Referral source- Unkn 
Exp = 15 
27. TeIch et al (1993) CT = 34 University clinic CT>WL 
WL = 33 Physician Psychiatrist 
and self referred 
28. Shear et al (1994) CBT =24 University clinic CBT=NP 
NP = 21 Referral source- Unkn 
29. Beck et al (1994) CT = 17 University clinic CT + ReI >MCC 
ReI = 19 Self referred via advert 
MCC =22 
30. Lidren et al (1994) CBT = 12 University clinic CBT=Bib> WL 
Bib = 12 Physician referred and 
WL = 12 self referred via advert 
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31. Cote e al (1994) CBT =10 University clinic CBT=RCCBT 
RCCBT =11 Psychiatrist GP and 
self referral 
32. Craske et al (1995) CBT = 16 University clinic CBT> NOT 
NOT =13 Self referred via advert 
33. Williams & Falbo CBT = 14 University clinic CBT = GM = CBT = 
(1996) GM = 12 Self referred via advert GM>WL 
CBT+GM = 13 
WL =9 
34. Bouchard et al Exp = 14 University clinic Exp= CT 
(1996) CT = 14 Psychiatrist GP and 
self referred 
35. Arntz & Van Den CT = 18 University clinic CT>AR>WL 
Hout (1996) AR = 18 Psychiatrist referred 
WL = 18 
36. Hecker et al (1996) CBT =5 University clinic CBT= SGCBT 
SGCBT =8 Physician Psychiatrist 
and self referred 
KEY: Unkn = unknown, Brev = Brevltal, BT = BehaVIOur Therapy, FL = Flooding, ReI = 
Relaxation, Exp = Therapist Guided Exposure, CT = Cognitive Therapy, CBT = Cognitive 
Behaviour Therapy, AT = Assertiveness Training, SST = Self Statement Training, PP = 
Programmed Practice Self Directed Exposure, PI = Paradoxical Intention, WL = Waiting List 
Control, AR = Applied Relaxation, Inf = Information, Pther = Dynalnic/Supportive Psychotherapy, 
BRT = Breathing Retraining, GM = Guided Mastery, NP = Non-prescriptive Treatment, MCC = 
Minimum Contact Control, Bib = Bibliotherapy, RCCBT = Reduced Contact CBT, NOT = Non-
directive Therapy, SGCBT = Self Guided CBT. 
Table 2.2 Psychological vs. Pharmacological Treatment Studies Included In Review 
AUTHORS TREATMENT STUDY SETTING OUTCOME 
COMPARISONS N = REFERRAL 
SOURCE 
1. Zitrin et al (1980) Ilnip + Exp = 41 Hospital clinic Ilnip + Exp > Plac 
Plac + Exp = 35 Medicall +Exp 
Psychiatric referral 
2. Barr-Taylor et al Diaz =8 Hospital clinic Diaz = Rei> Plac 
(1982) Plac =10 Self referred via >WfL 
ReI =10 advert 
W fL Control = 11 
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3. Zitrin et al (1983) lmip+BT = 56 Hospital clinic lmip + BT > Plac 
Plac + BT = 57 self referred +BT= Imip+ 
lmip+ Pther = 58 pther 
4. Marks et al (1983) lmip + Exp + PP = 12 Hospital clinic lmip+ Exp+ PP= 
lmip + ReI + PP =11 Referral source- Plac + Exp + PP > 
Plac + Exp + PP = 10 Unkn lmip + ReI + PP = 
Plac + ReI + PP = 12 Plac + ReI + PP 
5. Mavissakalian et al lmip =7 Hospital clinic lmip + BT > lmip 
(1983) lmip+BT =8 Referral source-
Unkn 
6. TeIch et al (1985) lmip+ Exp = 12 University clinic lmip + Exp > Plac 
Plac + Exp =13 Referral source- + Exp = lmip + No 
lmip= NoExp = 12 Unkn Exp 
7. Michelson & lmip + Exp + PP = 14 University/ hospital lmip + Exp + PP = 
Mavissakalian (1985) lmip+PP = 17 clinic lmip + PP = Plac + 
Plac + Exp + PP = 17 Referral source- Exp + PP > Plac + 
P1ac + PP =14 Unkn PP 
8. Charney et al (1986) lmip+BT =24 Hospital clinic lmip+BT= 
Traz +BT =27 Referral source- Alpraz +BT> 
Alpraz + BT = 23 Unkn Traz +BT 
9. Tobena et al (1990) Alpraz + BT = 32 University clinic 
--
Self referred via 
advert 
10. Klosko et al (1990) Alpraz = 16 University clinic CBT = Alpraz > 
CBT = 15 self referred W IL, CBT > P1ac, 
Plac =11 Alpraz = Plac 
WIL Control = 15 
11. Mavissakalian lmip+Exp = 38 Hospital clinic 
--
(1990) Referral source-
Unkn 
12. Fahyet al (1992) Clomip + CBT = 18 Hospital clinic Clomip + CBT = 
Lofep+ CBT =24 GPReferral Lofep+ CBT> 
Plac+ CBT = 24 Plac+ CBT 
13. Black et al (1993a) Fluvox = 21 Hospital clinic Fluvox > CBT + 
Plac = 18 Physician referred Plac 
CBT = 16 and self referred via 
advert 
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14. Marks et aI (1993) Alpraz -t Exp - 34 Hospital clinic Alpraz + Exp = 
Alpraz + ReI =34 Physician referred Plac+ Exp> 
Plac + Exp = 30 and self referred Alpraz + ReI = 
Plac + ReI = 31 Plac + ReI 
15. Clark et al (1994) CT+PP - 16 Hospital clinic CT+PP>AR+ 
AR+PP = 16 Psychiatrist GP and PP = lmip + PP > 
lmip+PP = 16 Psychologist WIL 
WIL Control = 16 referred 
16. Hegel et al (1994) Alpraz + CBT = 22 University clinic 
--
Physician referred 
17. Cottraux et al Busp+CBT = 21 University clinic Busp+ CBT> 
(1995) Plac+ CBT =27 Referral source- Plac+CBT 
Unkn 
18. Oehrberg et aI Parox+ CBT = 55 Setting-Unkn Parox+ CBT 
(1995) Plac+ CBT = 52 Referral source- >Plac+ CBT 
Unkn 
19. De Beurs et aI Fluvox + Exp = 19 University clinic Fluvox +Exp>Plac 
(1995) Plac + Exp = 19 GP Referred and + Exp = PM + Exp 
PM+Exp = 20 Self referred =Exp 
Exp = 18 
20. Sharp et al (1996) FIuvox =29 Primary care Fluvox = CBT = 
Plac = 28 GP referred Fluvox + CBT = 
CBT = 30 Plac + CBT > Plac 
Fluvox + CBT= 29 
Plac+ CBT = 33 
KEY: Unkn = Unknown, loop = Iooprarmne, Traz = Trazodone, Alpraz = Alprazolam, Clooop = 
Clomipramine, Lofep = Lofepramine, Busp = Buspar, Parox = Paroxetine, Fluvox = Fluvoxamine. 
CT = Cognitive Therapy, CBT = Cognitive Behaviour Therapy, BT = Behaviour Therapy, Exp = 
Exposure, ReI = Relaxation, WIL = Waiting List, Pther = Psychotherapy, 
PP = Programmed practice self directed exposure, PM = Panic Management. 
2.2 Overall Study Design 
The dilemma in this area is that the design of any study must permit an accurate and 
controlled investigation of the treatments studied, whilst controlling for as many 
potentially confounding factors as possible. For the results of such studies to be of 
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value, however, the delivery of the treatments employed must be as close as possible 
to their use in wider clinical practice. 
The design of a study may also be influenced by the purpose of the study. A 
distinction has been drawn (Schwartz & Lellouch 1967) between studies conducted 
simply to inform or audit normal clinical practice, i.e. pragmatic designs, and those 
designed to acquire scientific information, i.e. explanatory designs. The rigour of 
scientific control differs between pragmatic and explanatory designs with more 
control being required in the latter to ensure that conclusions are not drawn from 
data confounded by uncontrolled artefact. It is likely that most study designs will 
reflect a careful balance of these design types. 
2.2.1 Psychological Treatment Studies 
Of the 36 studies reviewed (Table 2. 1), 11 are open trials of a single psychological 
treatment. The open trial design lends itself to maximising the similarity between 
research treatments and wider clinical practice but represents the minimum of 
scientific control. Other researchers have employed waiting list or no-treatment 
groups (Table 2.1. 18,20,27,33,35). This allows researchers to calibrate the 
effectiveness of the target treatment against the established effect of no treatment, 
but does not allow a conclusion that it is the treatment itself that is effective as 
opposed to simple contact with a therapist or other secondary factors. To resolve 
this problem, some have recommended the use of psychological placebo treatments 
(Marks et al 1993). Psychological placebo treatments are rarely used in psychological 
treatment outcome studies as their applicability and validity have been questioned 
(Parloff 1986). It is indeed difficult to conceive of a psychological intervention which 
would fulfil the criteria of being therapeutically inert whilst at the same time retaining 
credible face validity. 
A minimum standard design for psychological treatment studies would be to 
employ a no treatment or waiting list control, or the use of a placebo psychological 
treatment condition. Given the controversy over placebo psychological treatments, a 
compromise strategy with more direct relevance to wider clinical practice would be 
to ensure that any psychological treatment under investigation is compared with the 
most widely used clinical alternative as well as a no treatment condition. Studies 
have compared psychological treatments, usually cognitive therapy or cognitive 
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behaviour therapy with other psychotherapies e.g. supportive psychotherapy (Table 
2.1. 19), or non-prescriptive therapy (Table 2.1. 28). If it is suggested that 
psychological treatments should be compared with the most widely used clinical 
alternative, however, then this will usually mean comparison with a pharmacological 
treatment. This will involve an increase in the complexity of study design and 
recognition and accommodation of the requirements of pharmacological study 
design. 
2.2.2 Psychological vs. Pharmacological Treatment Studies 
A major requirement of any study investigating a drug treatment is the use of a pill 
placebo group. The pill placebo group permits a control for the drug responsiveness 
of the sample. When using drugs of proven efficacy for panic disorder, such as 
imipramine or alprazolam, the lack of a drug vs. pill placebo difference would 
indicate that caution should be taken in interpreting results. Klein (1996) argues that 
the lack of a drug vs. pill placebo difference in such circumstances indicates that the 
sample under study is atypically unresponsive to drug treatment, unrepresentative of 
the wider clinical population and that results from such samples should be 
discounted. Others (McNally 1996, Jacobson & Hollon 1996), suggest that lack of 
response to drug treatment is only one possible reason for finding a lack of drug vs. 
pill placebo difference, which could plausibly be due to equal ineffectiveness, or 
equal effectiveness of drug and pill placebo treatments. Nevertheless, the inclusion of 
both a drug and a pill placebo group are required for any research design to untangle 
these potential effects. The pill placebo group also controls for other non-drug 
effects such as basic therapist contact or attention effects. Such factors may be 
powerful in panic disorder (Fossey & Lydiard 1990, Mellergard & Rosenberg 1990). 
Of the 20 studies reviewed (Table 2.2) 14 employed pill placebo groups with only 
one study (Table 2.2. 10) failing to find a drug vs. pill placebo difference. Ofthe 6 
studies which did not employ a pill placebo, 3 were open trials of combined 
pharmacological plus psychological treatments, (Table 2.2.9,11,16). Open trials of 
combined drug + psychological treatments cannot provide information on the relative 
merits of each treatment used alone, or address the issue of drug responsiveness of 
the sample. The other 3 studies (Table 2.2.5,8,15) all attempted drug versus 
psychological treatment comparisons, or comparisons of differing drug + 
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psychological treatment combinations (Table 2.2. 5,8) without employing pill 
placebo groups. This omission makes these studies more difficult to interpret. The 
inclusion of pill placebo controls satisfies the demands of good pharmacological 
research design, and is to be recommended as a design standard. A further design 
standard to be considered refers to the psychological treatment element of drug vs. 
psychological treatment comparisons. Previous studies have employed a wide variety 
of designs from simple between group comparisons of various drug + psychological 
treatment conditions (Table 2.2. 17,18) to more complex 2 x 2 designs comparing 
drug vs. pill placebo with exposure vs. relaxation. These designs have four treatment 
groups; drug + exposure, drug + relaxation, pill placebo + exposure, and pill placebo 
+ relaxation. The essence of this design rests in the assumption that relaxation 
operates as a "placebo" psychological treatment, and thus both drug and 
psychological treatments are assumed to be represented by an active and a placebo 
index (Table 2.2. 4,14). As already mentioned there is disagreement over the validity 
of psychological placebos in general (Parloff 1986), and relaxation treatments as 
psychological placebos in particular (Ost et al 1993). Also, as no treatment is 
represented independently used alone within these designs, such studies do not 
permit a calibration of the relative efficacies of the drug and psychological 
treatments. 
Only five studies have employed a psychological treatment alone condition (Table 
2.2. 10,13,15,19,20). All other studies have assumed a pill placebo + psychological 
treatment to be equivalent to a psychological treatment alone condition and have 
employed only the former. Lack of psychological treatment alone conditions in 
previous studies is a serious design flaw. In four of the five studies which do include 
a psychological treatment alone condition, three (Table 2.2. 10,13,15), do not 
include any combined treatment conditions, whilst the fourth (Table 2.2. 19), does 
not include a drug alone or a pill placebo alone condition. Thus in these four studies 
the definitive comparison of each treatment used alone and in combination is not 
possible. 
Hollon & DeRubies (1981) argue that a minimum of 5 groups are required to 
adequately compare the relative and combined efficacies of a drug and a 
Psychological treatment, namely; drug alone, pill placebo alone, drug + psychological 
treatment, pill placebo + psychological treatment, and psychological treatment alone. 
Chapter 2 53 
This represents the minimum design standard for comparative studies. Only two 
studies, one recent (Table 2.2. 20), the other (Barlow 1994) ongoing, have used the 
five group design with panic disorder patients. 
2.2.3 Design Solutions 
The need for wider clinical application suggests that psychological treatments should 
be compared with the most widely used clinical alternative, i.e. pharmacological 
treatments. A consideration of the design of drug vs. psychological treatment studies 
suggests that any such comparison should be conducted within the framework of a 
five group study design. The adoption of this design standard is not without some 
cost. The immediate and obvious cost of this suggested solution to the dilemmas of 
study design is the increase in the number of study groups required in any 
comparison and the consequent increase in sample size required to ensure sufficient 
statistical power. 
2.3 Definition/Classification of Sample 
Once study design is established the next major stage in any research study is the 
definition of the patient group to be studied. Treatment outcome studies must 
employ a system whereby the group under study can be defined. Such a system 
should be described in sufficient detail to permit other researchers to replicate it. In 
wider clinical practice, however, patient groups are rarely well defined and typically 
show considerable co-morbidity and varying chronicity and severity. The dilemma for 
the researcher here rests in reconciling the requirement for definition and control in 
treatment research with the wider variability in presentation found in clinical practice. 
2.3.1 Psychological Treatment Studies 
Many studies make no mention of classificatory systems (Table 2.1. 1,3,4,6,8,9, 
11,13,18) and comparisons with these studies are less reliable as a result. Other 
studies do use classification systems but do not describe the procedures employed for 
assessing patients against the criteria of the classificatory system (Table 2.1. 
2,5,10,22, 24). Others have employed "semi-structured interviews" which are rarely 
available for inspection thus compromising replicability. Barlow (1989) argues that 
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the only acceptable method of classification is by standardised interview schedules 
based upon internationally accepted classificatory systems such as the ADIS-R (Di 
Nardo & Barlow 1988) or SCID (Spitzer et aI1988). Most of the more recent 
psychological treatment studies have used one of these methods (Table 2.1. 
7,14,16,17,19,20,23,25-36). 
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A further problem as regards classification is the use of additional criteria above 
those of the standardised system. Some studies included moderate to severe 
agoraphobics in their samples (Table 2.1. 1-8,12,14,17,26,33), while others included 
patients with mild or no agoraphobic avoidance (Table 2.1. 7,10,16,18,23,25,35). 
Still others included a large proportion of agoraphobic subjects in the sample but did 
not define levels of severity of agoraphobic avoidance (Table 2.l. 9,11,13,15,19,22, 
25,27,28,31,32,34,36). The exclusion of severe agoraphobics may bias the sample 
towards responsiveness (Clum 1989, Williams & Falbo 1996), giving an overly 
optimistic picture of the efficacy of psychological treatments. 
Clinical samples can show considerable co-morbidity, particularly with regard to 
depression (Witt chen & Essau 1993). Although measures of depression are 
commonly employed as outcome measure, most studies of psychological treatments 
did not employ any controls for concurrent depression or make any mention of pre-
treatment depression levels in their samples. Seven studies excluded subjects with 
major depression if this was judged to be the primary disorder (Table 2.1. 10,16,20, 
26,30,31,35), whilst a further 3 studies employed the stringent criterion of excluding 
any subjects who had any history of depressive disorder, including that prior to the 
onset of their panic disorder (Table 2.1. 5,12,21). The effect of this strict control on 
the representativeness of these samples is unknown. Patients with high levels of 
concurrent depression may be more treatment resistant (Wittchen & Essau 1993), 
thus a controlled investigation of the influence of depression levels on treatment 
outcome is required. 
2.3.2 Psychological vs. Pharmacological Treatment Studies 
Review of studies investigating psychological vs. pharmacological treatment studies 
revealed findings similar to those for psychological treatments alone. Less studies 
failed to use any recognised classificatory system (Table 2.2. 1,3), however many 
others did not specify any standardised or replicable procedures for assessing patients 
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against the criteria of the classificatory system employed (Table 2.2.2-7,9,18,19). 
Others again employed "semi-structured interviews" (Table 2.2. 17,20). As with the 
psychological treatment studies, these were unavailable for inspection thus 
replicability was equally compromised. Most of the more recent studies in this group 
have employed recognised classificatory systems and standardised interview 
schedules such as the ADIS-R or SCID (Table 2.2. 10, 12-16). Regarding criteria 
over and above those of the standardised classificatory system, some studies have 
excluded severe agoraphobics from their samples (Table 2.2. 15,16), with the same 
implications for treatment responsiveness as before. Other additional criteria used 
include chronicity and severity (Table 2.2. 19,20), the effect of which on treatment 
responsiveness is unclear. These are issues worthy of increased attention. 
Regarding depression, a larger proportion (9 out of20) of the psychological vs. 
pharmacological treatment studies excluded patients suffering from concurrent major 
depression. Unfortunately, many of these studies did not state the explicit criteria on 
which such exclusions were made (Table 2.2.4,5,7,10,12). Others have rectified this 
problem by excluding patients whose rated depression exceeds pre-determined levels 
on standardised rating scales (Table 2.2.9,18,20). Such exclusions may nonetheless 
bias these samples towards treatment responsivity. 
2.3.3 Design Solutions 
How a research sample is defined has major ramifications for the representativeness 
of that sample and consequently the applicability of findings to wider clinical 
practice. The constitution of a sample may also have implications for treatment 
responsiveness. The use of recognised classificatory systems, standardised interviews 
and the investigation of and controls for the influence of co-morbid conditions would 
be important improvements, but would not completely resolve the initial dilemma. 
Any classification of a condition, by definition, restricts the number of patients who 
can be so classified. Thus any research sample will not wholly replicate the disorder 
as seen in wider clinical practice. Scientific rigour and replicability of research is 
inevitably traded against the representativeness of the sample, and to this extent the 
dilemma still stands. Further research effort should consider the areas where samples 
differ from the wider clinical population, and the ramifications of such differences. 
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The representativeness of the sample should also be borne in mind when interpreting 
results from any research study. 
2.4 Definition of Treatment 
Research treatments must be defined sufficiently to permit replication. Definition may 
cause problems if treatments are then unrepresentative of the treatments used in 
wider clinical practice. This is possibly a less convincing dilemma in that good 
clinical practice also requires well defined replicable treatments. Some of the 
flexibility in actually delivering treatments in wider clinical practice may, however, be 
lost in the more strictly controlled research setting. 
2.4.1 Psychological Treatment Studies 
Psychological treatments are complex to deliver and require detailed specification in 
a research protocol. A minimum specification of a psychological treatment would 
include the use of a treatment manual that details the essentials of the treatment in 
question (Barlow 1989). Several of the studies reviewed failed to use a treatment 
manual. Other studies have used a treatment manual (Table 2.1. 4,11,16,19,23,25,28, 
36), although this may not be sufficient in itself as no further check was made to 
ensure that the directions of the manual were adhered to. The problem of definition 
of treatments may be resolved by the use of treatment manuals with checks on 
treatment integrity possibly by the use of audio or video recordings of treatment 
sessions as adopted by some studies (Table 2.1. 12,20,22,29,30,32-34). 
2.4.2 Psychological vs. Pharmacological Treatment Studies 
A noticeable difference exists between pharmacological and psychological 
treatments. The use of pharmacological treatments is generally well defined with the 
use of specified dosage ranges and schedules. Compliance with drug treatments is 
routinely assessed either by return pill count, or by blood screen. A different situation 
holds for the psychological treatments employed in comparative studies, which are 
more complex to deliver and require more detailed specification. Several studies 
failed to use treatment manuals (Table 2.2. 1-6,9,12,18), or used manuals but did not 
make any checks on the integrity of treatment delivery (Table 2.2.4,11,13,16,17). 
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Only 5 of the 20 comparative studies reviewed used treatment manuals along with 
audio or video taped integrity checks (Table 2.2. 10,14,15,19,20). 
2.4.3 Design Solutions 
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The resolution of this area requires the adequate specification of treatments, using 
treatment manuals for psychological treatments, with subsequent checks on 
treatment integrity possibly by the use of audio or video tapes of treatment sessions. 
These procedures undoubtedly enhance the replicability of treatments but 
nonetheless involve some cost. Specification of treatment procedures by the use of 
manuals may restrict some of the essential ingredients of treatment such as the 
quality of the therapist patient relationship or the ability of the treatment to 
accommodate and respond to variations in individual patients circumstances (Kendal 
& Lipman 1991). Also, audio or video taped integrity checks may exert a 
confounding influence on the sessions taped, rendering this an invalid reflection of 
the treatment as practised in wider clinical practice. This is a research topic in itself 
that is worthy of further investigation. 
2.5 Therapist Contact 
In normal clinical practice treatments vary between patients in the number of sessions 
given and the length of individual sessions, these factors reflecting the circumstances 
of individual patients. In treatment research, however, therapist contact must be 
controlled. In both within and between group comparisons, it is essential to be sure 
that differences in outcome are due to genuine differences between treatments and 
not to differences in the amount of therapist contact received. There is a clear 
dilemma over reconciling these obviously conflicting requirements. This is an 
example where the demands of research methodology must take precedence over 
those of clinical practice if study results are to have any explanatory value. 
2.5.1 Psychological Treatment Studies 
Several studies have failed to control for therapist contact within treatments with 
patients receiving differing numbers of sessions and amounts of therapist contact 
(Table 2.l. 1,7,1 0,23-25). Others attempt to control for therapist contact by ensuring 
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all subjects receive an equal number of treatment sessions (Table 2.1. 3,4,9,12,26). 
Thus in a study comparing a relaxation treatment with a therapist assisted graded 
exposure treatment, all patients are given exactly the same number of treatment 
sessions. The therapist contact element ofthe graded exposure is, however, reduced 
as treatment progresses. Thus, whilst all subjects receive an equal number of 
treatment sessions within this design, there is still considerable variation in actual 
therapist contact. Overall therapist contact is generally well controlled in outcome 
studies of psychological treatments with 20 of the 36 studies employing adequate 
balances for this factor. 
2.5.2 Psychological vs. Pharmacological Treatment Studies 
Therapist contact is of particular relevance to the comparison of pharmacological 
versus psychological treatments. In normal clinical practice there are usually large 
differences in the amount of therapist contact required to deliver drug treatment or 
psychological treatment. Differences in outcome between the two treatment types 
may simply reflect this substantial procedural difference. An explanatory research 
design must recognise and control this factor. Unfortunately some studies (Table 2.2. 
5,6,15), do not address the issue while others attempt balance by ensuring that all 
subjects receive equal numbers of treatment sessions but fail to ensure that these are 
of equal duration (Table 2.2. 10,13). A more sophisticated attempt to balance 
therapist contact across groups was made in studies which employ a 2x2 design 
(Table 2.2.4,7,14), where all patients in all four treatment groups received an equal 
number of sessions. To deal with the confounding effects of high levels of therapist 
contact during psychological treatment versus low levels of contact during drug 
treatment, an approach that balances for therapist contact across all treatments is 
required. 
2.5.3 Design Solutions 
The suggestion that all treatments in a comparative study should receive equal 
amounts of therapist contact is not difficult to accommodate within a comparison of 
psychological treatments. It is in the area of drug versus psychological treatment 
comparisons where there are substantial natural differences in therapist contact 
between the two treatment types that problems arise. In the later studies patients 
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allocated to drug alone or pill placebo alone conditions must be given the same 
amount of therapist contact as those in the psychological treatment groups. One 
possible means of achieving this the sessions for the drug and pill placebo alone 
groups focus on non-directive empathic reflection of patients problems with no 
active therapeutic advice being offered. This may at best represent only a partial 
solution to the problem, or at worst, no solution at all. It could be argued that 
therapist contact which involves empathic reflection may be therapeutically active 
(Rogers 1957) and thus an unsuitable analogue for simple therapist contact. 
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Attempts made to date to balance for therapist contact using non directive empathic 
reflection (Power et al 1990a, Sharp et al 1996) may simply have introduced yet 
another confounding factor into such study designs rather than provide a solution. 
This observation notwithstanding, when comparing phannacological versus 
psychological treatments, in an explanatory as opposed to a pragmatic design, the 
overall recommendation remains that therapist contact should be balanced between 
groups. This should take place within a five group framework where each treatment 
is represented both used alone and in combination. This method does have a major 
drawback in that with the balance for therapist contact included the drug alone 
groups (drug, and pill placebo alone) receive significantly more therapist contact than 
would be the case in wider clinical practice, thereby resulting in an ecologically 
invalid representation of drug alone treatments and possibly producing an over 
estimate of the effectiveness of drug treatments. In explanatory designs, if therapist 
contact is to be balanced across groups within a five group framework it would 
therefor seem necessary that a further two groups are run, these being drug + 
standard (i.e. shorter) contact and pill placebo + standard contact. In this way the 
contribution of the enhanced therapist contact can be calibrated. The strategy does 
have obvious costs, in that the number of study groups has now increased to a 
possible seven with the commensurate increase in number of subjects required per 
group. In order to assess whether such an increase in the complexity of study design 
is in fact necessary, research should be conducted comparing drug or pill placebo + 
standard contact versus drug or pill placebo + enhanced (i.e. balanced) therapist 
contact. Until results from such research are available the dilemma over controls for 
therapist contact remains. 
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2.6 Control For Concurrent Treatments 
In normal clinical practice patients undergo both drug and psychological treatments 
whilst receiving other treatments. An explanatory research design demands that 
patients be free from concurrent treatments in order that target treatments can be 
properly assessed. The dilemma here rests in the conflicting demands of scientific 
control and wider clinical practice. This is an area of considerable importance which 
has a direct impact on the validity of study results, and where the demands of 
research methodology must take precedence if results are to have any explanatory 
meaning. The problem is easily resolved in practical terms by simply prohibiting the 
use of concurrent psychotropic medications and concurrent psychological treatments. 
2.6.1 Psychological Treatment Studies 
Concurrent psychotropic medication is unfortunately rarely controlled in studies of 
psychological treatments with 29 of the 36 studies either failing to mention 
concurrent psychotropic drugs, or employing inadequate controls. This has been 
suggested to be a failing in research design (Beck et al 1994, Power & Sharp 1995), 
although others have suggested that outcome results are not affected (Otto et al 
1996). Controls usually consist of requiring patients to maintain the dose of 
concurrent psychotropic medication at a constant level throughout the study period, 
assuming that the influence of the drug on the outcome of the psychological 
treatment under investigation will thus be controlled. This does not take account of 
the possibility of medication by psychological treatment interaction effects, nor 
control for differential medication effects or for actual medication dosage. Some 
studies have attempted post hoc controls for concurrent psychotropic medication by 
comparing the outcomes of those patients taking psychotropic medication with those 
Who were not (eg Table 2.1. 27) and finding no differences between the two groups. 
Limited sample sizes and the dangers of interpreting findings for the null hypothesis, 
suggest that these results be approached with caution. 
Some studies (Table 2.1. 5,6,35), employed partial controls for concurrent 
psychotropics by prohibiting the use of certain classes of psychotropics, usually 
antidepressants, whilst permitting the continued use of others, e.g. benzodiazepines. 
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Such partial control procedures are hard to justify. Others (Table 2.l. 3,4,12,15,21, 
28, 29), prohibited the use of concurrent psychotropic medication but employed 
variable wash-out periods from 0 days (Table 2.1. 3,4), to 14 days (Table 2.1. 
12,15,21,23,29). The surreptitious use of psychotropic medications has also been 
identified (Clark et al 1990). Surprisingly, only one study has employed checks on 
surreptitious medication use by using urine screens (Table 2.1. 28). 
Regarding concurrent psychological treatments, the majority of psychological 
treatment studies (17 of 36) make no mention of concurrent psychological treatment. 
Other studies fail to control for concurrent psychological treatment as a result of 
basic study design (Table 2.l. 4,9,12,15,26), in that treatment groups were given 
programmed practice self exposure instructions in addition to the research treatment. 
Programmed practice has been shown to be an effective treatment in its own right 
(Mathews et al 1981) and is suggested to be a common active ingredient in many 
psychological treatments (Al-Kubaisy et al 1992). Thus treatment effects are 
confounded rendering these studies uninterpretable. Another study permitted 
concurrent psychological treatments if these were not directly targeting patients 
panic disorder (Table 2. 1. 20). Knowledge of the active ingredients in any 
psychological treatment is not sufficiently advanced to permit such a control to be 
used with any confidence. Five studies prohibited concurrent psychological 
treatments during the study period (Table 2.1. 4,28,33,34,35). Controls for both 
concurrent psychotropic medication and concurrent psychological treatments were 
employed in only two studies (Table 2.1. 4,28). 
2.6.2 Psychological vs. Pharmacological Treatment Studies 
Concurrent psychotropic medication use is generally well controlled in comparative 
treatment studies with only one study having failed to prohibit concurrent 
psychotropics (Table 2.2. 15), although a post hoc analysis in this study failed to find 
any difference in treatment response between patients taking concurrent psychotropic 
medication and those who were not. Two other studies operated partial controls of 
similar dubiety to those mentioned previously by prohibiting the use of antidepressant 
medications but not other psychotropics (Table 2.2. 6,19). The remaining 17 studies 
all prohibited the use of concurrent psychotropic medication but did employ variable 
wash-out periods, from 7 days (Table 2.2. 9,10), to 28 days (Table 2.2. 13,20). 
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Again few studies (Table 2.2. 14) employed screens to identify surreptitious drug 
use. 
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Controls for concurrent psychological treatments in comparative studies are less 
impressive. Many studies simply do not mention concurrent psychological treatment 
(Table 2.2. 1-3,5,9,11,16-18). Others fail to control for concurrent psychological 
treatments as a result of basic study design. As was the case for psychological 
treatment studies, in these studies all treatment groups were given programmed 
practice self exposure instructions in addition to their prescribed research treatment. 
Some studies have required patients to be free from concurrent psychological 
treatments (Table 2.2. 10,13,14,19). These studies did not, however, specify any 
time limit on how recent any previous psychological treatment could be, prohibiting 
such treatments for the duration of the study only. As it is unlikely that psychological 
treatments can be said to ''wash-out'' within a predetermined and relatively short time 
span (e.g. 1 week), some reasonable time should have elapsed between the end of 
any psychological treatment and the start of study treatments. One study (Table 2.2. 
20), included a ''wash-out'' time of 6 months between previous psychological 
treatments and study treatments. Although this may seem more satisfactory, it is 
nonetheless an arbitrary choice of timescale. If psychological treatments bring about 
lasting changes in patients, it is possible that they may not ''wash-out'' in any 
meaningful sense at all. 
2.6.3 Design Solutions 
An adequate study should be expected to control for concurrent drug and 
psychological treatments. For concurrent psychotropics the solution is a 
straightforward ban on the use of non study psychotropics with a pharmacologically 
sound wash-out period. For concurrent psychological treatments problems arise over 
how close to the study treatment such concurrent treatments can be allowed to 
occur. One solution might be to exclude any patient with any previous exposure to 
any psychological treatment. This would greatly reduce study recruitment rates. Such 
a strategy would mean that study populations were comprised mostly of cases of 
recent onset and short duration and thus would not be representative of the more 
chronic cases seen in wider clinical practice. Controls for concurrent treatments do 
have some cost. Any control that restricts concomitant treatments is likely to restrict 
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study access thus reducing recruitment rates and sample representativeness. The 
obvious exclusion of patients who are unable to discontinue concurrent psychotropic 
medications is a good example of this. The extent to which patients who are able to 
discontinue concurrent psychotropic medication differ from those who are not is not 
yet clear. Further research on the possible differences between patients who are able 
to discontinue concurrent treatments and those who are not, particularly with regard 
to treatment response, may help clarify this difficult area. 
2.7 Assessment of Treatment Outcome 
Assessment of treatment outcome in wider clinical practice is frequently 
unstandardised and limited in scope. Research assessment requires a broad range of 
standardised and comprehensive measures to adequately reflect process and 
outcome. This might at first appear to be an area where there is little dilemma in 
reconciling the conflicting demands of research and clinical practice, nevertheless 
there are some problems. 
2.7.1 Psychological Treatment Studies 
Many previous studies have employed inadequate assessment procedures, using only 
non-standardised measures (Table 2.l. 9,10,18,22,24), or focusing on only one 
aspect of the disorder, usually avoidance (e.g. Table 2.1. 1,2). It has been suggested 
(Kellner & Uhlenhuth 1991) that as there is no consensus on the boundaries of the 
constructs underlying anxiety and the anxiety disorders, the focus on specific factors 
such as avoidance may be premature. Surprisingly many studies have omitted to 
assess anxiety state in any way (Table 2.1. 1-4,6,8,11,14,33), with only 7 studies 
employing both therapist and patient rated measures of anxiety level (Table 2.1. 
16,20,21,23,26,28,34). The outcome measure common to most studies is 
percentage of patients panic free at treatment end point. Methods employed to assess 
panic attack frequency vary greatly between studies and the comparability of results 
is questionable. Percentage of patients panic free at end point may be an unreliable 
and overly optimistic measure of treatment outcome (Barlow 1988, Shear & Maser 
1994). The assessment of panic attack frequency in most studies is made 
retrospectively thereby tending to overestimate the occurrence of panic (Rapee et at 
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1990b, De Beurs et al 1992). Prospective diary based methods are advocated as a 
more suitable alternative. Some studies record only panic attacks, specifically 
excluding limited symptom attacks (Table 2.1. 27,34). It is currently unknown 
whether this is a restrictive assessment procedure, although some data suggests that 
panic attacks may be regarded as equivalent to limited symptom attacks (Margraf et 
al1987, Katerndahl1990, Krystal et al1991, De Beurs et aI1994). Further problems 
arise in some studies where patients were tutored as to the number of symptoms 
required for a definition of a panic attack (4 symptoms or more), (Table 2.1. 
23,24,34), potentially influencing patients recording of panic attacks. The nature of 
this influence (increasing or decreasing reporting) remains unknown and requires 
further investigation. The majority of studies discuss and report panic attacks in 
terms of frequency or retrospective composite ratings of frequency and intensity. 
Possible panic attack variables such as prospectively rated intensity and duration of 
panic attacks are rarely employed and their status as outcome variables remains 
unclear. 
A further point regarding assessment concerns the personnel who conduct the 
assessments. Whilst psychological therapists can provide important insights into 
change in treatment, they are not blind to treatment condition. Therapist bias or 
treatment allegiances, whether conscious or unconscious, may influence assessments. 
The use of independent assessors who are blind to treatment group is to be 
recommended. The majority of studies reviewed did not use an independent assessor, 
with most limiting assessments to patient rated measures only. The use of an 
independent assessor is an essential element of a sound methodology, but the 
strategy does have some drawbacks. The use-ofblind independent assessors 
throughout treatment would be a cumbersome procedure that may have a negative 
effect on compliance. A compromise solution is for therapists to conduct process 
assessments throughout treatment with end point assessments conducted by a blind 
independent assessor. This method has been employed in 6 studies (Table 2.1. 
1,3,7,16,20,28). The use of an independent assessor at any point in treatment also 
requires checks to be made on inter-rater reliability. 
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2.7.2 Psychological vs. Pharmacological Treatment Studies 
The situation described above for psychological treatment studies applies equally to 
the psychological vs. pharmacological treatment studies. Early studies in this area 
also failed to assess anxiety level and focused more on measures of avoidance (Table 
2.2.4,14). The measure common to most studies was again percentage of patients 
panic free at treatment end point, with there being the same problems with 
retrospective measurement of panic attacks, and exclusion of limited symptom 
attacks in these assessments (Table 2.2. 13,15). Other studies also tutored patients 
on the number of symptoms required for a classification of a panic attack (Table 2.2. 
10,13) with the same ramifications for measurement. Again other possible panic 
attack variables such as severity or duration of attacks have not been investigated. 
2.7.3 Design Solutions 
The first problem in attempting to design an inclusive and comprehensive assessment 
package for use in panic disorder treatment outcome studies is the lack of agreement 
over what measures should be included in such a package (Kellner & Uhlenhuth 
1991). Fortunately the recent deliberations of the Consensus Conference on 
Standardised Measurement for Panic Disorder Research have now been published 
(Shear & Maser 1994). The Conference suggested that treatment outcome should be 
measured across several domains and recommended that measures of anxiety, 
depression, anticipatory anxiety, fear of bodily sensations, and panic related fear and 
avoidance should form the basic core of any assessment package. The Conference 
also recommended that panic attacks and limited symptom attacks should be 
recorded by prospective diary based methods. The inclusion of separate ratings of 
panic and limited symptom attack intensity and duration would also be of interest. 
Further assessments were suggested for impairment of work, social and family life 
and also the use of global assessments of severity and outcome preferably completed 
by therapist, patient and if possible a third party such as an independent evaluator or 
referring clinician. The improvements to assessment procedures suggested by the 
Conference are likely to enhance the measurement of treatment outcome, although 
few studies have as yet adopted these procedures (Table 2.1. 28,34. Table 2.2. 20). 
A further problem is the size, complexity and time consuming nature of the required 
assessment procedure. This has led to suggestions (King 1997, Sharp et al 1997b) 
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that there may be some value in investigating measures that are more suitable to use 
in wider clinical practice, particularly in the primary care setting. 
2.8 Analysis of Outcome 
In wider clinical practice patients receive varying amounts of treatment and are 
regarded as having completed treatment at whichever point is appropriate to their 
individual circumstances. In explanatory research designs, there is a need to ensure 
equivalence between treatments and that all treatments are offered under optimal 
conditions. Thus for the purpose of explanatory design and subsequent analysis 
patients should all receive equivalent amounts of treatment. There is an obvious 
dilemma here in attempting to balance the demands of research and wider clinical 
practice, and considerable debate over appropriate study design and analysis plans. 
2.8.1 Psychological Treatment Studies 
All of the 36 psychological treatment studies reviewed carried out analyses on full 
completers samples where data were analysed only for those patients who completed 
the entire treatment period. This is not representative of wider clinical practice and 
may bias outcome in favour of the treatments under investigation as the results of 
treatment drop-outs cannot influence the analysis. This is especially the case for 
treatments with high drop-out rates. An intent to treat analysis which is more akin to 
wider clinical practice, may nonetheless bias against treatments by allowing early 
drop-outs an undue influence. None of the studies reviewed employed an intent to 
treat analysis. Thus in opting for a full completers analysis all of the studies reviewed 
employed the less stringent method of analysis which was more likely to bias 
outcome in favour of the treatments studied depending on the drop-out rates 
recorded for each treatment. Whilst drop-out rates are commonly recorded in the 
studies reviewed, their influence on outcome analyses is rarely discussed. A 
compromise solution to the problems inherent in both full completers and intent to 
treat analyses may be provided by a defined completers analysis which includes with 
full completers the results for patients who have completed treatment up to a pre-
detennined minimum, often half the full treatment period. Thus those with an 
Unrealistically brief experience of treatment do not influence the results, nor is 
Chapter 2 
analysis restricted solely to those who fully complete treatment. Somewhat 
surprisingly, none of the psychological treatment studies employed a defined 
completers method. 
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Further dilemmas can arise in that an outcome that achieves conventional levels of 
statistical significance may nonetheless be of little importance clinically. More 
stringent methods of assessing the clinical significance of outcomes are required. 
Several studies have employed methods of assessing clinical significance or high end-
state functioning (Table 2.1. 8,12,14,15,20) which were unique to each study making 
comparisons between studies difficult. Standardised procedures for assessing clinical 
significance of outcomes based on explicit statistical criteria have already been 
established (Jacobson & Truax 1991). The procedures entail the calculation of cut-
off scores on target measures and have been employed in several studies (Table 2.1. 
16,21,26,27,34). These procedures have also been criticised for failing to take 
account of the magnitude of change (Hollon & Flick 1988), and for failing to relate 
criteria of clinically significant change to the social validity or relevance of that 
change (Baer 1988). The process of establishing a cut-off score on a given measure 
and assuming that scores below that cut-off reflect a clinically significant change will 
also be valid only to the extent that the chosen target measure accurately reflects the 
clinical condition being assessed. That is to say, the target measure must have 
sufficient construct validity. As previously mentioned there is still debate on the 
constructs representative of anxiety and the anxiety disorders (Kellner & Ulenhuth 
1991). Early discussions on the issue of clinical significance (Kazdin 1977, Strupp & 
Hadley 1977) suggest that clinical significance might also be assessed by obtaining 
global ratings of change from patients, clinicians, or other significant observers. This 
method has the appealing directness of asking those undergoing a treatment to rate 
its effect upon them. Global ratings may also avoid the problems of construct validity 
of chosen measure, given that the constructs which global ratings reflect are by 
definition less specific, for example global severity or distress, or global change or 
improvement. Global scales are rarely used in treatment outcome studies and then 
usually for either patient or therapist (Table 2.1. 21,23,28), rather than for both. 
Assessing treatment outcome at follow-up is important. This is recognised in the 
majority of studies (21 of 36) which include follow-up analyses. Unfortunately none 
of the studies took account of treatment received during the follow-up period. Thus 
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it cannot be clear whether results gained at follow-up can be attributed to the 
experimental treatments or to additional treatments given during the follow-up 
period. This is an important point with direct bearing on the value of follow-up 
results. Follow-up results contaminated by intervening treatment have little 
explanatory value. One study (Table 2.1. 26) did note intervening treatment but did 
not take account of this in the analysis of the follow-up data. Where it is difficult to 
ensure the absence of intervening treatment during the follow-up period, the 
occurrence of such treatment should be noted and these patients excluded from 
follow-up analysis. 
2.8.2 Psychological vs. Pharmacological Treatment Studies 
The same problems in analysis of outcome, as outlined above, occur for the 
psychological vs. pharmacological treatment comparative studies. The majority of 
these studies also employ full completers analyses with the attendant potential to bias 
outcome in favour of the treatments studied. One study (Table 2.2. 18) also 
employed an intent to treat analysis. The recommended compromise analysis, the 
defined completers analysis, was used in 4 of the 20 studies reviewed (Table 2.2. 
3,14,15,20). Regarding the assessment of clinical significance of outcome, several 
comparative studies have employed methods of assessing clinical significance or high 
end-state functioning according to criteria unique to each study (Table 2.2. 
3,10,11,14,15,18). Standardised procedures for the assessment of clinical 
significance (Jacobson & Truax 1991) were employed in only one study (Table 2.2. 
20), and global measures of outcome in only two studies (Table 2.2. 13,14). The 
assessment of status at follow-up is surprisingly much less common in the 
comparative studies with only 5 studies including follow-up assessments. Of these 5, 
three did not assess whether any intervening treatment had occurred during the 
follow-up period and their results cannot therefor be relied upon. Only two studies 
carried out follow-ups on samples free from intervening treatment (Table 2.2. 14,20). 
2.8.3 Design Solutions 
Clinical relevance and comparability between studies could be enhanced by the use of 
a defined completers analysis. Such a method still involves some potential 
controversy with the selection of an acceptable minimum period of treatment for 
Chapter 2 69 
defined completer status being essentially an arbitrary decision. The clinical 
significance of outcomes should be assessed preferably using available standardised 
methods. Follow-ups should be regarded as an important part of any treatment study 
and should include a record of, and a control for, intervening treatments. Little 
obvious cost would result from the adoption of these procedures, although these 
more stringent methods of assessment might depress current estimates of treatment 
efficacy especially at follow-up. 
2.9 Miscellaneous 
The foregoing discussion has covered the major dilemmas of treatment outcome 
research design and has suggested potential improvements to study design. Other 
points merit attention. As these apply equally well to psychological treatment studies 
and to psychological vs. pharmacological comparative treatment studies they will not 
be discussed separately for each study type. 
Method of patient recruitment may be important, as it has been suggested 
(Aronson 1987b), that self-referred patients may differ in presenting characteristics 
from those referred by medical practitioners. An inspection of Table 2.1 and Table 
2.2 highlights the variation in recruiting source of samples. Also the setting where 
the study is actually conducted may be important. Most studies have been conducted 
in specialist hospital or university clinics with patients travelling to these facilities to 
receive treatment, rather than being seen in their local primary care health centre. 
This is perhaps a surprising arrangement given that the majority of panic disorder and 
agoraphobia cases are seen and treated in the primary care setting (Ashcroft et al 
1988, Katemdahl & Realini 1995). The applicability of the findings of previous 
research to patients treated in primary care has been questioned (Wilkinson & Lewis 
1990). The effect of this study setting on sample configuration and treatment 
outcome has not been investigated empirically as yet. 
Therapist competence is also an area that may require further attention. There is 
considerable variation across studies in the clinical experience of the personnel 
employed as therapists ranging from undergraduate students through postgraduate 
doctoral students to qualified clinical practitioners. This variation in experience may 
influence research findings. The clinical competence of therapists may also have a 
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bearing on treatment outcome. This is a sadly neglected topic although recent 
research has confirmed that therapist competence can influence outcome result~ in 
the area of anxiety disorders (Kingdon et al 1996). 
2.10 Conclusion 
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In conclusion it is hoped that the points raised in this review might serve to stimulate 
further debate on study design and methodology, which is the foundation on which 
any scientific endeavour rests. The main issues highlighted in this review have been 
presented in detail by Sharp & Power (1997a) and Sharp & Power (Submitted){a). 
The review set out to be neither exhaustive nor conclusive, rather the aim was to 
highlight the dilemmas inherent in psychological and psychological vs. 
pharmacological treatment study design, and to outline methodologies which might 
overcome these problems. In virtually every case, however, the solutions to 
methodological inadequacies have an associated cost. In deciding whether research 
should, or should not, exert the extra effort necessary to conduct more rigorously 
controlled studies with hopefully more valid outcomes, the demands of wider clinical 
practice must continue to have relevance. Research must have clinical relevance. This 
final point is, after all, one of the main reasons why we conduct treatment outcome 
research. 
Chapter 3 71 
CHAPTER 3. OUTLINE AND AIMS OF THE PRESENT RESEARCH 
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3. 1 Introduction 
Chapter 1 summarised panic disorder with or without agoraphobia as a prevalent, 
clinically demanding condition, which presents predominantly in the primary care 
setting. There is therefor considerable pressure to develop effective treatments for 
the condition, and to demonstrate their efficacy in a manner relevant to wider clinical 
practice. Evidence for the efficacy of pharmacological and psychological treatments 
has been provided by studies of medications and psychological treatments used singly 
or in combination. These studies have varied in design and quality and various 
attempts have been made to assess the relative merits of pharmacological and 
psychological treatments while controlling for this variation in methodology. Meta-
analysis was described as a technique commonly used to overcome between study 
differences in methodology. Chapter 1 concluded, however, that within study control 
was more effective than the post hoc controls employed in between study analyses, 
and, consequently, a controlled comparison of a pharmacological and a psychological 
treatment was recommended. Recent interest has been shown in the selective 
serotonin reuptake inhibitor (SSRI) antidepressants and psychological treatments 
based on cognitive behaviour therapy, however, there are few comparisons of SSRI 
medications with cognitive behaviour therapy in recent meta analyses. More 
importantly, no previous study has adequately compared an SSRI medication with 
cognitive behaviour therapy and an adequate comparative trial of these two 
treatments is therefor timely and important. Such a comparison would have to 
recognise and address the methodological shortcomings of previous treatment 
outcome research. Chapter 2 critically reviewed previous treatment outcome study 
methodology, both in terms of scientific validity and applicability to wider clinical 
practice. This latter point was emphasised as an essential component of any valuable 
clinical study. The need to recognise and accommodate clinical reality in research 
design will be central to the studies conducted in the present research. In Chapter 2 
various suggestions were made to improve on scientific control and ecological 
validity, and their cost in use discussed. These recommendations were considered in 
the design of the present study which represents a controlled investigation of the 
relative and combined efficacies of two treatments for panic disorder with or without 
agoraphobia conducted in the primary care setting. The treatments studied were the 
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SSRI, fluvoxamine and the psychological treatment, cognitive behaviour therapy. 
The overall aim of the investigation was the assessment of treatment efficacy with 
emphasis placed on the clinical relevance of findings. The study is reported as the 
Main Study (Chapter 4), followed by the Global Measures Study (Chapter 5), The 
Panic Attack Measures Study (Chapter 6), and finally the Prognostic Indicators 
Study (Chapter 7). A concluding discussion is presented in Chapter 8. 
3.2 Main Study 
73 
Reported as Chapter 4. A controlled comparison of the relative and combined 
efficacies of the SSRI fluvoxamine and cognitive behaviour therapy in the treatment 
of panic disorder with or without agoraphobia. The comparison was undertaken 
within a 5 group framework and comprised a comparison of fluvoxamine, placebo, 
fluvoxamine plus cognitive behaviour therapy, placebo plus cognitive behaviour 
therapy, and cognitive behaviour therapy alone. This was the first time that this five 
group framework, essential to any comparison of a pharmacological and a 
psychological treatment, had been employed in an outcome study with panic disorder 
patients. The 5 group design is the minimum design standard required to permit the 
assessment of the relative and combined efficacies of the treatments under 
investigation. To ensure a meaningful comparison of the relative efficacies of the 
pharmacological and psychological treatments, therapist contact was balanced 
between groups. The use of concurrent treatments for panic disorder and 
agoraphobia, both pharmacological and psychological, was prohibited during the 
treatment phase of the study. Outcome was assessed across a range of therapist and 
patient report measures of general anxiety, agoraphobic avoidance, panic attacks, 
and depression. To enhance the clinical relevance of the results, the study was 
conducted in the primary care setting with all patients receiving treatment in their 
local surgery or health centre. The study design attempted to balance the requirement 
for scientific control to achieve meaningful results, with the need for methodology 
and procedure to match wider clinical practice as closely as possible, whilst at the 
same time taking account of the previous methodological problems highlighted in 
Chapter 2. 
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3.3 Global Measures Study 
Reported as Chapter 5. An investigation of the relative and combined efficacies of 
fluvoxamine and cognitive behaviour therapy in the treatment of panic disorder with 
or without agoraphobia with treatment outcome expressed in terms of brief global 
measures more suited to use in wider clinical practice, particularly the primary care 
setting. Treatment outcome research of the type reported in Chapter 4 often employs 
cumbersome assessment procedures such as long self-report or therapist report 
scales which do not easily lend themselves to use in wider clinical practice, 
particularly the primary care setting where time is often limited and consultation 
times short. It is important therefor to demonstrate that improvement that is 
identifiable using these research-based assessment measures can also be picked up 
using more brief global measures suitable for use by the primary care clinician. This 
section of the study reports an investigation of the value of global ratings of 
outcome, and ratings of general wellbeing and social disruption, as treatment 
outcome measures. Ratings of outcome were completed by, psychologist therapist, 
general practitioner, and by patients themselves. If shown to be useful, these global 
measures would provide a viable, and more succinct, method of assessing outcome in 
wider clinical practice. 
3.4 Panic Attack Measures Study 
Reported as Chapter 6. Previous studies have tended to report outcome in terms of 
panic attacks as proportion of patients panic free at treatment end point only. This 
study attempted a more detailed investigation of panic attack and limited symptom 
attack variables as treatment outcome measures. The study was of an exploratory 
nature and included measures of panic and limited symptom attacks, such as rated 
intensity and duration of attack, in addition to the simple measures of frequency 
commonly employed in previous studies. Previous studies have often excluded 
limited symptom attacks from their analyses. It is not clear as yet whether such 
exclusion is warranted as few studies have compared panic with limited symptom 
attacks in a controlled fashion. Measures of panic attack and limited symptom attack 
frequency, severity, and duration were recorded pre, mid, and post treatment using a 
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prospective event recording method via patient diaries. These measures were 
employed within the controlled comparison of fluvoxamine, placebo and cognitive 
behaviour therapy in the treatment of panic disorder with or without agoraphobia 
reported as Chapter 4. The aim of the study was twofold, to assess the value of panic 
attack measures as treatment outcome indicators, and to assess their ability to 
discriminate between differing treatments in a controlled comparison in patients with 
panic disorder and agoraphobia. A within subjects comparison of panic attacks vs. 
limited symptom attacks at each assessment point was also undertaken. 
3.5 Prognostic Indicators Study 
Reported as Chapter 7. The previous chapters in the present study have reported on 
treatment outcome in terms of research based measures, global clinically appropriate 
measures, and panic attack based measures. Whilst measuring outcome is of course 
important, it has long been an ambition of clinicians to attempt to predict treatment 
response preferably from pre-treatment measures. Such ability holds the promise of 
more precise programmes of pre-treatment screening and treatment allocation. 
Previous attempts at predicting treatment outcome from pre-treatment assessments 
have employed either inadequate between group designs, or have used multiple 
regression strategies. Whilst the latter do illustrate the amount of variance in 
treatment response accounted for by pre-treatment measures, they do not give any 
indication of the clinical significance of the predictions they provide. There is little 
practical value in a perfect prediction of a clinically meaningless outcome. Other 
methods of assessing prognostic indicators are therefor required. The aim of the 
reported study was an investigation of measures of mood state, personality and social 
disruption as pre-treatment prognostic indicators of treatment response in the 
patients receiving pharmacological (fluvoxamine), or psychological (cognitive 
behaviour therapy), treatments for panic disorder with or without agoraphobia as 
part of the main study reported as Chapter 4. The study design employed a logistic 
regression analysis for the first time with patients with panic disorder and 
agoraphobia, and is therefor of an exploratory nature. 
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CHAPTER 4 MAIN STUDY 
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4.1 Introduction 
This study is an attempt to address the methodological shortcomings of previous 
comparative studies of psychological and pharmacological treatments for panif disorder 
• 
and agoraphobia outlined in Chapter 2. Many studies have investigated the relative and/or 
combined efficacies of psychological and pharmacological treatments for panic disorder 
and agoraphobia. Unfortunately, this research suffers from a series of methodological 
flaws that compromise outcome findings. Firstly, as discussed in Chapter 2, many studies 
neglect to control for concurrent treatments, both pharmacological and psychological, 
received along with the study treatment. The presence of such concurrent treatment 
makes interpretation of study results extremely difficult. Secondly, no study comparing a 
psychological treatment with a pharmacological treatment for panic disorder within a 
placebo controlled framework has employed a psychological treatment alone group, with 
all previous studies using a psychological treatment plus placebo treatment to represent 
this group. It was suggested in Chapter 2 (c.f Hollon & DeRubies 1981), that a complete 
study comparing a drug with a psychological treatment must employ five treatment 
groups, namely, drug, placebo, drug plus psychological treatment, placebo plus 
psychological treatment, and psychological treatment alone. A third problem for 
comparative studies has been the lack of control for therapist contact. When comparing a 
relatively time-consuming treatment (cognitive behaviour therapy) with a comparatively 
quickly administered treatment (medication), it is essential to attempt to balance 
treatments for therapist contact time to try to control for this possible confounding factor. 
The fourth problem with previous research studies discussed in Chapter 2, is the variation 
between studies in quality and quantity of outcome assessment. Finally, whilst it is 
recognised that the bulk of morbidity in the anXiety disorders is encountered in general 
practice (Ashcroft et al 1987), previous treatment outcome studies on panic disorder and 
agoraphobia have been conducted in specialist clinics or hospital settings. This has led 
some (Wilkinson & Lewis 1990) to question the applicability of this previous work to the 
majority of patients who do not reach specialist hospital settings. 
The present study attempts to correct these methodological problems by ( a) requiring 
that all patients received no concurrent psychological treatments for 6 months prior to 
study entry, and no concurrent psychotropic medication during the treatment phase of the 
study. Patients referred to the study whilst taking concurrent psychotropic medication 
were required to undergo a 28 day wash-out period prior to study entry; (b) employing a 
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five group methodology, including a psychological treatment alone group; (c) ensuring 
that an attempt is made to balance therapist contact time across all groups; (d) assessing 
treatment outcome across a range of patient and therapist rated measures of anxiety, 
depression and avoidance, including prospective monitoring of panic attacks, with 
treatment end-point assessments conducted, where possible, by an independent assessor 
blind to treatment group; and ( e) conducting the investigation in the primary care setting. 
The study involves randomised allocation to treatment group and is conducted double-
blind for medication. This study is also the first to compare the relative and combined 
efficacies of cognitive behaviour therapy and the SSRI fluvoxarnine within a controlled 5 
group framework, and entails a comparison of fluvoxamine (FL), placebo (PL), 
fluvoxamine plus cognitive behaviour therapy (FL +CBT), placebo plus cognitive 
behaviour therapy (pL+CBT), and cognitive behaviour therapy (CBT). 
4.2 Method 
4.2.1 Subjects 
Patients were recruited via referral from general practitioners (GP) and were those 
considered suitable for pharmacological and/or psychological treatment. All patients 
were seen for all appointments in their local GP clinic. Following initial GP assessment 
and referral, patients were seen by a Clinical Psychologist for semi-structured interview to 
ascertain patient characteristics, presenting condition and severity of illness. The 
following entry criteria were employed. 
4.2.2InclusionlExclusion Criteria 
4.2.2.1 Inclusion Criteria 
(a) Patients presented with panic disorder with or without agoraphobia which 
conformed to the Diagnostic and Statistical Manual of Mental Disorders, Third Edition-
Revised criteria (DSM ID-R, AP A 1987); (b) Patients scored a minimum of 15 on the 
Hamilton Anxiety Scale (HAM-A) (Hamilton 1959) at both entry (Day -7) and after one 
Week wash-in (Day 0); (c) Duration of the problem greater than or equal to 3 months; (d) 
patients aged between 18 and 70 years inclusive; ( e) patient willing and able to provide 
informed written consent to participation. 
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4.2.2.2 Exclusion Criteria 
(a) Patients on any concurrent psychotropic medication, all patients were required to 
undergo a 4 week wash-out from concurrent psychotropic medication prior to entry, if 
required; (b) Patients suffering from a major depressive disorder as operationalised as a score of 
21 or greater on the Montgomery Asberg Depression Rating Scale (MADRS) 
(Montgomery and Asberg 1979); (c) patients suffering from obsessive-compulsive 
disorder, paranoid personality disorder, schizophrenia, schizo-affective disorder, manic 
disorder, or other unspecified psychosis; (d) patients with severe concurrent somatic 
disease, particularly impairment of hepatic/renal function, or heart disease of significant 
clinical importance; (e) patients with evidence of epilepsy, organic brain disease, or other 
serious neurological deficit; (t) patients who were alcohol dependent or drug dependent, 
or showed a risk of dependency; (g) patients considered a high suicide risk; (h) female 
patients who were pregnant, breast feeding, or who were not taking adequate 
contraceptive precautions; (i) patients who suffered from a physical disability which 
severely restricted mobility; (j) patients who had received psychological treatment for 
panic disorder and agoraphobia within the 6 months prior to entry; (k) patients who 
attended other therapists whether lay or professional. 
Over a period of 3 years a total of 23 8 patients were referred by GPs for study 
inclusion. Of these, 45 were not entered for the following reasons: - 8 patients failed to 
attend for assessment, 5 declined entry at first appointment, 14 were classified as 
disorders other than panic disorder and agoraphobia, 5 failed to meet the criteria of the 
DSM llI-R classification, 5 scored less than 15 on the HAM-A, 5 declined to discontinue 
concurrent psychotropic medication for the prescribed wash-out period, 2 were assessed 
as a serious suicide risk, and 1 patient was suffering from concurrent illness (epilepsy). A 
total of 193 patients were, therefore, entered into the study. 
4.2.3 Procedure 
At Day -7 patients were randomised to CBT alone or to the medication groups. 
Those patients in the medication groups received 1 week of single blind placebo 
medication at one tablet placebo/day, (Day -7 to Day 0). This procedure was employed 
to control for the effect of early placebo responders on outcome in the medication 
groups. All patients scoring below the established minimum of 15 on the Hamilton 
Anxiety Scale (HAM-A) at Day 0 were to be excluded. No exclusions on this criterion 
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were made. Three patients were excluded from the trial during the placebo wash-in week, 
one patient used psychotropic medication, one patient refused further participation, and 
one patient did not return for further treatment. At Day 0 all patients in the medication 
groups who continued to satisfY entry criteria were randomised to one of the 4 groups 
receiving medication, i.e. FL, PL, FL+CBT or PL+CBT. Patients in the CBT alone group 
did not receive the single blind placebo during wash-in. No patients in the CBT group 
were excluded during this period (Day -7 to Day 0). A total of 190 patients were, 
therefore, entered into the randomised phase of the study at Day O. All patients were 
thereafter seen for the same number of sessions to the same schedule of contact. Each 
session lasted a maximum of60 minutes and a minimum of30 minutes. All patients were 
seen by the one clinical psychologist therapist. A random sample of appointments were 
audio taped as a check on treatment integrity. Patients were then seen at Day -7 and 0 for 
initial assessment. Following Day -7 and Day 0 appointments, all patients were seen for 
assessment and treatment at Day 7, Day 14, Day 28, Day 42, Day 56, Day 70 and at Day 
84 when end point assessment was carried out. Follow up at 6 months was also carried 
out. At each session all patients were asked to report any medication taken since the last 
visit. Patients were notified at entry that the use of non-study psychotropic medication 
would result in withdrawal from the study. Patients continued to have access to their GP. 
Access to the study investigators outside of treatment sessions was available via 
telephone or radio pager. Patients who failed to complete the entire study period having 
withdrawn due to early effectiveness or ineffectiveness, who received at least 42 days 
treatment, and who provided adequate end-point data were included in the final analysis 
as "defined completers". A total of 149 completers and defined completers from the entry 
group of 190 were included in the final analysis. Details of completers, defined 
completers and the drop out/withdrawals per group are given in Table 4.1, demographic 
details for each treatment group included in the analysis are given in Table 4.2. 
4.2.4 Treatments 
4.2.4.1 Medication 
Following 1 week of single blind placebo, patients in the FL and PL groups received 
12 weeks of either fluvoxamine or placebo. Patients receiving fluvoxamine received an 
initial dose of50mglday fluvoxamine at Day 0, this was increased by 50mg to 100mglday 
at Day 7, and by a further 50mg to ISOmglday at Day 14. Thereafter the dose was 
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maintained at 150mglday for the remaining 10 weeks of the study period. Medication 
was discontinued without taper at Day 84. Medication was supplied in 50mg tablets, 
patients receiving placebo were given the equivalent number of tablets at each 
appointment thus maintaining the double blind status. 
Table 4.1 Sample characteristics by group for number of patients randomised, completers, defined 
completers, patients excluded from analysis, drop-out, number included in completers analysis and 
proportion of completers sample with independent end point assessment. 
FL PL FL+CBT PL+CBT CBT 
No randomised 36 37 38 36 43 
Excluded! 7 9 9 3 13 
drop-outs 
Completers 24 20 27 32 30 
Defined completers 5 8 2 1 0 
No included in completers 29 28 29 33 30 
analysis 
No (%) of patients in completers analysis 19 16 15 26 22 
with independent end point assessment (65.5) (57.1) (51. 7) (78.8) (73.3) 
Table 4.2 Demographic features of (n = 149) completers sample 
FL PL FL+CBT PL+CBT CBT 
(n = 29) (n = 28) (n = 29) (n = 33) (n = 30) 
Mean age (yrs) 36.62 42.28 37.27 38.81 33.23 
Sex M5, F23 M6, F22 M7, F21 M6, F27 M8, F22 
Mean duration of panic 7.32 7.74 7.00 6.93 5.11 
disorder (Years since first 
panic attack) 
Mean duration of 5.04 3.75 6.18 8.35 4.04 
agoraphobic avoidance 
(years) 
Mean duration of current 34.03 51.53 61.41 57.42 28.66 
episode (months) 
Patients who were unable to tolerate the maximum dose of medication had the dosage 
reduced from three to two tablets/day (i.e. 150mglday to 100mglday for the tluvoxamine 
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groups). Reduction was necessary for 8 patients, (FL = 2 patients, PL+CBT = 2 patients, 
FL+CBT = 4 patients). Compliance was assessed by return pill counts, no formal 
recordings of drug plasma levels were taken. Session content for the FL and PL groups 
focused on assessment of current status and progress. Patients were aware that the 
psychologist/assessor would not offer any therapeutic advice, and no direct advice on 
anxiety management was given. For example, patients who asked about anxiety or 
avoidance management were told, "you must feel free to do whatever you want to do". 
The emphasis in these groups was on the provision of a warm and empathic therapeutic 
relationship without the provision of active therapeutic advice. This was similar to the 
approach used by Power and colleagues (power et al 1990a) in their study employing a 5 
group, balanced therapist contact methodology. 
4.2.4.2 Cognitive Behaviour Therapy 
A cognitive behaviour therapy was employed which emphasised both gross exposure 
techniques and cognitive and behavioural panic management techniques as contributing 
factors to emotional processing (Foa & Kozak 1986) and thus fear reduction. The areas 
targeted in treatment were those outlined by Barlow and co-workers (Barlow 1988, 
Zinbarg et al1992) and included (a) the action tendencies associated with panic, (b) the 
sense of lack of control, and (c) hypervigilant and avoidant information processing 
strategies. The first 2 sessions of treatment (Day -7 and Day 0) were given over to 
assessment. Patients detailed both gross avoidances, e.g. of situations, and more subtle 
control and avoidance behaviours employed in an attempt to control panic attacks, such 
as holding on to supports, or cognitive and behavioural distraction techniques. Patient's 
personal understanding of their panic attacks mcluding any fears of catastrophic outcome 
were also investigated. At Day 0 patients were informed of the basic nature of panic 
attacks and informed that full explanation of their disorder would be given at their next 
appointment (Day 7). This educational component of treatment has previously been 
emphasised as important, (Shear & Francis 1988). Patients were informed that their 
spouse, partner or other relative could attend this appointment if desired. At Day 7 a full 
explanation of the likely causes, course and nature of patient's panic disorder was given. 
Treatment instructions were given in keeping with the above-suggested essential targets 
of change. Treatment emphasised the importance of patients confronting their panic 
attacks and attempting to replace avoidance responses, both behavioural and cognitive, 
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with more approach centred actions. In this way patients were enabled to appreciate that 
their worst fears were not realised and that if unsupported by avoidant actions their panic 
attacks dissipated and gradually settled over time. Treatment, therefore, attempted to 
follow the principles of emotional processing (Foa & Kozak 1986). Traditional exposure 
requiring a return to avoided situations was presented as a useful and ecologically valid 
means to encounter the panic attacks and thus present a forum for change. Artificial 
methods of panic provocation or simulation such as interoceptive exposure (Barlow 
1988) were not employed. All patients received a standardised treatment manual 
(Appendix I) at the Day 7 appointment. All further sessions (Days 14-84) were devoted 
to a review of progress, discussion of any possible problems in treatment, and 
identification of future targets for exposure and change. Treatment was presented as a 
profoundly patient led endeavour with efforts between sessions seen as an essential 
component of change. This being the case, targets were decided by patients with therapist 
dictated "homework" being kept to a minimum wherever possible. Patients in the 
cognitive behaviour therapy group (CBT) received no medication throughout treatment. 
4.2.4.3 Combined Treatments 
Patients receiving either fluvoxamine + cognitive behaviour therapy (FL +CBT) or 
placebo + cognitive behaviour therapy (pL+CBT) received medication to the identical 
protocol and cognitive behaviour therapy to the identical protocol to those detailed 
above. The medication was emphasised as adjunctive or complementary to the cognitive 
behaviour therapy in the combined treatment groups in an attempt to engage an equal 
commitment to the cognitive behaviour therapy in these groups. 
4.2.4.4 Therapists 
All patients were treated by the current author, DS, a clinical psychologist with 13 
years post qualification experience. A second clinical psychologist (KGP) with 16 years 
post qualification experience was the independent end-point assessor and provided cover 
for absences of the first author. A GP principal and consultant psychiatrist (RJS) acted as 
medical supervisor and carried the radio pager with occasional cover being provided by 
KGP and DS. Data collected were monitored by an independent monitor (JAA) at 
monthly intervals throughout the duration of the study. 
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4.3 Measures 
Although a variety of treatment process and outcome measures were employed, only 
the main measures are reported here. Copies of all measures are given in Appendix n. 
4.3.1 Mood 
Anxiety was measured by the Hamilton Anxiety Scale (HAM-A) (Hamilton 1959). 
This therapist rated scale was completed using a more structured scoring system than that 
originally used by Hamilton (1959) based on the frequency, severity and duration of 
symptoms (Hamilton Anxiety Glossary; Power et al1983, Appendix ill). The HAM-A 
was completed for all groups at Days -7, 0, 7, 14,28,42,56, 70, 84 and 6 month follow 
up. 
Patients provided a self rating of anxiety using the Kellner and Sheffield Symptom 
Rating Test (SR T) (Kellner & Sheffield 1973). This scale, designed as a measure of 
symptom change in neurotic patients undergoing treatment in therapeutic trials such as 
drug trials, was completed at Days 0, 7, 14,28,42,56, 70, 84 and 6 month follow up. 
Depression was rated by therapist rating using the Montgomery-Asberg Depression 
Rating Scale (MADRS), a scale designed to be sensitive to change in depression during 
treatment (Montgomery & Asberg 1979). This was completed at Days -7, 0, 42, 84 and 
6 month follow up. 
4.3.2 Phobic Avoidance 
Avoidance was measured by means of the Fear Questionnaire (FQ) (Marks & 
Mathews 1979). This self rated instrument provides a rating of agoraphobic, social and 
blood injury avoidance and further ratings of mood disruption and global distress. For the 
sake of brevity only results from the Agoraphobia Subscale (FQ-AG) are reported here. 
This was completed at Days 0, 42, 84 and 6 month follow up. 
4.3.3 Panic Attacks 
Panic attacks were assessed by inspection of patients panic diaries which were 
completed for 7 day periods throughout the treatment phase of the trial. Patients were 
provided with the DSMIll-R list of panic symptoms and asked to identifY those which 
had occurred during anyone panic attack, and to provide an overall rating of intensity 
and estimate of duration for each panic attack. Patients were instructed that panic attacks 
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constituted episodes of anxiety of sudden onset but were not informed as to the number 
of symptoms required to constitute a panic attack in DSMIII-R. Panic attacks versus 
limited symptom attacks were thus assessed post hoc by the therapist. In this report for 
the sake of brevity, only the percentage of patients panic free at end point will be 
reported. More detailed analysis of panic data will be reported in Chapter 6. 
4.4 Results 
Table 4.1 lists the sample configurations for each group. The groups showed some 
difference in attrition with the PL+CBT group showing the lowest drop out/exclusion 
rate and the CBT group the highest. Drop out/exclusion rates were not statistically 
different across groups however (x2 = 5.99, df= 4, n.s.). The proportion of defined 
completers differed significantly between groups (x2 = 16.604, df= 4, P < 0.05) with the 
PL group having the highest number of defined completers (n = 8). The reasons for drop 
out or exclusion from completers sample were as follows: 1 patient from the FL group, 2 
from PL, 3 from FL+CBT, 2 from PL+CBT, and 8 from CBT did not return for 
treatment. One patient from the FL group, 1 from PL, 1 from PL+CBT and 3 from CBT 
were found during treatment to have failed to meet study entry criteria, either by the 
emergence of a contra-indicated condition (e.g. alcohol abuse) or the use of concurrent 
psychotropic medication, these patients were excluded from analysis. One patient from 
the FL group and 1 from the CBT group stated ineffectiveness as the reason for drop out. 
One patient in the CBT group refused treatment after 3 sessions. Concern over study 
medication compliance or obvious failure to comply with medication regimen led to, 1 
patient in the FL group and 3 patients in the PL group being excluded from analysis. One 
patient each from the PL and the FL +CBT groups were excluded due to administrative 
errors, namely failure to complete questionnaire assessments adequately. Drop out rates 
stated to be due to medication side effects were n = 3 (8.3%) for the FL group, n = 2 
(5.4%) for the PL group, n = 0 for the PL + CBT group and n = 5 (13.1 %) for the 
FL+CBT group. This gives a combined drop out rate attributed to side effects ofn = 8 
(10.8%) for those patients receiving Fluvoxamine. 
A previous study (power et al1990a) had established a strong concordance (pearson r 
= 0.86) on ratings made on the HAM-A by the personnel in the present study (KGP, 
DS). As a further check, correlations between Day 70 HAM-A scores and Day 84 HAM-
A scores for all patients receiving independent end-point assessment were calculated, for 
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the whole sample and for each treatment group individually. Correlations obtained were, 
Whole Sample r = 0.82, FL r = 0.77, PL r = 0.87, FL+CBT r = 0.61, PL+CBT r = 0.90, 
CBTr=0.85. 
4.4. 1 Statistical Analysis 
One-way analysis of variance between groups on age, duration of panics and 
agoraphobic avoidance, duration of current episode, Day -7 and Day 0 HAM-A, Day 0 
SRT, Day -7 and Day 0 MADRS, and Day 0 FQ+AG, revealed no significant differences. 
Groups were therefore comparable on the main dependant measures prior to active 
treatment and following one-week wash-in. 
A one way analysis of variance between groups on total amount of therapist contact 
revealed a significant difference between groups (F (4,144) = 16.86, P < 0.001). Using 
post hoc Scheffe tests, FL (x = 360.38 min, s.d. = 27.42) differed from FL+CBT (x = 
395.17 min, s.d = 45.85) (p < 0.05); whilst both FL and PL (x = 380.07 min, s.d = 39.77) 
differed from both PL+CBT (x = 424.36, s.d = 29.93) and CBT (x = 422.66 min, s.d = 
38.92) (p < 0.01). This suggested that the procedural attempt to balance therapist contact 
time across groups had not been entirely successful. In order to assess the relevance of 
this difference in contact time as potential covariate in analysis, a specimen analysis was 
conducted. A change score was computed for all subjects by subtracting end point, Day 
84, HAM-A scores from entry Day -7, HAM-A scores. A specimen analysis of 
covariance was conducted between groups on this score with total amount of therapist 
contact as the covariate. This yielded a non-significant covariate term (F (1,143) = 2.19, 
n.s.) suggesting that the covariate, total amount of therapist contact, had exerted little 
influence on treatment response as measured by HAM-A difference score. Inspection of 
scatterplots for total amount of therapist contact by HAM-A difference score for each 
group revealed an absence of obvious non-linear relationship between the variables. A 
final check comparing the observed and adjusted group means on HAM-A difference 
score for each treatment group revealed minimal differences again suggesting little 
influence of the covariate, total amount of therapist contact, on the dependant measure, 
HAM-A difference score. The observed versus adjusted means for each group were as 
follows, F (13.31 vs. 13.21), PL (7.50 vs. 7.45), FL + CBT (16.58 vs. 16.58), PL + CBT 
(15.51 vs. 15.58), CBT (14.90 vs. 14.96). 
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It appeared, therefore, that whilst there were some differences between the groups on 
total amount of therapist contact, these differences were not exerting a sufficient 
influence on outcome results to warrant the use of a full scale analysis of covariance. Also 
the assumptions of equal and linear regression within groups between the covariate and 
dependant variables, and the assumption that the covariate was not affected by the 
experimental (i.e. treatment group) variable required by an analysis of covariance 
(Huitema 1980) were not met by the data from this study. A full scale analysis of 
covariance was, therefore, liable to yield results of dubious validity and was thus deemed 
inappropriate. 
Main treatment effects were, therefore, investigated using repeated measures analysis 
of variance (ANOVA) with treatment group as the between subjects factor and time of 
assessment as the within groups factor. F-tests for simple effects were then carried out for 
each time of assessment, and specific between group differences illustrated using post-
hoc Scheffe tests. The Scheffe test was chosen as a conservative criterion minimising the 
risk of type I error. Within group changes in scores were investigated by comparison of 
entry versus end-point scores using related t-tests. 
4.4.2 Hamilton Anxiety Scale (HAM-A) 
Table 4.3 lists the mean scores for the HAM-A for each group at each assessment 
point. 
Two factor analysis of variance (treatment group and time of assessment) on HAM-A 
SCOres over the wash-in phase (Day -7 to Day 0) revealed a significant effect for time (F 
(l,I44) = 71.74, P < 0.001) and an interaction effect (F (4,144) = 4.15, P < 0.005) 
indicating a differential reduction in HAM-A o~er wash-in between groups. Simple 
effects F-tests revealed a significant reduction in HAM-A score over wash-in for FL (F 
(l,28) = 30.13, P < 0.001), PL (F (1,27) = 14.72, P < 0.001), FL+CBT (F (1,28) = 
18.85, P < 0.001) and PL+CBT (F (1,32) = 31.31, P < 0.001) but not for CBT (F (1,29) 
:::: 0.10, n.s). 
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Between groups analysis gave a significant group (F (4,144) = 4.56, P < 0.002) time 
(F (8,1152) = 270.39, P < 0.001) and interaction effect (F (32,1152) = 4.89, P < 0.001) 
indicating differential changes across groups. 
Table 4.3 Means and standard deviations (s.d.) for Hamilton Anxiety Scale HAM-A for all groups 
at each assessment point during treatment. 
HAM-A FL PL FL+CBT PL+CBT CBT 
DAY-7 21.3 21.4 21.4 22.0 19.8 
(3.7) (4.5) (3.6) (4.2) (3.6) 
DAY 0 18.9 19.6 18.9 19.5 19.6 
(3.8) (4.1) (3.1) (4.2) (4.2) 
DAY 7 16.8 17.9 18.2 16.5 17.1 
(5.6) (5.3) (5.6) (5.3) (5.5) 
DAY 14 13.9 15.9 12.8 14.5 12.7 
(7.0) (6.1) (5.2) (6.0) (5.8) 
DAY 28 11.6 16.0 9.6 12.1 11.3 
(6.9) (6.1) (5.6) (5.8) (5.8) 
DAY 42 9.8 15.1 8.2 10.0 9.9 
(6.0) (7.3) (5.4) (6.9) (6.0) 
DAY 56 8.5 15.0 6.5 9.0 8.1 
(5.9) (7.7) (4.9) (6.5) (4.4) 
DAY 70 7.6 13 5.4 7.8 7.5 
(6.6) (8.3) (5.0) (6.6) (5.3) 
DAY 84 7.9 13.9 4.8 6.5 4.9 
(7.0) (8.4) (5.7) (6.7) (4.4) 
The data in Table 4.3. are further illustrated in Figure 4.1. overleaf 
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Table 4.4 Analysis of variance and simple effects on Hamilton Anxiety Scale (HAM-A) scores at 
each assessment point for all groups 
(i) 
Two factor ANOVA with repeated measures on B 
Factor A (treatment group) 
Factor B (time of measurement) 
Interaction A x B 
(ii) Simple effects (SS, Factor A) 
df F P Scheffe 
Day-7 4, 144 1.30 0.272 
Day 0 4, 144 0.27 0.896 
Day 7 4,144 0.55 0.697 
Day 14 4, 144 1.37 0.244 
Day 28 4,144 4.34 0.002** 2-3** 
Day 42 4,144 4.89 0.001** 2-3** 
Day 56 4, 144 8.39 0.0000*** 2-3*** 
Day 70 4, 144 5.49 0.0004*** 2-3*** 
Day 84 4, 144 9.29 0.0000*** 2-3*** 
(iii) Simple effects (SS Factor B) 
df F p 
FL 8,224 63.38 0.000*** 
PL 8,216 11.08 0.000*** 
FL+CBT 8,224 99.07 0.000*** 
PL+CBT 8,256 76.42 0.000*** 
CBT 8,232 68.32 0.000*** 
* p < 0.05, ** P < 0.01, *** P < 0.001. 
KEY : Post hoc Scheffe treatment group comparisons : 
1 = FL, 2 = PL, 3 = FL+CBT, 4 = PL+CBT, 5 = CBT. 
df 
4, 144 
8, 1152 
32, 1152 
2-1* 
2-1** 
2-1** 
2-1* 
Groups separated by a hyphen differ significantly from each other. 
F P 
4.56 0.002** 
270.39 0.000*** 
4.98 0.000*** 
2-5* 2-4* 
2-5** 2-4** 
2-5* 2-4* 
2-5*** 2-4** 
From Table 4.4 it can be seen that no significant between group differences emerged until 
day 28 when the PL and FL+CBT groups differed. This difference persisted and widened 
throughout the treatment period. By Day 42 all other treatment groups (FL, FL+CBT 
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and CBT) differed significantly from PL with these differences being maintained at 
varying levels of significance throughout the treatment period. At no point did the active 
treatment groups show a statistically significant difference between them. 
Within groups analysis revealed a significant reduction in HAM-A scores for all 
groups. Comparison of pre- (Day 0) and post- (Day 84) treatment HAM-A scores 
revealed a significant reduction for FL (t = 10.993, df = 28, P < 0.0001), PL (t = 4.09, df 
= 27, P < 0.001), FL+CBT (t = IS.28, df= 28, P < 0.0001), PL+CBT (t = 14.4S, df= 
32, P < 0.0001) and CBT (t = 13.88, df= 29, P < 0.0001). 
4.4.3 Symptom Rating Test (SRT) 
Table 4.Slists the mean scores for the SRT for each group at each assessment point. 
These data are also illustrated as Figure 4.2. 
Between group analysis gives a significant group (F (4,144) = 3.96, P < O.OOS), time 
(F (7,1008) = 6S.63, P < 0.001) and interaction effect (F (28,1008) = 2.34, P < 0.001) 
indicating differential changes across groups. 
Table 4.5 Means and standard deviations (s.d) on Kellner and Sheffield (SRT) for all groups at 
each assessment point during treatment. 
SRT FL PL FL+CBT PL+CBT CBT 
DAY 0 33.5 38.4 33.0 33.9 35.5 
(17.2) (18.2) (15.5) (14.3) (16.6) 
DAY 7 28.5 30.1 27.8 26.2 30.2 
(16.7) (16.8) (16.5) (16.9) (17.3) 
DAY 14 24.0 30.7 18.9 23.4 23.1 
(16.6) (18.0) (14.0) (16.4) (15.5) 
DAY 28 21.6 32.0 15.2 21.2 20.3 
(17.4) (19.3) (15.3) (16.9) (12.4) 
DAY 42 20.2 31.4 13.9 17.5 19.9 
(17.7) (21.1) (15.3) (16.4) (14.2) 
DAY 56 15.4 31.2 11.0 14.5 16.5 
(15.1) (21.9) (15.2) (14.5) (11.8) 
DAY 70 14.4 27.2 9.2 15.3 16.7 
(17.3) (22.1) (14.7) (17.3) (14.6) 
DAY 84 16.2 30.2 10.3 13.3 13.9 
(17.1) (23.1) (16.3) (15.2) (12.5) 
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Table 4.6 Analysis of variance and simple effects on Kellner and Sheffield (SRn scores at each 
assessment point for all groups 
(i) 
Two factor ANOVA with repeated measures on B 
Factor A (treatment group) 
Factor B (time of assessment) 
Interaction A x B 
(ii) Simple effects (SS, Factor A) 
df F P Scheffe 
Day 0 4, 144 0.50 0.730 
Day 7 4, 144 0.31 0.869 
Day 14 4, 144 1.98 0.100 
Day 28 4,144 3.97 0.004** 2-3** 
Day 42 4,144 4.23 0.002** 2-3** 
Day 56 4, 144 6.83 0.000*** 2-3*** 
Day 70 4, 144 4.08 0.003** 2-3*** 
Day 84 4, 144 5.93 0.0002*** 2-3** 
(iii) Simple effects (SS, Factor B) 
df F P 
FL 7, 196 13.67 0.000*** 
PL 7, 189 2.41 0.02* 
FL+CBT 7, 196 37.33 0.000*** 
PL+CBT 7,224 17.60 0.000*** 
CBT 7,203 16.37 0.000*** 
* p < 0.05, ** P < 0.01, *** P < 0.001. 
KEY: Post hoc Scheffe treatment group comparisons: 
1 = FL, 2 = PL, 3 = FL+CBT, 4 = PL+CBT, 5 = CBT. 
df 
4,144 
7, 1008 
28, 1008 
2-4* 
2-4** 
2-4** 
Groups separated by a hyphen differ significantly from each other. 
F P 
3.96 0.004 .... 
65.63 0.000*** 
2.34 0.000*** 
2-5* 2-1* 
2-5* 
93 
Table 4.6 indicates that no significant group differences occurred until Day 28 when 
the PL and FL +CBT groups differed. This difference being maintained throughout the 
treatment period. The PL and PL +CBT groups differed significant on three occasions, 
Days 42,56 and 84; the PL and CBT groups differed significantly on two occasions at 
Day 42 and 84 and the PL and FL groups differed significantly on one occasion at Day 
56. There were no other between group differences. Comparison of pre- (Day 0) with 
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post- (Day 84) treatment scores for SRT within groups revealed a significant reduction 
for FL (t = 4.96, df= 28, P < 0.001), PL (t = 2.61, df= 27, P < 0.01), FL+CBT (t = 8,41, 
df= 28, P < 0.0001), PL+CBT (t = 8,17, df= 32, P < 0.0001) and CBT (t = 6,21, df= 
29, P < 0.0001). 
4.4.4 Montgomery Asberg Depression (MADRS) 
Table 4. 7 lists the mean scores on the MADRS for each group at each assessment 
point. 
Two factor analysis of variance on MADRS scores over the wash-in period (Day -7 to 
Day 0) revealed a significant effect for time only (F (1,144) = 61.06, P < 0.001) indicating 
that all five groups showed a significant reduction in MADRS scores during wash-in. 
Between group analysis on MADRS scores during the entire treatment period revealed a 
significant group (F (4,142) = 3.22, P < 0.01), time (F (3,426) = 103.31, P < 0.001) and 
interaction effect (F (12,426) = 5.11, P < 0.001) indicating differential changes between 
groups. 
Table 4.7 Means and standard deviations (s.d.) for Montgomery Asberg Depression Rating Scale 
(MADRS) for all groups at each assessment point during treatment. 
MADRS FL PL FL+CBT PL+CBT CBT 
DAY-7 13.5 14.6 13.S 14.2 14.0 
(4.6) (4.2) (3.9) (3.6) (4.1) 
DAY 0 I1.S 13.2 12.1 11.9 12.6 
(4.7) (4.3) (4.3) (4.1) (5.4) 
DAY 42 S.2 13.1 6.S 7.7 7.0 
(6.5) (9.0) (6.1) (7.4) (4.3) 
DAYS4 6.9 13.4 3.S 6.0 3.9 
(7.7) (10.9) (6.5) (S.3) (4.6) 
Differences from the PL group were shown by the FL+CBT group at Day 42 (p < 
0.05) and Day 84 (p < 0.001), the CBT group at Day 42 (p < 0.05) and Day 84 (p < 
0.001) and the PL+CBT and FL groups at Day 84 only (both p < 0.05). There were no 
other between group differences. Comparison of pre- (Day 0) with post (Day 84) scores 
within groups revealed a significant reduction in MADRS scores throughout treatment 
for FL (t = 5.13, df= 28, P < 0.0001), FL+CBT (t = 7.92, df= 28, P < 0.0001), PL+CBT 
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(t = 4.46, df= 32, P < 0.0001) and CBT (t = 7.98, df= 29, P < 0.0001), but not for PL (t 
= 0.13, df= 27. n.s.). 
4.4.5 Fear Questionnaire - Agoraphobia Scale (FQ - AG) 
Table 4.8 lists the mean scores on the FG-AG for each treatment group at each 
assessment point. Between group analysis of variance for FQ-AG scores revealed a 
significant time (F (2,284) = 72.88, P < 0.001), and interaction effect (F (8,284) = 6.01, p 
< 0.001). The group effects did not reach significance. Significant differences existed 
between groups at Day 84 only when the FL +CBT, CBT, and FL groups differed 
significantly (all p < 0.05) from PL. 
Table 4.8 Means and standard deviations (s.d.) for Fear Questionnaire-Agoraphobia Scale (PQ-
AG) for all groups at each assessment point during treatment. 
FO-AG FL PL FL+CBT PL+CBT CBT 
DAY 0 11.4 13.5 16.4 19.9 15.0 
(l0.Q) (11.4) ( 11.5) (14.9) (11.2) 
DAY 42 8.0 12.3 6.9 10.2 7.0 
(8.8) (11.7) (8.8) (10.6) (5.5) 
DAY 84 5.5 13.7 4.7 7.2 5.1 
(7.9) (13.2) (7.8) (10.6) (5.4) 
The PL+CBT group did not differ significantly from PL at any point. Comparison of 
pre- (Day 0) with post- (Day 84) scores on the FQ-AG within groups showed a 
significant reduction throughout treatment for all treatment groups, (FL, t = 3.44, df = 
28, P < 0.002~ FL+CBT, t = 7.24, df= 28, p'< 0.0001~ PL+CBT, t = 5.99, df= 32, P < 
0.0001~ CBT t = 4.82, df= 29, P < 0.0001) with the exception of the PL group (t = 0.16, 
df= 27, n.s.). 
4.4.6 Panic Attacks 
The number and percentage of each treatment group who were free of major panic 
attacks at Day 84 wereFL n = 20, 68.golo~ PL n = 17, 60.7%~ FL+CBT n = 24, 82.7%~ 
PL+CBT n = 25, 75.7%~ CBT n = 21, 70.0%. A more detailed analysis of panic data 
collected at all assessment points and including measures of panic attack and limited 
symptom attack frequency, severity and duration will be given in Chapter 6. 
Panic attacks were rated for one week prior to Day 84. 
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4.4.7 Clinical Significance of Outcome Results 
The foregoing results are described entirely in terms of the statistical significance of 
change in treatment. It has been argued (Jacobson & Ravenstorf 1988, Jacobson & Truax 
1991), that statistically significant results may nonetheless have little clinical relevance. 
Jacobson and colleagues argued for the further analysis of outcome data in terms of the 
clinical significance of change and suggest criteria of assessment. For measures where 
data is available for normal as well as clinical populations, a cut-off score for clinically 
significant change can be calculated, reflecting change from the clinical to the non-clinical 
population. Such a criterion was established for the FQ-Ag scores using the data 
collected on a non-clinicaJ population by Mizes & Crawford (1988). A cut-off score of8 
or below indicated clinically significant change on this measure. Where data on a non-
clinical population do not exist, Jacobson and Ravenstorf (1988) recommend a cut-off 
score for clinically significant change where a patient score falls outside the range of the 
dysfunctional population by two standard deviations from the pre-treatment mean of that 
population, in the direction of functionality. This criterion was employed with two 
measures, firstly the HAM-A, where it established a criterion of moderate severity (cut-
off score of 12 or below) and secondly, with the SRT, where the variance in this measure 
gave rise to large standard deviations, and thus a highly stringent criterion of clinically 
significant change (cut-off score of 5 or below). 
Table 4.9 Number (%) of patients in each group achieving criterion "clinically significant change" 
on HAM-A, SRT, and FQ-AG at Day 84. 
FL PL FL+CBT PL+CBT CBT 
n=29 n=28 n= 29 n= 33 n= 30 
DAY 84 
Clinically significant change on : 
HAM-A 24 13 25 29 28 
(82.8) (46.4) (88.2) (87.8) (93.3) 
SRT 8 5 16 14 12 
(27.6) (17.8) (55.2) (42.4) (40.0) 
FQ-AG 24 14 24 24 23 
(82.8) (50.0) (82.8) (72.7) (76.7) 
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Table 4.9 reports the number of patients in each treatment group achieving clinically 
significant change at Day 84 on the HAM-A, SRT, and FQ-AG. All of the active 
treatment groups (FL, FL+CBT, PL+CBT, and CBT) had a large proportion of patients 
achieve clinically significant change on the HAM-A Proportions of patients achieving 
clinically significant change on the more stringent criterion for the SRT were lower with 
only the FL+CBT group achieving clinically significant change in more than half the 
patients in that group. For the FQ-AG a substantial proportion of patients achieved 
clinically significant change with the FL+CBT, and FL groups achieving the highest 
proportion. On all measures the PL group showed the lowest proportion of patients 
achieving clinically significant change. 
4.4.8 Follow-Up 
Meaningful follow-up data can be difficult to collect and evaluate particularly in the 
primary care setting as patients may require or receive subsequent treatment between the 
end-point assessment and follow-up assessment. It is essential therefore to exclude from 
any follow-up analysis those patients who have received subsequent treatment during the 
follow-up phase. 
All patients were requested to attend a 6 month follow-up appointment. Patients who 
had taken any psychotropic medication, regardless of quantity, or who had attended any 
appointments with psychologist, psychiatrist, or had any other secondary mental health 
referral during the follow-up period were deemed to have received follow-up treatment. 
Table 4.10 illustrates the numbers in each treatment group who had received no 
follow-up treatment according to this strictly ~efined criterion. This number was highest 
for the FL+CBT group. Figures are also given for number of patients who failed to attend 
for follow-up, this proportion was highest for the CBT group. As no follow-up 
information was available on non-attenders they cannot be included in follow-up analyses. 
Table 4.11 illustrates the numbers (and percentages) of patients in each treatment 
group who received no intervening treatment and who continued to achieve clinically 
significant change on the HAM-A, SRT and FQ-AG at 6 month follow-up. Overall the 
proportion of patients achieving clinically significant change in each group is lower than 
at end-point (Day 84). This is obviously partly due to the exclusion of patients who 
received intervening treatment and of those who failed to attend. 
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Table 4.10 Number (%) of patients in each group attending follow-up and number (%) receiving 
post study treatment at 6 month follow-up 
FL PL FL+CBT PL+CBT CBT 
Completers sample n = 29 28 29 33 30 
No. offollow-up attenders 23 21 24 30 28 
98 
(79.3) (75.0) (82.8) (90.9) (93.3) 
No. offollow-up attenders with no 12 8 18 20 15 
subsequent treatment (41.4) (28.6) (62.1) (60.6) (50.0) 
Table 4.11 Number (%) offollow-up attenders in each group with no subsequent treatment who 
continue to achieve clinically significant change on HAM-A, SRT and FQ-AG at 6month follow-
up. 
FL PL FL+CBT PL+CBT CBT 
6 MonthFU Clinically significant 
change on: 
HAM-A 11 8 18 18 15 
(37.9) (28.6) (62.1) (54.5) (50.0) 
SRT 4 4 10 II 11 
(13.8) (14.3) (34.5) (33.3) (36.7) 
FQ-AG 10 7 16 17 15 
(34.5) (25.0) (55.2) (51.5) (50.0) 
A consistent pattern is observable, in that the groups who received psychological 
treatment (FL +CBT, PL +CBT, and CBT) showed a greater preservation of clinically 
significant change over follow-up from those receiving medication alone (FL and PL). 
4.5 Discussion 
At end-point assessment all ofthe active treatment groups (FL, FL+CBT, PL+CBT, 
and CBT) showed statistically significant improvement on all measures. There were no 
statistically significant differences between active treatment groups on any measures 
during treatment. The overall impression therefore, is one of equal improvement 
following treatment with either fluvoxarnine alone, fluvoxarnine or placebo in 
combination with cognitive behaviour therapy, and with cognitive behaviour therapy used 
alone. This pattern of equal efficacy amongst active treatments has been noted for 
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previous outcome studies (Kazdin & Bass 1989). However, a closer inspection of the 
pattern of results and levels of clinically significant change, indicates qualitative 
differences between groups in treatment response and over follow-up. The placebo group 
(PL) showed statistically significant change in treatment on the HAM-A and SRT only 
with 60.7% of this group being free from major panic attacks at Day 84. These 
reductions in therapist and patient rated anxiety and panic frequency indicate a relatively 
strong placebo response in this study and it is against this response that the improvement 
in the active treatment groups is compared statistically. The placebo group also evidenced 
the lowest proportions of patients achieving clinically significant change on the HAM-A, 
SRT, and FQ-AG. This overall picture of poor outcome is further reinforced by results at 
follow-up where the placebo group showed the lowest number of patients who had 
received no additional treatment during the follow-up period. 
Patients receiving fluvoxamine (FL) showed significant gains in treatment pre- post on 
the HAM-A, SRT, and FQ-AG. These gains were statistically significantly different from 
patients receiving placebo (PL) on the HAM-A, from Day 42 onwards. Ofpatients in the 
FL group, 67% (n = 20) were free from major panic attacks at end-point, Day 84. It is 
reasonable to conclude from this pattern of results that the drug fluvoxamine was 
statistically more effective than placebo in the treatment of panic disorder and 
agoraphobia, and that this advantage appeared from mid-point (Day 42) in treatment on 
the HAM-A and between mid-point and end-point (Day 84) on the other measures. 
These findings of statistical significance are further reinforced when clinical significance is 
considered. The FL group showed a high proportion of patients (82.8%, n = 24) 
achieving clinically significant change on the ~-A, and an equal proportion (83.0010, n 
= 24) achieving such change on the FQ-AG. Indeed, this was the highest proportion of 
clinically significant change on the FQ-AG (equal to that of the FL+CBT group). 
The FL group showed a smaller proportion of patients achieving clinically significant 
change on the patient rated measure of anxiety, SRT, than on the HAM-A and FQ-AG, 
with only 27.6% (n = 8) of patients achieving this status. 
Results for the FL group were not entirely unequivocal. Scores on the patient-rated 
measure of anxiety, SRT, for the FL group were statistically different from the PL group 
on one occasion only at Day 56. Results from the follow-up of the FL group showed that 
41.4% (n = 12) of patients in this group had received no additional treatment during the 
follow-up phase. This figure was higher than that of the PL group (28.6%, n = 8) but 
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lower than those for the groups receiving either fluvoxarnine or placebo plus CBr (FL + 
CBT, PL + CBT) or CBT alone. 
Patients receiving cognitive behaviour therapy alone (CBT) showed statistically 
significant improvement pre-post on all the target measures (HAM-A, SRT, FQ-AG). 
These improvements were statistically significantly different from the placebo (PL) group 
on the HAM-A from Day 42 onwards and the FQ-AG at Day 84. At end-point (Day 84) 
70.0010 (n = 21) of the CBT group were free from major panic attacks. As for other 
treatment groups, improvements on the patient rated anxiety measure, SRT, were less 
robust, with scores on this measure being statistically significantly different from the PL 
group on two occasions only, at Day 56 and at end-point, Day 84. These results attest to 
the overall efficacy of this psychological treatment used without any adjunctive 
psychotropic medication in the treatment of panic disorder and agoraphobia. This finding 
is significant, given the relative scarcity of studies of psychological treatments for panic 
disorder carried out on medication-free populations (power & Sharp 1995). 
The statistical significance of improvements in the CBT group are again reinforced by 
the findings on clinical significance of change. The CBT group achieved the highest 
proportion of patients (93.3%, n = 28) achieving clinically significant change on the 
HAM-A. As with other groups the proportion of patients achieving the more stringent 
criterion of clinically significant change on the SRT was lower (40.0010, n = 12). Of the 
individual treatments (FL, PL, CBT) the CBT group showed the strongest and most 
comprehensive response. The CBT treatment did, however, show a higher drop out rate 
(32.2%, n = 13) than the other treatment groups. Since the majority ofCBT patients lost 
to treatment did not return for treatment tennjnation assessment, we cannot be sure of 
the reasons for their drop out. Similar drop out rates (circa 20-25%) from psychological 
treatments were, however, found for panic disorder patients in a series of studies by 
Michelson and colleagues (Michelson et al1985, 1990) using graded therapist assisted 
exposure and programmed practice, and by Black and colleagues (Black et al 1993a) 
using cognitive therapy. Interestingly, these are the only other reports of drop out rates 
from psychological treatments given in the controlled absence of concurrent psychotropic 
medication. 
Patients in the PL+CBT group showed statistically significant improvements pre-post 
on all target measures, (HAM-A, SRT, FQ-AG). These improvements were statistically 
significantly different from the placebo (PL) group from Day 42 onwards on the HAM-A 
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The PL+CBT group differed from the PL group on the patient rated SRT on three 
occasions at Day 42, Day 56, and Day 84, again reflecting the more volatile results 
from this scale. At end-point (Day 84) 75.7% (n = 25) of the PL+CBT group were free 
from major panic attacks. The PL+CBT group failed to show a significant difference 
from PL on the FQ-AG. This suggests that although the PL+CBT treatment showed a 
statistically significant improvement in rated agoraphobic avoidance pre-post, the 
combination of placebo plus cognitive behaviour therapy did not produce 
improvements statistically significantly greater than those achieved by using placebo 
medication plus therapist contact. The drop-out rate for patients receiving CBT alone, 
however, was higher than for placebo + CBT. 
Results assessed in terms of clinical significance suggest a general equivalence for 
the CBT and PL+CBT groups although the CBT group did produce slightly higher 
proportions of patients achieving clinically significant change on the HAM-A and FQ-
AG. Over follow up, the PL+CBT group showed a proportion of patients receiving no 
post study treatments which at 60.6% (n = 20) was similar to that for the other 
combined treatment group FL+CBT, (62.1%, n = 18). The proportion of patients 
achieving clinically significant change on the target measures (HAM-A, SRT, FQ-AG) 
surviving to 6 month follow up with no subsequent treatment was also similar to that 
for the other groups receiving CBT (CBT and FL+CBT) and higher than that for the 
group receiving medication without active psychological treatment. This suggests that 
cognitive behaviour therapy whether used alone or in combination with fluvoxamine 
or placebo, enhances the maintenance of treatment gains over 6 month follow up. 
As with all the other active treatment groups the FL +CBT group showed 
statistically significant improvements pre-post (HAM-A, SRT, FQ-AG). These 
improvements were all statistically significantly different from placebo (PL). The 
FL+CBT and CBT groups were the only groups to show statistically significant 
differences from placebo on all target measures. The FL+CBT group showed 
statistically significant differences from placebo earlier than any other group with 
differences on the HAM-A and the SRT differing significantly from Day 28 onwards. 
The FL +CBT group was the only active treatment group to show a statistically 
significant difference from the PL group on the patient rated measure of anxiety, SRT, 
at all assessment points from Day 28 onwards. At end-point 82.7% (n = 24) of the 
FL+CBT group were free from major panic attacks, the largest proportion of all the 
treatment groups. Thus the active combination treatment, FL+CBT can be seen to have 
resulted in the most robust treatment gains with significant 
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gains being noticeable earlier in treatment than for the other active treatment groups. The 
FL+CBT group showed some advantage over other treatment groups in terms of 
clinically significant change, achieving the largest proportion of patients (55.0010, n = 16) 
to achieve this criterion on the SRT. These findings carried over into follow-up with this 
group having the largest proportion of patients noted to have required no subsequent 
treatment (62.1%, n = 18). It is reasonable to conclude, therefore, that the active 
combination treatment, FL+CBT, produced the most robust treatment response showing 
the earliest significant differences from the PL group. 
Overall, the absence of statistically significant differences between the active treatment 
groups (FL, CBT, PL+CBT, FL+CBT), initially suggested therapeutic equivalence. 
When clinical significance was investigated, however, and compared with that of the 
placebo group (PL), differences emerged between treatment groups that were suggestive 
of differing therapeutic potency. The two treatment groups providing the most consistent 
treatment response were the CBT group, and the FL+CBT group, with the latter 
showing gains earlier in treatment. 
When considering these findings there are problems with the present study that should 
be borne in mind. A single therapist (DS) carried out all treatments and outcome results 
may therefore reflect factors associated with the presentation of treatments by this 
therapist rather than factors associated with the treatments themselves. The present study 
did not employ any biochemical assessments of either levels of study medication or as a 
screen for the use of non-permitted concurrent psychotropic medication, as this was 
found to be logistically impractical due to the study being conducted in a primary care 
setting rather than a central specialist clinic. ~ompliance with study medication was 
assessed via return pill counts and use of non-permitted medication by interview at each 
assessment session. Whilst these methods are less reliable than biochemical assay a small 
number of exclusions from analysis were made on each criterion(n = 4 and n = 2, respectively). 
An attempt has been made in this study to balance therapist contact across all 
treatment groups, thus patients receiving FL or PL alone had appointments of 
equivalent duration to those for patients in the CBT groups. This being the case the 
superiority for the CBT groups found here cannot be attributed solely to the 
increased therapist contact that CBT entails. The balance for therapist contact 
employed in this study has however meant that the drug alone groups received 
appointments which were significantly longer than those employed in standard 
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general practice. As such the FL and PL groups in this study may not be truly 
representative of these treatments as actually employed in the primary care setting. 
To rectify this a study is required employing a further two groups of patients given 
FL or PL alone to an identical schedule of contact to this study with the exception of 
duration of appointment which would be reduced to 5-10 minutes. This would 
constitute a more realistic test of the performance of the drug alone treatments in 
primary care. Another aspect of the current study worthy of comment also relates to 
therapist contact. All of the treatment groups in this study were seen on nine 
occasions (including initial assessment, but excluding follow-up). This is substantially 
fewer treatment sessions than the 12-16 sessions employed in previous studies of 
CBT in the treatment of panic disorder and agoraphobia (Shear et a11991, Clark et 
aI1994). The CBT employed in the current study might reasonably be referred to as 
briefCBT. The findings of strong efficacy for this shorter duration CBT in the 
treatment of panic disorder and agoraphobia is therefore of potential relevance to the 
management of this prevalent condition in primary care. 
Regarding the assessments employed in this study, results for panic attacks were 
quoted as percentages or patients in each group free from major panic attacks at 
treatment end point only. Whilst this is the panic measure common to most previous 
studies, no information is provided on other possible panic variables such as limited 
symptom attack frequency and panic intensity and duration. Emphasis was also placed on 
the primary care setting of the study and yet the measures employed were all complex 
and time-consuming rating scales which may not lend themselves to use as outcome 
measures in this setting (King 1997). Both o~these issues warrant further investigation 
and will be addressed in Chapter 5 and Chapter 6. The follow up data from this study also 
present some problems. The use of strict criteria for post -study treatment, namely any 
psychotropic medication use, and any psychology, psychiatry, or other mental health 
attendance may well have served to depress the size offollow up samples in this study. 
This was considered to be preferable to the procedure wherein post-study treatments are 
not given sufficient attention. Indeed, "treatment free" follow up results are quoted for 
samples where a proportion of patients had been taking concurrent psychotropic 
medication during the study period, and presumably over follow up also (Clark & Ehlers 
1993, Chambless & Gillis 1993). Follow-up results were also affected by the lack of 
information available for patients who defaulted on follow-up appointments. The question 
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of maintenance of gains post -treatment is of considerable clinical relevance, given the 
finding that patients with panic disorder and agoraphobia make heavy demands on 
primary care resources prior to treatment (Simpson et al 1994). Further assessment of 
patients patterns of treatment use post-study may therefore be important. 
In summary, the present study suggests that tluvoxamine does produce gains in the 
treatment of panic disorder and agoraphobia when compared with placebo. There is 
however some fall-off in these gains over follow-up. Cognitive behaviour therapy also 
produces gains in treatment that are better maintained over follow-up. The use of a 
placebo plus cognitive behaviour therapy combination appeared generally less effective in 
comparison with placebo than did cognitive behaviour therapy used alone. This is in 
keeping with the prediction of Hollon & DeRubies (1981) that placebo plus 
psychotherapy combinations are likely to underestimate the effectiveness of the 
psychotherapy. The gains produced by cognitive behaviour therapy used alone in the 
controlled absence of concurrent psychotropic medication were slower to emerge than 
those for the group receiving the active treatment combination of tluvoxamine plus 
cognitive behaviour therapy. In all cases, any significant improvement over placebo was 
not evident until after four weeks of treatment, this suggesting that the treatments 
employed in this study required some time to bring about significant change. 
Clinically, the results of this study suggest that cognitive behaviour therapy provides 
an effective, treatment for panic disorder and agoraphobia, which may be enhanced by the 
addition of the selective serotonin reuptake inhibitor, tluvoxamine. The exact mechanism 
underlying clinical change in these treatments, used either alone or in combination, 
remains unclear, but should be the focus of ~ture research effort. The present study has 
also been reported in detail by Sharp et al (1996). 
Chapter 5 105 
CHAPTER 5 GLOBAL MEASURES STUDY 
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5. 1 Introduction 
Studies investigating the relative and combined efficacies of pharmacological and 
psychological treatments for panic disorder, have been conducted primarily in 
specialist university clinics or hospital settings despite the bulk of morbidity in panic 
disorder and agoraphobia being encountered in general practice (Ashcroft et a11987, 
Katemdahl & Realini 1995). The applicability of these previous treatment outcome 
studies to the majority of patients seen and treated solely in primary care settings is 
questionable (Wilkinson & Lewis 1990). 
Treatment outcome in clinical trials has generally been reported as percentages of 
patients free of major panic attacks at treatment end-point, although the reliability of 
this measure has been questioned (Shear & Maser 1994). Outcome has also been 
reported in terms of patient rated questionnaires, such as the Fear Questionnaire 
(Marks & Mathews 1979), which concentrates principally on avoidance behaviours 
and thus represents only a partial assessment of the clinical presentation of panic 
disorder and agoraphobia. This problem has been rectified in some studies (Marks et 
al1993, Clark et al1994, Ost et al1993) by the use of therapist rated anxiety scales, 
often the Hamilton Anxiety Scale (Hamilton 1959). The use of such scales is time 
consuming and therefore they may not be easily employed in primary care settings 
(King 1977). Whilst reductions pre- to post-treatment on such scales may achieve 
statistical significance they do not, in the absence of comparative normative data, 
give a clear indication of the clinical significance of any improvement, nor do they 
indicate whether any improvement noted i~ accompanied by significant 
improvements in the patient's general wellbeing and social functioning. 
As outlined in Chapter 2, there is a need for more brief global assessment 
measures in clinical trials of pharmacological and psychological treatments for panic 
disorder which are applicable for use in primary care settings, and which provide 
information useful to the management of panic disorder patients. Some studies have 
employed global measures of outcome but have used different measures for therapist 
and patient thus making comparison impossible (Michelson et al 1990, Shear et al 
1991). Others have employed global measures for therapist only (Black et alI993a). 
Only one study to date has employed the same global outcome measure for therapist 
and patient however no comparison of ratings was made (Marks et alI993). Only 
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two studies have employed measures of the impact of treatment on patient's level of 
social functioning (Marks et al 1993, Black et al 1993a). This is a considerable 
omission given that one of the main aims of treatment for panic disorder and 
agoraphobia is to increase patients level of social functioning and facilitate a return 
to a more normal lifestyle. Furthermore none of the previous studies that included 
global measures made any comparison between outcome as assessed on these 
measures and on the more complex standardised scales also employed. A 
demonstration of concordance between these global measures and the more complex 
standardised measures is required to establish the validity of the global measures. 
Chapter 4 reported the results of a treatment outcome study comparing 
pharmacological and psychological treatments for panic disorder and agoraphobia. 
The study was conducted in the primary care setting and outcome was reported in 
terms of detailed and complex research focused measures. The present study reports 
the outcome of the same treatment study using brief global measures of outcome 
completed by therapist, patient, and referring general practitioner, along with brief 
patient self-report measures of general wellbeing and social functioning. All of these 
measures were selected to be shorter and less time consuming to complete than the 
more research oriented and standardised measures more commonly used in research 
outcome studies. Thus the measures reported in the present Chapter were selected to 
be more ''user friendly" and therefor more applicable to use in routine general 
practice. If demonstrated to be viable, these brief global ratings would show promise 
as quick and easy outcome measures suitable for use in routine clinical audit. 
5.2 Method 
5.2.1 Subjects 
The patients in this study were those treated in the main study reported as 
Chapter 4. All patients were referred by general practitioners (GP) and were those 
considered suitable for pharmacological and/or psychological treatment. Patients 
were seen for all appointments in their local GP clinic. Following initial GP 
assessment and referral patients were seen by a clinical psychologist for semi-
structured interview to ascertain patient characteristics, presenting condition, and 
severity of illness. 
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5.2.2. Inclusion criteria 
Inclusion criteria were those employed in the main treatment outcome study and are 
reproduced in detail elsewhere (Sharp et al 1996, Chapter 4). Main inclusion criteria 
were: panic disorder with or without agoraphobia conforming to Diagnostic and 
Statistical Manual of Mental Disorders Third Edition - Revised (DSMIII-R, 1987) 
criteria; a minimum score of 15 on the Hamilton Anxiety Scale (Hamilton 1959); a 
maximum score of 20 on the Montgomery Asberg Depression Rating Scale 
(Montgomery & Asberg 1979); symptoms which had lasted three months or longer; 
no psychotropic medication in the 28 days prior to entry and throughout the study 
treatment period; aged between 18 and 70 years inclusive. 
Over three years 238 patients were referred by GPs, of these 193 entered the 
study. Analysis was conducted on a sample of 149 completers and defined 
completers. Patients were randomly allocated to one of five treatment groups; 
fluvoxamine (FL) (n = 29), placebo (PL) (n = 28), fluvoxamine plus cognitive 
behaviour therapy (FL+CBT) (n = 29), placebo plus cognitive behaviour therapy 
(PL+CBT) (n = 33), and cognitive behaviour therapy (CBT) (n = 30). Demographic 
details of the sample have been given in detail previously (Sharp et a11996, Chapter 
4). 
5.2.3.Treatments 
All patients were seen to an identical schedule of contact and received either 
fluvoxamine, placebo, fluvoxamine plus cognitive behaviour therapy (CBT), placebo 
plus CBT, or CBT alone. Treatment specifications and schedules of contact were 
those of the main study and are described in more detail elsewhere (Sharp et al 1996, 
Chapter 4). 
5.2.4. Procedure 
Following assessment and referral by their GP, patients were seen by the 
psychologist therapist for initial assessment (Day -7) when they were randomised to 
treatment groups. Over the 12 week treatment period all patients received treatment 
to an identical schedule of contact with treatment appointments at Day -7,0, 7, 14, 
28,42,56, 70 and 84. Pre, and post treatment assessments for the present study 
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were conducted at days -7, and 84. Patients were also seen for follow-up at 6 
months. Individual appointments lasted a minimum of 30 and a maximum of 60 
minutes with all groups receiving an approximately equivalent amount of therapist 
contact. 
5.2.5. Measures 
(a) Severity of illness: was measured using the Global Symptom Severity Scale (Guy 
1976). This seven-point scale, designed to rate outcome in psychopharmacological 
research, gives a range of clinical severity from 1 'normal' to 7 'extreme'. This scale 
was completed by the psychologist therapist, and referring GP at Day -7 and Day 84. 
(b) Change in symptoms: was measured using the Clinical Global Improvement Scale 
(Guy 1976). This seven-point scale, designed with the same aim as above, rates 
symptom change on a range of 1 'very much improved' to 7 'very much worse', was 
completed by the psychologist therapist, referring GP, and patients at Day 84. 
(c) The General Health Questionnaire (GHQ, Goldberg 1978) was used to provide 
an overall self-rated measure of psychiatric wellbeing, with results reported as total 
scores. The 60 item version of the scale was completed by patients at Day 0 and Day 
84. 
(d) The Sheehan Disability Scale (SD, Sheehan 1986) is a simple measure of social 
functioning which assesses disruption to daily lifestyle and comprises three 10 point 
subscales where patients self-rate disruption to work, social life, and familylhome life 
completed by patients at Day 0 and Day 84. Copies of measures are given in 
Appendix II. 
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5.3. Results 
5.3.1. Statistical Analysis 
Repeated measures analysis of variance with a between subjects factor, treatment 
group, and a within subjects factor, assessment point, were conducted, with simple 
effects one-way analyses of variance to investigate significant results. Further post 
hoc analysis was conducted using defined contrasts to investigate differences 
between drug and placebo groups, both with CBT (FL, FL+CBT vs. PL, PL+CBT) 
(1 -1 1 -1 0) and without CBT (FL vs. PL) (1 -1 000) and those groups employing 
cognitive behaviour therapy with those not employing this treatment (FL, PL vs. 
FL+CBT, PL+CBT, CBT) (3 3 -2 -2 -2). The particular defined contrasts chosen 
were decided prior to the analysis of the present data, and following consideration of 
the pattern of findings obtained with the more complex measures used in the main 
study (Sharp et al 1996, Chapter 4). Within group comparisons of ratings before and 
after treatment were carried out using paired two-tailed t-tests. 
5.3.2. Severity of Symptoms 
Table 5.1 presents the mean ratings and statistical analyses of Global Symptom 
Severity before (Day -7) and after (Day 84) treatment by the psychologist therapist. 
For psychologist therapist ratings of symptom severity, analysis of variance 
revealed significant group (F(4, 144) = 5.16, P < 0.001), time (F(l, 144) = 389.91, P 
< 0.0001) and interaction (F(4,144)= 10.98, P < 0.0001) effects indicating differential 
changes between groups. No significant differences existed between groups before 
treatment (Day -7) where the largest propqrtion of patients for each group fell in the 
"moderate" or "marked" categories. Differences had emerged by Day 84 with 73%-
80% of patients in the groups, including CBT (FL+CBT, PL+CBT, CBT) in the 
"normallborderline" categories compared to 55% for FL and 29% for PL. Defined 
contrasts confirmed this finding, there being a significant interaction between group 
and symptom severity score after treatment (F(I,I44) = 9.98, P < 0.0001). The 
contrast comparing the groups including CBT with those which did not was 
significant, (p < 0.0001), as was that comparing FL with PL, both without CB T, (p < 
0.0001), and with CBT (p < 0.001). The contrast comparing all four drug groups 
with CBT alone i.e. (1111 -4) was also significant (p < 0.01). All five treatment 
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groups showed a significant reduction in symptom severity scores over treatment 
(p < 0.01 and above). 
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Table 5.1 One-way ANOV As, t-tests, and Means (s.d) for psychologist and GP ratings of Global 
Symptom Severity for each group pre and post treatment. 
FL PL FL+CBT PL+CBT CBT F 
P~chologjst 
Global 
SmJ,Qtom 
Severity 
PRE 4.34 4.14 4.28 4.42 4.16 0.71 
(Day -7) (0.77) (0.76) (0.65) (0.79) (0.87) n.s. 
POST 2.28 3.46 1.72 2.03 1.70 9.98**** 
(Day 84) (1.22) (l.48) (1.06) (1.33) (0.95) 
t 10.13**** 2.64** 11.07**** 11.02**** 10.34**** 
GP Global 
SymQtom 
Severity 
PRE 4.34 4.43 4.59 4.27 4.46 0.65 
(Day -7) (0.72) (0.84) (0.78) (0.84) (0.90) n.s. 
POST 4.10 5.29 4.24 4.51 4.47 0.53 
(Day 84) (3.47) (2.99) (3.61) (3.17) (3.37) n.s. 
t 0.38 n.s. 1.66 n.s. 0.51 n.s. 0.43 n.s. 0.01 n.s. 
** p < 0.01, *** P < 0.001, **** P < 0.0001, n.s. not significant. 
GP's ratings of mean severity of Global Symptom Severity before and after 
treatment are also given in table 5.1. Analysis of variance indicated no significant 
differences between groups on GP ratings of symptom severity both before and after 
treatment. Within group analysis indicated no significant change in GP CGI during 
treatment, and few notable differences between groups in the proportions of patients 
allocated to the categories of severity of symptoms before (Day 0), and after 
treatment (Day 84). 
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GP's ratings of Global Symptom Severity showed a weak but significant 
relationship with psychologist's rating of Global Symptom Severity using both pre 
treatment (pearson r = 0.27, p<O.Ol), and post treatment (Pearson r = 0.26, p<O.Ol) 
scores. There was therefor little agreement between referring GPs and the 
psychologist as to global severity of symptoms either before or after treatment. 
5.3.3. Clinical Global Improvement 
Means, standard deviations, and statistical analyses for the change in patients 
symptoms rated on the Clinical Global Improvement scale by psychologist therapist, 
GP and by patients themselves are given in Table 5.2. 
Table 5.2 One-way ANOV As, and Means (s.d.) for GP, Psychologist, and Patient ratings of Clinical 
Global Improvement for each group post treatment (Day 84). 
FL PL FL+CBT PL+CBT CBT F 
n=29 n=28 n= 29 n= 33 n= 30 
GP Clinical Global 3.93 4.85 3.93 4.03 4.06 0.35 
Improvement (3.52) (3.35) (3.71) (3.39) (3.61) n.s. 
P~cholog!st Clinical 2.27 2.93 1.37 1.82 1.60 8.11 *** 
Global Improvement (1.71) (1.30) (0.68) (1.07) (0.72) 
Patient Clinical Global 2.27 2.92 1.34 1.69 1.53 5.33*** 
Improvement (2.08) (1.80) (0.85) (1.57) (0.68) 
** = p< 0.01, *** = p< 0.001, n.s. not significant. 
Results for these measures were similar to those for Global Symptom Severity. 
There were significant differences between groups for change in symptoms rated by 
both psychologist therapist (F(4,144) = 8.1'1, P < 0.001) and patients (F(4,144) = 
5.33, P < 0.001), but not for GP ratings. Defined contrasts comparing the drug alone 
groups (FL, PL) with those including CBT were significant for both psychologist 
therapist (p < 0.0001), and patients (p < 0.001), ratings. Psychologist therapist rated 
85%-89% of patients in the CBT groups as "much improved/very much improved" 
compared to 75% for FL and 35% for PL. Similarly patients self-rated 88%-90% of 
the CBT groups as "much improved/very much improved" compared to 78% for FL 
and 48% for PL. The contrasts comparing drug with placebo were also significant 
for both psychologist therapist and patients ratings when drug alone groups were 
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compared without CBT, psychologist (p < 0.001), patient (p < 0.001), and with 
CBT, psychologist (p < 0.0001), patient (p < 0.01). 
For psychologist therapist ratings the contrast comparing all four drug groups 
with CBT alone was also significant (p < 0.05). 
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The psychologist therapist and patients ratings of change in symptoms following 
treatment showed considerable agreement (Pearson r = 0.89, P < 0.01), whereas 
relationships were weaker between psychologists and GP ratings of change of 
symptoms (Pearson r = 0.21, P < 0.01), and GP and patient ratings (Pearson r = 
0.18, P < 0.05). 
5.3.4. General Health Questionnaire 
Table 5.3 gives the means, standard deviations, and statistical analyses for total 
GHQ score before and after treatment. 
Analysis of variance revealed significant group (F(4,144) = 2.64, P < 0.05), time 
(F(l,144) = 68.51, P < 0.0001) and interaction (F(4,144F 2.58, P < 0.05) effects, 
indicating differential changes between groups. No differences existed between 
groups before treatment. Significant differences between groups emerged after 
treatment (Day 84), (F(4,144) = 6.38, P < 0.0001). Defined contrasts again yielded 
an identical pattern to previous measures with a superiority in GHQ scores for CBT 
groups over drug alone groups (p < 0.0001), and a superiority ofFL over PL both 
with CBT (p < 0.01) and without CBT (p < 0.01). The contrast comparing CBT 
alone with all four drug groups was also significant (p < 0.05). Comparison of before 
(Day 0) with after (Day 84) treatment scores showed a significant reduction in GHQ 
scores for all groups with the exception of placebo. 
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Table 5.3 One-way ANOV As, t-tests, and Means and standard deviations (s.d.) for GHQ and 
Sheehan Disability Scale before and after treatment 
FL PL FL+CBT PL+CBT CBT 
n=29 n=28 n=29 n= 33 n= 30 
GHQ 
PRE 19.56 22.82 19.93 19.78 21.47 
(Day 0) (17.35) (17.29) (16.79) (15.95) (16.39) 
POST 8.17 19.39 4.55 5.94 3.97 
(Day 84) (14.50) (20.25) (11.88) (10.95) (6.43) 
t= 3.42·· 0.84 n.s. 5.28···· 4.76···· 5.19···· 
Sheehan Disability 
Scale 
Work: 
PRE 4.66 4.64 5.24 5.46 4.80 
(Day 0) (3.23) (3.13) (3.35) (3.23) (3.42) 
POST 2.24 4.29 1.38 2.10 1.87 
(Day 84) (2.85) (3.13) (2.77) (2.58) (2.64) 
t= 3.86··· 0.61 n.s. 5.74···· 5.11···· 4.32···· 
Social Life 
PRE 5.03 5.18 6.97 6.12 5.73 
(Day 0) (2.76) (3.72) (2.92) (3.43) (2.86) 
POST 2.24 4.57 , 1.31 2.24 1.70 
(Day 84) (2.76) (3.23) (2.25) (2.92) (2.37) 
t= 5.86···· 0.85 n.s. 8.52···· 5.84···· 8.08···· 
Home Life 
PRE 4.03 5.57 5.17 5.39 4.60 
(Day 0) (2.84) (3.20) (2.78) (3.21) (2.90) 
POST 1.93 4.04 1.00 1.46 1.60 
(Day 84) (2.87) (3.34) (2.09) (2.12) (2.22) 
t= 4.39**** 2.73** 8.01·**· 7.09**** 4.99**·· 
** p < 0.01, **. P < 0.001, **** P < 0.0001, n.s. not Significant. 
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F 
0.21 
n.s. 
6.38···· 
0.39 
n.s. 
4.36·· 
0.75 
n.s. 
6.11···· 
1.30 
n.s. 
6.12···· 
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Comparison of before (Day 0) with after (Day 84) treatment scores showed a 
significant reduction in GHQ scores for all groups with the exception of placebo. 
5.3.5. Sheehan Disability Scale (SD) 
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The means and standard deviations for scores on this scale before and after 
treatment are also given in Table 5.3. Analysis of variance for the work scale 
revealed a significant time (F(1,144) = 79.18, P <0.001) and interaction (group x 
time) (F(4,144)= 4.20, P < 0.01) effect. The social life scale also revealed significant 
time (F(l,144) = 146.41, P < 0.001) and interaction (F(~,144)= 7.13, P < 0.001) 
effects. The home/family life scale gave significant group (F(4,144) = 2.95, P < 0.05) 
time (F(l,144) = 144.79, P < 0.0001) and interaction (F(4,144F 4.26, P < 0.01) 
effects. 
All groups, except PL, showed a significant reduction in scores on work (all p < 
0.001) and social life (all p < 0.0001). All groups including PL showed a significant 
reduction in home/family life scores (p < 0.01 and above). 
Differences existed between groups at Day 84 on work (F(4,144) = 4.36, P < 
0.01), social life (F(4,144) = 6.12, P < 0.0001) and home/family life (F(4,144) = 
6.11, P < 0.0001). 
Defined contrasts showed an identical pattern to previous measures. The CBT 
groups were superior to the drug alone groups for work (p < 0.01), social life (p < 
0.0001), and home/family life (p < 0.0001). Contrasts also revealed a superiority of 
FL over PL, without CBT for work (p < 0.01), social life (p < 0.01), and 
home/family life (p < 0.01). Results were similar for the comparison including CBT, 
work (p < 0.01), social life (p < 0.001), and home/family life (p < 0.01). 
5.3.6. Further Analysis 
Results presented thus far indicate that the global measures in this study were 
able to detect clinical changes in the active treatment groups. Results have also 
highlighted a considerable difference in acuity between psychologist and patient 
ratings on the one hand and GP ratings on the other. It is not clear as yet whether 
GPs or psychologist and patients ratings more accurately reflect patients clinical 
presentation as measured by the more complex measures employed in the main study 
(Chapter 4). This was investigated using correlations to assess the strength of 
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relationship between the global ratings (Global Symptom Severity and Clinical 
Global Improvement) and the standardised measures of outcome (HAM-A, SRT, 
and FQ-AG), employed in the main study (Sharp et al 1996, Chapter 4). Means, 
standard deviations, and analyses for the HAM-A, SRT and FQ-AG are given in 
Table 5.4, the correlations are given in Table 5.5. 
Table 5.4. One-way ANOV As, t-tests, and Means (s.d) for HAM-A, SRT, and FQ-AG for each 
d group pre an post treatment 
FL PL FL+CBT PL+CBT CBT F 
n=29 n=28 n= 29 n= 33 n= 30 
HAM-A 
PRE 21.3 21.4 21.4 22.0 19.8 1.30 
(Day -7) (3.7) (4.5) (3.6) (4.2) (3.6) n.s. 
POST 7.9 13.9 4.8 6.5 4.9 9.24**** 
(Day 84) (7,0) (8.9) (5.7) (6.7) (4.4) 
t= 10.19**** 4.09*** 15.28**** 14.5**** 13.88**** 
SRT 
PRE 33.5 38.4 33.0 33.9 33.5 0.51 
(Day -7) (17.2) (18.2) (15.5) (14.3) (16.6) n.s. 
POST 16.2 30.2 10.3 13.3 13.9 5.93*** 
(Day 84) (17.1) (23.1) (16.3) (15.2) (12.2) 
t= 4.96*** 2.61** 8.41**** 8.17**** 6.21 **** 
FQ-AG 
PRE 11.4 13.5 16.4 19.9 15.0 2.16 
(Day 0) (10.0) (11.4) (11.5) (14.9) (11.2) n.s. 
POST 5.5 13.7 4.7 7.2 5.1 4.95*** 
(Day 84) (7.9) (13.2) (7.8) (10.6) (5.4) 
t= 3.44*** 0.16 n.s. 7.24**** 5.99**** 4.82**** 
** = p< 0.01, *** = p< 0.001, **** = p< 0.0001, n.s. not significant. 
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Table 5.5. Correlations (pearsonJ:} between post treatment scores on HAM-A, SRT, FQ-AG, GP 
and Psychologist Global Symptom Severity, and GP, Psychologist and Patient Clinical Global 
I mprovement. 
HAM-A SRT FO-AG 
GP Global Svrnptom Severity 0.33** 0.35** 0.18* 
GP Clinical Global Improvement 0.31** 0.32** 0.14 n.s. 
Psychologist Global Symptom Seventy 0.95** 0.85** 0.70** 
Psychologist Clinical Global Improvement 0.80** 0.72** 0.56** 
Patient Clinical Global Imnrovement 0.76** 0.70** 0.51** 
* = p< 0.05, ** = p< 0.01 
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GP Global Symptom Severity ratings correlated weakly with HAM-A, SRT and 
FQ-AG scores whereas psychologists Global Symptom Severity ratings correlated 
strongly with HAM-A, SRT and FQ-AG. Thus GP's ratings symptom severity were 
not strongly related to either the psychologist's ratings or to standardised measures 
of anxiety and avoidance. By contrast the psychologist's ratings of symptom severity 
were in close agreement with anxiety as measured by the HAM-A and SRT, and 
avoidance as rated on the FQ-AG. 
A similar pattern emerged for GP, psychologist and patient Clinical Global 
Improvement, with GP ratings correlating weakly with HAM-A and SRT scores 
while the correlation with FQ-AG scores failed to reach significance. By contrast 
psychologist and patient ratings of Clinical Global Improvement showed strong 
correlations with HAM-A and SRT scores, whilst the correlations with FQ-AG 
scores tended to be slightly lower but remained statistically significant. Thus for 
improvement following treatment a greater degree of agreement between global 
ratings and standardised measures was found for psychologist and patient ratings 
than for GP ratings. It would appear therefor that GP's global ratings symptom 
severity and improvement following treatment did not accurately reflect the clinical 
picture as presented by psychologist and patient ratings and by standardised 
measures of anxiety and avoidance behaviours. 
The lower correlations found with the FQ-AG indicate that this measure of 
agoraphobic avoidance behaviour was, in this study, a potentially a less sensitive 
indicator of global symptom severity, and in particular clinical global improvement 
I 
than were the measures of anxiety (HAM-A, SRT). 
5.4. Discussion 
Outcome in the present study was assessed using brief global measures which are 
potentially more suitable for use in general practice. Results of the study indicate that 
these measures, despite their relative simplicity, are able to indicate differential 
outcomes between groups. Similar measures, in particular, psychologist and patient 
ratings have previously been shown to be sensitive to change in generalised anxiety 
disorder patients treated in primary care by either pharmacological or psychological 
interventions (power et al 1990b). 
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All measures employed in the current study also gave virtually the same result, 
there being no disagreement between measures on the main pattern of findings. This 
again attests to the robustness of these relatively simple measures. As with any other 
rating measure, these global ratings do, however, rely on the accuracy of the raters 
used, as demonstrated by GP's ratings of symptom severity and global improvement. 
The GP's ratings were at variance with those of the psychologist and the patients 
themselves. This difference was further reinforced by the noticeably weaker 
correlations between GP ratings and the measures of anxiety and avoidance. A more 
forthright statement of the finding would be that GPs were unable to detect the large 
changes following treatment that were obvious to both the psychologist and the 
patients. 
One possible explanation may be simply the length of time spent with the patients, 
and thus familiarity with the clinical picture. The psychologist had 9 appointments 
with each patient over a 13 week period, representing a maximum of 9 hours 
contact. The patients' familiarity with their own condition needs little elaboration. 
GPs, however, are unlikely to have had anything like the same amount of 
concentrated contact with the patients, and thus the accuracy of their assessments, as 
compared with those of the psychologist and the patients, may have been reduced as 
a result. It may also be the case that the GPs in the present study were insufficiently 
experienced in rating outcomes of panic disorder and agoraphobia. In the only 
previous study to employ GP ratings, (Power et al 1990b) the referring GPs were all 
members of a research group and had received training in research assessment 
methods. The Power et al (1990b) study found that GPs ratings were highly 
correlated with those of the psychologist. This would suggest that training of 
referring GPs might be required prior to their ratings being used in future studies. 
If replicated in future studies, the lack of concordance with more complex 
outcome measures demonstrated by GP raters in this study would have relevance 
beyond the measurement of experimental treatment outcome. Researchers 
investigating, for example, service usage or number of drug prescriptions following 
an experimental treatment may have to be aware that such post study treatment 
would be likely to be provided by patient's GPs, and its provision would be informed 
by the GPs perception of treatment outcome, whether accurate or not. 
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Results obtained using these brief measures nonetheless indicated that all four 
active treatment groups (FL, FL+CBT, PL+CBT and CBT) were superior to the 
placebo (PL) group, but that those treatment groups which included CBT (FL+CBT, 
PL+CBT, CBT) showed a consistent and significant trend of superiority over 
fluvoxamine alone (FL). This pattern of outcome was found not only for the 
therapist and patient global rating scales, but also for the measures of general 
psychiatric wellbeing (GHQ) and for the ratings of social functioning (SD). These 
latter two measures indicated that the active treatments (FL, FL+CBT, PL+CBT, 
CBT) all brought about improvements in patients self-rated general wellbeing and 
social functioning, whereas the placebo (PL) group showed a significant 
improvement only on the home/family life subscale of the SD. This is an important 
finding suggesting that the improvements which did occur following treatment with 
placebo medication plus therapist contact despite being statistically significant on the 
measures of general anxiety employed in the main study (HAM-A, SRT), were not 
robust enough for the patients to feel any improvement in their general wellbeing or 
their functioning at work or socially. Obtaining patient ratings of changes in social 
functioning and general wellbeing following treatment might be regarded as an 
alternative method of assessing the clinical significance of the outcome of that 
treatment. These findings are of course of considerable relevance given that one of 
the main aims of treatment is to return patients to an acceptable level of social 
functioning. Taken in the light of this lack of improvement in wellbeing and social 
functioning, the report in Chapter 4, of only n = 8 (28.6%) ofPL patients attending 6 
month follow-up without having required further treatment, is easily understood. 
Overall the findings of the present study are in agreement with those of the main 
study (Sharp et al 1996, Chapter 4) and reinforce the suggested efficacy for CBT 
either alone or in combination with fluvoxamine in the treatment of panic disorder 
and agoraphobia in primary care. Of further relevance to the primary care setting of 
the study, the brief measures employed in this study proved to be as discriminative 
and treatment responsive as the more complex measures used in the main study. 
Given the saving in time their use entails this is of potential relevance to the 
assessment of treatment outcome in primary care whether as a part of treatment 
outcome research or in the assessment or audit of everyday treatment efficacy. The 
findings for GP ratings would suggest, however, that some training of raters might 
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be required in future studies employing brief global measures of the type shown to be 
of value in the current study. The present study has been reported elsewhere as 
Sharp et al (1997b), and Sharp & Power (In Press). 
Chapter 6 121 
CHAPTER 6 PANIC ATTACKS AS TREATMENT OUTCOME VARIABLES 
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6.1 Introduction 
Panic attacks have been given a central role in the classification of panic disorder 
either with or without agoraphobia. The operationalisation and measurement of panic 
attacks is therefor an important part of any study investigating the efficacy of treatments 
for panic disorder and agoraphobia. The most widely used measure is panic attack 
frequency, indeed this aspect of panic attacks is embodied in DSM III, and DSM III-R 
as a defining factor in the classification of panic disorder. Panic frequency has commonly 
been assessed by asking patients to estimate the number of panic attacks they have 
experienced during a given time period, e.g. the last week or month. This method is 
included in diagnostic interviews such as the ADIS-R (Di Nardo et al 1983), and 
questionnaires such as the panic frequency sub scale of the Mobility Inventory 
(Chambless et al 1985). In treatment studies, outcome is often expressed in terms of 
percentage of patients free of panic attacks at treatment end-point. The validity of panic-
free status as a treatment outcome measure has been questioned (Shear & Maser 1994) 
particularly as it represents a single occasion measurement and therefor gives no 
indication of change in panic frequency during treatment. Percentage of patients panic 
free at treatment end-point has also been suggested to be a lenient measure of treatment 
efficacy which indicates treatment response more readily than other standardised 
outcome measures (Barlow 1988). The ability of panic free status to operate as a 
discriminative and informative treatment outcome measure might also be questioned, as 
it disregards the panic status of patients prior to the commencement of treatment. Thus a 
, 
patient who suffered no panic attacks during the treatment period would be classified as 
a treatment responder using this measure, whereas another patient who had shown a 
notable reduction in panic attacks as a result of treatment but who experienced one 
further panic attack during the final assessment period would not. Investigation of the 
presenting features of panic attacks is necessary however firstly, to further 
understanding of the condition, and secondly to investigate how panic attacks change 
following treatment. 
Studies investigating panic attack variables have had as their aim either the 
investigation of the phenomenology of panic attacks or, have employed panic attack 
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measures as outcome measures in treatment outcome studies. The phenomenological 
studies will be discussed first as their findings have potential ramifications for the 
measurement of panic as an index of treatment outcome. 
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The aim of phenomenological investigations has been to investigate the nature and 
pattern of the panic attacks suffered by panic disorder patients. The first finding of 
importance from these studies relates to the manner in which panic attacks are recorded. 
Three studies (Margrafet al1987, Rapee et al1990b, De Beurs et al1992) compared 
the frequency of panic attacks in patient samples with panic frequency recorded both 
retrospectively and prospectively by using patient completed panic-monitoring diaries. 
All three studies found that frequency of panic attacks was exaggerated in retrospective 
report as compared to prospective continuous monitoring. This finding means that 
retrospective reports of panic attacks cannot be relied upon to provide an accurate 
indication of patients condition regarding panic attacks. Along with these three studies a 
further six studies (Street et al1989, Krystal et al1991, Basoglu et al1992, De Beurs et 
al 1993, De Beurs et al 1994, Someya et al 1996) have investigated the phenomenology 
of panic attacks. All of these studies employed a prospective, event sampling method 
which requires patients to record details of any panic attack during or immediately after 
it's occurrence, thus avoiding the over-reporting bias found for retrospective reports. 
These studies have produced findings of relevance to clinical practice. Four studies have 
compared spontaneous and situationally triggered panic attacks and found few 
differences between them (Margrafet al1987, Street et al1989, Krystal et al1991, 
Basoglu et al 1992) suggesting that differentiating between spontaneous and situational 
panic attacks may be unnecessary in clinical practice. Studies have also compared full 
DSM IIIIDSM III-R panic attacks, which must include 4 or more symptoms, and limited 
symptom attacks, which consist of 3 or fewer symptoms (Margraf et al 1987, Krystal et 
al1991, De Beurs et alI994). One study (Krystal et al 1991) found panic attacks 
produced higher ratings of severity than limited symptom attacks, whilst another (De 
Beurs et al1994) found panic attacks to be of longer duration than limited symptom 
attacks. No other differences were found however, leading some researchers (Margraf et 
al1987, Krystal et al1991) to conclude that the distinction between panic attacks and 
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limited symptom attacks enshrined in DSM III-R and DSM IV has little diagnostic or 
clinical validity. This finding must be regarded as preliminary however as only one study 
(Krystal et al 1991) compared panic attacks with limited symptom attacks using a 
within-patients design. The other studies (Margrafet al1987, De Beurs et al1994) used 
a between subjects design, which assumes that all patients perceive and report the 
experience of panic in an equivalent way. Given the evidence suggesting considerable 
variation in reporting of panic attacks over time even within patients (Basoglu et al 
1992, De Beurs et alI994), this assumption is hard to justify. A within subjects 
comparison is therefor more appropriate, and further within subjects comparisons of 
panic attacks and limited symptom attacks are required. Such studies should include 
measures of panic severity and duration, as these have been shown to possibly 
differentiate panic attack and limited symptom attacks (Krystal et al 1991, De Beurs et al 
1994), and may also have some utility as treatment outcome variables. 
The above findings are relevant to the measurement of panic in wider clinical 
practice and suggest that panic should be assessed by prospective diary based 
monitoring and that it may not be necessary to distinguish between spontaneous and 
situational panic attacks. The inclusion of limited symptom attacks in any record of panic 
would seem to be important given that some evidence suggests more similarity than 
difference between panic attacks and limited symptom attacks (Margraf et al 1987, 
Krystal et al 1991). It is also suggested that any record of panic attacks should include 
measures of panic severity and duration. In order to assess the extent to which the above 
recommendations have been taken up in the' assessment of panic in treatment outcome 
research a more detailed review of the measurement of panic in treatment outcome 
studies is required. To achieve this the treatment outcome studies reviewed in Chapter 2 
were re-examined with particular regard to panic attack measurement. In the treatment 
outcome studies investigating psychological treatments (Table 2.1, Chapter 2), panic 
attacks were commonly assessed using prospective diary methods with only 3 of the 36 
studies (Michelson et al 1990, Beck et al 1994, Lidren et al 1994) employing less reliable 
retrospective methods. Unfortunately other methodological inadequacies were more 
common. In many studies only panic attacks, as opposed to limited symptom attacks, 
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were recorded with patients being specifically briefed on the distinction prior to their 
recording their panic attacks. Given the lack of empirical evidence indicating any major 
distinction between panic attacks and limited symptom attacks this procedure is hard to 
justify. In other studies only panic frequency was recorded there being no measures of 
panic severity or duration. Severity and duration of panic attacks were recorded along 
with panic frequency in only six studies (Ost 1988, Barlow et al1989, TeIch et al1993, 
Cote et al 1994, Bouchard et al 1996, Hecker et al 1996), but only two of these six 
studies (Ost 1988, Hecker et al 1996) actually reported results for severity and duration 
variables. Only one study (TeIch et al1993) included measures of panic attack and 
limited symptom attack frequency, severity and duration, unfortunately the data 
collected for limited symptom attacks in this study were not reported. Three of these six 
studies on psychological treatments failed to differentiate between treatments using 
panic attack frequency as an outcome variable (Barlow et a11989, Cote et al1994, 
Bouchard et al 1996), whilst a fourth (Hecker et al 1996) failed to differentiate between 
treatments using panic attack frequency, severity and duration. Only two studies found 
panic attack variables to differentiate between treatment groups at end-point. Ost (1988) 
found panic severity at treatment end-point significantly lower in their applied relaxation 
group than in the progressive relaxation group, while Teich et al (1993) found that panic 
attack frequency was significantly lower following group cognitive behaviour therapy as 
compared to a waiting list control group. Given the comparator this latter finding is 
hardly surprising. All six studies showed statistically significant pre to post treatment 
improvement in all panic variables used. It 'appears, in general, that the recording of 
panic attack data has been poor in psychological treatment outcome studies with very 
few studies including measures of severity and duration or including limited symptom 
attacks in their analyses. Furthermore, panic variables did not appear to strongly 
differentiate between competing treatments when employed as treatment outcome 
measures. 
When treatment outcome studies comparing pharmacological with psychological 
treatments are considered the position is arguably worse. Of the 20 pharmacological vs. 
psychological treatment studies reviewed, (Table 2.2, Chapter 2) only six studies (Teich 
,. 
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et al 1985, Tobena et al 1990, Klosko et al 1990, Hegel et al 1994, Oehrberg et al 1995, 
De Beurs et al 1995) employed prospective measurements of panic attacks. In all the 
other studies the less reliable retrospective method was used. None of these six 
pharmacological vs. psychological treatment studies reported ratings of severity or 
duration, and the issue of panic attacks versus limited symptom attacks was rarely 
mentioned and was not specifically investigated in any study. Regarding treatment 
outcome, in two studies (Tobena et al1990, Hegel et al1994) the ability of panic 
variables to differentiate between treatments could not be assessed, as these were single 
treatment open trials. In a further two studies panic attack frequency did not differentiate 
between groups at treatment end-point (TeIch et al1985, Klosko et alI990). The only 
significant differences between treatments in prospectively recorded panic attack 
variables in psychological vs. pharmacological treatment studies were found in the final 
two studies (De Beurs et al 1995, Oehrberg et al1995) using non-parametric analyses of 
proportion of patients panic free at end point. 
Overall it is clear that there is considerable variability in the quality of assessment of 
panic attacks in treatment outcome studies. The studies that have employed prospective 
methods have tended nonetheless to focus only on panic attack frequency failing to 
measure other potentially informative characteristics such as severity and duration of 
attacks. Limited symptom attacks are commonly excluded from analyses in 
psychological treatment studies and rarely mentioned in pharmacological vs. 
psychological treatment studies. Treatment outcomes in terms of panic attacks are most 
commonly expressed as proportions (usually percentages) of patients in a given 
treatment group panic-free at treatment end-point. Panic attack variables have rarely 
been employed as continuous measures throughout treatment and have consisted of pre-
post difference or change in frequency of panic attacks. It is not clear as yet how 
valuable and discriminative a treatment outcome measure they may be. The value of 
panic frequency as an outcome measure was questioned in one study (De Beurs et al 
1993) which employed treatments consisting of panic management techniques followed 
by the addition of in vivo exposure. Study results showed an increase in panic frequency 
when the exposure component of treatment was added making the panic frequency 
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variable less sensitive to overall change in treatment and at times difficult to interpret 
(De Beurs et al 1993). A final point concerns data configuration. The distributions found 
amongst the panic attack variables employed were mentioned in only three studies. 
Arntz & VanDen Hout (1996) noted that panic variables in their study were highly 
positively skewed and logarithmic transformations were employed to solve this problem. 
De Beurs et al (1995) also noted positively skewed distributions and consequently 
employed non-parametric analyses, as did Bouchard et al (1996) for their "non-normal" 
distributions. Distributions of data collected in all other studies were not mentioned and 
no corrective transformations or analyses described. Such are the flaws in previous 
research. 
As panic attack variables are argued to be the core feature of the diagnostic 
classification of panic disorder, the main targets of clinical intervention, and the focus of 
many treatment outcome measures, the inconsistencies highlighted in the forgoing 
discussion suggest that more thorough and detailed investigation of panic attack 
variables in rigorously controlled outcome studies is required. The present study was 
designed to address the methodological shortcomings in previous research and describes 
the investigation of measures of frequency, severity and duration for both panic and 
limited symptom attacks each separately and combined as total measures rated by a self-
report prospective event sampling method employed within a large controlled treatment 
outcome study. Panic measures were collected pre, mid and post treatment. Patients in 
the present study received treatment for panic disorder and agoraphobia by fluvoxamine, 
placebo, fluvoxamine + cognitive behaviour therapy (CBT), placebo + CBT, or CBT 
alone. 
6.2 Method 
6.2.1 Subjects 
Patients in the present study were those treated in the main study (Sharp et al 1996), 
reported here as Chapter 4. Patients were referred by general practitioners (GP) and 
were those considered suitable for pharmacological and/or psychological treatment. All 
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patients were seen for all appointments in their local GP clinic. Following initial GP 
assessment and referral all patients were seen by a clinical psychologist for semi-
structured interview to ascertain patient characteristics, presenting condition, and 
severity of illness. 
6.2.2. Inclusion criteria 
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Inclusion criteria were those employed in the main treatment outcome study and are 
reproduced in detail elsewhere (Sharp et al 1996, Chapter 4). Main inclusion criteria 
were: panic disorder with or without agoraphobia conforming to Diagnostic and 
Statistical Manual of Mental Disorders Third Edition - Revised (DSMIII-R, 1987) 
criteria~ a minimum score of 15 on the Hamilton Anxiety Scale (Hamilton 1959)~ a 
maximum score of 20 on the Montgomery Asberg Depression Rating Scale 
(Montgomery & Asberg 1979)~ symptoms which had lasted three months or longer~ no 
psychotropic medication in the 28 days prior to entry and throughout the study 
treatment period~ aged between 18 and 70 years inclusive. 
Over three years 238 patients were referred by GPs, of these 193 entered the study. 
Analysis was conducted on a sample of 149 completers and defined completers. Patients 
were randomly allocated to one of five treatment groups~ fluvoxamine (FL) (n = 29), 
placebo (PL) (n = 28), fluvoxamine plus cognitive behaviour therapy (FL+CBT) (n = 
29), placebo plus cognitive behaviour therapy (pL+CBT) (n = 33), and cognitive 
behaviour therapy (CBT) (n = 30). Demographic details of the sample have been given 
in detail previously (Sharp et al 1996, Chapter 4). 
6.2.3. Treatments 
All patients were seen to an identical schedule of contact and received either 
fluvoxamine, placebo, fluvoxamine plus cognitive behaviour therapy (CBT), placebo 
plus CBT, or CBT alone. Treatment specifications and schedules of contact were those 
of the main study and are described in more detail elsewhere (Sharp et al1996, 1997b, 
Chapter 4). 
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6.2.4. Procedure 
Following assessment and referral by their GP, patients were seen by the psychologist 
therapist for initial assessment (Day -7) when they were randomised to treatment 
groups. Over the 13 week treatment period all patients received treatment to an identical 
schedule of contact with treatment appointments at Day -7,0, 7, 14,28,42,56, 70 and 
84. Pre, mid and post treatment assessments were conducted at days -7, 42, and 84 
respectively. Patients were also seen for follow-up at 6 months. Individual appointments 
lasted a minimum of 30 and a maximum of 60 minutes with all groups receiving an 
approximately equivalent amount of therapist contact. 
6.2.5 Measures 
Panic attacks and limited symptom attacks were measured using a prospective self-
report event-sampling method. Patients were given a panic diary in which they were to 
record any panic attacks, if possible, immediately after they occurred, and certainly on 
the same day as they occurred. Thus retrospective reporting bias was minimised. For 
each attack patients were required to rate, the severity of the attack on a scale ranging 
from ° -"not at all severe" to 1 ° -"extreme the worst it could be", and the duration of 
the attack in minutes. The rating form also listed the 13 DSM III-R panic symptoms and 
patients were required to mark each symptom felt during the attack. Copies of the panic 
diary are given in Appendix II. Patients were not informed of the number of symptoms 
required for the attack to be classified as either a full panic attack (4 symptoms or more), 
or a limited symptom attack (3 symptoms or less). Thus patients record of number of 
symptoms endorsed would not be influenced by any prior definition of panic attacks. 
Definition of attacks as either panic or limited symptom attacks was carried out by the 
therapist after data collection. As in previous studies (TeIch et al 1993, De Beurs et al 
1993, De Beurs et al1995), panic diaries were completed by patients in the present 
study for one week recording periods prior to Day 0, Day 42, and Day 84. Measures of 
frequency, mean severity, and mean duration were derived for each treatment group for 
panic attacks and limited symptom attacks both separately and combined as total attacks 
(panic attacks plus limited symptom attacks) for each assessment point (Day 0, Day 42, 
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and Day 84). As some doubt has been expressed regarding patient compliance with 
panic diary procedures (Shear & Maser 1994), and given the procedural complexities 
and lack of monitoring possible for longer term recording periods, patients were not 
requested to complete panic attack diaries during the follow-up phase of the treatment 
outcome study. Patients who attended the six month follow-up assessment were 
however asked if they had experienced any panic attacks during the follow-up period 
and a ''yes'' or "no" answer recorded. 
6.3 Results 
6.3. 1. Statistical Analysis 
As one of the main intentions of the study was to investigate panic measures as 
treatment outcome variables the sample included data only from those patients who had 
experienced panic attacks and/or limited symptom attacks during the week prior to the 
first assessment point (Day 0). In this way meaningful changes during treatment could be 
assessed and the difficulties in interpreting apparent increases in panic found during 
treatment for patients scoring zero at initial assessment in some previous studies (De 
Beurs et al 1993) avoided. The numbers of subjects in each treatment group for the 
purposes of the present study were FL = 22, PL = 24, FL+CBT = 27, PL+CBT = 28, 
and CBT = 27. Potential differences between groups in panic variables were assessed by 
means of repeated measures analysis of variance with a between subjects factor, 
treatment group, and a within subjects factor, assessment point. Significant results were 
further investigated for each assessment point using simple effects one-way analysis of 
variance with post hoc Scheffe tests of significance. Within group changes over 
treatment were further tested using paired two-tailed t-tests on pre vs. post-treatment 
scores. 
Initial inspection of the data revealed that most measures showed distributions that 
were highly positively skewed. In accordance with Ferguson & Cox (1993), any measure 
which showed a positive skew greater than 1.0 was deemed to require transformation. 
Distributions for total mean severity, panic mean severity, and limited symptom attack 
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mean severity, were within acceptable limits and analyses were performed on 
untransformed data for these variables at all assessment points (Days 0, 42 & 84). 
Distributions for other measures showed positive skews which varied from 1.76 to 6.02 
and therefor required transformed to approximate a more normal distribution and reduce 
the risk of type I error in analyses. Logarithmic transformations (Log I 0 (variable + I», 
were employed. Transformations were performed on total frequency, panic frequency, 
limited symptom attack frequency, total mean duration, panic mean duration, and limited 
symptom attack mean duration at all three assessment points (Days 0, 42, & 84). For 
these six variables analyses were performed on transformed data. Means and standard 
deviations for all variables are reported as original untransformed values. Panic attacks 
were compared with limited symptom attacks on the variables of frequency, mean 
severity, and mean duration at each assessment point (Days 0, 42, & 84) using two-
tailed paired t-tests. These comparisons were made within subjects and thus included 
data only for those subjects who recorded both panic attacks and limited symptom 
attacks at each assessment point. 
Results will be presented for (a) total attacks variables (total attacks frequency, total 
attacks mean severity, total attacks mean duration), followed by (b) panic attack 
variables (panic attack frequency, panic attack mean severity, panic attack mean 
duration) and finally (c) limited symptom attack variables (limited symptom attack 
frequency, limited symptom attack mean severity, limited symptom attack mean 
duration). 
6.3.2. Total attacks frequency, mean severity, and mean duration. 
One-way ANOV As, t-tests, means and standard deviations for total attacks 
frequency, mean severity, and mean duration are presented in Table 6.1. 
Analysis of variance for total attacks frequency revealed significant group (F(4,122) 
= 2.23, P < 0.05), and time (F(2,244) = 85.89, p < 0.0001) effects, but a non-significant 
interaction term (F(8,244)= 1.38, n.s.). Further analysis revealed a significant difference 
between groups at Day 0 (F(4,124) = 2.53, P < 0.05), but this difference did not achieve 
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significance on the post hoc Scheffe tests of significance. No other significant differences 
between groups were found at any other assessment point. 
Table 6.1. One-way ANOV As, t-tests, and means (s.d.) for total attacks frequency, total attacks mean 
severity, and total attacks mean duration for all groups at each assessment point. 
FL PL FL+CBT PL+CBT CBT 
Total Attacks 
Frequency 
Day 0 5.27 4.25 4.81 5.86 7.71 
(3.76) (3.87) (4.39) (5.22) (5.07) 
Day 42 3.23 3.13 1.81 2.41 4.81 
(3.69) (4.12) (2.37) (3.28) (4.52) 
Day 84 2.18 2.63 1.63 1.03 3.37 
(3.36) (3.89) (2.83) (1.99) (5.04) 
t 4.28**** 4.11**** 6.50**** 6.88**** 4.73**** 
Total Attacks Mean 
Severity 
Day 0 4.05 3.70 3.46 3.66 4.13 
(1.97) (1.89) (1.93) (1.78) (1.72) 
Day 42 2.93 2.88 1.39 2.25 3.41 
(2.49) (2.54) (1.93) (2.28) (2.75) 
Day 84 2.02 2.34 0.74 1.28 2.20 
(2.72) (2.61) (1.29) (2.35) (2.40) 
t 3.04** 2.30* 6.19**** 5.58**** 3.45** 
Total Attacks Mean 
Duration 
Day 0 48.40 59.57 38.48 50.32 52.04 
(69.80) (70.38) (44.54) (73.01) (54.51) 
Day 42 29.11 55.90 29.61 51.54 30.00 
(41.03) (66.86) (64.21) (75.38) (35.71) 
Day 84 35.78 55.31 11.0 12.84 23.27 
(76.79) (107.38) (22.73) (33.47) (37.46) 
t 3.79*** 2.41* 6.11 **** 5.18**** 4.58**** 
* p < 0.05, ** P < 0.01 *** P < 0.001, **** P < 0.0001, n.s. not SIgnificant 
t-test refer to pre (Day 0) vs. post (Day 84) comparisons 
F 
2.53* 
2.15 
n.s. 
2.03 
n.s. 
0.60 
n.s. 
2.72* 
2.42 
n.s. 
0.44 
n.s. 
1.03 
n.s. 
1.55 
n.s. 
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Within group analyses revealed significant reductions in total frequency for all groups 
(all p < 0.0001). Thus the frequency of panic attacks and limited symptom attacks 
combined reduced significantly during treatment for all treatment groups with there 
being no significant differences between groups at any point during treatment. 
Analysis of variance for total attacks mean severity revealed significant group 
(F(4,119) = 2.76, P < 0.05), and time (F(2,238) = 45.79, P < 0.0001) effects, but no 
significant interaction term (F(8,238F 0.88, n.s.). Further analysis revealed a significant 
difference between groups at Day 42 only (F(4, 120) = 2.72, p < 0.05) although between 
group differences were not sufficient to achieve significance on post hoc Scheffe tests. 
All groups showed significant within group pre-post treatment improvement with the 
active treatment groups (FL, FL+CBT, PL+CBT, CBT) showing a stronger response 
(all p < 0.001 and above) than the PL group (p < 0.05). 
Analysis of variance for total attacks mean duration revealed a significant finding for 
time (F(2,202) = 52.35, p < 0.0001) only, with neither the group (F(4,101) = 1.46, n.s.) 
nor the interaction (F(~,202F 0.86, n.s.) terms reaching significance. Within group t-tests 
showed significant improvement (all p < 0.001 and above) for the active treatment 
groups (FL, PL, FL+CBT, PL+CBT, CBT). Pre-post analysis was also significant for 
the PL group although at a lower level of significance, (p < 0.05). 
The overall pattern of results for the measures of total attacks frequency, mean 
severity, and mean duration, was of one of significant, and equivalent improvement in 
these measures across all groups throughout treatment. 
6.3.3. Panic attack frequency, mean severity, and mean duration. 
One-way ANOV As, t-tests, means and standard deviations for panic attack 
frequency, mean severity, and mean duration are presented in Table 6.2. 
Analysis of variance for panic attack frequency revealed a significant effect for time 
only (F(2, I 56) = 55.90, P < 0.0001) only, with neither the group (F(4,78) = 0.48, n.s.), 
nor the interaction (F(~,156)= 0.55, n.s.) terms reaching significance. Thus all groups 
showed significant change over treatment, there being no significant differences between 
Chapter 6 
groups at any assessment point. All groups showed significant pre-post treatment 
changes in panic frequency (all p < 0.01 and above). 
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Table 6.2. One-way ANOV As, t-tests, and means (s.d.) for panic attack frequency, mean severity, and 
mean duration. for all groups at each assessment point. 
FL PL FL+CBT PL+CBT CBT 
Panic attack frequency 
OayO 4.19 3.57 4.00 4.26 4.50 
(3.19) (3.72) (3.66) (3.16) (4.15) 
Oay42 2.13 2.64 1.20 1.84 2.26 
(2.60) (3.81) (2.11) (1.80) (2.77) 
Oay84 1.56 2.00 0.73 1.21 1.30 
(2.83) (3.46) (1.62) (2.18) (2.49) 
t 3.72*** 4.78**** 5.93**** 4.51 **** 4.43**** 
Panic attack mean 
severity 
OayO 5.12 4.86 4.14 4.65 6.15 
(1.95) (1.47) (1.97) (2.15) (2.05) 
Oay42 3.45 2.58 1.03 2.43 2.84 
(2.66) (2.91) (1.99) (2.45) (3.27) 
Oay84 2.41 2.52 0.66 1.81 1.12 
(2.85) (3.31) (1.41) (2.75) (2.19) 
t 4.10*** 3.55*** 7.44**** 5.90**** 6.70**** 
Panic attack mean 
duration 
Day 0 38.93 96.08 56.14 68.72 63.68 
(29.04) (93.38) (54.13) (93.21) (77.92) 
Oay42 34.15 68.27 3.62 47.36 20.35 
(43.75) (80.21) (6.44) (73.82) (35.09) 
Oay84 34.92 41.18 2.46 10.69 15.79 
(71.14) (76.59) (6.42) (21.11) (44.82) 
t 2.86*** 3.41*** 7.29**** 4.57**** 5.65**** 
* p < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, n.s. not SIgnificant. 
t-test refer to pre (Day 0) vs. post (Day 84) comparisons 
F 
0.26 
n.s. 
0.69 
n.s. 
0.44 
n.s. 
2.45 
n.s. 
1.64 
n.s. 
2.21 
n.s. 
0.45 
n.s. 
2.07 
n.s. 
1.13 
n.s. 
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Analysis of variance for panic attacks mean severity revealed an identical pattern to 
that for panic attack frequency with a significant finding for time only (F(2,154) = 58.00, 
P < 0.0001}, with the group (F(4,72) = 2.12, n.s.} and interaction (F(8,I54)= 1.39, n.s.} 
terms failing to reach significance. This again indicates improvement over treatment that 
is equivalent across groups. Within group analysis also showed significant improvement 
in panic attack severity for all groups (p < 0.01 and above). 
Analysis of variance for panic attack mean duration showed yet again the same 
pattern with a significant finding for time (F(2,122) = 56.34, P < 0.0001} only. The 
group (F(4,61) = 1.53, n.s.} and interaction (F(8,12f)= 1.03, n.s.) terms again failed to 
reach significance. Within groups analysis again showed a significant reduction in panic 
attack duration across treatment for all groups (p < 0.01 and above). Thus for panic 
attack measures the same consistent pattern emerged once more indicating significant 
improvement over time with no significant differences between groups at any point. 
6.3.4. Limited symptom attack frequency, mean severity, and mean duration 
One-way ANOV As, t-tests, means and standard deviations for limited symptom 
attack frequency, means severity, and mean duration are presented in Table 6.3. 
Analysis of variance for limited symptom attack frequency revealed a significant 
effect for group (F(4,99) = 2.48, P < 0.05}, and time (F(2,198) = 75.99, P < 0.0001}, but 
an insignificant interaction term (Ii:8,198)= 1.20, n.s.}. Further analysis showed a 
significant difference between groups at day 84 (F(4,99) = 2.79, P < 0.05} only with post 
hoc Scheffe tests indicating a difference between the PL+CBT and CBT groups (p < 
0.05). Within groups analysis revealed a significant reduction in limited symptom attack 
frequency across treatment for all groups (p < 0.01 and above). 
Analysis of variance for limited symptom attack mean severity revealed a significant 
effect for group (F(4,94) = 2.98, P < 0.05) and for time (F(2,188) = 77.23, P < 0.0001) 
but not for the interaction term (F(8,188)= 1.49, n.s.). Further analysis indicated a 
significant difference between groups at Day 84 only (F(4,94) = 3.01, P < 0.05} with 
post hoc Scheffe test indicating a significant difference between the PL+CBT and CBT 
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groups (p < 0.05). Within group analysis revealed a significant reduction in limited 
symptom attack frequency across treatment for all groups (p < 0.001 and above). 
Table 6.3. One-way ANOV As, t-tests, and means (s.d.) for limited symptom attack frequency, mean 
severity, and mean duration, for all groups at each assessment point. 
FL PL FL+CDT PL+CDT CDT F 
Limited symptom 
attack frequency 
Day 0 2.72 3.25 2.92 3.87 4.92 1.57 
(1.71) (3.55) (2.21) (3.68) (3.92) n.s. 
Day 42 1.83 2.06 1.13 2.26 2.92 1.74 
(2.53) (2.65) (1.48) (2.51) (3.71) n.s. 
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Day 84 1.11 1.75 1.25 0.27 2.80 2.79· 
(1.99) (3.84) (2.42) (0.94) (4.23) 
t 4.31···· 3.70··· 5.22···· 9.10···· 3.95··· 
Limited symptom 
attack mean severity 
Day 0 3.26 2.73 2.82 3.02 3.11 
(1.84) (1.41) (1.87) (1.59) (1.42) 
Day 42 1.20 1.93 1.03 1.14 2.58 
(1.44) (2.23) (1.63) (1.69) (2.45) 
Day 84 1.35 1.31 0.47 0.22 1.86 
(2.44) (2.03) (0.98) (0.69) (2.36) 
t 3.83··· 4.07··· 7.53···· 11.90···· 3.78··· 
Limited symptom 
attack mean duration 
Day 0 53.0 57.57 32.09 23.85 45.65 
(79.29) (101.23) (36.64) (23.87) (41.85) 
Day 42 17.26 36.43 23.55 30.21 28.22 
(31.27) (53.06) (59.41) (61.65) (36.80) 
Day 84 22.26 37.46 11.24 9.47 22.41 
(48.81) (78.61) (24.15) (34.72) (34.65) 
t 4.48···· 3.16··· 5.89·· .. 5.18···· 3.57··· 
• p < 0.05, •• P < 0.01, ••• P < 0.001, •••• P < 0.0001, n.s. not Significant. 
t-test refer to pre (Day 0) vs. post (Day 84) comparisons 
0.31 
n.s. 
2.28 
n.s. 
3.01· 
0.78 
n.s. 
2.27 
n.s. 
1.58 
n.s. 
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Analysis of variance for limited symptom attack mean duration revealed a pattern 
identical to that found with panic attack data with a significant effec~ for time only 
(F(2,170) = 130.25, P < 0.0001). Results for group (F(4,85) = 1.86, n.s.) and the 
interaction term (F(8,170)= 0.76, n.s.) did not reach significance. This pattern is indicative 
of significant change across treatment with there being no significant differences 
between groups at any point. Within group analysis supported this finding with all 
groups showing a significant reduction in limited symptom attack mean duration pre-
post (all p < 0.01 and above). 
6.3.5. Follow-up data 
Table 6.4 gives the information on panic attacks given at 6 month follow-up. Patients 
were asked at 6 month follow-up if they had experienced any panic attacks during the 
follow-up period. 
Table 6.4. Number (%) of patients in each group attending follow-up, receiving post study treatment 
and suffering continued panic attacks over follow-up period. 
FL PL FL+CBT PL+CBT CBT 
n= 29 n= 28 n= 29 n= 33 n= 30 
No (%) of Ss free of major panic attacks at Day 20 17 24 25 21 
84 (68.9) (60.7) (82.7) (75.7) (70.0) 
No of attenden at 6 Month follow up 23 21 24 30 28 
(79.3) (75.0) (82.8) (90.9) (93.3) 
No of attenden at 6 Month follow up with no 12 8 18 20 15 
subsequent treatment (41.4) (28.6) (62.1) (60.6) (50.0) 
No of attenden at 6 Month follow up with no 6 4 II 13 10 
subsequent treatment and no panic attacks (20.7) (14.3) (37.9) (39.3) (33.3) 
This data was collected using a retrospective procedure, which furthermore does not 
differentiate between panic, and limited symptom attacks, these findings must therefor be 
treated with some caution. The criteria for post study treatment were exactly those 
employed in the main study and are detailed elsewhere (Sharp et al 1996, Chapter 4). 
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The table indicates a falloff in the number of patients remaining panic free during the 
follow-up period as compared with patients panic free at Day 84. This falloff is less 
marked in those patients who received CBT (FL+CBT, PL+CBT, CBT). This pattern of 
apparent superiority for patients receiving CBT was also found for other follow-up data 
in the main study (Sharp et al1996, Chapter 4). 
6.3.6. Panic attacks vs. Limited symptom attacks 
A comparison of panic attacks and limited symptom attacks was made for each 
variable (frequency, mean severity, and mean duration) at each assessment point (Day 0, 
Day 42, and Day 84). Comparisons were made using two-tailed t-tests for related 
samples. Data were compared only for subjects who had experienced both panic attacks 
and limited symptom attacks at a given assessment point and was thus a within subjects 
analysis. Results are given in Table 6.5, and are expressed as t-scores. A clear pattern 
emerges from Table 6.5, panic attacks did not differ significantly from limited symptom 
attacks in terms of frequency at any assessment point, and differed significantly in terms 
of mean duration at Day ° only where panic attacks showed a significantly longer mean 
duration. Panic attacks did differ significantly and consistently from limited symptom 
attacks in terms of mean severity with panic attacks being rated as significantly more 
severe at Day 0, Day 42, and Day 84. 
Table 6.5 Comparison of panic attacks with limited symptom attacks on frequency, mean severity and 
mean duration at each assessment point using t-te~t for related samples. 
Frequency Mean severity Mean duration 
DAY 0 t=l.1l, df=59 t = 10.61, df= 58 t=3.35, df-51 
n.s. p< 0.0001 p< 0.01 
DAY 42 t = 0.83, df= 34 t = 3.66, df= 34 t = 0.26, df= 28 
n.s. p< 0.001 n.s. 
DAY 84 t = 1.94, df= 20 t = 3.51, df= 20 t = 0.26, df= 17 
n.s. p< 0.01 n.s. 
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6.4 Discussion 
The current study set out to investigate the use of panic attack variables as treatment 
outcome measures and in so doing to improve on the methodology of previous studies. 
In the current study panic attacks were rated prospectively using a self-report event 
recording method. Patients recorded the severity and duration of any attacks as well as 
their frequency. Patients were not briefed on the distinction between panic attacks and 
limited symptom attacks in terms of number of symptoms thus permitting a post hoc 
comparison of panic attacks with limited symptom attacks in terms of frequency severity 
and duration. This comparison was made within subjects. 
The overall impression gained from the treatment outcome results of the present 
study is that all variables showed significant improvements pre-post over treatment with 
there being very few instances of differences between groups. This is in accord with the 
previous studies reviewed, where only four of the 12 studies discussed (Ost 1988, TeIch 
et al 1993, De Beurs et al 1995, Oehrberg et al 1995) actually found panic variables to 
differentiate between competing treatments. In the present study, for total variables, 
possible between group differences on total frequency at Day 0, and total mean severity 
at Day 42, indicated on one-way analyses of variance failed to reach significance on the 
post hoc Scheffe test, an admittedly conservative criterion. Panic attack variables 
showed a consistent pattern across all variables and assessment points. All five treatment 
groups showed significant improvement over treatment with there being no differences 
between treatment groups on any variable at any assessment point. The only significant 
between group differences were found for the limited symptom attack variables where at 
Day 84, the CBT group showed a greater frequency and greater severity oflimited 
symptom attacks than the PL+CBT group. There were no other significant between 
group differences in the limited symptom attack variables. This pattern of findings is 
relevant to a consideration of the utility of panic attack variables as indices of between 
group differences in comparative treatment outcome studies. The measures of panic 
attack and limited symptom attack frequency, severity, and duration employed in this 
study all showed change over treatment with all groups showing statistically significant 
improvement pre to post-treatment. The measures did not discriminate between groups 
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in strength or speed of response and as such may not be particularly informative 
discriminatory variables in treatment outcome research. This is perhaps surprising given 
that other measures of therapist and patient rated anxiety, depression, and avoidance 
employed with this patient group (Sharp et al 1996, Chapter 4) did show some 
differences between treatment groups in strength and consistency of response. An 
inspection of the group means for the panic attack variables in this study might suggest 
the existence of significant between group differences particularly at treatment end point, 
Day 84, however these failed to reach statistical significance. The relatively large 
standard deviations found for most variables suggest that panic attack variables are 
rather volatile. This point has indeed been noted by other researchers (Basoglu et al 
1992). Furthermore, in accord with previous suggestions (Barlow 1988), panic attack 
variables would appear to be a rather lenient way of assessing treatment outcome, 
showing significant change over treatment even for the PL treatment group, and as such 
are therefor of limited utility as discriminating treatment outcome variables. In the 
present study, panic attacks improved as much in a group receiving placebo medication 
and balanced therapist contact (PL) as in the other groups receiving targeted active anti-
panic treatments (FL, FL+CBT, PL+CBT, CBT). This is an important finding as the 
present study is the first to investigate panic attack variables within a design that 
includes a therapist contact control condition (PL). In studies reviewed above, those that 
have included control conditions have used no treatment waiting-list controls. The novel 
finding of a strong treatment response in terms of panic attack variables found here for 
the PL group which included a therapist contact control is therefor significant. This 
finding suggests that caution should be exercised in interpreting studies which claim 
support for specific anti-panic properties of treatments if these are based on study 
designs which measure panic attacks but do not include a control for therapist contact or 
do not show panic attack results for the active treatments to be significantly superior to 
those for therapist contact controls, as such positive findings may simply be due to non-
specific elements of treatment. Some potential differences between groups did appear in 
the follow-up analysis where patients in the groups receiving CBT (FL+CBT, PL+CBT, 
CBT), showed a greater preservation of panic free status at 6 month follow-up than did 
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those patients receiving medication alone (FL, PL). This pattern is identical to that found 
for preservation of clinical significance of outcome found for patient and therapist rated 
measures of anxiety and avoidance reported elsewhere (Sharp et al1996, Chapter 4). 
Some caution must be exercised in interpreting these follow-up findings. The continuous 
prospective event recording method of measuring panic variables during the treatment 
phase of the study was not continued over the follow-up period. Thus panic attacks 
were assessed retrospectively at follow-up and the accuracy and validity of this method 
can be questioned. It is nonetheless noteworthy that this less reliable retrospective 
method did produce a pattern of results in keeping with other assessment measures. 
The analysis comparing panic attacks with limited symptom attacks at each 
assessment point yielded results in keeping with the only other study to date to compare 
panic attacks with limited symptom attacks within patients (Krystal et al 1991). The 
Krystal et al (1991) study and the present study found that patients rated full panic 
attacks as more severe than limited symptom attacks and furthermore the present study 
found that this difference in severity persisted throughout treatment across all three 
assessment points. The present study also found a significant difference between panic 
attacks and limited symptom attacks in duration as had a previous study (De Beurs et al 
1994) with panic attacks being of longer duration. This difference existed at pre-
treatment assessment (Day 0) only and disappeared once treatments had been initiated. 
The present study is the first investigation to compare panic attacks with limited 
symptom attacks throughout a program of treatment. It should be borne in mind, 
however, that the validity of the post hoc distinction of panic attacks from limited 
symptom attacks employed in the present study does rely on the accuracy and 
consistency of patients reporting of number of symptoms experienced during any given 
attack. Given the evidence from the present study already discussed on the universal 
effect of all treatment interventions in reducing scores on all panic attack and limited 
symptom attack variables, the persistence of the panic vs. limited symptom attack 
difference on severity throughout the treatment period is noteworthy, testifying to the 
robustness of this difference. 
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The present study did not require patients to distinguish between spontaneous and 
situational panic attacks. Some valuable discriminatory data may have been lost as a 
result although this is unlikely given the weight of evidence suggesting the equivalence 
of these two forms of panic (Margrafet al1987, Street et al1989, Krystal et al1991, 
Basoglu et al 1992). The necessary conclusion from the current study is that the 
employment, in treatment outcome studies, of more detailed panic attack variables 
including measures of panic attack and limited symptom attack severity and duration 
such as those employed here, is unlikely to yield much in the way of useful data. In the 
present study, panic attacks improved significantly and equally regardless of intervention 
employed. The follow-up results do however suggest that the occurrence of panic 
attacks during post treatment follow-up may be a more promising subject of study, and 
may reveal differential rates of recurrence of panic attacks during follow-up. It is 
regrettable that in the present study, patients were not required to continue completing 
the panic diaries over the follow-up period. This methodology is required to reinforce 
the tentative follow-up results of the present study. The comparison of limited symptom 
and full-blown panic attacks suggests that limited symptom attacks can be regarded as 
less severe versions of the full panic attacks, however, this difference does not in itself 
justifY the exclusion of limited symptom attacks from treatment outcome analysis as has 
been done in many previous studies. As a final point, replication of the present study is 
required, firstly as some aspects of the study design are novel, and secondly to further 
investigate the seemingly counterintuitive conclusion that panic attack variables appear 
to rather uninformative treatment outcome measures when applied to treatments for 
panic disorder and agoraphobia. The present study has been reported elsewhere as Sharp 
& Power (Submitted) (b). 
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CHAPTER 7 AN INVESTIGATION OF PROGNOSTIC INDICATORS OF 
TREATMENT OUTCOME 
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7. 1 Introduction 
Treatment outcome studies have as their principal goal the identification and 
measurement of treatment responses both within and between treatments. It has long 
been the ambition of clinicians to further supplement findings of treatment efficacy by 
identifying pre-treatment or early treatment variables which might act as predictors of 
final post-treatment response. Armed with such information the clinician might be more 
able to fine-tune treatments according to the requirements of each patient. Knowing at 
the outset of treatment which patients were likely to respond and which were more liable 
to require, for example, additional support would be of great advantage to the clinician. 
The assumption that responses to pre-treatment measures may predict longer term 
outcome is derived from early investigations with patients suffering from schizophrenia 
(e.g. Wing 1973, Strauss & Carpenter 1974). Given the clinical prevalence of panic 
disorder with and without agoraphobia it is not surprising that an interest in possible 
prognostic indicators has also developed in this area. The relatively few studies that have 
been conducted with patients suffering from panic disorder and agoraphobia have 
usually employed exposure based treatments and have often produced equivocal 
findings. The overall picture of few remarkable or consistent findings is an often 
mentioned feature of this research (Thomas-Peter et al 1983, Jansson et al 1987, 
Keijsers et al 1994). Methodological problems exist with previous research that might 
account for the disappointing results obtained thus far. Problems such as differences 
between studies in the measurement of prognostic variables and in the definition of 
treatment outcome, and small sample sizes employed to support too many variables 
leading to sample-bound nonreplicable findings, have been noted (Chambless & Gracely 
1988, Keijsers et al 1994). Other problems exist with basic study design. These will be 
discussed first. Some studies (Emmelkamp & Van Der Hout 1983, Cox et al1988, 
Fischer et al 1988), have employed simple between group designs where patients were 
defined as successes or failures according to criteria applied to post-treatment response. 
Among such studies these two groupings of patients have been compared on mean 
scores for a variety of pre-treatment measures using between group statistics. The 
assumption underpinning this procedure is that having differentiated two groups of 
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patients according to post-treatment variables, any subsequent between group 
differences on pre-treatment variables will be related meaningfully to the post-treatment 
differentiation. Without further empirical justification this assumption cannot be 
accepted unconditionally. The studies which have employed this methodology have 
found between group differences on pre-treatment variables such as, marital satisfaction, 
quality of therapeutic relationship, and perceived parental characteristics (Emmelkamp & 
Van Der Hout 1983), and the psychoticism and positive symptom index subscales of the 
Hopkins Symptom Checklist-90 (Cox et al 1988). The existence of these between group 
differences in pre-treatment variables has undoubtedly been established, given the study 
designs, however, their power and validity as predictors of post-treatment response has 
not. A method of analysis is required whereby the relationship between pre, and post 
treatment variables can be assessed. A simple form of such an analysis would be the use 
of multiple bi-variate correlations calculated between pairings of pre and post treatment 
variables. One study used such a method (Thomas-Peter et alI983), conducting 46 
individual bi-variate correlations (Pearson's r) on a sample size ofn = 17.Given that only 
three significant correlations were found (all at p < 0.05) and no correction for multiple 
testing was employed, the results of this study must be treated with caution. The study 
clearly illustrates the problems inherent in simple correlational analyses. More 
sophisticated and potentially more controlled analyses are possible using multivariate 
techniques such as multiple regression analysis. This technique has been favoured in 
more recent studies. Three studies have employed regression analyses in an attempt to 
assess the viability of a number of potential prognostic variables. The first of these 
(Chambless & Gracely 1988), investigated treatment response as measured by the 
Avoidance Alone scale of the Mobility Inventory (Chambless et al 1985) in a sample of 
n = 134 patients with DSM III agoraphobia with panic attacks who were treated with an 
intensive exposure-based treatment programme. The relationship between post treatment 
scores on this single dependant variable and a range of intervening variables was 
investigated using a series of regression analyses with each predictor being analysed in a 
separate regression. Predictors employed included demographic information, and 
measures of assertion, agoraphobic avoidance, anxiety based body sensations, 
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depression, trait anxiety, social avoidance, and marital satisfaction. Only two variables 
were found to be significant predictors of treatment end-point agoraphobia avoidance 
scores, these were anxiety based body sensations, and marital dissatisfaction with the 
latter variable appearing to operate as a suppressor variable. There are some problems 
with this study, some specific to the individual study design, others more general to the 
type of analysis. The more general points will be discussed later. Regarding the problems 
specific to this study design, by employing a series of separate and individual regression 
analyses Chambless & Gracely (1988) did not allow any control for the potential 
intercorrelation of their chosen predictor variables. Given that these included measures 
of, for example, trait anxiety, social avoidance, and anxiety based bodily sensations, 
some degree of inter correlation is likely. This makes the few significant findings in this 
study difficult to interpret. The second study (Jansson et al 1987) differed from the 
Chambless & Gracely (1988) study in employing four dependant variables all of which 
were derived from a behavioural test walk. Patients were required to attempt a hierarchy 
of 15 agoraphobic situations and the percentage of situations completed recorded. 
Measures of subjective anxiety (on a 0-1 0 scale), and heart rate were also taken during 
the test walk. These three measures along with a composite measure of the change 
scores on each constituted the dependant variables for this study. Scores on the 
dependant variables were available for treatment end-point and 7 and 15 month follow-
up. A total ofn = 33 patients with agoraphobia received an equal number of sessions of 
either exposure in vivo or applied relaxation. Potential intervening variables in this study 
were, demographic variables, patient's treatment expectancies, depression, agoraphobic 
avoidance, autonomic perception, panic attack variables, and marital relationship. Each 
of these intervening variables was entered stepwise into a multiple regression for each 
dependent variable at each assessment point (treatment end-point, 7 and 15 month 
follow-up). Again few significant predictors were found. Outcome immediately after 
treatment was predicted by age and self-rated anxiety during the behavioural test walk. 
Outcome at follow-up was predicted again by self-rating of anxiety, and initial behaviour 
scores and initial heart rate scores from the first behavioural test walk. The authors 
concluded that only directly phobia-related measures such as self-rated anxiety, and 
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heart rate were good predictors of outcome. This of course may reflect no more than the 
fact that the chosen dependant variables for this study were all derived from a directly 
phobia related behavioural test walk. The study is however noteworthy as an attempt to 
employ a more comprehensive assessment and analysis strategy than previous 
investigations, although the sample size (n = 33) was small relative to the number of 
intervening variables used thus results may represent an over-prediction. A more serious 
problem with the study concerns the follow-up findings. No mention is made of post 
study treatment received during the follow-up phase of the study. Patients were followed 
up to 15 months post treatment thus there was considerable opportunity for such 
treatment to occur. As post study treatment was not reported in this study it's influence 
on both outcome results and on subsequent regression analyses cannot be estimated. 
This is a potentially serious flaw. The third study to employ a regression analysis 
(Keijsers et al 1994) investigated treatment outcome indexed by agoraphobic avoidance 
and frequency of panic attacks, measured using the Mobility Inventory (Chambless et al 
1985), and frequency of physical panic symptoms measured using a non-standardised 
self-report scale. Predictor variables included catastrophic agoraphobic cognitions, levels 
of depression and general anxiety, quality of therapeutic relationship, patient motivation 
for treatment, personality psychopathology, and marital dissatisfaction. A sample ofn = 
60 DSM IlI-R panic disorder with agoraphobia patients were treated with a 12 session 
standardised exposure-based behavioural treatment programme. Linear regression 
analyses on each of the outcome variables revealed a small number of significant 
predictor variables. Catastrophic agoraphobic cognitions correlated significantly with all 
three outcome variables, as did patients motivation for treatment. Level of depression 
correlated significantly with frequency of panic attacks, and personality psychopathology 
with agoraphobic avoidance. After applying a correction for multiple testing (Bonferroni 
correction) only catastrophic agoraphobic cognitions remained as a significant predictor 
variable. This study (Keijsers et al 1994) used a more controlled assessment and analysis 
strategy and employed a larger sample size than previous studies (e.g. Jansson et al 
1987), and findings can be regarded as more robust as a result. The Keijsers et al (1994) 
nonetheless suffers from a significant problem common to all the studies employing 
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regression methodology, that is, whilst regression techniques are suitable for identitying 
any relationship between outcome variables and predictor variables they can give no 
indication of whether these relationships have any real clinical relevance. Predictor 
variables are regressed onto outcome variables with the latter operating usually as 
continuous variables. Whilst an outcome variable may show statistically significant 
change following treatment such change may not be of sufficient magnitude to constitute 
a genuinely clinically significant improvement. Methods have been developed to establish 
standardised criteria of clinically significant change (Jacobson & Ravenstorf 1988, 
Jacobson & Truax. 1991), and these are now being recommended for use in treatment 
outcome studies (Shear & Maser 1994). Unfortunately regression techniques which 
employ continuous outcome variables do not permit the investigation of the clinical 
significance of change over treatment. This is unfortunate, as it is the prediction of 
clinically significant change, rather than change of lesser magnitude, which is of principal 
interest to the clinician. 
This problem has been recognised by some researchers who have attempted further 
analyses over and above the standard regression techniques. These attempts usually 
involve dichotomising the sample as treatment successes or failures and attempting to 
predict group membership using the predictor variables employed in their regression 
analyses. Chambless & Gracely (1988) used Jacobson et ai's (1984) Reliable Change 
Index (RCI) to classify their sample as treatment successes or failures according to 
scores on their outcome measure of agoraphobic avoidance. The RCI formula expresses 
the reliability ofan outcome score as a function of the post-test minus the pre-test score 
divided by the standard error .of the difference scores. If this value is greater than a prior 
established cut-off point, the change can be regarded as reliable. Caution should be 
exercised here however, as a change which is reliable may not necessarily be clinically 
significant. This caveat notwithstanding, Chambless & Gracely (1988) dichotomised 
their sample using the RCI and investigated their chosen predictor variables using a 
series of point-biserial correlations. This method suffers from the same problem as the 
repeated single regression analysis used in this study and criticised above. A series of 
individual point-biserial correlations do not permit any assessment of potential 
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intercorrelations amongst predictor variables, thus any significant findings are difficult to 
interpret. As it happens, Chambless & Gracely (1988) found no significant predictors of 
treatment success using this methodology. In the only other attempt to investigate the 
clinical significance of outcome in an investigation of prognostic indicators Keijsers et al 
(1994) calculated an "improvement percentage index" for each of their three outcome 
variables. This measure was idiosyncratic to this study and no other investigation of its 
validity as an index of clinically significant change was reported. The improvement 
percentage index classified approximately 50% of the sample as treatment failures on 
their agoraphobic avoidance and physical panic symptoms outcome variables, and 20% 
were treatment failures on the panic attack frequency outcome variable. Keijsers et al 
(1994) employed a discriminant function analysis to identify those predictor variables 
that predicted group membership (success versus failure) on each of the outcome 
variables. Such an analysis of course makes assumptions as to the quality of distributions 
of, and nature of the interrelationships amongst, the predictor and outcome variables. 
For agoraphobic avoidance, treatment successes and failures were significantly 
discriminated by catastrophic agoraphobic cognitions, therapeutic relationship, and 
patient's motivation for treatment. For frequency of panic attacks, the significant 
predictor variables were catastrophic agoraphobic cognitions, level of depression, 
therapeutic relationship, and patient's motivation for treatment. For the third outcome 
variable, physical panic symptoms, group membership was significantly predicted by 
catastrophic agoraphobic cognitions, level of depression, patient's motivation for 
treatment, and personality psychopathology. Overall 75% of the sample were classified 
correctly to the success or failure group. These two studies (Chambless & Gracely 1988, 
Keijsers et al1994) are the only two attempts to date to include the clinical significance 
of treatment as a factor in outcome assessments. Unfortunately in both studies the 
methods of assessing clinical significance chosen were either idiosyncratic (Keijsers et al 
1994), or were not directly related to clinical significance (Chambless & Gracely 1988). 
Established criteria of clinical significance of treatment outcome exist (Jacobson & 
Truax 1991) which are based on the assumption that patients start a treatment with 
scores which place them within the distribution of a clinical population, and following a 
l 
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successful treatment have scores which fall within the distribution for a normal non-
clinical population. Several criteria exist for establishing the occurrence of this shift from 
clinical to non-clinical distributions and could be used as indices of clinically significant 
change in investigations of potential prognostic indicators. The selection of the 
dependant or outcome variables on which the assessments of clinically significant change 
are made is also important. Previous studies have used assessments that tap only one 
aspect of panic disorder, usually agoraphobic avoidance (Chambless & Gracely 1988), 
without employing other potential measures of outcome such as general level of anxiety. 
Other studies have employed non-standardised measures as outcome variables (Thomas-
Peter et al 1983), despite early calls for the use of standardised measures as outcome 
variables in such research (Huxley et al 1979). Care must also be taken to ensure the 
validity of chosen outcome measures. In one study (Keijsers et al1994) outcome 
measures of panic attack frequency and frequency of physical panic symptoms were 
used, derived from retrospective ratings contained in the Mobility Inventory (Chambless 
et al 1985). There is now evidence which indicates that retrospective ratings of panic 
attack variables are often inflated as compared with prospectively assessed panic attack 
variables (Margraf et al 1987, Rapee et al 1990b, De Beurs et al 1992), and that 
retrospective ratings are not therefor an accurate reflection of the clinical reality of the 
disorder. The effect of employing retrospectively rated panic attack variables as either 
outcome or predictor variables in prognostic research is not known. The use of such 
variables should therefor be treated with some caution. The methodological rigour of 
investigations of prognostic indicators of treatment outcome would be improved if 
outcome measures based on standardised measures were used. The definitions of 
clinically significant change derived from these measures should also be conducted using 
replicable, standardised procedures based on reasonable theoretical principles. The 
clinically significant change criteria developed by Jacobson and colleagues (Jacobson & 
Ravenstorf 1988, Jacobson & Truax 1991) are suitable for this purpose. 
Having discussed the treatment outcome, or dependant, variables in prognostic 
studies, some comment on the intervening, or predictor, variables is warranted. As 
Keijsers et al (1994) note, a large range of predictor variables have been investigated, 
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often with only limited success. Demographic variables, complaint-related variables such 
as levels of anxiety depression or agoraphobia, psychological variables such as 
personality psychopathology, and social psychological variables such as marital 
relationship, have all been investigated as potential predictors of treatment response. The 
quality and replicability of such measures has varied greatly between studies, and the 
comments above in relation to outcome variables apply equally well to predictor 
variables. That is, methodological rigour and study replicability would be enhanced by 
the use of standardised measures as predictor variables. The construct validity of the 
measures used as predictor variables is also important. This is well illustrated in the case 
of measures of personality. All the studies which have assessed personality have included 
assessments ofDSM Axis II personality disorders only. Thus the only facet of 
personality investigated is personality psychopathology (e.g. Keijsers et al 1994). This is 
also the case in other studies of the relationship between personality and panic disorder 
and agoraphobia (Mavissakalian & Hamann 1987, Chambless et al1992, Tyrer et al 
1993). This is a flawed strategy that assumes that only classifiable disorders of 
personality will have deleterious effects on treatment outcome, and also denies, by 
implication, that personality can have a positive influence on treatment response. Less 
clinically focused measures of personality might repay investigation. 
The foregoing discussion has suggested that research into possible prognostic 
indicators of treatment outcome for panic disorder and agoraphobia may provide 
clinically useful information. Improvements in study methodology including the use of 
standardised measures of outcome and predictor variables, and the controlled definition 
of the clinical significance of treatment outcome may increase the value of such research. 
The present study reports an investigation of prognostic indicators of outcome following 
treatment for panic disorder with and without agoraphobia using either tluvoxamine, 
placebo, and cognitive behaviour therapy, each alone and in combination. 
I 
l 
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7.2 Method 
7.2.1. Subjects 
Patients in the present study were those who received treatment in the main study (Sharp 
et al1996, Chapter 4). Patients were referred by general practitioners (GP) and were 
those considered suitable for pharmacological and/or psychological treatment. All 
patients were seen for all appointments in their local GP clinic. Following initial GP 
assessment and referral all patients were seen by a clinical psychologist for semi-
structured interview to ascertain patient characteristics, presenting condition, and 
severity of illness. 
Inclusion criteria were those employed in the main treatment outcome study and are 
reproduced in detail elsewhere (Sharp et al 1996, Chapter 4). Over three years 238 
patients were referred by GPs, of these 193 entered the study. Analysis was conducted 
on a sample of 149 completers and defined completers. Demographic details of the 
sample have been given in detail previously (Sharp et al 1996, Chapter 4). 
7.2.2. Treatments 
All patients were seen to an identical schedule of contact and received either 
fluvoxamine, placebo, fluvoxamine plus cognitive behaviour therapy (CBT), placebo 
plus CBT, or CBT alone. Treatment specifications and schedules of contact were those 
of the main study and are described in more detail elsewhere (Sharp et al 1996, Chapter 
4). Following assessment and referral by their GP, patients were seen by the 
psychologist therapist for initial assessment (Day -7) when they were randomised to 
treatment groups. Over the 12 week treatment period all patients received treatment to 
an identical schedule of contact of 9 treatment appointments. Assessments for the 
present study were conducted pre and post treatment, and at 6 months follow-up. 
l 
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7.2.3. Measures 
7.2.3.1. Outcome Measures 
Treatment outcome was assessed on three standardised scales, a therapist report anxiety 
scale, the Hamilton Anxiety Scale HAM-A (Hamilton 1959), a patient self-report anxiety 
scale, the Kellner Sheffied Symptom Rating Test SRT (Kellner & Sheffield 1976), and 
the patient self-report agoraphobia subscale of the Fear Questionnaire FQ-AG (Marks & 
Mathews 1979). Clinical significance of outcome on these measures was assessed using 
the criteria proposed by Jacobson and colleagues (Jacobson & Ravenstorf 1988, Jacobson 
& Truax 1991). These were the measures and procedures used to establish measures of 
clinically significant improvement in the main study (Sharp et al 1996, Chapter 4). A cut-off 
score was established for the FQ-AG scores using the data collected on a non-clinical 
population by Mizes and Crawford (1988). A cut-off score of8 or below indicated clinically 
significant change on this measure. Where data on a non-clinical population do not exist, 
Jacobson and Ravenstorf(1988) recommend a cut-off score for clinically significant change 
where a patient score falls outside the range of the dysfunctional population by two standard 
deviations from the pre-treatment mean of that population, in the direction of functionality. 
This criterion was employed with the other two measures, firstly the HAM-A, where it 
established a criterion of moderate severity (cut-off score of 12 or below) and secondly, with 
the SRT, where the variance in this measure gave rise to large standard deviations, and thus a 
highly stringent criterion of clinically significant change (cut-off score of 5 or below). These 
cut-off scores for clinically significant change were used to divide the total sample ofn = 149 
completers into two groups, those achieving clinically significant improvement, and those 
failing to achieve clinically significant improvement at two assessment points, firstly at 
treatment end-point, and secondly at 6 month follow-up. At treatment end point (Day 84) the 
sample was divided into those achieving clinically significant versus non-significant 
improvement on Day 84 HAM-A, Day 84 SRT, and Day 84 FQ-AG. A fourth division was 
created, Day 84 treatment responders versus non-responders. To qualifY as a treatment 
responder patients had to achieve the strict criterion of clinically significant change on all 
three outcome variables. At 6 month follow-up a further criterion was added to the 
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classification of clinically significant change. It has already been argued (Sharp et al 1996, 
Chapter 2, Chapter 4), that the occurrence of additional treatment during the follow-up phase 
confounds follow-up results. In an attempt to avoid this problem, patients who had taken any 
psychotropic medication, regardless of quantity, or who had attended any appointments with 
psychologist, psychiatrist, or had any other secondary mental health referral during the 
follow-up period were deemed to have received follow-up treatment and were excluded from 
the current analysis. At 6 month follow-up therefor a further four outcome differentiations 
were available, those without follow-up treatment achieving clinically significant 
improvement at 6 month follow-up versus all other patients (i. e. those with non-significant 
improvement at 6 month follow-up and those with significant improvement at 6 month 
follow-up but additional follow-up treatment) on 6 Month HAM-A, 6 Month SRT, and 6 
Month FQ-AG. A fourth division was again created and designated 6 Month Follow-up 
Responder. To qualifY as a 6 Month Follow-up Responder a patient had to achieve clinically 
significant improvement on all three outcome measures and receive no follow-up treatment. 
This again constitutes a fairly stringent criterion of follow-up responder. 
7.2.3.2. Predictor Measures 
Predictor measures were divided into four broad groupings, demographic variables, panic 
attack variables, complaint-related variables, and personality and social variables. The aim 
was to attempt as broad a range of measurement as possible without overloading the analysis 
with a large number of potentially redundant measures. All measures were taken in the week 
prior to the start of active treatment. The measures in each grouping will be described in 
tum. Copies of each measure are given in Appendix II. 
7.2.3.2.1. Demographic Variables 
Patients age and sex were recorded, as was duration of current episode of panic disorder (in 
months). GP report of previous psychiatric history was also recorded and operationalised as 
number of previous psychiatric diagnoses given prior to study entry. 
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7.2.3.2.2. Panic Attack variables 
Panic attack variables have been suggested to be a major defining feature of panic disorder. 
These variables were recorded using a prospective event recording method by patient diary 
on a weekly basis. A more detailed description of the measurement of panic attack variables 
and the reasoning behind them is given in Chapter 6. Both panic attacks and limited symptom 
attacks were measured. In order to reduce the overall number of predictor variables in this 
study, the scores for panic attacks and limited symptom attacks combined were used i.e. total 
scores. Pre-treatment scores for total attack frequency, total mean severity, and total mean 
duration, were used as predictor variables. 
7.2.3.2.3. Complaint Related Variables 
These variables were included to investigate the influence of aspects of the clinical 
presentation of panic disorder and agoraphobia on treatment outcome. A measure of 
therapist rated anxiety was taken using the Hamilton Anxiety Scale HAM-A (Hamilton 
1959), and patient self-rated anxiety using the Kellner Sheffield Symptom Rating Test SRT 
(Kellner & Sheffield 1973). Patients also self-rated agoraphobic avoidance using the 
agoraphobia subscale of the Fear Questionnaire, FQ-AG (Marks & Mathews 1979). 
Therapist also rated depression using the Montgomery Asberg Depression Rating Scale 
MADRS (Montgomery & Asberg 1979). All of these measures were completed at pre-
treatment assessment. 
7.2.3.2.4. Personality and Social Variables' 
These measures were included to investigate aspects of patient's personality and social 
circumstances and their usefulness as predictor variables. Patients completed the Anxiety 
Sensitivity Index, AS!, (Reiss et al1986, Peterson & Reiss 1992). This is a 16 item self-
report questionnaire that measures fear of, or sensitivity to, anxiety symptoms. Patients 
respond to questions such as ''when I notice that my heart is beating rapidly, I worry that I 
might have a heart attack" by recording their degree of endorsement of each item on a 5-
point Lickert type scale ranging from 0 (''very little"), to 4 (''very much"). Anxiety sensitivity 
is argued to have a single factor structure (Taylor et all992b), and to be conceptually 
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distinct from trait anxiety (McNally 1989). Patients also completed the Eysenck Personality 
Questionnaire, EPQ, (Eysenck & Eysenck 1978) from which the Extroversion, E, and 
Neuroticism, N, scales are reported. In this way two broad dispositional personality traits (E 
and N), were measured along with a dispositional trait argued to be more specifically related 
to panic disorder in particular (ASI). Social factors were measured using two scales. Patients 
completed the Social Maladjustment Questionnaire (SocMal), (Corney & Clare 1985). This 
is a 33 item self-report questionnaire designed to identifY social problems, difficulties, and 
dissatisfaction. The questionnaire is has 7 sections covering, housing, work, financial 
situation, social and leisure activities, child/parent and marital relationships, social 
relationships, and legal problems. Patients endorsed each section that represented an area of 
difficulty for them, thus a score representing the total number of sections endorsed was 
recorded. Patients also recorded disruption caused by their panic disorder using the Sheehan 
Disability Scale, SD total, (Sheehan 1986). This is a simple measure of social functioning 
which assesses disruption to daily lifestyle and comprises three 1 ° point subscales where 
patients self-rate disruption to work, social life, and familylhome life. For the purposes 
of the current analysis a total score on the SD, representing the sum of the scores on the 
three scales was used. 
7.3. Results 
7.3.1. Statistical Analysis 
Data were checked for abnormalities of distribution, presence of outliers, and 
multicollinearity . 
Relationships between variables were also investigated by examining Pearson r correlations. 
Whilst there were intercorrelations amongst the data, no bivariate correlation exceeded 0.70, 
and thus no variables were excluded from the analysis on these grounds (Tabachnick & Fidell 
1996). The distributions for the panic attack variables, Total Frequency, and Total Mean 
Duration were highly positively skewed (i.e. skew> 1.0, c.f Ferguson & Cox 1993) and thus 
lOgarithmic transfonnations (Log 10 (variable + 1», were performed on these variables, as 
described in Chapter 6. As goodness offit tests which compare observed with expected 
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frequencies were to be used, adequacy of expected frequencies was checked and found to be 
within acceptable limits. No other operations on data were required. 
The study design entails an investigation of the relationship between a dependant variable, 
dichotomised in terms of clinical significance of outcome, and a series of predictor variables 
measured at pre-treatment, in an attempt to identify predictors which discriminate between 
the clinically significant, and non-significant groups at post -treatment. Discriminant function 
analysis was deemed unsuitable for this purpose for a variety of reasons. Firstly, the predictor 
variables included a mix of continuous and categorical measures, and secondly, group sizes 
(clinically significant vs. non-significant), were, at times, very unequal. It was also expected 
that the distribution of the responses on the dependant variable would be non-linear with one 
or more of the predictor variables. That is to say, the probability of a patient being clinically 
significantly improved following treatment may be affected very differently by, for example, a 
10 point change in rated anxiety over treatment depending on where across the range of 
potential anxiety scores this 10 point change occurred. A reduction of 10 points on an initial 
score of, for example, 15 points is highly likely to be a clinically significant change, whereas a 
10 point reduction in an initial score of, say 30 points, is much less likely to represent a 
clinically significant improvement. In this example the relationship between group allocation 
and rated anxiety level would be described as non-linear. These factors violate the 
assumptions underlying discriminant function analysis and an alternative strategy of analysis is 
required. Logistic regression was therefor selected as the appropriate statistical technique 
(Tabachnick & Fidell 1996), as this technique is more flexible and does not require that the 
predictors be normally distributed, linearly related, or of equal variance within each group. 
Data were analysed employing logistic regression using the SPSS-X statistical package. 
Outcome was dichotomised as clinically significantly improved = 1, versus not clinically 
significantly improved = O. The sample was dichotomised at treatment end-point (Day 84), 
on four separate criteria, namely, clinically significant improvement vs. non-improvement 
separately on each of the HAM-A, SRT, and FQ-AG, and also on a composite Day 84 
responder criteria which required clinically significant improvement on all three outcome 
variables (HAM-A, SRT, FQ-AG) for a patient to be classified as a Day 84 responder. The 
sample was dichotomised again at 6 month follow-up, again on the same four criteria, 
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(clinically significant improvement on 6 month follow-up HAM-A, SRT, FQ-AG, and 6 
month FU responder) with the added restriction in each case that the clinically significant 
improvement had occurred in the absence of intervening treatment during the follow-up 
phase. Separate logistic regression analyses were performed for each of these eight 
dependant variables. 
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Logistic regression permits several assessments of statistical significance. The significance 
of the contribution of individual predictors is assessed using the Wald Chi-Square test, which 
is noted as a particularly conservative criterion (Norusis 1990). Results for individual 
predictor variable are also reported as the log coefficients, Beta, and, standard error of Beta. 
A figure is also given for exponentiated Beta (Exp (B». Sometimes known as the odds ratio, 
exponentiated Beta indicates the increase (or decrease) in odds of being in one outcome 
category when the value of the predictor variable is increased by one unit of measurement. 
As most of the predictor variables in the present study showed negative relationships with the 
outcome group clinically significantly improved, the values for exponentiated Beta are less 
than 1. Thus the smaller the value for Exp (B), for a particular predictor variable, the greater 
the influence of small changes in that variable on membership of the clinically significantly 
improved group. Ifa predictor variable has an Exp (B) value o( for example, 0.5, this means 
that an increase of one unit of measurement in this variable will reduce by half(0.5) the 
patients chances of being in the clinically significantly improved group. The adequacy of 
models constructed by logistic regression can be further tested in a variety of goodness of fit 
combinations, the most commonly used of these being firstly, a comparison of the devised 
model with a model containing the constant only (reported in SPSS as "model chi-square"). 
A finding of significant difference in this comparison indicates that the predictor variables in 
the model are contributing significantly to the prediction of outcome. A second combination 
involves a comparison of the devised model with the ''perfect'' or ''hypothetical'' model 
(reported in SPSS as" -2 log likelihood"). The perfect model is hypothesised to contain 
exactly the right set of predictors to duplicate the actual observed frequencies. A finding of 
non-significance of difference in this comparison represents a strong endorsement of the 
devised model as an equally adequate set of predictors as the hypothesised or perfect model. 
As a control for intercorrelation amongst variables, the predictor variables were entered into 
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the analysis sequentially, in the same order for each analysis. The first predictor variable 
entered was a control variable for treatment received. Treatment group was coded as a 
dichotomous variable as active (FL, FL+CBT, PL+CBT, CBT) versus inactive (PL), 
treatment. This variable reflected the findings of the main study (Sharp et al1996, Chapter 4) 
where all active treatments showed a significant superiority over the placebo group (PL), and 
no statistically significant differences between the active treatment groups themselves on the 
main outcome variables (HAM-A, SRT, FQ-AG). Entering the treatment variable as the first 
predictor variable in the analysis permits the assessment of the predictive power of the other 
variables relative to the contribution of treatment to clinical outcome. This is an essential step 
in analysing data from a treatment outcome study. Other predictor variables were entered 
next, in the following order, first demographic predictors, age, sex, duration of current 
episode, and psychiatric history, then the panic attack variables, total frequency, total mean 
severity, and total mean duration, followed by the complaint-related variables, HAM-A, 
SRT, FQ-AG, and MADRS, and lastly the personality and social variables, ASI, SocMal, E, 
N, and SD total. Predictor variables were retained in the model if, at their stage of entry they 
showed a significant Wald test (p < 0.05) indicating the significance of that particular 
predictor variable, and also a significant difference (p < 0.05) for the model comparison with 
the constant only model indicating that the model including this variable had predictive 
advantages over a model containing the constant only. Any predictor variable that failed to 
achieve these criteria was discarded from the analysis. Results are reported for significant 
predictors only. 
7.3.2. Treatment end-point (Day 84) results 
Patient numbers for clinically significantly improved versus non-significantly improved for 
each outcome variable at Day 84 were, HAM-A, 119 vs. 30, SRT, 55 vs. 94, FQ-AG, 109 
vs. 40, and Day 84 Responder, 53 vs. 96. Tables 7.1.1. to 7.1.4. show the significant 
predictor variables for each outcome variable. From these tables it can be seen that all four 
outcome variables showed high accuracy of prediction with between 71.9"10 and 84.5% of 
patients being correctly classified as achieving significant or non-significant improvement, 
with the highest predictive accuracy being found for membership of the significantly 
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improved groups. Also, for all four outcome variables the constructed model was 
significantly different from the constant only model, but not significantly different from the 
perfect model, indicating that the predictive models for the Day 84 end-point outcome were 
strongly predictive and approximated the best possible prediction of clinically significant 
outcome. Results for each outcome variable varied, with different predictors significant for 
each outcome variable. 
For Day 84 HAM-A, (Table 7.1.1.) treatment group, SRT, and EPQ-E, were significant 
predictors indicating that lower levels of self-rated anxiety (SRT), and higher levels of 
extraversion (EPQ-E), along with receiving active treatment disposed towards clinically 
significant change in therapist rated anxiety at end-point. 
Table 7.1.1. Prediction of treatment end-point (Day 84) clinically significant improvement on HAM-A 
HAM-A Variable B S.E. Wald Sig 
Treabnent Group -1.277 0.277 21.23 0.0001 
SRT -0.043 O.oI5 7.77 0.005 
EPQ-E 0.131 0.052 6.29 0.01 
Perfect Model Chi-Square = 111.52, df. = 145, n.s. 
Constant Model Chi-Square = 40.87, df = 3, P < 0.0001 
Exp(B) Ovemll % correctly 
Classified 
0.278 
.957 
1.137 84.5% 
The values for Exp (B) indicate that treatment group (Exp (B) = 0.278) had the greatest 
influence on membership of the clinically significantly improved group, with an increase of 
one unit on this measure reducing a patienfs odds of being in the clinically significantly 
improved by approximately 72%. With SRT and EPQ-E showing values closer to 1, larger 
changes on these measures would be predictive of change from the significant outcome 
group. This is only to be expected as treatment group represents a dichotomised variable 
(active vs. inactive treatment), thus a one unit change on this measure represents a complete 
change of treatment received, whereas both the SRT, and EPQ-E are continuous measuring 
scales with much larger potential ranges of scores. It is reasonable therefor, to expect 
changes in scoring larger than one unit to be required to influence outcome results. 
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For Day 84 SRT (Table 7.1.2.), treatment group, total panic frequency, and SRT, were 
significant predictors, indicating that a lower frequency of panic episodes (both panic attacks 
and limited symptom attacks), lower levels of self-rated anxiety (SRT), and receiving active 
treatment all disposed towards clinically significant improvement in patient self-rated anxiety. 
Total panic frequency had the greatest influence on membership of the clinically significantly 
improved group (Exp (B) = 0.237) with an increase in one unit on this measure reducing the 
odds of being in the clinically significantly improved group by approximately 76%. Treatment 
group showed a lesser effect on membership of the clinically significantly improved group 
(Exp (B) = 0.618). SRT showed the least influence on clinically significant improvement 
(Exp (B) = 0.96). 
Table 7.1.2. Prediction of treabnent end-point (Day 84) clinically significant improvement on SRT. 
SRT Variable B S.E. Wald Sig 
Treabnent Group -0.481 0.272 3.22 0.05 
Total Panic Frequency -1.437 0.599 5.75 0.01 
SRT -0.041 0.141 8.33 0.005 
Perfect Model Chi-Square = 163.65, df. =145, n.s. 
Constant Model Chi-Square = 27.64, df. =3, P < 0.0001 
Exp(B) Overall % Correctly 
Classified 
0.618 
0.237 
0.960 76.0% 
For Day 84 FQ-AG (Table 7.1.3.), treatment group, and patient self-rated agoraphobic 
avoidance (FQ-AG) were significant predictors. 
Table 7.1.3. Prediction of treatment end-point (Day 84) clinically significant improvement on FQ-AG. 
FQ-AG Variable B S.E. Wald Sig 
Treabnent Group -1.012 0.273 13.74 0.001 
FQ-AG -0.103 0.020 26.72 0.0001 
Perfect Model Chi-Square = 129.48, df. =146, n.s. 
Constant Model Chi-Square = 43.86, df. = 2, p< 0.0001 
Exp(B) Overall % Correctly 
Classified 
0.363 
0.901 79.2% 
Thus only receipt of active treatment, and lower initial levels of rated agoraphobic avoidance 
were related to clinically significant improvement in agoraphobic avoidance at treatment end-
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point, with treatment group being by far the more influential of the two predictors. Receiving 
inactive treatment reduced a patients chances of being in the clinically significantly improved 
group by approximately 64%. 
For the composite outcome variable Day 84 Responder (Table 7.1.4.), membership of the 
clinically significant outcome group was predicted by treatment group, total panic frequency, 
patient self-rated anxiety (SRT), and level of social maladjustment (SocMal). The direction of 
the relationship between outcome group and the treatment group, panic attack, and SRT 
predictors was identical to that found for the individual outcome variables (HAM-A, SRT, 
FQ-AG). The additional predictor variable, SocMal (Exp (B) = 0.715), indicated that 
increased levels of social maladjustment at treatment entry disposed against membership of 
the clinically significantly improved group. With an increase in one unit on the SocMal 
measure reducing a patient's chances of being in the clinically significantly improved group 
by approximately 30010. As for the SRT outcome variable, total panic frequency (Exp (B) = 
0.298) was the most potent predictor, with treatment group and SocMal occupying an 
intermediate position with SRT (Exp (B) = 0.975), the weakest of the four predictor 
variables. Thus much larger increases in scores on SRT would be needed to reduce a patients 
chances of being in the clinically significantly improved group at treatment end-point. 
I.able 7.1.4. Prediction of treatment end-point (Day 84) clinically significant improvement on Day 84 
Responder criterion. 
Day 84 Variable B S.E. Wald 
Responder 
I--
""-
Treatment Group -0.642 0.285 5.06 
Total Panic -1.209 0.599 4.07 
Frequency 
SRT -0.240 0.014 3.122 
SocMaI -0.335 0.155 4.64 
Perfect Model Chi-Square = 160.76, df. = 141, n.s. 
Constant Model Chi-Square = 29.38, df. = 4, P < 0.0001 
Sig Exp(B) Overall % 
Correctly 
Classified 
0.05 0.525 
0.05 0.298 
0.05 0.975 
0.05 0.715 71.9% 
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The only predictor variable common to all four analyses was treatment group, the generally 
low values for Exp (B) for this predictor attesting to the obvious relationship between 
receiving active treatment and achieving clinically significant improvement. Indeed receiving 
inactive treatment reduced the odds of being in the clinically significantly improved group at 
Day 84 by between 38% and 71 % depending on which outcome measure was used. 
7.3.3.6 month follow-up results 
A total ofn = 126 patients (out ofa possible n = 149) attended for 6 month follow-up 
assessment. The numbers for clinically significantly improved without intervening treatment 
versus non-significantly improved for each outcome variable were, HAM-A 70 vs. 56, SRT 
40 vs. 86, FQ-AG 65 vs. 61, and 6 Month follow-up responder 37 vs. 89. Tables 7.2.1. to 
7.2.4. show the significant predictor variables for each outcome variable. From these tables it 
can be seen that the strength of prediction continued clinically significant improvement at 6 
month follow-up was reduced compared to the Day 84 analyses. From 61.6% to 68.3% of 
patients were correctly classified as achieving clinically significant or non-significant 
improvement at 6 month follow-up, with the highest predictive accuracy being found for 
membership of the non-significantly improved groups. The reduced efficacy of the follow-up 
predictions was also suggested by the fact that, with the exception of the composite 6 Month 
FU Responder outcome variable, all analyses showed significant differences between the 
constructed models and both the constant only model and the perfect model. This indicates 
that whilst the constructed models were a significant improvement on the constant only 
model, they nonetheless did not represent the optimum prediction of outcome. There are 
therefor likely to be further influences on achievement of clinically significant improvement at 
follow-up which were not picked up by the predictor variables employed in this study. 
Regarding models constructed here, for 6 Month HAM-A (Table 7.2.1.), membership of 
the significantly improved group was predicted by treatment group, and initial therapist rated 
depression level (MADRS). This suggests that patients with initially high levels of depression 
are less likely to achieve clinically significant improvement at follow-up, although with Exp 
(B) = 0.91, this is not a powerful relationship. Treatment group was also a stronger predictor 
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(Exp (B) = 0.652), with receipt of inactive treatment reducing the odds of being in the 
clinically significantly improved group by around 35%. 
Table 7.2.1. Prediction of 6 month follow-up clinically significant improvement on HAM-A 
HAM-A Variable B S.E. Wald Sig 
Treatment Group -0.426 0.218 3.82 0.05 
MADRS -0.093 0.044 4.53 0.05 
Perfect Model Chi-Square = 194.44, df. = 122, P < 0.005 
Constant Model Chi-Square = 9.14, df. = 2, P < 0.01 
Exp(B) Overall % Correctly 
Classified 
0.652 
0.910 63.8% 
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For 6 Month SRT (Table 7.2.2.), only one predictor variable, total panic frequency, was 
significant indicating that a high frequency of panic and limited symptom attacks at the outset 
of treatment disposed to membership of the non-significantly improved group. The Exp (B) 
value of 0.398 indicating that an increase in one unit on this predictor variable would reduce 
the odds of being in the clinically significantly improved group at 6 month follow-up by 
around 60010. 
Table 7.2.2. Prediction of 6 month follow-up clinically significant improvement on SRT. 
SRT Variable B S.E. Wald Sig 
Total Panic Frequency -0.921 0.494 3.46 0.05 
Perfect Model Chi-Square = 187.75, df. = 124, P < O.ot 
Constant Model Chi-Square = 3.54, df. = 1, P <0.05 
Exp(B) Overall % Correctly 
Classified 
0.398 61.6% 
For 6 Month FQ-AG (Table 7.2.3.), treatment group and patient self-rated agoraphobic 
avoidance (FQ-AG) were significant predictors. Thus clinically significant improvement at 
follow-up on FQ-AG was predicted by the same predictor variables at treatment end-point 
(Day 84), and 6 month follow-up. The similar Exp (B) values suggest that FQ-AG has much 
the same influence on group membership at Day 84 and 6 month follow-up, whereas the 
influence of treatment group was reduced at follow-up as indicated by the increased Exp (B) 
value. 
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Table 7.2.3. Prediction of 6 month follow-up clinically significant improvement on FQ-AG. 
FQ-AG Variable B S.E. Wald Sig 
Treatment Group -0.507 0.223 5.18 0.05 
FQ-AG -0.033 0.14 5.62 0.01 
Perfect Model Chi-Square = 195.39, df. = 122, P < 0.01 
Constant Model Chi-Square = 10.35, df. = 2, P < 0.005 
Exp(B) Overall % Correctly 
Classified 
0.601 
0.966 63.8% 
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For the composite follow-up outcome variable, 6 Month FU Responder (Table 7.2.4.), only 
social maladjustment (SocMal) was a significant predictor, and showed a moderate influence 
on group membership (Exp (B) = 0.671), with an increase in one unit on this measure 
reducing the odds of clinically significant improvement by 33%. 
Table 7.2.4. Prediction of6 month follow-up clinically significant improvement on 6 month FU responder 
criterion. 
6MontbFU Variable B S.E. Wald 
Responder 
SocMal -0.397 0.187 4.52 
Perfect Model Chi-Square = 136.63, df. = 124, n.s. 
Constant Model Chi-Square = 5.19, df. = 1, p< 0.05 
Sig Exp(B) Overall % Correctly 
Classified 
0.05 0.671 68.3% 
Importantly however, 6 Month Follow-up Responder was the only follow-up outcome 
model which yielded a non-significant result in the comparison with the perfect model. The 6 
Month FU Responder model also showed the highest percentage of patients correctly 
classified (68.3%) of all the follow-up models. Thus prediction of which patients will achieve 
clinically significant improvement on all three outcome measures (HAM-A, SRT, FQ-AG), 
without receiving any intervening treatment during the follow-up period is adequately 
predicted by level of social maladjustment at treatment entry, with high levels of social 
maladjustment disposing against clinically significant improvement. 
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7.4. Discussion 
It is worth recognising at the outset that regression analyses of the sort presented here are 
highly sensitive to variations in sample size and configuration, the nature and type of measure 
used, and intercorrelation between variables and consequent order of entry effects. The fact 
that the logistic regression employed here is more robust than other forms of regression 
analysis notwithstanding, the above, and other restrictions, mean that the findings of the 
present study should be regarded as, at best, provisional, and certainly requiring replication. 
The more so because the current study is the first to employ a logistic regression with 
treatment outcome data from patients with panic disorder and agoraphobia and results are 
therefor best seen as preliminary. Furthermore, regression analyses on treatment outcome 
results are not only vulnerable to the structure of the analysis itself, but also to the effects of 
the treatments investigated. As already argued, treatment received should be coded as a 
predictor variable and preferably entered first into the analysis. If this is not done the 
influence of treatment on outcome cannot be accounted for. This influence will also vary 
depending on the efficacy or potency of any given treatment. A powerfully effective 
treatment which brings about clinically significant changes in patients regardless of initial 
severity of problem, or other social or personal factors is likely to leave little variance in 
outcome to be explained by other non-treatment related factors. On the other hand, outcome 
following a weak or partially effective treatment may be strongly influenced by non-treatment 
factors such as personality or other social or demographic variables. Thus any regression 
analysis on treatment outcome results cannot easily be divorced from the treatments that 
produced those outcomes, and such treatments should be borne in mind when interpreting 
the results from these regression analyses. 
Moving on to consider the results of the present study, the first finding of note, concurrent 
with previous studies (Jansson et al1987, Keijsers et al1994), is that few of the predictor 
variables entered into the analysis yielded significant results. Demographic variables were 
found to have no predictive utility. This is again in keeping with previous studies (Jansson et 
al1987, Chambless & Gracely 1988) which found no relationship between patient 
demographics and treatment outcome. Such findings attest to the wide clinical utility of 
treatments for panic disorder and agoraphobia in that they are not apparently restricted by 
.. 
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considerations of age, gender, and so forth. Panic attack variables were significant predictors 
in only three of the eight regression analyses (Day 84 SRT, Day 84 Responder, 6 Month FU 
SRT). For these three outcome variables they were however highly influential predictors, 
showing smaller values ofExp (B) than any other predictor variables. This was for total panic 
frequency only, neither the severity or duration measures were retained in any of the analyses. 
Nonetheless, the frequency of panic and limited symptom attacks pre-treatment appears to be 
a powerful predictor of subsequent treatment outcome. 
Personality variables showed little predictive utility. Previous studies that had investigated 
personality had concentrated on personality psychopathology. In the current study the 
explicit aim was to investigate more broadly based personality dimensions. No significant 
findings were found for the Neuroticism scale of the EPQ, nor were there any significant 
findings for the ASI which is argued to be a specific and sensitive predictor of panic sensitive 
personality (McNally 1994). This latter result is contrary to expectation and requires some 
explanation. Previous predictive studies (Chambless & Gracely 1988, Keijsers et al 1994) 
have found measures tapping agoraphobic catastrophic cognitions, or other fear offear 
variables, to have predictive utility, and have suggested that these findings are in keeping with 
cognitive explanations of panic disorder (e.g. Clark 1986). Such a relationship between fear 
offear, as measured by the ASI, and treatment outcome was absent in the present study. 
There are two potential explanations for this both of which may have operated with the 
current data set. Firstly the effect of the ASI in the analysis may have been reduced due to 
intercorrelation with other variables and it's late entry into the analysis. Indeed ASI did show 
moderate correlations with HAM-A, SRT,'and FQ-AG, all of which were entered into the 
analysis before the ASI. A second explanation refers to actual treatments used in the study. 
The studies which found significant effects with fear of fear type variables (Chambless & 
Gracely 1988, Keijsers et al 1994) both employed behavioural exposure based treatments. 
These treatments would not therefor have focused directly on cognitions and cognitive 
change. Thus variance existing between the dispositional variables and treatment outcome 
may only have been minimally effected by such treatment interventions thus a predictive 
relationship was found. The present study employed a cognitive behavioural treatment (CBT) 
which was much more directly targeted at cognitive change, and also a medication treatment, 
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the SSRI fluvoxamine, which has also been shown to bring about cognitive change 
(Weinstein & Nutt 1995). Thus all of the active treatments in the present study will have 
exerted a significant effect on treatment outcome in terms of cognitive change and as such 
are likely to have obscured any relationship between the ASI and treatment outcome. This 
suggested effect of treatment would have been all the more powerful iflarge quantities of the 
predictive variance of the ASI had been further taken up by other variables entered earlier in 
the analysis such as the HAM-A, SRT, or FQ-AG. In this analysis the ASI added no 
predictive utility over that supplied by the more commonplace clinical measures of general 
anxiety and agoraphobic avoidance. 
Regarding the findings of significant relationships between predictor variables and clinical 
significance of outcome, firstly prediction of outcome was not achieved by a single consistent 
predictor variable or even a small number of predictor variables. This is not surprising really 
as, to echo Keijsers et al (1994), if one, or even two or three, such consistent predictors 
existed it is unlikely that 15 years of research could have been conducted without their being 
identified. It is clinically more credible that a range of predictor variables exist with a range of 
relationships to differing outcome variables. An individual patient's chances of being a 
treatment success or failure will be related to the number and pattern of these predictors 
operating in their case. The pattern of results in the present study is one of variety of 
predictors across outcome variables and across occasions of measurement, and as such is in 
keeping with previous research. The tests of adequacy of the obtained models which is 
possible within logistic regression yielded informative results with all of the models derived 
from the Day 84 analyses being an adequate representation of the actual observed 
frequencies for outcome group membership (clinically significantly improved vs. non-
improved) and large proportion of patients were correctly classified in each analysis. At 
treatment end-point (Day 84) one predictor was consistently related to all four outcome 
variables, namely treatment group (active vs. inactive). That is to say, the most consistent 
determinant of whether the patients in this study achieved clinically significant improvement 
immediately following treatment was whether they received active or inactive treatment. This 
finding makes clinical sense and is in keeping with the considerable evidence presented thus 
far (Sharp et al 1996, Chapter 4, Sharp et al 1997b, Chapter 5) indicating the significant 
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advantage of the active over the inactive treatments employed in this study. The finding of 
significance for treatment group is also relevant to the forgoing discussion of the importance 
of considering the relative power or efficacy of the treatments used when interpreting the 
results of regression analyses on treatment outcome data. To avoid the problem of over 
prediction as a result of small sample sizes, the treatment groups were subdivided only as 
active versus inactive treatment in the current analysis. The estimation of the predictive value 
of each treatment individually was not therefor possible. The investigation of this interesting 
area will require further research employing much larger sample sizes. 
Some of the initial complaint-related variables employed in this study showed some 
promise as predictors of clinically significant improvement. This again is reassuring to the 
research clinician, suggesting that the measures of general anxiety and agoraphobic avoidance 
employed as treatment outcome measures actually show a relationship to outcome when 
used as predictor variables in regression analyses. Patient rated measures of general anxiety, 
SRT, and agoraphobic avoidance, FQ-AG, were significant predictors although it is clear 
from the odds ratios (Exp (B)) for these variables that fairly large changes on these measures 
would be required to influence group membership. Interestingly, these variables showed 
significant results for their related outcome measures only. That is, the anxiety based 
outcome variables of clinically significant improvement on the HAM-A, and SRT, were both 
predicted by initial level of patient self-rated anxiety on the SRT, whereas clinically significant 
improvement in agoraphobic avoidance on the FQ-AG, was predicted by initial scores on the 
FQ-AG. The predictive value of self-rated anxiety has been noted in previous studies 
(Jansson et al 1987) as has the relationship between good treatment outcome in terms of 
agoraphobic avoidance and low initial scores on measures of agoraphobia (Chambless & 
Gracely 1988, Fischer et al1988, Keijsers et al1994). Neither of the therapist-rated 
variables, the HAM-A for anxiety or the MADRS for depression showed any significant 
relationship with outcome at treatment end-point (Day 84). Variables related to panic attacks 
did show significance as predictors for the SRT and Day 84 Responder composite outcome 
measures, with higher pre-treatment frequencies of panic attacks plus limited symptom 
attacks disposing towards non-significant change at treatment end point. This finding does 
lend some support to the view that frequency of panic attacks is an important defining feature 
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of panic disorder. Panic attack variables have been shown to be significant predictor 
variables in other studies (Jansson et al 1987), this is however the first time that panic 
attack variables recorded using a prospective event recording method, and thus less 
effected by retrospective bias, have been used as predictors in a regression analysis. 
The expected reduction in reported frequency of panic attacks due to the prospective 
recording does not seem to have removed the significance of panic frequency as a 
potentially useful predictor. The significant fmding for total panic frequency is also in 
accord with the observed trend amongst predictor variables relating to initial severity 
of complaint, that the more severe the initial complaint the less the likelihood of 
achieving clinically significant improvement. Treatment outcome at Day 84 was also 
predicted by two other variables. For the HAM-A outcome variable the extroversion 
score, E, from the EPQ, showed a significant value suggesting that more extrovert 
patients were more likely to achieve clinically significant improvement on the HAM-
A. The converse of this being of course, that more introverted individuals will fair less 
well. This finding is noteworthy, as it is an indication that personality assessed as a 
general disposition may have some bearing on treatment outcome. It may be the case 
however that, given that there was a single therapist, this finding may reflect a 
therapeutic relationship factor, that is, the therapist worked better with extroverts. 
Consideration should be given in future to including measures of "normal" personality 
variables in treatment outcome studies rather than including only assessments of 
personality disorders as has been the case until now. For the Day 84 Responder 
outcome variable group membership was also predicted by the measure of social 
maladjustment (SocMal). This indicates that membership of the strictly defined group 
who achieve clinically significant improvement on all three outcome measures (HAM-
A, SRT, FQ-AG) is partly defined by the level of social disruption in patients lives at 
the start of treatment. This reinforces the commonly held clinical wisdom that those 
patients with more ongoing life events or hassles fair less well in treatment. Overall for 
Day 84 treatment end-point assessment, results of this study suggest that higher patient 
self-ratings of pre-treatment severity, lower levels of extroversion, and the presence of 
multiple social problems all militate against a positive treatment outcome. Armed with 
such information the clinician may be more able to appropriately monitor the progress 
of "at risk" patients and provide remedial intervention if required. Further study will be 
required to ascertain whether the provision of such remedial intervention will actually 
result in further clinical improvement. Unrestrained optimism is perhaps inappropriate, 
given that some investigations with panic 
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disorder patients (Brown & Barlow 1995) have suggested that the provision of extra 
treatment to treatment non-responders does not consistently result in further improvement. 
An inspection of the pattern of findings for the prediction of clinically significant 
improvement at 6 month follow-up reveals a reduced number of significant predictor 
variables, lower proportions of patients correctly classified, and only one of the four 
prediction models (6 Month FU Responder) showing a non-significant comparison with the 
perfect model. Thus prediction of clinically significant improvement at 6 month follow-up 
was not achieved with the same degree of success as prediction of outcome at treatment end-
point. The significant differences found between the models derived from this analysis and the 
so-called perfect models suggest that a proportion of the variance in outcome at 6 month 
follow-up is not predicted by the full set of predictor variables entered into the analyses used 
here, and that other factors unmeasured in this study, influence outcome at follow-up. 
Further research is obviously required to discover the nature of other possible predictors and 
to assess their influence on outcome at follow-up. As an example of such other possible 
predictors, in the present study social maladjustment was formally assessed at treatment entry 
only, thus no record was available of any major life events or social disruption occurring 
during the follow-up period. This is a potentially important variable which should certainly be 
investigated in further. Treatment group remained a significant predictor at follow-up for 
HAM-A and FQ-AG only. Thus the importance of which treatment (active vs. inactive), was 
no longer a significant influence on follow-up outcome as indexed by patient rated anxiety, 
SRT, and 6 Month FU Responder variables. Clinically significant improvement at follow-up 
on the SRT outcome variable was predicted by total panic frequency only, this being a 
continuation of the significance shown at Day 84 for this predictor. The FQ-AG outcome 
variable showed the same predictors at follow-up as at Day 84, namely treatment group and 
initial FQ-AG. For the composite outcome measure 6 Month FU Responder only social 
maladjustment (SocMal), was retained as a significant predictor. This was the only follow-up 
outcome variable to show an insignificant Chi-Square in the perfect model comparison 
suggesting that SocMal represents an adequate predictor of the observed frequencies of 
outcome group membership for this variable. Thus number of social problems at treatment 
entry has a significant bearing on whether patients achieve clinically significant improvement 
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on a strict index which requires clinically significant change on all three target measures 
(HAM-A, SRT, FQ-AG) and no intervening treatment during the follow-up phase. This 
finding taken together with the significant finding for SocMal for Day 84 Responder 
outcome, suggests that level of social disruption is an important predictor. The only 
significant predictor variable at follow-up that had not shown significance at Day 84 was 
initial depression score on the MADRS which was a significant predictor for clinically 
significant improvement on the HAM-A Several previous studies have found no relationship 
between outcome at treatment end-point and initial depression level (Chambless & Gracely 
1988, Fischer et al1988, Keijsers et al1994), as did the present study. It appears however 
that initial depression level may have some bearing on follow-up results with patients with 
higher initial levels of depression being less likely to achieve clinically significant improvement 
on the HAM-A at 6 month follow-up. 
The current study represents an initial investigation of the value of possible prognostic 
indicators of treatment outcome. In an attempt to increase the clinical relevance of results, 
outcome was defined in dichotomised groups using theoretically grounded measures of 
clinically significant improvement. The use of the Jacobson procedures in this study did result 
in particularly stringent criteria of clinically significant improvement for the SRT, and 
consequently for the Day 84 Responder criteria which required clinically significant 
improvement on all three outcome measures. The follow-up outcome measures were further 
restricted by the requirement that no intervening treatment should occur during the follow-up 
period. These requirements may have led to rather restricted groups in some cases and thus 
the generalisability of the findings may be rompromised to some extent. The use of the 
Jacobson procedures was, however, deemed to be of more relevance to wider clinical 
practice than an investigation focused solely on variance accounted for in outcome scores, or 
the dichotomisation of outcome groups according to non-standardised or idiosyncratic 
procedures. Logistic regression was employed to identifY predictor variables that influenced 
membership of outcome groups. Significant results were obtained with the most influential 
predictor variables (smallest values for Exp (B», being treatment group, and total panic 
frequency. It is worth noting that, of the significant predictor variables, treatment group and 
total panic frequency were entered first and second in the analyses, and some of their power 
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as predictor variables may be attributable to this early entry to the analysis. In general the 
findings from the present study provide some reassurance for clinicians to the extent that 
predictive validity was shown for measures taken as standard in clinical practice. Thus 
frequency of panic attacks, general anxiety, agoraphobic avoidance, and level of depression 
all showed some influence on outcome. The significance of other predictors such as social 
maladjustment, and extroversion show however that other influences on treatment outcome 
should be considered. Of course, indications of significance in regression analyses such as this 
do not denote direct causal relationships. More controlled experimental study will be required 
to investigate and define the nature of the relationships between treatment outcome and the 
potential predictors found in this study. The present study has been reported elsewhere as 
Sharp et al (Submitted). 
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CHAPTER 8 DISCUSSION 
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8.1. Discussion 
Chapter 1 of this thesis discussed the development of the clinical concept of panic 
disorder and agoraphobia, it's classification, and suggested antecedents and 
consequences. Chapter 1 also discussed the development of pharmacological and 
psychological treatments for panic disorder and agoraphobia and the investigation of 
their comparative efficacy using techniques such as meta-analysis. Following this 
discussion, it was argued that greater scientific control was required in studies 
comparing pharmacological and psychological treatments for panic disorder, and that 
further comparative studies were required. It was suggested that a current and 
informative study would be one investigating the relative and combined efficacies of the 
most recently developed and most promising pharmacological and psychological 
treatments. A study investigating the treatment efficacy of the SSRI fluvoxamine, and 
the psychological treatment, cognitive behaviour therapy was therefor conducted. This 
study was designed following a thorough review of previous treatment outcome study 
methodology, reported in Chapter 2. This critical review assessed the adequacy of 
treatment outcome study design, in terms of both necessary scientific controls and the 
need for studies to produce relevant and clinically meaningful results. Balancing the, at 
times conflicting, demands of research and clinical practice inevitably means that 
compromises are made in study design. These compromises, discussed in detail in 
Chapter 2, relate not only to the actual conduct of treatment outcome studies but also, 
as a first step, to the recruitment and construction of the experimental sample of patients 
who will receive the treatments. If results from a well designed study are to be applicable 
to wider clinical practice they must arise from a sample which is as representative as 
possible of the patients seen in wider clinical practice. Factors affecting the 
representativeness of the sample employed in the present studies will be discussed next 
with particular emphasis on inclusion/exclusion criteria, classificatory systems, referral 
source, and study setting. 
The requirement that patients fulfil stipulated inclusion/exclusion criteria prior to 
entry to treatment is a potentially confounding factor. If large numbers of patients were 
referred for the present studies but were not permitted entry on these criteria, the overall 
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clinical representativeness of the results would have to be questioned. Some previous 
studies have employed inclusion/exclusion criteria which led to up to 70% (Clark et al 
1994), of the patients referred for study treatment being rejected. Fortunately, of the n = 
238 patients referred for inclusion in the studies reported here, only n = 45 (18.9%) 
were excluded as unsuitable, and the sample was not therefor heavily skewed by 
restrictive inclusion/exclusion criteria. It should be noted however that the figures above 
give no indication of the number of patients whom general practitioners might have 
considered suitable for referral for either pharmacological or psychological treatment but 
nonetheless did not refer for entry assessment. As GPs were not requested to keep a 
record of patients considered potentially suitable but not referred, no conclusions can be 
reached on this subject. Such a record could be kept in future studies as part of the 
process of establishing the representativeness of research populations. One 
inclusion/exclusion criterion that may have caused problems was the requirement that 
patients should be free from concurrent psychotropic medication for 28 days prior to 
study entry. It is not known how many patients were offered study referral by their GP 
but declined on the grounds that they did not wish to discontinue medication or because 
they actively preferred pharmacological treatment provided by their GP as an alternative 
to study referral. Patients may also not have been offered referral if their GP considered 
them unlikely to be able to discontinue concurrent psychotropic medication. Of the 
patients actually referred for study entry, n = 5 patients were referred whilst taking 
psychotropic medication which they declined to discontinue for the required 28 day 
wash-out period. Further research is again required to investigate possible differences 
between patients taking concurrent psychotropic medication and those who are not, and 
to investigate the ramifications of any differences for treatment responsiveness and thus 
influence on study results. Data collected by the current author subsequent to the 
present studies may provide the opportunity to investigate this. A series of patients with 
DSM III-R panic disorder and agoraphobia were treated with CBT to the same protocol 
as that used in the present studies. A proportion of these latter patients continued taking 
concurrent psychotropic medication whilst receiving the CBT. Thus the potential 
influence of concurrent psychotropic medication on CBT might be assessed. Further 
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data will be required if the effects of concurrent psychotropic medication on 
pharmacological treatments are to be investigated. 
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The present research was conducted using the DSM III-R classificatory system, as 
DSM IV was not yet published when the present treatment study began recruiting. 
There are differences between DSM III-R and DSM IV that need to be considered. The 
major difference between the two classificatory systems is that DSM IV requires a 
frequency criterion (recurrent panic attacks) and, a fear of recurrence criterion 
(persistent fear of recurrence of panic attacks or avoidance or other alteration of 
behaviour as a result of panic attacks), before a classification of panic disorder is 
permitted. In DSM III-R, on the other hand, either the frequency, or the fear of 
recurrence criteria alone would permit a classification of panic disorder. Patients could 
therefor be classified as suffering from panic disorder if they had only one panic attack 
followed by at least one month of persistent fear of recurrence. Thus it is possible that 
under DSM III-R many patients could be classified as panic disorder although they 
suffered panic attacks only very infrequently, and as such may not be representative of 
the wider population of panic disorder patients. It is also possible that these patients 
present a less severe form of the disorder, indeed severity of panic disorder is assessed in 
DSM III-R in terms of frequency of panic attacks. A large proportion of infrequent 
panickers in a study may therefor make the sample less representative of the wider 
clinical population. It is important to know how many of the patients in the present 
studies suffered from infrequent panic attacks, and thus achieved only one of the two 
classificatory criteria now required by DSM IV. These patients can be easily identified 
from their DSM III-R classificatory profiles and comprised n = 36 (18.6%) of the sample 
of n = 193 patients who entered treatment in the present studies. This proportion of the 
total number of patients entering treatment is unlikely to have had an undue influence on 
treatment outcome findings, or reduced the representativeness of the sample, given that 
by far the largest proportion of patients had more frequent panic attacks. 
The patients treated in the present studies were all referred for treatment by their GP 
and received treatment in the primary care setting. These are both notable departures 
from previous study methodology where patients were often self-referred, or recruited 
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via advertisement, and received treatment in specialist hospital or university clinics. The 
first point has a bearing on the treatment responsiveness of the sample. As previously 
discussed in Chapter 2, Aronson (1987b) found self-referred patients to present with 
more chronic disorders and to be less treatment responsive than physician referred 
patients. The present sample may conversely, therefor, have been more treatment 
responsive than those of previous research. The present studies were conducted within 
the National Health Service where in wider clinical practice patients gain access to 
treatment only through referral by other agencies, most commonly GPs. It was a 
conscious decision in the present research to mirror standard Health Service practice 
regarding referrals rather than to emulate previous research practice. In this way findings 
from the present studies have more relevance to wider clinical practice which was 
deemed to be the more important focus. Regarding treatment setting, this was the first 
pharmacological vs. psychological treatment study on panic disorder and agoraphobia to 
be conducted in the primary care setting. It cannot be clear therefor whether the patients 
treated in the present study differed in any substantive way from those treated in 
previous studies conducted in larger institutions as no specific comparison of the two 
groups has ever been made. An interesting area where treatment setting may have 
influenced study results, however, relates to treatment drop-outs. In a review of drop-
out rates from psychotherapy delivered in a variety of settings Hunt & Andrews (1992) 
reported that drop-out rates were around 8% in controlled explanatory studies delivered 
to restricted populations in research centres, and rose to circa 17-20% for treatments 
delivered in specialist centres. They noted however that drop-out rates rose to between 
30-60% for psychotherapies delivered in community facilities. Thus, accepting firstly the 
large assumption that treatments were of equivalent quality in each facility, the setting in 
which a treatment is delivered may have a considerable influence on drop-out rate. As 
noted in Chapter 4, the CBT group in the main treatment study showed a high drop-out 
rate (32.2%, n = 13). This was suggested to be similar to the drop-out rates found for 
psychological treatments given in the absence of concurrent psychotropic medication in 
previous studies (Michelson et al 1985, 1990, Black et al 1993a), but higher than those 
reported in other studies of psychological treatments (Barlow et al1989, Clark et all994). 
Chapter 8 179 
The forgoing argument suggests that the conduct of the study in the primary care setting may 
also have operated to inflate the drop-out rate from CBT in the present study. The choice to 
conduct the studies in the primary care setting was again a conscious one and was taken 
once more to ensure the greatest overlap between study method and wider clinical 
practice, including factors such as treatment drop-out. The forgoing discussion indicates 
that whilst there may inevitably be differences between the experimental sample 
employed in the present studies, and the range of patients seen in wider clinical practice 
with panic disorder and agoraphobia, these have been minimised as much as possible, 
and the findings of the studies presented here can be related to wider clinical practice 
with some confidence. 
The wider clinical implications of the findings of the studies conducted here will 
now be considered. Findings from the main treatment study (Chapter 4) indicated that all 
of the treatments studied showed statistically significant effects to some extent. This 
included the placebo group who received placebo medication plus balanced therapist 
contact but no active treatment advice or instruction. The results from this group (PL) 
constituted a strong placebo effect against which the active treatments were compared. 
Strong placebo responses have been reported fairly consistently with panic disorder 
patients (Mavissakalian 1988, Fossey & Lydiard 1990, Mellergard & Rosenberg 1990). 
Despite this evidence of efficacy, the placebo group showed the lowest levels of 
clinically significant improvement at treatment end-point, and the greatest requirement 
for additional treatment during the follow-up phase. What this means in clinical practice 
is that panic disorder and agoraphobia patients appear to be responsive to intervention 
and show some gains even with supposedly inert treatments such as placebo medication 
and simple therapist contact which provided the opportunity to describe current state 
and symptoms. It is possible therefor, that many interventions of differing focus, and 
indeed quality, may on initial inspection appear to be effective in panic disorder. To truly 
and accurately distinguish effective treatments for panic disorder and agoraphobia, 
however, careful measurement of the full range of the disorder, investigation of the 
clinical significance of results, and assessment of post treatment status at follow-up are 
all required. Using this approach the main treatment outcome study indicated that of the 
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active treatments, FL + CBT and CBT alone were the most consistently effective, 
with patients receiving FL+CBT showing a significant advantage over placebo 
earlier in treatment than the CBT alone group. The drop-out rate for patients 
receiving CBT alone was, however, higher than that for placebo + CBT. This 
finding affords the clinician the possibility of offering patients either a combined 
pharmacological and psychological treatment, with the possibility of an earlier 
treatment response, or, for those patients who express a preference not to take 
medication, the psychological treatment can be used alone with negligible loss of 
efficacy. The clinical usefulness of cognitive behaviour therapy is however limited 
by its availability (Lader 1994). The relative lack of trained clinicians available to 
offer CBT is a practical limitation to the usefulness of this treatment. In this context 
the finding of relative efficacy for the group receiving fluvoxamine alone suggests 
that this SSRI medication may represent a useful treatment in circumstances where 
treatments such as CBT are not available. It is true that the patients receiving 
fluvoxamine alone did show a weaker response on some measures (e.g. SRT), and 
there was some fall off in efficacy over the 6 month follow-up period. The 
substantial relapse and rebound rates found for other medications such as the 
benzodiazepine alprazolam (pecknold et al 1988), were not found for fluvoxamine 
in the present study, or in other studies investigating withdrawal effects for 
fluvoxamine (Black et al 1993b). Also of considerable interest is the fact that the 
outcome results for fluvoxamine in the present study were obtained after a short 12 
week trial of the medication followed by abrupt discontinuation. It is commonly 
suggested (Johnson et al 1995), that antidepressant medications used to treat panic 
disorder should be continued for 6-8'months before being gradually tapered. The 
current finding of efficacy for fluvoxamine in short-term use whilst interesting, 
should be treated with some caution. Patients receiving fluvoxamine alone in the 
current study also received balanced therapist contact and thus had treatment 
appointments substantially longer than the norm for a patient receiving a medication 
treatment in general practice. The true efficacy of fluvoxamine for panic disorder as 
it would be used in the primary care setting could only be assessed if a further group 
of patients were to be run to an identical treatment protocol to the current study with 
the exception of treatment appointments of a duration and frequency more typical of 
normal primary care practice. Ideally this group of patients would be run with 
l 
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a double-blind placebo for medication. This secondary study would be an important 
addition to the findings reported thus far. The finding here of some short-term efficacy 
for fluvoxamine particularly when supported with therapist contact, nonetheless suggests 
a possible development in treatment service delivery. Patients receiving SSRI 
medications where full CBT treatments are not available could be provided with some 
form of psychosocial support if this were shown to have enhanced efficacy over the use 
of medication alone. This clinical approach of supported medication use may be 
achievable using personnel other than scarce clinical psychologists. A full investigation 
of such possible treatment approaches will, of course require a properly designed 
controlled study methodology. 
The outcomes described above were all indicated across a wide range of assessments 
of patient and therapist report measures of anxiety, depression, and agoraphobic 
avoidance. The assessment strategy adopted in this study, of increasing the breadth of 
assessments employed, permitted a more detailed description of treatment outcome. This 
held true for most of the measures employed with the notable exception of the panic 
attack measures. It is clear from Chapter 6 that panic attack variables are not useful 
outcome variables proving to be responsive to all the interventions used and failing to 
discriminate between them. This finding would suggest that panic attack variables do not 
provide the best indication of treatment response and should certainly not be employed 
as the sole indication of outcome following treatment for panic disorder and 
agoraphobia, but should be used in combination with the other measures of anxiety, 
depression and agoraphobic avoidance which proved to discriminate better between 
treatments. This is a potentially important finding given the number of previous 
treatment outcome studies which have discussed findings in terms of changes in panic 
attack frequency, or more often proportion of patients panic attack free at treatment 
end-point. This note of caution to researchers holds equally well for clinicians. 
Improvements in panic attack patients should not be judged simply in terms of changes 
in panic attack frequency if an accurate picture of clinical response to treatment is to be 
gained. Chapter 4 also described outcome in terms of assessments of clinical 
significance. The trend towards the further description of treatment outcome results in 
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terms of their clinical significance is one which is now widely recommended (Shear & 
Maser 1994). The methods developed by Jacobson and colleagues (Jacobson & Truax 
1991), used in Chapter 4, are derived from a statistical argument and thus have a more 
rational basis than other previous attempts to define clinical significance in terms of 
individual and different definitions of "high end-state functioning" (Barlow et al 1989, 
Michelson et al1990, Clark et al1994). Using the Jacobson methods of defining clinical 
significance of improvement in the main study led to a greater clarification of results and 
a clearer differentiation between treatment groups. This alone makes the inclusion of 
assessments of clinical significance an essential ingredient in any future treatment 
outcome study, and a potentially valuable addition to assessment in wider clinical 
practice. These assessments of clinical significance do have some problems however. 
The statistical strength of the Jacobson methods is also paradoxically their weakness. 
These methods of defining clinical significance of outcome whilst based on sound 
statistical reasoning requiring a shift away from the distribution of a clinical population, 
towards a non-clinical distribution, are nonetheless statistical rather than clinical criteria. 
Further work is required to compare the statistical measures of clinically significant 
improvement with more directly clinically relevant indices such as surgery attendance, 
medication use, referral to secondary care, and so forth. These latter indications of 
service usage were all shown to be inflated in panic disorder patients as compared with 
age sex matched controls (Simpson et al 1994). If a treatment is to be regarded as 
having a truly clinically significant impact one would expect a reduction in these service 
usage variables post treatment. Earlier, alternative, methods of assessing the clinical 
significance of treatment outcomes relied on the use of global measures of outcome 
completed by patients and relevant clinical personnel (Kazdin 1977, Strupp & Hadley 
1977). These therapist and patient ratings of change following treatment have also been 
suggested to be more likely to relate criteria of clinically significant change to the social 
validity or personal relevance of that change (Baer 1988). Just such global measures 
were employed in Chapter 5, along with ratings of general psychiatric wellbeing, and 
social disruption also relevant to the assessment of the clinical significance of outcome. 
The study reported in Chapter 5 was designed to assess the viability of treatment 
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outcome measures designed to be more informative and more suitable for use in wider 
clinical practice, particularly in the primary care setting. The appropriate measurement of 
treatment outcome in everyday clinical practice has been the subject of some comment 
particularly as it applies to the primary care setting (King 1997). The study reported in 
Chapter 5 showed that patient and therapist report ratings of global outcome expressed 
as current distress and improvement since commencing treatment were valuable brief 
outcome indicators. The findings have additional intuitive appeal in that the individual 
undergoing the treatment, and the individual delivering it, agree with the more 
traditional outcome measures and with each other, on the progress being made in 
treatment. This agreement was also found for the ratings of general wellbeing and social 
disruption. It is clear therefor that these brief measures do function as acceptable 
indicants of treatment outcome and can therefor be recommended for use in wider 
clinical practice. It was also clear from Chapter 5 that further training of general 
practitioners may be required if they are to be included in the assessment process. The 
wider use in clinical practice of treatment outcome measurement, of any form, is likely 
to increase knowledge and understanding and would therefor be of considerable 
advantage. 
The treatment outcome findings produced by the studies presented here can be 
considered with some confidence given the extent of the scientific controls adopted in 
the study designs. Results may also be generalised to wider clinical practice with a 
similar degree of confidence. It is fairly clear therefor that the psychological treatment, 
cognitive behaviour therapy, used here is a viable and generally effective treatment for 
the prevalent and disruptive condition that is panic disorder and agoraphobia. The recent 
interest in the SSRI antidepressants as potential pharmacological treatments for panic 
disorder has also been supported, although further work is needed to investigate the 
extent to which the efficacy shown here depended on the concurrent therapist contact 
given with the fluvoxamine and placebo medications in this study. The final investigation 
(Chapter 7) of this thesis attempted to take the discussion beyond straightforward 
treatment outcome by attempting an investigation of potential predictors of treatment 
response. In keeping with the overall aim of this thesis, to ensure relevance to clinical 
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practice, the study attempted the prediction of clinically significant treatment outcome 
rather than simple treatment response. Whilst essentially an exploratory study and as 
such requiring replication and expansion, some findings of relevance to wider clinical 
practice did emerge. Although panic attack variables were found in Chapter 6 to be 
indiscriminate treatment outcome variables, the pre-treatment frequency of panic attack 
plus limited symptom attacks was found to be a powerful predictor of treatment 
response. This finding was in keeping with the general trend in the analysis in Chapter 7 
for poorer outcome to be predicted by higher pre-treatment scores on patient rated 
measures of anxiety and agoraphobic avoidance. Also of relevance clinically, were the 
significance of personality and social disruption measures in the prediction of treatment 
outcome. These latter findings reinforce the clinical wisdom that it is not only the 
disorder itself which is relevant to outcome, but also the person who is suffering from it, 
and the social circumstances in which they find themselves. The predictions for 
immediate treatment outcome were all strong and reasonably statistically sound. Further 
work is of course required to replicate these results and to further investigate the value 
of these variables as clinically useful outcome predictors. This might be achieved by 
including the significant predictor variables in a prospective study of their ability to 
identify treatment response. In contrast to the treatment end-point results, the 
predictions for outcome at follow-up were less sound, and it is clear that more work will 
be required to increase our understanding of the factors and processes which contribute 
to continued wellbeing after treatment is complete. Follow-up is indeed the area where 
more information on the present cohort 'of patients is definitely required. The 6 month 
follow-up period employed in the studies reported here is relatively short and further 
information on the continued status of the patients treated here would be of considerable 
interest. The present research findings would therefor be strengthened by a long term 
follow-up study. Such a study should pay close attention not only to patients' status at 
follow-up assessment but should also make an assessment of any post study treatment 
received. This could be best achieved by a methodology entailing a review of patients' 
GP case records. Such a method was employed in the study comparing panic disorder 
patients' service usage with that of age, sex matched controls (Simpson et al1994) and 
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provides a record of patients'post treatment health service usage, thus permitting a truly 
clinically relevant assessment of post-treatment improvement. These longer term findings 
are necessary to fully assess the efficacy of the treatments studied here. In the short term 
however, it is hoped that the studies presented here have gone some way to providing 
further scientifically accurate and clinically relevant information on the treatment of 
panic disorder and agoraphobia. It is further hoped that the demonstration of treatment 
efficacy for panic disorder and agoraphobia in the primary care setting provided here will 
stimulate interest in the wider and more local provision of treatments for this prevalent 
and disruptive condition. 
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APPENDIX I TREA TMENT MANUAL 
Patient Manual 1 
AGORAPHOBIA - PATIENT MANUAL 
You have been told that you are suffering from agoraphobia and that what causes this 
problem is anxiety. 
People who are suffering from agoraphobia feel frightened or panicky when they go 
far from home, or into crowded places, or on buses or trains. They often feel anxious and 
frightened ifleft on their own or if they feel they are far from help. When they feel 
frightened they may experience very strong and unpleasant physical feelings. These are 
feelings offear, anxiety and panic. 
The short description above probably doesn't tell you anything you don't already know 
very well. The purpose of this leaflet is to explain to you why you feel the way you do; 
what makes it happen; why it started happening in the first place; and most important of 
all what you can do about it to sort the problem out. 
It's best to be honest right from the start. The treatment for agoraphobia and anxiety 
will involve a lot of effort and commitment from you. You will have to do difficult 
things. On the positive side though, if you do these things, if you put in the effort, the 
chances of success are really very good. In other words, if you do what is asked of you, 
it works! 
This leaflet is intended to help you remember what your therapist has explained to 
you. You are not expected to remember it all in one go. 
Read the leaflet carefully several times - the more you understand your problem the 
better. 
1. ANXIETY 
You will already have been told that anxiety is the cause of your difficulties. Most 
people who have not experienced the kind of problems you have would be amazed to 
discover just how strong and unpleasant the feelings of anxiety can be. That is not to say 
you are unusual though, there are a lot of people who have problems very similar to 
yourself Anxiety based problems are some of the most common and yet least talked 
about difficulties there are. Most people who have these problems tend to keep them to 
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themselves. This can at times leave you feeling very alone and fiightened. There are 
some very important things you should remember about anxiety: 
Firstly, it is not an illness 
2 
Anxiety is not an illness, it is not a sign that there is anything wrong with your body or 
mind in any real way at all. 
Anxiety is on occasion a perfectly natural and normal way to feel. All human beings 
feel anxious at some time or other, we all have good days and bad days. Not only is 
anxiety a normal way to feel, but there is a reason for being able to feel like this, anxiety 
has a purpose. Anxiety is as important a part of being a human being as having a heart 
that beats or lungs that breathe. 
Secondly. it is not in your imagination 
Anxiety is real, the physical feelings and sensations you get are really happening to 
you. Again, most people who have not felt anxiety at its strongest would be staggered to 
find out just how strong these feelings of anxiety are. Anxiety can effect you in many 
ways. It can effect you: 
( a) Physically - with feelings like racing heart, dizziness, blurred vision, churning 
stomach, breathlessness, chest pains and tightness, wobbly legs and so on. 
(b) Mentally - anxiety can effect the way you think. You may think 'something awful will 
happen to me'. You may think you will lose control or collapse or have a heart attack, 
and you will watch out for signs of these things happening. 
( c) Behaviour - anxiety effects what you do and how important it feels to do it. Anxiety 
often drives you to do things right away without hesitation. Very often it will also 
make you avoid doing things and avoid going places. 
Thirdly. it is not dangerous 
The feelings of anxiety will not hurt you in any way at all. Regardless of how strong 
these feelings are (and they really do feel that strong!) they will not cause you any harm at 
all. 
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To explain this better perhaps it would be best to explain what anxiety is. I have said 
it has a purpose and if that purpose is explained to you, you will be able to see why I can 
say it will not hurt you or hann you in any way. 
2 WHAT IS ANXIETY? 
Anxiety is your body's natural alann system. It is the bit of your body that gets you 
ready to deal with danger. More than just warning you that danger is there, anxiety 
works to actually get you ready to deal with it. It peps up your body all at once so that 
you can be ready to either run or fight in a dangerous situation. This is called the 'fight or 
flight' reaction. 
The anxiety system works through the stress hormones, the best known of which is 
adrenaline. There is nothing subtle or sophisticated about the way it works, in fact it is 
very primitive. If you are in a dangerous situation adrenaline is passed into your blood 
and it travels around your body causing the physical effects you feel. These physical 
effects happen so that you can get out of danger, so that you can get out of trouble. 
They would not be able to do this if all they did was make you lose controL faint. have a 
heart attack or whatever. If these feelings did that to you then anxiety would be no use 
for the very job it is designed to do! All these feelings have a reason for happening and 
that reason is to get you out of trouble, not put you further in it. 
Think how you would feel if you were walking down the road past a garden and a 
large dog suddenly bounced at the fence barking and snarling. You might feel your heart 
racing, sweating, or you may feel dizzy, stomach churning and so on. You might also 
find yourself thinking that a disaster will happen, such as the dog might get you, then 
anxiety would make you "think the worst" . You might even run for a short distance. 
These are all things which happen when the anxiety system suddenly gets' switched on' all 
at once. The main thing here though is that once the danger is past. the feelings pass off. 
In other words, if the dog couldn't get through the fence you would walk on your way 
and all the strong feelings would gradually die away to nothing. 
The adrenaline going into the bloodstream when the anxiety is switched on is rather 
like putting sugar into tea - you can put it in, but once it is in you can't take it back out 
again, but if you leave it. it dissolves away fairly guickly. In other words, if you leave 
these feelings of anxiety, even the strongest ones, they will die away and pass off without 
doing you any hann at all. 
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The explanation above refers to what happens in a real, dangerous situation. This 
raises some questions. Why are you feeling anxious in situations which you know are not 
dangerous, e.g. in busy shops or crowds? To explain this we need to look at how the 
problems of agoraphobia and anxiety develop in the first place. 
3. HOW AGORAPHOBIA DEVELOPS 
The way the problem develops obviously varies from person to person. There are 
some general rules though. 
What usually happens is that someone who develops agoraphobia will have been 
under pressure for some time, often without realising it. This may have been because of a 
serious or sudden event such as the death of someone close or a serious illness. Or, it 
may have been due to other upsets or changes in their circumstances, e.g. losing a job, the 
break up of a marriage, moving to a new area or getting a new job. Problems can also 
develop after a long period of strain or wony or if the person has been depressed for a 
while. 
What happens is that these strains and pressures cause the person to gradually become 
more anxious often without realising it. As their anxiety level goes up they become more 
irritable, have less patience and often find themselves much more easily wound up. When 
they are in this state the person's general level of anxiety is much higher than it was before 
and it takes really very little pressure for them to become so wound up that they 
experience very high levels of anxiety, or even panic. 
Why does this happen in shops or crowds? The answer is simple - we all feel a bit 
more aroused or worked up in crowds or busy places. How many people have you heard 
complaining about being frazzled or wound up after a busy afternoon's shopping, e.g. at 
Christmas time? The thing is, this increase in anxiety level is easy to cope with if you are 
generally feeling fairly calm. However, if you are generally tense and anxious this small 
increase in arousal can be enough to cause strong feelings of panic and anxiety. These 
feelings are very strong and unpleasant, they also seem unexpected and appear to come 
out of the blue. Looking back on it though you may be able to see where your problem 
started and that there is usually a fairly straightforward explanation for how they started. 
It may also be that the pressures that first started the problem have been sorted out now. 
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Why does the problem keep going? This is simply because anxiety is unpleasant enough 
to make the person wony about the feelings. This keeps their general level of anxiety 
fairly high so they continue to get strong feelings of anxiety in situations where they 
would only have felt a little aroused before. 
5 
Even though you may now understand how the problem started that doesn't change 
the fact that these feelings of anxiety are strong, unpleasant and frightening. Very often 
you are frightened that something awful will happen to you, that you might collapse, have 
a heart attack and so on. Not surprisingly, what people do is try to avoid this happening 
by running out of the place they are in and/or trying to control or fight off the feeling of 
fear and anxiety. Then the next time the person is in that place they are frightened they 
will feel anxious again -they start to feel frightened and because of this they leave the 
situation again. Over time the person begins to avoid a whole range of places and things, 
anything in fact which they feel might bring on the feelings. Unfortunately this only 
makes things worse. The old saying holds true here: 
'Actions speak louder than words' 
We have been told so far that these feelings won't hurt you. You may even know 
yourself that there is nothing really to be frightened of That is why you may sometimes 
feel embarrassed about telling others about your problem. Even though you know in the 
back of your mind that nothing will happen to you, if you run away from the feelings or 
fight them you are still acting as if something dangerous will happ~ and if you act as if 
something is dangerous then you will feel it ~ dangerous, and you will feel anxious and 
frightened. Your body's natural alarm system will get you ready to deal with this 
supposed danger by passing more adrenaline into the bloodstream, which causes more 
strong feelings, which in tum frightens you even more, so you try even more to avoid 
them. This builds up into a vicious circle which can be represented by the diagram on the 
next page: 
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Outside pressure 
(e.g. busy shop) 
Fear of something ______ +-__ --
happening 
Acting as if feelings 
were dangerous 
e.g. runrung away 
Strong feelings of 
anxiety 
So in fact someone who has agoraphobia is not fiightened of shops or crowds or 
buses, they are fiightened of the feelings that they get in shops or crowds or buses and 
these feelings are the physical feelings offear and anxiety. The problem really is FEAR 
OF FEAR - you are fiightened of being anxious and fiightened. 
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This is a very difficult position to be in because the more anxious you feel the more 
you try to stop the feelings by fighting them off or leaving the situation, and the more you 
are acting as if they really are dangerous, which makes you feel more anxious in turn. 
The problem is this - you have been told that the feelings are not dangerous. Avoiding 
them or trying to fight them off only makes them worse, so how do you prove to yourself 
that these feelings are not dangerous when they feel so strong and convincing when they 
are there? 
4 HOW TO DEAL WITH THE PROBLEM - GETTING RID OF AGORAPHOBIA 
The solution is easy to explain, but harder to do. 
It is the feelings that you are fiightened o( so how do you prove to yourself that there 
is really nothing to be afraid of in these feelings? Simple - you let them be there, you 
don't try and avoid them, you just let them happen, let them pass off: without acting as if 
they are dangerous in any way at all. 
For you to be able to do this, the feelings are obviously going to have to be there in 
the first place. In other words, you are going to have to feel anxious to get over this 
problem. 
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This is not really so bad, though - all right so you have to feel anxious so that you can 
practise not running away and not trying to fight it off: so you can practise being in 
control and letting the feelings run their course. To do this the feelings have to be there. 
Really the feelings have been there until now anyway, except this time they are going to 
be there for a reason, which is so that you can get better and control the problem. What 
you have to do then is deliberately set out to feel anxious. 
The easiest way for you to get the feelings to be there is to go back and try doing all 
the things you have been avoiding up until now. If you have been avoiding going to the 
shops, now you go. If you havent been on a bus for a while, now is the time to try. You 
must get back to doing all the things you have stopped doing as quickly as possible. You 
must also expect to feel anxious when you do this at first - that is good - the whole point 
of the treatment is for you to practise not acting as if you are frightened of the feelings 
and letting them pass offin their own time. Gradually, over time, the more you do this 
the less the feelings will happen. 
How do you deal with the feelings of anxiety when they happen? 
When you go back to a place you've been avoiding and you start to feel anxious, 
DOm TRY TO RUN AWAY OR FIGHT OFF THE FEELINGS - follow these rules. 
Rules for coping with panic 
i) The best advice you can ever be given is to let the anxiety and panic happen keep going 
and wait until it passes. 
ii) Remember these are natural normal feelings 
- they are not dangerous 
- they will not hurt you 
- they will pass in their own time if you let them. 
They may be unpleasant, BUT THAT IS ALL THEY ARE. 
It sounds strange, but just relax and let yourself feel anxious. You must accept that the 
feelings are happening, say to yourself "all right so I'm feeling anxious but I'm not going 
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to let it stop me doing anything and I'll control these feelings instead of the feelings 
controlling me. These feelings are not going to push me around ". 
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iii) Do not act as if the feelings are dangerous in any way at all. Don't act fiightened, 
don't run away, stay where you are. Don't rush to get the shopping finished faster so you 
can get out of the shop sooner. Don't tense up and do try to see the feelings through, just 
relax and let them happen. Deliberately act calm, even though you will not feel calm to 
begin with. 
If the anxiety makes you feel as if you must do something to stop a disaster - DO THE 
OPPOSITE. For example, if you feel as if you must hold on to something to avoid falling 
over, deliberately walk. away from hand holds. Or, if you feel you have to walk. closer to 
the shelves in the supermarket because it makes you feel more comfortable -then walk. 
down the middle of the aisles. Remember. you are in controL you are in charge. 
So you will have to think quite carefully about aU what things you do when you feel 
anxious or panicky and decide II •• am I doing this to try and fight off the anxiety or avoid 
a disaster ?" - if so, this is something you will have to change so you are doing the 
opposite of what the anxiety says to do. 
There will be many of these important little tricks which you have to learn. Many of 
them will be particular to your own problem. Try out your alternative actions and 
remember the golden rule, DONT ACT FRIGHTENED OF THE FEELINGS. Don't let 
them push you into doing things just earry on and act as if they weren't there - you rule 
them, don't let them rule you, you control them by not giving in to them. 
iv) The most important thing ofaU to remember is NEVER LEAVE A SITUATION 
UNTIL THE FEAR OR PANIC HAS STARTED TO GO DOWN. 
v) Regard each time you feel anxious or each panic attack as an opportunity to practise 
not acting fiightened of these feelings, an opportunity to practise coping with the feelings. 
The more you practise the better you learn to cope and gradually the less the feelings will 
happen. 
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You will have realised by now that you have quite a bit of work ahead of you, even 
though the task will seem daunting at first you don't have to keep following these rules 
for ever, just until your anxiety fades and the problem is sorted out. Just now, you 
shouldn't avoid any situation that makes you feel anxious, then once the problem is sorted 
out you will be free from it and you can go back to living your life however you please. 
For the moment though you have a lot of practising to do. To make this easier for 
yourself think about what you have to do and organise and plan it as much as possible. 
You can write down your plans too - to make them more definite. 
5 HOW TO PLAN YOUR PRACTICE 
The first thing here is that planning your practice is not half as important as doing it! 
However, there are some things which can help you get back to doing all the things you 
used to avoid. 
i) Draw up a list of targets, and be specific. Don't just say "I'll go to the shops sometime", 
be definite, e.g. "rn go to Fine Fare tomorrow and spend at least an hour shopping". 
Once you have drawn up this list try and tackle the most difficult target you feel you 
can manage to begin with. After you have practised this a lot work your way up the list 
tackling the more difficult targets. 
ii) The time you spend in a situation is vital. Fifteen minutes is just not enough - that 
would be like dipping your toe in a swimming pool and then saying you'd learned to 
swim. You must stay in the situation until the anxiety begins to pass off More than this 
though -the longer you stay the better. Plan to stay in a situation for at least one hour if 
possible. If you can get yourself out for 1-2 hours a day or more, this would be excellent. 
iii) How often you practise is vital too - once a week would be no use. Plan to go out 
even' day. The rule is quite simply, 'PRACTICE MAKES PERFECT'. The more you 
practise the quicker you get over the problem. 
iv) Once is not enough - after you have tried something once -don't just leave it and think 
'that's it sorted now' -IT'S NOT: practise things again and again until you really feel 
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you've mastered them. Keep going until you can really believe there is no danger there 
now. 
v) 'You've got to be cruel to be kind' - don't let yourself take it too easy. You've got to 
push yourself a bit. You decide what targets you have to face, you take charge of your 
treatment. This is the best possible thing to do because if you decide to do something you 
used to be fiightened of then just by deciding like that you have already stopped being so 
fiightened of it. 
vi) 'Don't put offuntil tomorrow what you can do today'. Try to do things as soon after 
you have decided on them as possible. Don't try and plan things weeks ahead. If you 
have a big target too far ahead you give yourself too much time to worry about it - it gets 
blown up out of proportion. Forget about the future, take things A DAY AT A TIME, a 
step at a time. Do things NOW not in the distant future. 
vii) Try not to rely on other people, try to do things as much as you can yourself (That's 
not to say you can't discuss it with other people though! In fact it is helpful if someone 
else knows what you are doing and is supportive). 
viii) Don't cheat! Be honest with yourself If you don't want to do something because 
you are afraid, admit it, accept it and plan to tackle it as soon as possible. Remember - if 
you cheat the only person you're cheating is yourself 
6 POINTS TO NOTE 
To finish with here are some points to bear in mind while you are practising: 
- It takes time - the problem didn't develop overnight and 
it has been there for a while, so don't expect it to 
disappear overnight either. It usually takes months not 
weeks to fully get over this kind of problem, but 
remember the more you work at it the quicker it goes. 
Patient Manual 
- Things may be a bit worse before they get better. 
Sometimes (but not always) people can find themselves 
feeling a bit more anxious when they first start 
practising. This is simply because they have started 
back doing a lot of things they had been avoiding doing 
for a while. If this happens to you, don't worry about 
it - it's perfectly normal and it usually passes fairly 
quickly. It is not a sign that you're failing or getting 
it wrong. 
- It is tiring - when you have gone through a panic and let 
the feelings pass you will feel tired. This is perfectly 
natural - being anxious is hard physical work so of 
course you will feel tired afterwards. Don't worry about 
this. 
- You may get occasional setbacks on the road to recovery. 
This is normal. Remember at the start of this leaflet I 
said that we all have good days and bad days. If once 
you start to feel better and you have a set back and 
perhaps have another panic attack, don't worry about it. 
You have not gone back to square one. Just deal with it 
the way you have been practising and keep going. This 
kind of anxiety based problem does not disappear all at 
once. What happens when you get better is you begin to 
have less anxiety less often - still with bad days in 
between but gradually the good days begin to outnumber the 
bad days until finally you realise that its been a while 
since you have had any really bad days. 
- There are some things which can affect you physically and 
make you more likely to feel anxious - try to avoid 
these if possible. 
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- Too much tea or coffee - if you drink a lot of coffee try switching to a 
decaffeinated brand. 
Also too many cigarettes have a similar effect. Try to 
avoid smoking in excess. 
- Too much alcohol - or to be specific, bad hangovers make 
you much more likely to feel anxious. Try and avoid these. 
- Too little food - if you are hungry, if you are missing 
meals you will feel more anxious. Eat sensible, regular meals. 
- Too little rest - being overtired and overworked means you are 
more likely to feel anxious. This treatment is definitely hard work 
so make sure you get the opportunity to rest and relax for a little 
while each day. 
- Finally, not enough relaxation. You are going to be doing 
something which is hard, tiring and demanding. Try to 
make sure that you get some time for yourself to do the 
things you enjoy doing. If you work hard, treat yourself 
12 
Read this leaflet carefully, several times. Make sure you understand what you have to do. 
THEN - its up to you - remember, work hard at it, do your best, no-one can ask for 
more than that. 
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APPENDIX II 
Measure 
DSM III-R Checklist 
Hamilton Anxiety Scale (HAM-A) 
(Hamilton 1959) 
Symptom Rating Test (SRT) 
(Kellner & Sheffield 1973) 
Montgomery Asberg Depression Rating Scale 
(Montgomery & Asberg 1979) 
Fear Questionnaire 
(Marks & Mathews 1979) 
Panic Attack Diary 
Global Severity of Illness/ Change in Symptoms 
(Guy 1976) 
General Health Questionnaire (GHQ) 
(Goldberg 1978) 
Sheehan Disability Scale (SD) 
(Sheehan 1986) 
Anxiety Sensitivity Index (ASI) 
(Reiss et at 1986) 
Eysenck Personality Questionnaire (EPQ) 
(Eysenck & Eysenck 1978) 
Social Maladjustment Questionnaire (SocMal) 
(Corney & Clare 1985) 
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DSM m-R Checklist 
~. 
~ 
INITIAL ASSESSMENT H.114.928 
Patient Initials: Date: 
A 
B 
C. 
DSM III·R CRITERIA FOR PANIC DISORDER 
(with or without agoraphobia) 
PANIC DISORDER Present Absent D. ONSET OF AITACKS 
One or more discrete periods of intense During some of the anacks: 
fear or discomfort have occurred that were four or more of the C symptoms 
(1) unexpected and (2) not triggere,j by [2J QJ developed suddenly Yes situations in which the person was the - increased in intens~y w~hin ten minUles [2J focus of others' attention. of the beginning of the lirst C symptom 
ONE OR MORE PANIC A IT ACKS E. ORGANIC FACTORS 
(must be ruled out) 
Four attacks, as defined in criterion A, 1. [2J 0 have occurred Within a four-week The disorder was initiated and maintained penod. by an organic factor, such as Yes 
amphetamine or caHeine intoxication QJ 2. One or more attacks have been or hyperthyroidism. 
followed by a period of at least a 
month of persistent fear of having QJ 0 F. TYPES OF PANIC DISORDER another attack o. Wnhout Agoraphobia 
FEATURES OF PANIC DISORDER 
At least four of the following symptoms must have developed 2. Wnh Agoraphobia: 
during at least one of the attacks: If present, rate severity: 
shortness of breath (dyspnea) or QJ 0 2 Mild: some avoidance smothering sensations 
3. Moderate: constricted life-style 
2 dizziness. unsteady feelings. or QJ 0 faintness 4. Severe: nearly housebound or 
unable to leave the house 
3 palpitations or accelerated heart QJ 0 unaccompanied. rate (tachycardia) 
[2J 0 1. • ""'" ,om.""', """ ." ..... } 4. trembling or shaking during past six months 
5. sweating [2J, 0 O. in full remission: no avoidance 
0 CD during past six months 6 choking 
~ 0 G. SEVERITY OF PANIC AITACKS 7 nausea or abdominal distress during the past month: 
8. depersonalization or derealization ~ 0 1. mild: either all have been limited symptom attacks or there has been 
9. numbness or tingling sensations QJ CD no more than one anack (paresthesias) 
~ 0 2. 
moderate: between mild and severe 
10. flushes (hot Hashes) or chills 3. severe: at least eight attacks 
11. chest pain or discomfort 2J 0 
12 fear of dying 2J 0 
13. fear of going crazy or doing QJ 0 something uncontrolled 
No 
0 
No 
0 
D 
0 
D 
0 
Investigators signature , .......................................................................................................... . 
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Hamilton Anxiety Scale (HAM-A) 
INITIAL ASSESSMENT 
Patient Initials: Date: 
HAMILTON RATING SCALE FOR ANXIETY 
For each item check the one response which best characterizes the patient now. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
ANXIOUS MOOD 
Worries, anticipation of the worst, 
fearful anticipation, irritat-ility 
TENSION 
Feelings of tension, fatigability, 
startle response, moved to tears 
easily, trembling, feelings of 
restlessness, inability to relax 
FEARS 
Of dark, of strangers, of being left 
alone, of animals, of traffic, 
of crowds 
INSOMNIA 
Difficulty in falling asleep, 
broken sleep, unsatisfying 
sleep and fatigue on waking, 
dreams, nightmares, night terrors 
INTELLECTUAL 
Difficulty in concentration 
poor memory 
" 
DEPRESSED MOOD 
Loss of interest, lack of pleasure 
in hobbies, depression, early 
waking, diurnal swing 
SOMATIC (Muscular) , 
Pains and aches, twitchings, 
stiffness, myoclonic jerks, 
grinding of teeth, unsteady voice, 
increased muscular tone 
8. SOMATIC (Sensory) 
Tinnitus, blurring of vision, 
hot and cold flushes, feelings 
of weakness, pricking sensation 
o 2 3 
I Not I Mild I Moderate I Severe I present 
I I I I I 
I I I I I 
I 1 I I I 
I I I I I 
I I I I I 
I I I I I 
H.114.928 
4 
Very 
severe 
I 
! 
I 
I 
----, 
I 
I 
i 
I 
I 
I 
I 
1 
I 
! , 
, 
I 
I~~{:" 
" INITIAL ASSESSMENT 
Patient Initials: 
HAMILTON RATING SCALE FOR ANXIETY - continued 
o 2 
I Not I Mild I Moderate I present 
9. CARDIOVASCULAR SYMPTOMS 
Tachycardia, palpitations, 
pain in chest, throbbing of 
vessels, fainting feelings, 
sighing, dyspnoea I 1 I I 
10 RESPIRATORY SYMPTOMS 
Pressure or constriction in chest, 
choking feelings, sighing, 
dyspnoea r I I I 
11 GASTROINTESTINAL SYMPTOMS 
Difficulty in swallowing, wind, 
abdominal pain, burning 
sensations, abdominal fullness, 
nausea, vomiting, 
borborygmi, looseness of 
bowels, loss of weight, constipation I I I I 
12 GENITOURINARY SYMPTOMS 
Frequency of micturition, urgency of 
micturition, amenorrhea, 
menorrhagia, development of 
frigidity, premature 
ejaculation, loss of libido, 
I impotence I I I 
13. AUTONOMIC SYMPTOMS 
Dry mouth, flushing, pallor, 
tendency to sweat, giddiness, 
tension headache, raising 
of hair f I 1 1 
BEHAVIOUR AT INTERVIEW 
Fidgeting, restlessness or 
, 
pacing, tremor of hands, 
furrowed brow, strained face, 
14. 
sighing or rapid respiration, 
facial pallor, swallowing, etc. I r I I 
TOTAL 
N.B.: PATIENT MUST SCORE 15 OR MORE TO BE ELIGIBLE FOR THE STUDY 
3 
Severe 1 
I 
T 
I 
! 
-I 
I 
H.114.928 
4 
Very 
severe 
I 
I 
I 
I 
Investigators signature ........................................................................................................... . 
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Symptom Rating Test (SRT) 
"'" ASSESSMENT 1 H.114.928 
Patient No: 
Date: Patient Initials: 
I 
I 
KELLNER/SHEFFIELD SELF RATING SCALE 
Describe how you have felt during the PAST WEEK. 
If you have not had the symptom at all make a check mark (V) in the box on the left like this. 
Extremely, 
A little A great deal, could n)t 
Not at all slightly qu ite a bit have been 
worse 
Headaches or head pains V 
If you have had the symptom describe hew much it has bothered you or troubled you, for 
example, like this: 
Extremely, 
A little A great deal, could not 
Not at all slightly :;u ite a bit have been 
worse 
Headaches or head pains V 
Please answer all questions. Do not think long beiore answering. 
Extremely, 
A little A great deal, could not 
Not at all sligntly qu ite a bit have been 
worse 
, Feeling dizzy or faint I I 
2 Feeling tired or :ack of 
I I I I energy 
3 Nervous I I 
4 Feeiings oi oressure or 
I I I I 
a tightness In head or 
body 
5 Scc:red or frigr.tened 
r I I I I 
6 Poor apoetite I i 
7 Heart beating quickly or 
strongly without rea~on 
(throobing or pounding) 
8 Feeling that tnere was I I I I no hope 
9 Restless or jumpy I 
10 Poor memor{ 
I 
Please turn over . .. 
ASSESSMENT 1 H.114.928 
Patient No: 
Patient Initials: 
Self·rating scale 
Extremely, 
A little, A great deal, could not 
Not at all slightly quite a bit have been 
worse 
, , Chest pains or breathing 
difficulties or feeling of 
not having enough air 
12 Feeling guilty I 
13 Worrying I 
14 Muscle pains or,aches, I or rheumatism 
15 Feeling that people look 
down on you or think 
badly of you 
16 Trembling or shaking 
17 Difficulty in thinking 
clearly or difficulty in 
;making up your mind 
18 Feeling unworthy or a I failure 
19 Feeling tense or 
'wound up' 
20 Feeling inferior to 
other people 
21 Parts of bod v 'eel numb I or tingling 
22 I rri .able I I 
23 Thoughts whlen you 
I cannot push out of r your mind 
24 Lost interest in most I I I things 
25 Unhaopy or depressed I I 
26 Attacks of panic I I I I 
27 Parts of your body I I feeiing weak 
28 Cannot concentrate I 
29 It takes a long time to 
fall asleep, or restless 
sleep or nightmares 
30 Awakening too early and 
not being able to fall 
asleep again 
:..-' 
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Montgomery Asberg Depression Rating Scale (MADRS) 
INITIAL ASSESSMENT H.114.928 
Patient Initials: Date: 
MADRSSCALE 
Please record severity of symptoms in the box on the right hand side. 
ITEM No. SYMPTOM SCORE 
1 Apparent Sadness 
Representing despondency, ~Ioom and despair, (more than just ordinary transient 
low spirits) reflected in speec ,facial expression, and posture. Rate by depth and 
inability to brighten up. 
No sadness. 0 
1 
Looks dispirited but does brighten up without difficulty 2 
3 
Appears sad and unhappy most of the time. 4 D 5 Looks miserable all the time. Extrem ... ly despondent. 6 
2 Reported Sadness 
Representing reports of depressed mood, regardless of whether it is reflected in 
appearance or not. Includes low spirits, despondency or the feeling of being 
beyond help and without hope. 
Rate according to intensity, duration and the extent to which the mood is reported 
to be influenced by events. 
Occasional sadness in keeping with the circumsta'1ces 0 
1 
Sad or low but brightens up without difficulty. 2 
3 
Pervasive feelings of sadness or gloominess. The mood is still influenced by D external circumstances. 4 5 Continuous or unvarying sadness, misery or despondency. 6 
3 Inner Tension I Representing feelings. of ill-defined discomfort, edginess, inner turmoil, mental tension mounting to 9IIh~r paniC, dread or anguish. 
I Rate according to intenSIty, frequency, duration and the extent of reassurance called for. 
I 
Placid. Only fleeting inner tension. 0 
I 1 Occasional feelings of edginess and ill-defined discomfort. 2 
3 
Continuous feelings of inner tension or intermittent panic which the patient D can only master With some difficulty. 4 5 Unrelenting dread or anguish. Overwhelming panic. 6 
4 Reduced Sleep 
Representing the experience of reduced duration or depth of sleep compared to 
I the subject's own normal pattern when well. 
Sleeps as usual. 0 
I 1 Slight difficulty dropping off to sleep or slightly reduced, light or fitful sleep. 2 3 
Sleep reduced or broken by at least two hours. 4 D 5 Less than two or three hours sleep. 6 
5 Reduced Appetite . . . 
Representing the feeling of a loss of appetite compared With when well. Rate by 
loss of desire for food or the need to force oneself to eat. 
Normal or increased appetite. 0 
1 
Slightly reduced appetite. 2 
3 
No appetite. Food is tasteless. 4 D 5 Needs persuasion to eat at all. 6 
INITIAL ASSESSMENT H.114.928 
Patient Initials: 
MADRS SCALE - continued 
ITEM No. SYMPTOM SCORE 
6 Concentration difficulties 
R~resenting diffi~ulties in coliectil'g one's thoughts mounting to incapacitating 
la of concentrallon. 
Rate accordin~ to intensity, frequency, and degree of incapacity produced. 
No difficu~les in concentrating 0 
1 
Occasional difficulties in collecting one's thoughts. 2 
3 
Difficu~ies in concentrating and sustaining thought which reduces ability to read 
D or hold a conversation 4 5 Unable to read or converse without great difficulty 6 
7 Lassitude 
Representing ~ .difficulty getting started or slowness initiating and performing 
everyday activities. 
Hardly any difficulty in getting started. No sluggishness. 0 
1 
Difficulties in starting activities. 2 
3 
Difficulties in starting simple routine activities which are carried out with effort. 4 D 5 Complete lassitude. Unable to do anything without help. 6 
8 Inability to Feel 
Representing the subjective experience of reduced interest in the surroundings, or 
activities that normally give pleasure. The ability to react with adequate emotion to 
circumstances or people is reduced. 
Normal interest in the surroundings and in other people. 0 
1 
Reduced ability to enjoy usual interests. 2 I 3 I Loss o.f interest in the surroundings. Loss of feelings for friends and I 
acquaintances. 4 
5 i The experience of being emotionally paralysed, inabilit
fc 
to feel anger, grief or D fr,easure and a complete or even painful failure to feel or close relatives and 1 riends. 6 i 
I 
9 Pessimistic thoughts 
Representing thoughts of guilt, inferiority, self-approach, sinfulness, remorse and 
rUin. 
No pessimistiC thoughts. 0 
1 
Fluctuating ideas of failure, self-reproach or self-depreciation. 2 
3 
Persistent self-accusations, or definite but still rational ideas of guilt or sin. 
Increasingly pessimistiC about the future. 4 D 5 Delusions of ruin, remorse or unredeemable sin. Self-accusations which are absurd and unshakable. 6 
10 Suicidal thoU~hts 
Representinlil t e feeling that life is not worth living, that a natural death would be 
welcome, SUicidal thOUPchts, and preparations for suicide. 
Suicidal attempts shou d not in themselves influence the rating. 
Enjoys life or takes it as it comes. 0 
1 
Weary of life. Only fleeting suicidal thoughts. 2 
3 
Probably better off de.ad. Suici?althoughts are com'!1on, and s~icide.is 
4 considered as a pOSSible solution, but Without speCific plans or intention. 
5 D Explicit plans for suicide when there is an opportunity. Active preparations for 6 suicide. 
TOTAL D N.B.: PATIENTS SCORING 21 OR MORE MUST BE EXCLUDED FROM THE STUDY 
Investigators signature ............................................................................................ . 
Appendix Vll 
Fear Questionnaire (FQ) 
ASSESSMENT 1 H.114.928 
Patient No: I '-_______ --' 
Date: Patient Initials: 
FQ 
Choose a number from the scale below to show how much you would avoid each of the 
situations listed below because of fear or other unpleasant feelings. Then write the number 
you choose in the box opposite each situation. 
012345678 
I------~I ----~I------rl----~I 
would not slightly definitely markedly always 
avoid it avoid it avoid it avoid it avoid it 
1. Main phobia you want treated (describe in your own 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
words) .................................................................... .. 
Injections or minor surgery 
Eating or drinking with other people 
Hospitals 
Travelling alone by bus or coach 
Walking alone in busy streets 
Being watched or stared at 
Going into crowded shops 
Talking to people in authority 
Sight of blood 
Being criticised 
Going alone far from home 
Thought of injury or illness 
Speaking or acting to an audience 
Large open spaces 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
Please turn over 
ASSESSMENT 1 H.114.928 
I 
Patient No: '----__ J 
Patient Initials: 
FQ(2) 
16. Going to the dentist D 
17. Other situations (describe) .......................................................... D 
............................................................................................................ 
leave 
blank 
o + D 
Ag Sf 
(5,6,8,12,15) (2.4,10,13,16) 
+ o 
Soc 
(3,7,9,11,14) 
Total: D 
Now choose a number from the scale below to show how much you are troubled by each 
problem listed and write the number in the box opposite 
0 2 3 4 5 6 7 8 
I I I I I 
hardly at slightly definitely markedly very 
all troublesome troublesome troublesome severely 
troublesome 
18. Feeling miserable or depressed D 
19. Feeling irritable or angry D 
20. Feeling tense or panicky D 
21. Upsetting thoughts coming into your mind D 
22. Feeling you or your surroundings are strange and unreal D 
23. Other feelings (describe)................................................... D 
Total D 
How would you rate the present state of your phobic symptoms on the scale below? 
0 2 3 4 5 6 7 8 
I I I I I 
no phobias slightly definitely markedly very 
present disturbing! disturbing! disturbing! severely 
not really disabling disabling disturbing! 
disabling disabling 
Please write one number between 0 and 8 D 
Appendix Vlll 
Panic Attack Diary 
Patient No 
Patient Initials 
Diary No 
D 
D 
PANIC DIARY 
Group No. 
Doctor / Health Centre 
IT IS IMPORTANT THAT YOU COMPLETE THIS DIARY OF PANIC ATTACKS EXPERIENCED EVERY DAY 
PLEASE REMEMBER TO BRING THIS DIARY TO YOUR NEXT APPOINTMENT 
YOUR NEXT APPOINTMENT IS ......................... . 
PLEASE COMPLETE THIS DIARY FOR THE 7 DAYS 
STARTING ............ AND FINISHING ............. . 
PANIC DIARY - INSTRUCTIONS 
This diary is for you to note down any panic attacks you might have. Each day note down the day £lnd 
the date. 
"you do not have a panic attack that day - tick the 'NO' box. If you do have a panic att£lck, tick the 'YES' 
box and fill in the diary 'olJowing these instructions: 
A panic £lttack is a sudden build-up of fear and anxiety £llong with unpleasant physic<ll feelings. If ,1 
panic occurs, note it down in the first column in the form COLUMN A. If YOll have anothm panic atl<ld<. 
that day, note it in COLUMN 8, and so on. 
First, rate how SEVERE the attack is on this 0 - 10 scale:-
o 1 
I 
Notal 
all severe 
2 
I 
Mild 
3 4 5 6 
I 
Moderate 
7 8 9 
I 
Marked 
10 
I 
Extreme worst 
iI could be 
Then, note down how long the panic lastmf (hOllrs I minutos) ill 11m PANIC DUrlAflON hox. 
Then, go down the list of physical symptoms and put a tick (v' ) next to the ones that you lell durin~, 1110 
panic arrack. 
If another panic attack happens that day, follow these instructions a~Flif1 for COLUMN J3. 
In the section marked 'SITUATIONS' ,note down only briefly wllnm YOll were cllld wlml you WP.lP. doillq 
OAY .......................... OATE 
SIt UA-IION - Where pallic happened 
PANIC ATTACKS YES [] NO r -l 
SovUlity of attack (0 -10) 
Panic Duration (mills) 
Symptoms experienced 
(tick boxes be/ow) 
Breathlessness 
Oizzynesslfeeling faint 
Palpitations or 
racing healt 
T ramiJling/shaking 
Sweating 
Choking 
Nausea 
Unreal feelings/ 
detachment 
Numbness or tingling 
sensations 
Hot or cold flushes 
Chest pain or discomfort 
Fear of dying 
Fear 01 losing control 
Other 
A B c D E 
I 
--r------- f--------
f----I----I -.--- -"_. 
.- -. -... ---- 1-·------· --. 
.-------l----+--
---.. ---1 - ---t----\---
--. ----t-o 
._~ ~ - -- _t ___ - -_.~ .. ~.-----_ 
_____ ._._,,~J ___ _ 
DAY .......................... DAlE 
SI I lJAllON . Where pclllir: happened 
PANIC ATTACKS 
Suverity 01 illlilCk (0 -10) 
Panic (Juration (millS) 
Symptoms experienced 
(lick boxes below) 
Oreat"It}ssness 
Oillyness/l~eling laint 
Palpitatiolls or 
racing healt 
I "~/lluling/sltakif1~ 
Sw~ating 
Choking 
Nausea 
Unreal feelings/ 
delac!lIllonl 
Numuness or tingling 
sensations 
t fot or cold /lushes 
Chest pain or discomfort 
Fear 01 dying 
fear 01 losing control 
OtltHr 
A 
YES L'I NO I 
B c 
'-LL 
-----.----1-
() E 
Global Severity of IIIness/ Change in Symptoms 
DAY 84 ASSESSMENT 
Patient No: Date: 
CLINICAL GLOBAL IMPRESSION SCALE 
Considering your total clinical experience of this condition. how 
emotionally distressed is the patient NOW? 
1 = Normal 
2 = Borderline 
3 = Mild 
4 = Moderate 
5 = Marked 
6 = Severe 
7 = Extreme 
~ 
Please enter score in box I 
I 
~
CLINICAL GLOBAL IMPROVEMENT 
Compared to his/her condition ON ENTRY to the study. how much 
has the patient changed? 
1 = very much improved 
2 = much improved 
3 = minimally improved 
4 = no change 
5 = minimally worse 
6 = much worse 
7 = very much worse 
Please enter score in box 
H.114.928 
Investigators signature ......................... , ................................................................................ . 
Appendix x 
General Health Questionnaire (GHQ) 
ASSESSMENT 1 H.114.92<' 
Patient No: 
Date: Patient Initials: L-__________________ __ 
GENERAL HEALTH QUESTIONNAIRE 
Please read this carefully: 
We should like to know if you have had any medical complaints. and how your health has been in general. 
OVER THE PAST FEW WEEKS. Please answer ALL the questions on the following pages simply by 
underlining the answer which you think most nearly applies to you. Remember that we want to know about 
present and recent complaints. not those that you had in the past. 
It is important that you try to answer ALL the questions. 
Thank you very much for your co-operation. 
HAVE YOU RECENTLY: 
1. Been feeling perfectly well Better Same Worse Much worse 
and in good health? than usual as usual than usual than usual 
2. Been feeling in need of a Not No more Rather more Much more 
good tonic? at all than usual than usual than usual 
3. Been feeling run down Not No more Rather more Much more 
and out of sorts? at all than usual than usual than usual 
4. Felt that you are ill? Not No more Rather more Much more 
at all than usual than usual than usual 
5. Been gettmg any pains Not No more Rather more Much more 
in your head at all than usual than usual than usual 
6. Been getting a feeling Not No more Rather more Much more 
of tightness or pressure at all than usual than usual than usual 
in your head? 
7. Been able to concentrate Better Same Less Much less 
on whatever you are doing? than usual as usual than usual than usual 
8. Been afraid that you were Not No more Rather more Much more 
going to collapse in a at all than usual than usual than usual 
public place? 
9. Been having hot or cold Not No more Rather more Much more 
spells? at all than usual than usual than usual 
10. Been perspiring Not No more Rather more Much more 
(sweating) a lot? at all than usual than usual than usual 
11. Found yourself waking early Not No more Rather more Much more 
and unable to get back to at all than usual than usual than usual 
sleep? 
12. Been getting up feeling Not No more Rather more Much more 
your sleep has not at all than usual than u~'..!31 than usual 
refreshed you? 
13. Been feeling too tired and Not No more Rather more Much more 
exhausted even to eat? at all than usual than usual than usual 
Please turn over . .. 
ASSESSMENT 1 H.114.928 
Patient No: 
GENERAL HEALTH QUESTIONNAIRE (2) 
14. -lost much sleep over Not No more Rather more Much more 
worry? at all than usual than usual than usual 
15. -been feeling mentally alert Better Same Less alert Much less 
and wide awake? than usual as usual than usual alert 
16. -been feeling full of Better Same Less energy Much less 
energy? than usual as usual than usual energetic 
17. -had difficulty in getting Not No more Rather more Much more 
off to sleep? at all than usual than usual than usual 
18. -had difficulty in staying Not No more Rather more Much more 
asleep once you are off? at all than usual than usual than usual 
19. -been having frightening Not No more Rather more Much more 
or unpleasant dreams? at all than usual than usual than usual 
20. -been having restless, Not No more Rather .. 11ore Much more 
disturbed nights? at all than usual than usual than usual 
21. -been managing to keep More so Same Rather less Much less 
yourself busy and than usual as usual than usual than usual 
occupied? 
22. -been taking longer over Quicker Same Longer Much longer 
the things you do? than usual as usual than usual than usual 
23. -tended to lose interest in Not No more Rather more Much more 
your ordinary activities? at all than usual than usual than usual 
24. -been losing interest in Not No more Rather more Much more 
your personal appearance? at all than usual than usual than usual 
25. -been taking less trouble More About same Less Much less 
with your clothes? trouble trouble 
26. -been getting out of the More Same Less Much less 
house as much as usual? than usual as usual than usual than usual 
27. -been managing as well as Better About Rather Much 
most people would in your than most the same less well less well 
shoes? 
28. -felt on the whole you were Better About Less well Much 
doing things well? than usual the same than usual less well 
29. -been late getting to work, Not No later Rather later Much later 
or getting started on your at all than usual than usual than usual 
housework? 
30. -been satisfied with the way More About same Less satis- Much less 
you've carried out your task? satisfied as usual fied than usual satisfied 
31. -been able to feel warmth and Better About same Less well Much less 
affection for those near to you? than usual as usual than usual well 
32. -been finding it easy to get Better About same Less well Much less 
on with other people? than usual as usual than usual well 
ASSESSMENT 1 H.114.928 
Patient No: 
GENERAL HEALTH QUESTIONNAIRE (3) 
33. -spent much time chatting More time About same Less Much less 
with people? than usual as usual than usual than usual 
34. -kept feeling afraid to say Not at all No more Rather more Much more 
anything to people in case than usual than usual than usual 
you made a fool of yourself? 
35. -felt that you are playing a More so Same as Less useful Much less 
useful part in things? than usual usual than usual useful 
36. -felt capable of making More so Same as Less so Much less 
decisions about things? than usual usual than usual capable 
37. -felt you're just not able to Not at all No more Rather more Much more 
make a start on anything? than usual than usual than usual 
38. -felt yourself dreading Not at all No more Rather more Much more 
everything that you have to than usual than usual than usual 
do? 
39. -felt constantly under Not at all No more Rather more Much more 
strain? than usual than usual than usual 
40. -felt you couldn't over- Not at all No more Rather more Much more 
come your difficulties than usual than usual than usual 
41. -been finding life a struggle Not at all No more Rather more Much more 
all the time? than usual than usual than usual 
42. -been able to enjoy your More so Same as Less so Much less 
normal day-to-day activities? than usual usual than usual than usual 
43. -been taking things hard? Not at all No more Rather more Much more 
than usual than usual than usual 
44. -been getting edgy and bad- Not at all No more Rather more Much more 
tempered? than usual than usual than usual 
45. -been getting scared or Not at all No more Rather more Much more 
panicky for no good reason? than usual than usual than usual 
46. -been able to face up to More so Same Less able Much less 
your problems? than usual as usual than usual able 
47. -found everything gelling on Not at all No more Rather more Much more 
top of you? than usual than usual than usual 
48. -had the feeling that people Not at all No more Rather more Much more 
were looking at you? than usual than usual than usual 
49. -been feeling unhapy and Not at all No more Rather more Much more 
depressed? than usual than usual than usual 
50. -been losing confidence in Not at all No more Rather more Much more 
yourself? than usual than usual than usual 
51. -been thinking of yourself as Not at all No more Rather more Much more 
a worthless person? than usual than usual than usual 
Please turn over . .. 
ASSESSMENT 1 H.114.928 
Patient No: 
GENERAL HEALTH QUESTIONNAIRE (4) 
52. -felt that life is entirely Not at all No more Rather more Much more 
hopeless? than usual than usual than usual 
53. -been feeling hopeful about More so About same Less so Much less 
your own future? than usual as usual than usual hopeful 
54. -been feeling reasonably More so About same Less so Much less 
happy, all things considered? than usual as usual than usual than usual 
55. -been feeling nervous and Not at all No more Rather more Much more 
strung-up all the time? than usual than usual than usual 
56. -felt that life isn't worth Not at JII No more Rather more Much more 
living? than usual than usual than usual 
57. Thought of the possibility Definitely I don't Has crossed Definitely 
that you might make away not think so my mind have 
with yourself? 
58. Found at times you couldn·t Not at all No more Rather more Much more 
do anything because your than usual than usual than usual 
nerves were too bad? 
59. Found yourself wishing you Not at all No more Rather more Much more 
were dead and away from it than usual than usual than usual 
all? 
60. Found that the idea of taking Definitely I don't Has crossed Definitely 
your own life kept coming not think so my mind has 
into your mind? 
Appendix Xl 
Sheehan Disability Scale (SD) 
ASSESSMENT 1 H.114.928 
Patient No: L-[ _______ J_ 
Date: Patient Initials: '-1 _______ ---11 
SHEEHAN SCALE 
Instructions: For each scale, circle only one number which best describes your 
situation now. 
1. Work The symptoms have disrupted your work: 
0 1 2 3 4 5 6 7 8 9 10 
I I. I .1 I, I ,I I. I ,I I 
Not at all Mildly Moderately Markedly Extremely 
2. Social Life The symptoms have disrupted your social/leisure activities: 
0 1 2 3 4 5 6 7 8 9 10 
I I. I .i I, I ,I I. I ,I I 
Not at all Mildly Moderately Markedly Extremely 
3. Family Life/Home The symptoms have disrupted your family life: 
Responsibilities 
0 1 2 3 4 5 6 7 8 9 10 
I I. ! ,! I, I ,I I. I ,I I 
Not at all Mildly Moderately Markedly Extremely 
Appendix XlI 
Anxiety Sensitivity Index (ASI) 
INITIAL ASSESSMENT 
Patient No: 
Patient Initials: Date: 
ASI 
Answer the following questions by ticking (v) the appropriate box. 
Tick one box for each question. 
0 1 2 
very little a little some 
It IS Important to me 
not to appear nervous 
When I cannot keep my mind 
on a task, I worry that I 
might be going crazy 
It scares me when I feel 
'shaky' (trembling) 
It scares me when I feel 
faint 
It is important to me to 
stay in .:ontrol of my 
emotions 
It scares me when my 
heart beats rapidly 
It embarrasses me when 
my stomach growls 
It scares me when I 
am nauseous 
When I notice that my 
heart is beating rapidly, 
I worry that I might have 
a heart attack 
It scares me when I 
become short of breath 
When my stomach is upset, 
I worry that I might be , 
seriously ill 
It scares me when I am 
unable to keep my mind on 
a task 
Other people notice when 
I feel shaky 
Unusual body sensations 
scare me 
When I am nervous, I 
worry that I might be 
mentally ill 
It scares me when I am 
nervous 
H.114.928 
3 4 
much very much 
Appendix Xlll 
Eysenck Personality Questionnaire (EPQ) 
INITIAL ASSESSMENT 
EPQ 
Date: 
Patient No: 
Patient Initials: 
INSTRUCTIONS Please answer each question by putting a circle 
around the "YES" or the "NO" following the question. There are no 
right or wrong answers, and no trick questions. Work quickly and do 
not think too long about the exact meaning of the questions. 
PLEASE REMEMBER TO ANSWER EACH QUESTION 
H.114.928 
Do you have many different hobbies? ............................................... '" ................................ YES NO 
2 Do you stop to think things over before doing anything? ...................................................... YES NO 
3 Does your mood often go up and down? .............................................................................. YES NO 
4 Have you ever taken the praise tor something you knew someone else 
had really done? ................................................................................................................... YES NO 
5 Are you a talkative person? .................................................................................................. YES NO 
6 Would being in debt worry you? ........................................................................................... YES NO 
7 Do you ever feel "just miserable" for no reason? ................................................................. YES NO 
8 Were you ever greedy by helping yourself to more than your share of anything? ................ YES NO 
9 Do you lock up your house carefully at night? ...................................................................... YES NO 
10 Are you rather lively? ............................................................................................................ YES NO 
11 Would it upset you a lot to see a child or an animal suffer? ................................................. YES NO 
12 Do you often worry about things you should have done or said? ......................................... YES NO 
13 If you say you will do something, do you always keep your promise no matter 
how inconvenient it might be? .............................................................................................. YES NO 
14 Can you usually let yourself go and enjoy yourself at a lively party? .................................... YES NO 
15 Are you an irritable person1 .................................................................................................. YES NO 
16 Have you ever blamed someone for doing something you knew was really 
your fault? ............................................................................................................................. YES NO 
17 Do you enjoy meeting new people? ...................................................................................... YES NO 
18 Do you believe insurance schemes are a good idea? .......................................................... YES NO 
19 Are your feelings easily hurt? ............................................................................................... YES NO 
20 Are aI/your habits good and desirable ones? ....................................................................... YES NO 
Please turn over . .. 
, I H.114.928 
EPQ(2) 
Patient Initials: L-__________________ ~ 
21 Do you tend to keep in the background on social occasions? .............................................. YES NO 
22 Would ycu take drugs which may have strange or dangerous effects? ................................ YES NO 
23 Do you often feel "fed-up"? ................................................................................................... YES NO 
24 Have you ever taken anything (even a pin or button) that belonged to someone 
else? .................. ···· .. ···· .. ·· .. ··········· ........................................................................................ YES NO 
25 Do you like going out a lot? ................................................................................................... YES NO 
26 Do you enjoy hurting people you love? ................................................................................. YES NO 
27 Are you often troubled about feelings of guilt? ...................................................................... YES NO 
28 Do you sometimes talk about things you k10w nothing about? ............................................ YES NO 
29 Do you prefer reading to meeting people? ........................................................................... YES NO 
30 Do you have enemies who want to harm you? ..................................................................... YES NO 
31 Would you call yourself a nervous person? .......................................................................... YES NO 
32 Do you have many friends? .................................................................................................. YES NO 
33 Do you enjoy practical jokes that can sometimes really hurt people? ................................... YES NO 
34 Are you a worrier? ................................................................................................................. YES NO 
35 As a child did you do as you were told immediately and without grumbling? ....................... YES NO 
36 Would you call yourself happy-go-lucky? .............................................................................. YES NO 
37 Do good manners and cleanliness matter much to you? ...................................................... YES NO 
38 Do you worry about awful things that might happen? ........................................................... YES NO 
39 Have you ever broken or lost something belonging to someone else?. ............................... YES NO 
40 Do you usually take the initiative in making new friends? .~ ................................................... YES NO 
41 Would you call yourself tense or "highly-strung"? ................................................................ YES NO 
42 Are you mostly quiet when you are with other people? ......................................................... YES NO 
43 Do you think marriage is old-fashioned and should be done away with? ............................. YES NO 
44 Do you sometimes boast a little? .......................................................................................... YES NO 
45 Can you easily get some life into a rather dull party? ........................................................... YES NO 
46 Do people who drive carefully annoy,you? ........................................................................... YES NO 
47 Do you worry about your health? .......................................................................................... YES NO 
48 Have you ever said anything bad or nasty about anyone? ................................................... YES NO 
49 Do you like telling jokes and funny stories to your friends? .................................................. YES NO 
50 Do most things taste the same to you? ................................................................................. YES NO 
51 As a child were you ever cheeky to your parents? ................................................................ YES NO 
52 Do you like mixing with people? ............................................................................................ YES NO 
53 Does it worry you if you know there are mistakes in your work? .......................................... YES NO 
54 Do you suffer from sleeplessness? ....................................................................................... YES NO 
H.114.928 
EPQ(3) 
Patient Initials: 
55 Do you always wash before a meal? .................................................................................... YES NO 
56 Do you nearly always have a "ready answer" when people talk to you? ............................. YES NO 
57 Do you like to arrive at appointments in plenty of time? ....................................................... YES NO 
58 Have you often felt listless and tired for no reason? ............................................................. YES NO 
59 Have you ever cheated at a game? ...................................................................................... YES NO 
60 Do you like doing things in which you have to act quickly? .................................................. YES NO 
61 Is (or was) your mother a good woman? .............................................................................. YES NO 
62 Do you often feel life is very dull? ......................................................................................... YES NO 
63 Have you ever taken advantage of someone? ..................................................................... YES NO 
64 Do you often take on more activities than you have time for? .............................................. YES NO 
65 Are there several people who keep trying to avoid you? ...................................................... YES NO 
66 Do you worry a lot about your looks? ................................................................................... YES NO 
67 Do you think people spend too much time safeguarding their future with 
savings and insurances? ...................................................................................................... YES NO 
68 Have you ever wished that you were dead? ......................................................................... YES NO 
69 Would you dodge paying taxes if you were sure you could never be found out? ................. YES NO 
70 Can you get a party going? ................................................................................................... YES NO 
71 Do you try not to be rude to people? .................................................................................... YES NO 
72 Do you worry too long after an embarrassing experience? .................................................. YES NO 
73 Have you ever insisted on having your own way? ................................................................ YES NO 
74 When you catch a train do you often arrive at the la5t minute? ............................................ YES NO 
75 Do you suffer from "nerves"? ............................................................................................... YES NO 
76 Do your friendships break up easily without it being your fault? ........................................... YES NO 
77 Do you often feel lonely? ..................................................................................................... YES NO 
78 Do you always practice what you preach? .......................................................................... YES NO 
79 Do you sometimes like teasing animals? .............................................................................. YES NO 
80 Are you easily hurt when people find fault with you or the work you do? ............................. YES NO 
81 Have you ever been late for an appointment or work? ......................................................... YES NO 
82 Do you like plenty of bustle and excitement around you? .................................................... YES NO 
83 Would you like other people to be afraid of you? .................................................................. YES NO 
84 Are you sometimes bubbling over with energy and sometimes very sluggish? .................... YES NO 
85 Do you sometimes put off until tomorrow what you ought to do today? ............................... YES NO 
86 Do other people think of you as being very lively? ............................................................... YES NO 
87 Do other people tell you a lot of lies? .................................................................................... YES NO 
88 Are you touchy about some things? ..................................................................................... YES NO 
89 Are you always willing to admit it when you have made a mistake? .................................... YES NO 
90 Would you feel very sorry for an animal caught in a trap? .................................................... YES NO 
PLEASE CHECK TO SEE THAT YOU HAVE ANSWERED ALL THE QUESTIONS 
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Social Maladjustment Questionnaire (Soc Mal) 
JNITIAL ASSESSMENT H.114.928 
Patient No: I ~ 
Date: Patient Initials: I 
SOCIAL QUESTIONNAIRE 
Please underline the most appropriate answer. 
A. HOUSING (EVERYONE ANSWER) 
1. Are your housing Adequate 
conditions adequate 
for you and your 
family's needs? 
2. How satisfied are 
you with your present 
accommodation? 
Satisfied 
Slightly 
inadequate 
Slightly 
dissatisfied 
B. WORK (FOR ALL MEN AND WOMEN WORKING OUTISDE THE HOME) 
3. How satisfied are 
you with your present 
job? 
4. Do you have problems 
getting on with any of the 
people at your work? 
Satisfied 
No problems 
(FOR HOUSEWIVES WITH NO OUTSIDE WORK) 
5. How satisfied are 
you with being a 
housewife? 
Satisfied 
Slightly 
dissatisfied 
Slight 
problems 
Slightly 
dissatisfied 
Markedly 
inadequate 
Markedly 
dissatisfied 
Severely 
inadequate 
Severely 
dissatisfied 
Tick box if not applicable D 
Markedly Severely 
dissatisfied dissatisfied 
Marked 
problems 
Severe 
problems 
Tick box if not applicable D 
Markedly Severely 
dissatisfied dissatisfied 
(FOR HOUSEWIVES WITH A FULL OR PART·TIME JOB OUTSIDE THE HOME) D 
Tick box if not applicable 
6. How satisfied are Satisfied Slightly Markedly Severely 
you with working and dissatisfied dissatisfied dissatisfied 
running a home? 
(FOR THOSE WHO ARE NOT WORKING-RETIRED, UNEMPLOYED OR OFF SICK) D 
Tick box if not applicable 
7. How satisfied are r Satisfied Slightly Markedly Severely 
you with this situation? dissatisfied dissatisfied dissatisfied 
C. FINANCIAL CIRCUMSTANCES (EVERYONE ANSWER) 
8. Is the money coming Adequate Slightly 
in adequate for you and inadequate 
your family's needs? 
Markedly 
inadequate 
Severely 
inadequate 
I 
Please turn over . ... 
INITIAL ASSESSMENT H.114.928- . 
Patient Initials: 
SOCIAL QUESTIONNAIRE (2) 
9. Do you have any No Slight Marked Severe 
difficulties in difficulties difficulties difficulties difficulties 
meeting bills and 
other financial 
commitments? 
10. How satisfied are Satisfied Slightly Markedly Severely 
you with your financial dissatisfied dissatisfied dissatisfied 
position? 
D. SOCIAL CONTACTS (EVERYONE ANSWER) 
11. How satisfied are Satisfied Slightly Markedly Severely 
you with the amount dissatisfied dissatisfied dissatisfied 
of time you are able 
to go out? 
12. Do you have any No problems Slight Marked Severe 
problems with your problems problems problems 
neighbours? 
13. Do you have any No problems Slight Marked Severe 
problems getting on problems problems problems 
with any of your 
friends? 
14. How satisfied are Satisfied Slightly Markedly Severely 
you with the amount dissatisfied dissat,sfied dissatisfied 
of time you see your 
friends? 
15. Do you have any No problems Slight Marked Severe 
problems gelling on problems problems problems 
with any close relative? 
(including parents, in-
laws, or grown-up 
children) 
16. How satisfied are Satisfied Slightly Markedly Severely 
you with the amount dissatisfied dissatisfied dissatisfied 
of time you see your 
relatives? 
E. MARRIAGE AND BOYFRIENDS/GIRLFRIENDS 
17. What is your 
marital status? 
Single Married! Widowed Separated Divorced 
cohabitating 
(FOR ALL THOSE WHO ARE MARRIED OR HAVE A STEADY RELATIONSHIP) D 
Tick box if not applicable 
18. Do you have No Slight MClrked Severe 
difficulty confiding difficulty difficulty difficulty difficulty 
in your partner? 
• 
" 
INITIAL ASSESSMENT H.114.928 
. -• 
Patient Initials: 
SOCIAL QUESTIONNAIRE (3) 
19. Are there any No problems Slight Marked Severe 
sexual problems in problems problems problems 
your relationship? 
20. Do you have any No problems Slight Marked Severe 
other problems getting problems problems problems 
on together? 
21. How satisfied in Satisfied Slightly Markedly Severely 
general are you with dissatisfied dissatisfied dissatisfied 
your relationship? 
22. Have you recently No Sometimes Often Yes, planned 
been so dissatisfied or recent 
that you have considered separation 
separating from your 
partner? 
(FOR ALL THOSE WHO ARE NOT MARRIED/DO NOT HAVE A STEADY RELATIONSHIP) D 
Tick box if not applicable 
23. How satisfied are 
you with this situation? 
Satisfied Slightly 
dissatisfied 
F. DOfJlESTIC LIFE (FOR THOSE WITH CHILDREN UNDER 18) 
24. Do you have any 
difficulties coping 
with your children? 
25. How satisfied do 
you feel with your 
relationship with the 
children? 
No 
difficulties 
Satisfied 
(FOR THOSE WITH CHILDREN OF SCHOOL AGE) 
26. Are there any 
problems involving your 
children at school? 
No problems 
Slight 
difficulties 
Slightly 
dissatisfied 
Slight 
problems 
Markedly Severely 
dissatisfied dissatisfied 
Tick box if not applicable D 
Marked Severe 
difficulties difficulties 
Markedly 
dissatisfied 
Severely 
dissatisfied 
Tick box if not applicable D 
Marked Severe 
problems problems 
(FOR ALL THOSE WITH OTHER ADULTS LIVING WITH THEM -INCLUDING RELATIVES BUT EXCLUDING SPOUSE) D 
Tick box if not applicable 
27. Do you have any No problems Slight Marked Severe 
problems about sharing problems problems problems 
household tasks? 
Please turn over . ... 
INITIAL ASSESSMENT 
SOCIAL QUESTIONNAIRE (4) 
28. Do you have any 
difficulties with the 
other adults in your 
household? 
29. How satisfied are 
you with this 
arrangement? 
No 
difficulties 
Satisfied 
G. LEGAL MAnERS (EVERYONE ANSWER) 
30. Do you have any 
legal problems 
(custody, maintenance, 
compensation, etc.)? 
No problems 
H. FOR THOSE WHO ARE LIVING ALONE 
31. Do you have any 
difficulties living 
and managing on your 
own? 
32. How satisfied are 
you with living on your 
own? 
I. OTHER (EVERYONE ANSWER) 
33. Do you have any 
other social problems 
or problems? 
No 
difficulties 
Satisfied 
No problems 
Patient Initials: 
Slight 
difficulties 
Slightly 
dissatisfied 
Slight 
problems 
Slight 
difficulties 
Slightly 
dissatisfied 
Slight 
problems 
Marked 
difficulties 
Markedly 
dissatisfied 
Marked 
problems 
H.114.928 .. 
Severe 
difficulties 
Severely 
dissatisfied 
Severe 
problems 
Tick box if not applicable o 
Marked Severe 
difficulties difficulties 
Markedly 
dissatisfied 
Marked 
problems 
Severely 
dissatisfied 
Severe 
problems 
If so please specify ............................................................................................................ , .. 
................................................................................................................ 
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INTRODUCTION 
The Hamilton Anxiety Scale and Glossary are intended for use with 
patients already diagnosed as suffering from neurotic anxiety states, 
and not for assessing anxiety in patients suffering from other 
disorders. 
A series of symptoms is assembled to form the fourteen items of the 
scale, each of the items being defined 1n a series of brief statements 
and headed by the name of the item. 
Examples of questions to elicit the severity of symptoms are written 
into the glossary. In addition the examiner will usually wish to 
ask other questio~s which are not written into the glossary> either 
general probes or more specific questions, depending on the nature 
of the patient's replies. 
Assessments are made on a five point scale, examples of scoring 
criteria for each grade being included. In practice, the last grade 
is rarely used for out-patients, and serves more as a marker, a 
method of delimiting the range> rather than as a grade of frequent 
pra~tical use. 
The interviewer should introduce himself briefly, describe the 
purpose of the interview and explain any recording equipment. 
, . 
(1) Anxious Mood (0-4) 
Anxious mood may be regerded as a continuous state of apprehension 
pervading all situations. 
part, by certain aspects of 
It is important to remember 
all sorts of ways. Useful 
"tense", or "up-tight". 
Milder anxious mood is relieved, at least in 
the environment such as familiarity or company. 
that patients interpret the word "anxious" in 
common terms are "nerves", "jittery", "on edge" 
" NOW, I WOULD LIKE TO ASK YOU ABOUT THE WAY YOU HAVE BEEN FEELING DURING 
THE LAST WEEK. HAVE YOU BEEN ON EDGE, OR HAD TROUBLE WITH YOUR NERVES? 
H~VE YOU BEEN FEELING ANXIOUS OR FRIGHTENED, AS THOUGH SOMETHING TERRIBLE 
WERE ABOUT TO HAPPEN TO YOU? HOW OF'!'EN? POES IT COME AND C-0? HOW 
LONG DOES IT LAST? HOW BAD IS IT? HOW MUCH DOES IT TROUBLE YOU? 
HAVE YOU BEEN IRRITABLE? HOW DO YOU SHOW IT?"" 
o = Absent 
1 = Mild. Inappropriate apprehensions or worries which are 
mild and present some of the time. a minor increase in 
irritability which occurs occasionally. 
2 = Moderate. Moderately severe symptoms, present much of 
the time which are of concern to the patient and result 
in minimal impairment to social functioning or work 
performance. Patient irritable much of the time. 
, = Severe. Severe symptoms which are present most of the 
time or intermittent panic attacks impairing social 
functioning or work performance. Irritable most of the 
time and shows anger by shouting or quarelling. 
4 = Very Severe. Persistent state of intense anxiety or 
intermitt~t severe panic attacks causing marked 
limitation of the patient's activities. Constantly 
irritable with violent outbursts of temper, possibly 
involving breaking obje~ts or physical violence. 
(2) Tension (0-4) 
Patients may complain of tension in a variety of ways. They may 
complain of feelings of tension, inability to relax, being startled 
easily, weeping easily, trembling and shaking, and feeling restless. 
" HAVE YOU FELT TENSE OR FOUND IT DIFFICtTLT TO RELAX DURING THE PAST 
WEEK? HAVE YOU BEEN "JUMPY" OR "SHAKY" OR "FIDGETY" AND "RESTLESS" 
DURING THE PAST WEEK? HAVE YOU BEEN MOVED TO TEARS DURING THE PAST 
WEEK? HOW MUCH AND HOW OFTEN HAVE THESE SORTS OF THINGS BOTHERED 
YOU? " 
o .. Absent. 
1 • Mild. Reporting a mild inability to relax on occasion. 
However a change in environment or cornpa~y tends to 
relieve such tension. 
2 - ~oderate. Reporting a moderate inability to relax 
and feelings of restlessness occurring much of the 
time. Not alleviated by a change of environment or 
company. 
3 • Severe. Reporting a marked inability to relax and 
feelings of restlessness present most of the time. 
4 • ~e!1 severe. A const \~t feeling of needing to be on 
the move. A total inability tel relax. Patient 
rarely stays seated for more than a short period of 
time. 
(3) Fears (0-4) 
Rate any specific fear that the patient reports e.g. fears of dark, 
strangers, being left alone, large animals, traffic, crowds, etc. 
Assess what restrictions the "fear" imposes on the patient. 
" IS THERE ANY PLACE,. SITUATION OR THING THAT YOU ARE AFRAID OF, THAT 
YOU TEND TO AVOID IF POSSIBLE, OR THAT MAKES YOU FEEL ILL AT EASE. " 
o • 'Absent. 
1 • Mild. An irrational fear or foreboding of situations 
which are not avoided and can be approached with 
apprehension. 
2 • Moderate. A moderate fear of situations, sometimes 
provoking panic. The patient prefers to avoid these 
situations but can approach if accompanied or if the 
situation demands. 
3 • Severe. A severe fear of situations provoking panic 
and is almost always avoided, unless accompanied or 
unless sheer necessity requires that the situation be 
approached. 
4 • Very severe. A very severe fear of situations which 
would produce total avoidance and which would produce 
a severe panic reaction if it were encountered. 
(4) Insomnia (0-4) 
Sleep disturbance may manifest itself in differing forms. 
present as: 
difficulty falling asleep 
Insomnia may 
broken or disturbed sleep (which is often difficult to assess) 
early wakening 
Patients may also complain of unsatisfactory sleep and fatigue on wakening, 
nightmares, dreams, and restlessness. When insomnia is severe it generally 
affects all phases of sleep and tends not to be relieved by hypnotics. 
Insomnia should be assessed on the degree to which sleep is lost over the 
course of the whole night compared with what may be normal for the popul-
ation and the age-group. 
VI WHAT HAS YOUR SLEEP BEEN LIKE OVER THE LAST WEEK? HAVE YOU BEEN TAKING 
SLEEPING PILLS? WHAT TIME DO YOU GO TO BED? WHAT TIME DO YOU GO TO 
SLEEP? WHEN YOU DO GET TO SLEEP DO YOU SLEEP WELL? WHAT TIME DO YOU 
WAKEN IN THE MORNING? WHAT TIME DO YOU NEED TO GET UP? " 
o • Absent. 
1 • Mild. Sleep loss of one hour or less, causing only 
minor concern to the patient. 
2 • Moderate. Sleep loss of one to two hours, resulting 
in a degree of impaired social functioning or work 
performance that is of concern to the patient. 
3 • Severe. Sleep loss of two to four hours, of much 
concern to the patient, and significantly impairing 
daily routine. 
4 • Very severe. Sleep loss of greater than four hours 
and sleep. only occurring in brief exhausted snatches. 
Severe functional impairment of daily routine tasks. 
(5) Intellectual (cognitive) (0-4) 
Intellectual and cognitive changes may manifest themselves as periods 
of forgetfulness, or complaints of inability to concentrate adequately. 
" HAVE YOU HAD ANY DIFFICULTY CONCENTRATING AT WORK, OR ON OTHER THINGS 
YOU DO, E.G. H~BBIES, READING, WATCHING T.V., HOUSEWORK, DAILY CHORES. 
HOW OFTEN? HOW BAD IS IT? WHAT IS YOUR MEMORY LIKE? HAVE YOU 
NOTICED A CHANGE IN YOUR ABILITY TO REMEMBER THINGS? 
o • Absent. 
1 • Mil~ A minor increase in forgetfulness or concentration 
but not persistent and performance can be improved with 
added effort. No si~nific.ant imoairment in performance. 
2 • Moderate. An increase in forgetfulness or concentration 
thereby impairing routine performance e.g. forgetting 
telephone numbers, inability to concentrate fully on T.V., 
reading or work. Results in a minor degree of impairment. 
3 • Severe. A marked reduction in the ability to concentrate 
or remember, restricting the patient's daily performance. 
Routine tasks may be lengthened or not completed. The 
impairment is noticeable to others and unable to be 
overcome by the patient. 
4 • Very severe. Unable to perform any series of routine 
tasks, or learn new information, due to a severe inability 
to concentrate or remember new information. Severely 
impaired. 
(6) Depressed Mood (0-4) 
Depressed mood may be characterized by a gloomy attitude, pessimism 
about the future.and feelings of hopelessness. Milder depressive 
mood may be relieved, at least in part, by environmental change, such 
as company or other forms of external stimulation. Patients may 
interpretlldepressed mood ll in different ways. Useful common phrases 
arell feeling down" or"feeling low': 
II 
, 
HAVE YOU BEEN FEELING REASONABLY CHEERFUL DURING THE PAST ~~EK OR 
HAVE YOU FELT DEPRESSED OR LOW SPIRITED? HOW WOULD YOU DESCRIBE IT? 
DOES IT CO~ffi AND GO? HAVE YOU LOST INTEREST IN THINGS? DO ANY 
ACTIVITIES GIVE YOU PLEASURE? DO Y0t.! FEEL BETTER OR WORSE AT ANY 
TIMES OF THE DAY? 
o 
-
1 
-
2 
-
3 
-
4 
-
Absent. Very mild or occasional feelings no worse 
than the patient's normal experience when well. 
Mild. Persistent feelings described as moody, 
downhearted or dejected. More intense occasional 
feelings may be relieved by company,or a change in 
environment, or in a change in activity. 
Moderate. Persisting or frequent feelings of 
dep:ession, blueness, etc.; often feels like 
crylng, may cry occasionally, not easily relieved 
by company or environmental change. 
Severe. More intense feelings; frequent bouts of 
crying and feelings of despondency and helplessness 
throughout the working day. 
Very severe. Persistent severe feelings, may be 
descr~bed as beyond tears, painful, no relief, 
excruciating, agonising, persistent, unrelieved 
feelings, suicidal. 
(7) General somatic (muscular) (0-4) 
This symptom consists of diffuse muscular aching or stiffness, ill-defined 
and often difficult to locate, but frequently in the back and sometimes 
in the limbs; these may also feel "heavy". Erratic muscular tone may 
result in clonic jerks, twitchings, grinding of teeth and an unsteady 
voice. 
" HAVE YOU HAD ANY ACHES OR PAINS DURING THE LAST WEEK? HAVE YOUR LIMBS 
FELT STIFF, TIGHT, TWITCHY OR JERKY? DOES YOUR VOICE FEEL UNSTEADY, 
HAVE YOU BEEN GRINDING YOUR TEETH? HOW'OFTEN? HOW BAD? 
o • Absent. 
1 • Mild. A slight increase in muscular tension, aches and 
pains, but of no significant concern to the patient. 
2 • Moderate. A noticeable increase in symptoms, of concern 
to the patient but of a sporadic nature and able to be 
relieved or brought under control by the patient to some 
extent. 
3 • Severe. A significant increase in symptoms being outwith 
the patient's control and occurring with such severity and 
regularity (on a daily basis) thereby causing the patient 
concern and impairment. Periods of total relief from 
symptoms being very infrequent. 
4 • Very severe. Continuous and severe stiffness, pain or 
clonic jerks. This results in a significant degree of 
motor impairment and is therefore greatly inhibiting and 
of much concern to the patient. 
i 
(8) General somatic (sensory) (0-4) 
Autonomic overactivity may manifest itself as blurring of V1Slon, 
tinnitus, hot and cold flushes, feelings of weakness, or prickling 
sensations. 
It HAVE YOU SUFFERED FROM ANY OF THE FOLLOWING RECENTLY: RINGING IN 
YOUR EARS, BLURRED VISION, FLUSHES, PRICKLY SENSATIONS OR FEELING·. 
WEAK? HOW OFTEN? HOW BAD? " 
o • Absent. 
1 • Mild. One or two definite symptoms of mild intensity 
occurring once or twice per week, leading to only mild 
interference with day to day activities. 
2 • Moderate. Marked symptoms occurring more than twice 
per week or continuous milder symptoms present most of 
the week. Presence of symptoms significantly 
upsetting daily routine; and while present, impairing 
daily performance. 
3 • Severe. Severe symptoms occurring at least daily or 
severe sporadic episodes that totally incapacitate 
while they last. Patient experiences difficulty in 
getting going and only occasionally experiences respite 
from symptoms. 
4 • Very severe. Patient experlences multiple severe 
symptoms much of the time or frequent severe sporadic 
episodes which totally incapacitate, resulting in 
marked impairment and an inability to perform daily 
tasks. Patient never totally symptom-free, symptoms 
only periodically reducing in intensity. 
(9) Cardiovascular symptoms (0-4) 
Patients may experience cardiovascular irregularities such as tachy-
cardia, and various other arhythmias may be present. Patient may 
attribute inappropriate degree of significance to minor abnormalities 
or be fearful of the consequence of such abnormalities. 
" HAVE YOU NOTICED RECENTLY ANY OF THE FOLLOWING: INCREASBD HEART 
RATE OR YOUR HEART SEEMING TO RACE OR RUN TOO FAST, PALPITATIONS, 
PAINS IN YOUR CHEST, THROBBING OF BLOOD VESSELS OF YOUR HEART, 
FEELING FAINT OR FEELING THAT YOUR HEART MISSES A BEAT? " 
o s Absent. 
1 • Mild. An increased awareness of heart rate or 
heart beat irregularities that do not incapacitate 
the patient in any way; occurs infrequently, 
usually not more than three times per week. 
2 • Moderate. More persistent tachycardia, arhythmias, 
angina, palpitations or faintness that are not, 
according to the patient, under his/her control and 
are a cause of concern, necessitating an adjustment 
of the patient's daily routine; occuring frequently 
almost daily. 
3 • Severe. Patient may severely restrict activity for 
fear of the consequences of tachycardia or irregular 
cardiac activity and palpitations. Symptoms may be 
present most of the time. 
4 • Very severe. Patient completely preoccupied with 
cardiovascular symptoms. Severe impairment of 
function. Symptoms continuously present. 
· . 
(10) Respiratory symptoms (0-4) 
Severe forms of these symptoms may result in hyperventilation and is 
therefore easy to detect although less severe forms are often less 
noticeable. The patient may complain of pressure or constriction in 
chest, choking feelings, sighings, dyspnoea, tightness or gasping for 
breath. 
" HAVE YOU HAD ANY DIFFICULTY IN BREATHING RECENTLY? WHEN? HOW OFTEN? 
HOW BAD? " 
o • Absent. 
1 • Mild. Experience of mild respiratory symptoms, not 
glvlng rise to undue concern and not restricting 
patient's daily activities. 
2 • Moderate. A more pronounced loss of regular breathing 
control necessitating termination of activities in 
order to regain control of breathing. (less than 5 
mins. x2 per day), 
3 • Severe. Patient feels he/she is unable to control 
erratic breathing pattern, unable to regain breathing 
control and unable to continue any task at hand when 
breathing pattern becomes disturbed. (greater than 
5-10 mins. x4 per day). 
4 • Very severe. Frequent and intense respiratory 
difficulty resulting in prolonged daily episodes of 
hyperventilation (greater than 30 mins.), and possible 
concomitant loss of consciousness. 
(11) Gastro-intestina1 symptoms (0-4) 
A great variety of gastro-intestina1 symptoms may exist ranging from 
a very occasional difficulty in swallowing to a medically diagnosed 
irritable bowel syndrome. 
A check list of gastro-intestinal symptoms fol10ws:-
Difficulty in swallowing; wind; dyspepsia; pain before and 
after meals, burning sensations, fullness, waterbrash, nausea, 
vomltlng, sinking feelings; "working"in abdomen; borborygmi; 
looseness of bowels; loss of weight; constipation. 
" HOW HAS YOUR APPETITE BEEN? HAVE YOU HAD ANY DIFFICULTY IN KEEPING 
YOUR FOOD DOWN RECENTLY? HAVE YOU BEEN CONSTIPATED RECENTLY OR 
P~VE YOUR BOWELS BEEN AS REGULAR AS YOU WOULD NORMALLY EXPECt? HAVE 
YOU HAD HEARTBURN RECENTLY? HAS YOUR STOMACH BEEN TROUBLING YOU AT 
ALL? HAVE YOU LOST ANY WEIGHT RECENTLY? " 
o • Absent. No major gastro-intestinal upset of any 
consequence in recent months. 
1 • Mild. A minor degree of gastro-intestinal, or bowel 
irregularity, resulting in a minor degree of irritation 
and annoyance as opposed to incapacitation. 
2 • Moderate. A moderate degree of gastro-intestinal or 
bowel irregularity, resulting in a degree of incapacit-
ation that is of concern to the patient. 
3 • Severe. A severe degree of gastro-intestina1 or bowel 
upset that is often unpredictable and uncontrollable 
even if food intake is modified, resulting in significant 
functional impairment. 
4 • Very severe. Frequently painful and incapacitating 
gastro-intestinal or bowel upset, possibly resulting in 
markedly reduced and modified food intake with concomitant 
loss of weight. Severe functional impairment. 
· . 
(12) Genito-urinary symptoms (0-4) 
Desire to micturate can reflect intense anxiety. Females may experience 
various menstrual irregularities, whilst males and females may experience 
a wide range of sexual dysfunctions. A check list of genito-urinary 
symptoms follows:-
Frequency of micturition) 
Urgency of micturition ) 
Amenorrhea 
Menorrhagia 
Development of 
) 
) 
frigidity) 
Ejaculatio praecox) 
in both males and females 
in females alone 
Loss of erection ) in males alone 
Impotence ) 
Patients need not experience symptoms from all the above categories of 
symptoms. 
" HAS THERE BEEN ANY CHANGE IN THE NUMBER OF TIMES, OR URGENCY WITH ~~ICH 
YOU HAVE TO GO TO THE TOILET TO URINATE? HAS THERE BEEN ANY CHANGE IN 
YOUR LOVE LIFE, SEX LIFE, OR INTEREST IN SEX, RECENTLY? HAS THERE BEEN 
ANY CHANGE IN THE REGULARITY OF YOUR PERIODS? (FEMALES ONLY). " 
o • Absent. 
1 • Mild. A noticeable increase in frequency or urgency of 
micturition which can be alleviated by partially reducing 
liquid intake and environmental change and is more of an 
inconvenience than a handicap. A mild decrease in sexual 
receptivity/performance/arousal etc. where such dysfunction 
would not normally be present. 
2 • Moderate. A marked increase in urgency or frequency of 
micturition cannot be brought under control by patient. 
Sexual dysrunction is evident on many occasions and is 
therefore of concern to both patient and sexual partner. 
Females may experience menstrual irregularity which is of 
concern to them. 
3 • Severe. Urgency and frequency of micturltlon is such 
that patient organises daily routine around presence and 
availability of toilets. Sexual dysfunction is evident 
on most occasions. Marked menstrual irregularity in 
female patients. 
4 • Very severe. Fear of involuntary voiding is such that 
patient needs to be constantly in reach of a toilet and is 
therefore severely functionally impaired. Sexual 
dysfunction is evident on all occasions of attempted 
sexual intercourse. Female patients are completely 
amenorrheaic. 
· ' 
(13) Autonomic symptoms (0-4) 
Autonomic accompaniments of anxiety may entail any of the following:-
dry mouth; flushing; pallor; tendency to perspire heavily; 
giddiness; tension headache; raising of hair. 
Various combinations of the above check list may be present to a greater 
or lesser degree. 
" HAVE THERE BEEN TIMES RECENTLY WHEN YOU HAVE FELT ANY OF THE FOLLOWING: 
GIDDY OR UNSTEADY, HAVE SWEATED A LOT, HAD A DRY MOUTH, FELT FAINT, 
DIZZY, HEADACHES, PIAN AT THE BACK OF THE NECK, BUTTERFLIES. HOW 
OFTEN? HOW BADLY? 11 
o • Absent. 
1 • Mild. One or a few of the above symptoms have.been 
present on occasion but were mild and did not cause 
concern. Present on occasion (not more than twice per 
week). 
2 • Moderate. A number of the above symptoms have been 
present on a number of occasions causing distress, 
(greater than twice per week), or a sin~le symptom 
has been present on a re~ular basis. 
3 • Severe. A number of the above symptoms have been 
present most of the time, resulting in some impairment 
to function and marked concern to patient. 
4 • Very severe. A number of the above symptoms have been 
continually present, to the extent that this has 
markedly impaired the patient carrying out daily routine 
tasks. Virtually no relief from symptoms. 
(14) Behaviour at interview (general) (0-4) 
This is not based on the patient's subjective report but is based upon 
the interviewer's observations of the patient's general appearance and 
behaviour throughout the whole assessment interview. 
Observe general anxiety checklist as follows:-
Tense, not relaxed. Fidgeting: hands, picking fingers, 
clenching, tics. Restlessness:.pacing. Tremor of hands. 
Furrowed brow. Strained face.or voice. Increased 
muscular tone. Sighing respirations. Facial pallor. 
Swallowing I belching, sweating. Tremor and eye-lid 
twitching. 
o • Absent. Calm and relaxed. 
1 • Mild. Exhibiting up to two of the above behaviours, 
occasionally throughout the interview. 
2 • Moderate. Intermittently exhibiting two to four of the 
above behaviours or continually exhibiting up to two of 
the above behaviours throughout the interview. 
3 • Severe. Frequently exhibiting at least four of the 
above behaviours or continually exhibiting less than 
four of the above behaviours, resulting in slightly 
impaired communication. 
4 • Very severe. Continually exhibiting the majority of 
the above behaviours to such an extent that communication 
is extremely difficult. 
